




(86) Date de dépôt PCT/PCT Filing Date: 2013/03/01
(87) Date publication PCT/PCT Publication Date: 2013/09/06
(45) Date de délivrance/Issue Date: 2020/01/21
(85) Entrée phase nationale/National Entry: 2014/08/29
(86) N° demande PCT/PCT Application No.: EP 2013/054224
(87) N° publication PCT/PCT Publication No.: 2013/128028
(30) Priorité/Priority: 2012/03/01 (EP12157751.4)

(51) Cl.Int./Int.Cl. *C07D 487/04* (2006.01),
A61K 31/53 (2006.01), *A61P 29/00* (2006.01),
A61P 31/00 (2006.01), *A61P 35/00* (2006.01),
A61P 9/00 (2006.01)
(72) Inventeurs/Inventors:
EICKHOFF, JAN, DE;
ZISCHINSKY, GUNTHER, DE;
KOCH, UWE, DE
(73) Propriétaire/Owner:
LEAD DISCOVERY CENTER GMBH, DE
(74) Agent: LAVERY, DE BILLY, LLP

(54) Titre : DERIVES PYRAZOLO-TRIAZINE UTILES EN TANT QU'INHIBITEURS DES KINASES DEPENDANT DES CYCLINES

(54) Title: PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS



(I)


(57) **Abrégé/Abstract:**

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives of the formula (I) and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives of the formula (I) and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives of the formula (I) as inhibitors for a protein kinase.

(see formula I)

Abstract

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives of the formula (I) and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said pyrazolo[1,5-a][1,3,5]triazine derivatives of the formula (I) and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said pyrazolo[1,5-a][1,3,5]triazine derivatives of the formula (I) as inhibitors for a protein kinase.



(I)

PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT
KINASE INHIBITORS

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory and immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical composition containing at least one of the pyrazolo[1,5-a][1,3,5]triazine derivatives and/or pharmaceutically acceptable salts thereof.

Cyclin-dependent kinase (CDK) family members that trigger passage through the cell cycle are being considered as attractive therapeutic targets, especially for cancer. CDK family members that control other processes such as transcription and RNA processing have caught less attention so far, although experimental evidence for their involvement in different pathological processes is emerging. The CDK-activating kinase, or CAK complex, consists of CDK7, cyclin H, and MAT1. As part of CAK, CDK7 phosphorylates other CDKs, an essential step for their activation. Therefore CDK7 is required for cell cycle progression, which suggests that CDK7 is a target for cancer therapy. As the kinase subunit of TFIIH, CDK7 participates in basal transcription by phosphorylating the carboxy-terminal domain of the largest subunit of RNA polymerase II. As a general regulator of transcription, CDK7 is a therapeutic target for treatment of diseases like inflammation, virus replication such as HIV, EBV, and HCV, cancer and cardiac hypertrophy.

HIV-1 gene expression is regulated by a viral transactivator protein (Tat) which induces transcriptional elongation of HIV-1 long tandem repeat. This induction requires hyperphosphorylation of the C-terminal domain repeats of RNA polymerase II. To achieve said hyperphosphorylation, Tat stimulates CTD kinases associated with general transcription factors of the promoter complex, specifically TFIIH-associated CDK7. (Nekhai et al.; Biochem. J. (2002) 364, 649-657). Also the inventors of US 615968 describe that Tat binds to CDK7 and that this interaction increases the ability of CAK to phosphorylate CTD. The authors of US 615968 further disclose that the transcriptional activation by Tat is dependent upon the kinase activity of CDK7. Additionally, Young Kyeung Kim and colleagues conclude that the recruitment and activation of TFIIH represents a rate-limiting step for the emergence of HIV from latency (Young Kyeung Kim, EMBO J (2006) 25, 3596-3604).

Levels of CDK7 and CDK9, as well as other components of the kinase complexes, MAT-1/cyclin H are upregulated during Human cytomegalovirus infection. In addition,

there is an increase in the kinase activities of CDK7 and CDK9 (Tamrakar et al., Journal of Virology, 2005, 79; 15477–15493).


Many antiviral drugs target viral proteins. These have the disadvantage that viruses often develop resistance against these drugs. Antiviral drugs targeting cellular proteins essential for viral process, like CDK7, could bypass this disadvantage. These drugs may further be effective in treating several unrelated viruses and their effects should be additive to traditional antiviral agents. Inhibitors of CDK7, which has its dual function of CDK-activating kinase and transcription regulation is very effective in the treatment of several viruses.

It is object of the present invention to provide compounds and/or pharmaceutically acceptable salts thereof which can be used as pharmaceutically active agents, especially for prophylaxis and/ or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases, as well as compositions comprising at least one of those compounds and/or pharmaceutically acceptable salts thereof as pharmaceutically active ingredients.

This object is solved by the compounds of the present invention and/or their pharmaceutically acceptable salts, the compounds of the present invention for use as pharmaceutically active agents, the use of the compounds of the present invention for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and the use of compounds according to the present invention as inhibitors for the protein kinase CDK7.

Further advantageous features, aspects and details of the invention are evident from the description, the examples and the drawings.

The pyrazolotriazine compounds according to the present invention are defined by the general formula (I)



wherein

R^1 represents $-H$ or $-CH_3$;

- 5 R^2 represents $-R^8$, $-Q-R^8$, $-R^9$, $-Q-(CH_2)_n-R^9$, $-(CH_2)_n-R^9$, $-(CH_2)_n-NH-R^8$,
 $-(CH_2)_m-NH-(CH_2)_n-R^9$, $-CO-NH-(CH_2)_n-NH_2$, $-CO-NH-(CH_2)_n-R^9$, $-CO-R^9$,
 $-SO-R^9$, $-(CH_2)_n-NR^{10}-R^8$, $-(CH_2)_m-NR^{10}-(CH_2)_n-R^9$, $-CO-NR^{10}-(CH_2)_n-R^9$,
 $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$, $-(Q)_b-(CH_2)_m-(G^1)_d-(CH_2)_e-R^8$,
 $-(Q)_b-(CH_2)_m-(G^1)_d-(CH_2)_n-R^9$, $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$,
 10 $-Q-R^{10}$, $-Q-CH(COOR^{10})-R^8$, $-Q-CH(R^{10})-R^8$, $-(CH_2)_n-OH$, $-CHO$, $-OH$;

- R^3 represents $-OH$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-I$, $-CN$, $-OR^{11}$, $-R^{11}$, $-CO-O-R^{11}$,
 $-NR^{11}-CO-OR^{12}$, $-NHR^{11}$, $-NR^{11}R^{12}$, $-CONR^{11}R^{12}$, $-O-CO-NR^{11}R^{12}$,
 $-O-CO-OR^{11}$, $-CH_3$, $-NR^{11}-CO-NR^{12}R^{13}$, $-SO_2NR^{11}R^{12}$, $-C(=NR^{11})-NR^{12}R^{13}$,
 15 $-C(R^{12})=NR^{11}$, $-N=CR^{11}R^{12}$, $-N=S(=O)R^{11}R^{12}$, $-CR^{11}R^{12}R^{13}$, $-CR^{11}=CR^{12}R^{13}$,
 $-C\equiv CR^{11}$, $-NR^{11}-C(=NR^{12})-NR^{13}R^{14}$, $-SR^{11}$, $-S(=O)R^{11}$, $-NR^{11}-S(=O)R^{12}$,
 $-O-S(=O)R^{11}$, $-SO_2-R^{11}$, $-NR^{11}-SO_2-R^{12}$, $-O-SO_2-R^{11}$, $-SO(=NR^{11})-R^{12}$,
 $-CO-R^{11}$, $-O-CO-R^{11}$, $-NR^{11}-CO-R^{12}$, $-CH_2F$, $-CHF_2$, $-CF_3$,
 3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6-
 20 membered heterocyclyl, monounsaturated 4-membered heterocyclyl,
 monounsaturated 5-membered heterocyclyl, monounsaturated 6-membered
 heterocyclyl, 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered
 carbocyclyl, 6-membered carbocyclyl, 6-membered aryl, 5-membered heteroaryl,
 6-membered heteroaryl, and

wherein all afore-mentioned ring systems can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 ;

Z^1 and Z^2 if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z^1 and Z^2 are attached;

5

R^3 together with R^4 can form a carbocyclic or heterocyclic 4-, 5-, 6- or 7-membered ring with the two carbon atoms of the benzo ring to which R^3 and R^4 are attached and that 4-, 5-, 6- or 7-membered ring can be partly saturated or unsaturated and can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 ;

10 Z^1 and Z^2 if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z^1 and Z^2 are attached;

$R^4 - R^7$ represent independently of each other -H, -F, -Cl, -CH₃;

15 R^8 represents $-(CH_2)_p-NH_2$, $-(CH_2)_p-N(R^{16}R^{17})$, carbocyclyl, heterocyclyl, spirocarbocyclyl, spiroheterocyclyl, wherein the afore-mentioned carbocyclyl, heterocyclyl, spirocarbocyclyl and spiroheterocyclyl residues are linked through a ring carbon atom and can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 ;

20 Z^5 and Z^6 if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z^5 and Z^6 are attached;

R^9 represents $-R^8$, nitrogenheterocyclyl, spironitrogencyclyl, wherein the afore-mentioned nitrogenheterocyclyl and spironitrogencyclyl residues are linked through a ring nitrogen atom and can be substituted with 1 to 3 substituents selected from Z^5 , Z^6

25 and Z^7 ;

Z^5 and Z^6 if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z^5 and Z^6 are attached;

R^{11} , R^{12} , R^{13} , R^{14} and R^{15} represent independently of each other

30 -H, linear or branched C₁-C₈-alkyl, C₃-C₈-cycloalkyl, C₁-C₉-heterocyclyl, linear or branched C₂-C₈-alkenyl, linear or branched C₂-C₈-alkynyl, C₆-C₁₄-aryl, C₁-C₁₀-heteroaryl,

wherein the afore-mentioned residues can be substituted with 1 to 5 substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} ;


35

R^{11} together with R^{12} can form a carbocyclic or heterocyclic 4-, 5- or 6-membered ring and that 4-, 5- or 6-membered ring can be saturated or unsaturated and can be substituted with 1 to 8 substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} , Z^{12} , Z^{13} , Z^{14} and Z^{15} ;

Z^8 and Z^9 if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z^8 and Z^9 are attached;

R^{10} , R^{16} and R^{17} represent independently of each other

5 $-H$, $-CH_3$, $-C_2H_5$, $-C_3H_7$, $-CH(CH_3)_2$, $-CH_2F$, $-CHF_2$, $-CF_3$,




cyclo- C_3H_5 , cyclo- C_4H_7 , cyclo- C_5H_9 , cyclo- C_6H_{11} , cyclo- C_7H_{13} ,

$-C_4H_9$, $-CH_2-CH(CH_3)_2$, $-CH(CH_3)-C_2H_5$, $-C(CH_3)_3$, $-C_5H_{11}$, $-CH(CH_3)-C_3H_7$,
 $-CH_2-CH(CH_3)-C_2H_5$, $-CH(CH_3)-CH(CH_3)_2$, $-C(CH_3)_2-C_2H_5$, $-CH_2-C(CH_3)_3$,
 $-CH(C_2H_5)_2$, $-C_2H_4-CH(CH_3)_2$, $-C_6H_{13}$, $-C_7H_{15}$, $-C_8H_{17}$, $-Ph$, $-CH_2-Ph$,
 $-CH_2-CH_2-Ph$, $-CH_2-CH=CH_2$, $-C(CH_3)=CH_2$, $-C_2H_4-CH=CH_2$,
 10 $-CH_2-CH=CH-CH_3$, $-CH_2-C(CH_3)=CH_2$, $-CH(CH_3)-CH=CH_2$, $-C(CH_3)=CH-CH_3$,
 $-CH_2-C\equiv CH$, $-C_2H_4-C\equiv CH$, $-CH_2-C\equiv C-CH_3$, $-C_2H_4-OCF_3$, $-C_3H_6-OCF_3$,
 $-C_2H_4-OCH_3$, $-C_3H_6-OCH_3$, $-C_2H_4-OC_2H_5$, $-C_3H_6-OC_2H_5$;

Q , G^1 , G^2 represent independently of each other $-O-$, $-S-$, $-NR^{15}-$, $-SO-$,
 15 $-NR^{15}-SO-$, $-SO-NR^{15}-$, $-SO_2-$, $-O-SO_2-$, $-SO_2-O-$, $-SO_2-NR^{15}-$,
 $-NR^{15}-SO_2-$, $-O-CO-$, $-O-CO-O-$, $-CO-$, $-CO-NR^{15}-$, $-NR^{15}-CO-$,
 $-NR^{15}-CO-NR^{15}-$, $-NR^{15}-CO-O-$, $-O-CO-NR^{15}-$, $-CO-O-$, $-(CH_2)_m-NR^{15}-$,
 bridging carbocyclyl-, bridging heterocyclyl-, bridging spirocarbocyclyl-, bridging
 spiroheterocyclyl-;

20 $Z^1 - Z^{15}$ represent independently of each other




cyclo- C_3H_5 , cyclo- C_4H_7 , cyclo- C_5H_9 , cyclo- C_6H_{11} , cyclo- C_7H_{13} ,

$-H$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OC_3H_7$, $-O-cyclo-C_3H_5$, $-OCH(CH_3)_2$,
 $-OC(CH_3)_3$, $-OC_4H_9$, $-OPh$, $-OCH_2-Ph$, $-OCPh_3$, $-CH_2-OCH_3$, $-C_2H_4-OCH_3$,
 $-C_3H_6-OCH_3$, $-CH_2-OC_2H_5$, $-C_2H_4-OC_2H_5$, $-C_3H_6-OC_2H_5$, $-CH_2-OC_3H_7$,
 25 $-C_2H_4-OC_3H_7$, $-C_3H_6-OC_3H_7$, $-CH_2-O-cyclo-C_3H_5$, $-C_2H_4-O-cyclo-C_3H_5$,
 $-C_3H_6-O-cyclo-C_3H_5$, $-CH_2-OCH(CH_3)_2$, $-C_2H_4-OCH(CH_3)_2$, $-C_3H_6-OCH(CH_3)_2$,
 $-CH_2-OC(CH_3)_3$, $-C_2H_4-OC(CH_3)_3$, $-C_3H_6-OC(CH_3)_3$, $-CH_2-OC_4H_9$,
 $-C_2H_4-OC_4H_9$, $-C_3H_6-OC_4H_9$, $-CH_2-OPh$, $-C_2H_4-OPh$, $-C_3H_6-OPh$,
 $-CH_2-OCH_2-Ph$, $-C_2H_4-OCH_2-Ph$, $-C_3H_6-OCH_2-Ph$, $-SH$, $-SCH_3$, $-SC_2H_5$,
 30 $-SC_3H_7$, $-S-cyclo-C_3H_5$, $-SCH(CH_3)_2$, $-SC(CH_3)_3$, $-F$, $-Cl$, $-Br$, $-I$, $-CN$,
 $-COCH_3$, $-COC_2H_5$, $-COC_3H_7$, $-CO-cyclo-C_3H_5$, $-COCH(CH_3)_2$,
 $-COC(CH_3)_3$, $-COOH$, $-COOCH_3$, $-COOC_2H_5$, $-COOC_3H_7$, $-COO-cyclo-C_3H_5$,
 $-COOCH(CH_3)_2$, $-COOC(CH_3)_3$, $-OOC-CH_3$, $-OOC-C_2H_5$, $-OOC-C_3H_7$,

- OOC-cyclo-C₃H₅, -OOC-CH(CH₃)₂, -OOC-C(CH₃)₃, -CONH₂,
 -CONHCH₃, -CONHC₂H₅, -CONHC₃H₇, -CONH-cyclo-C₃H₅,
 -CONH[CH(CH₃)₂], -CONH[C(CH₃)₃], -CON(CH₃)₂, -CON(C₂H₅)₂,
 -CON(C₃H₇)₂, -CON(cyclo-C₃H₅)₂, -CON[CH(CH₃)₂]₂, -CON[C(CH₃)₃]₂,
 5 -NHCOCH₃, -NHCOC₂H₅, -NHCOC₃H₇, -NHCO-cyclo-C₃H₅,
 -NHCO-CH(CH₃)₂, -NHCO-C(CH₃)₃, -NHCO-OCH₃, -NHCO-OC₂H₅,
 -NHCO-OC₃H₇, -NHCO-O-cyclo-C₃H₅, -NHCO-OCH(CH₃)₂, -NHCO-OC(CH₃)₃,
 -NH₂, -NHCH₃, -NHC₂H₅, -NHC₃H₇, -NH-cyclo-C₃H₅, -NHCH(CH₃)₂,
 -NHC(CH₃)₃, -N(CH₃)₂, -N(C₂H₅)₂, -N(C₃H₇)₂, -N(cyclo-C₃H₅)₂,
 10 -N[CH(CH₃)₂]₂, -N[C(CH₃)₃]₂, -SOCH₃, -SOC₂H₅, -SOC₃H₇, -SO-cyclo-C₃H₅,
 -SOCH(CH₃)₂, -SOC(CH₃)₃, -SO₂CH₃, -SO₂C₂H₅, -SO₂C₃H₇,
 -SO₂-cyclo-C₃H₅, -SO₂CH(CH₃)₂, -SO₂C(CH₃)₃, -SO₃H, -SO₃CH₃,
 -SO₃C₂H₅, -SO₃C₃H₇, -SO₃-cyclo-C₃H₅, -SO₃CH(CH₃)₂, -SO₃C(CH₃)₃,
 -SO₂NH₂, -SO₂NHCH₃, -SO₂NHC₂H₅, -SO₂NHC₃H₇, -SO₂NH-cyclo-C₃H₅,
 15 -SO₂NHCH(CH₃)₂, -SO₂NHC(CH₃)₃, -SO₂N(CH₃)₂, -SO₂N(C₂H₅)₂,
 -SO₂N(C₃H₇)₂, -SO₂N(cyclo-C₃H₅)₂, -SO₂N[CH(CH₃)₂]₂, -SO₂N[C(CH₃)₃]₂,
 -O-S(=O)CH₃, -O-S(=O)C₂H₅, -O-S(=O)C₃H₇, -O-S(=O)-cyclo-C₃H₅,
 -O-S(=O)CH(CH₃)₂, -O-S(=O)C(CH₃)₃, -S(=O)(=NH)CH₃, -S(=O)(=NH)C₂H₅,
 -S(=O)(=NH)C₃H₇, -S(=O)(=NH)-cyclo-C₃H₅, -S(=O)(=NH)CH(CH₃)₂,
 20 -S(=O)(=NH)C(CH₃)₃, -NH-SO₂-CH₃, -NH-SO₂-C₂H₅, -NH-SO₂-C₃H₇,
 -NH-SO₂-cyclo-C₃H₅, -NH-SO₂-CH(CH₃)₂, -NH-SO₂-C(CH₃)₃, -O-SO₂-CH₃,
 -O-SO₂-C₂H₅, -O-SO₂-C₃H₇, -O-SO₂-cyclo-C₃H₅, -O-SO₂-CH(CH₃)₂,
 -O-SO₂-C(CH₃)₃, -OCH₂F, -OCHF₂, -OCF₃, -CH₂-OCF₃,
 -C₂H₄-OCF₃, -C₃H₆-OCF₃, -OC₂F₅, -CH₂-OC₂F₅, -C₂H₄-OC₂F₅,
 25 -C₃H₆-OC₂F₅, -O-COOCH₃, -O-COOC₂H₅, -O-COOC₃H₇, -O-COO-cyclo-C₃H₅,
 -O-COOCH(CH₃)₂, -O-COOC(CH₃)₃, -NH-CO-NH₂, -NH-CO-NHCH₃,
 -NH-CO-NHC₂H₅, -NH-CO-NHC₃H₇, -NH-C(=NH)-NH₂, -NH-CO-N(C₃H₇)₂,
 -NH-CO-NH[CH(CH₃)₂], -NH-CO-NH[C(CH₃)₃], -NH-CO-N(CH₃)₂,
 -NH-CO-N(C₂H₅)₂, -NH-CO-NH-cyclo-C₃H₅, -NH-CO-N(cyclo-C₃H₅)₂,
 30 -NH-CO-N[CH(CH₃)₂]₂, -NH-C(=NH)-NHCH₃, -NH-C(=NH)-NHC₂H₅,
 -NH-C(=NH)-NHC₃H₇, -O-CO-NH-cyclo-C₃H₅, -NH-C(=NH)-NH-cyclo-C₃H₅,
 -NH-C(=NH)-NH[CH(CH₃)₂], -O-CO-NH[CH(CH₃)₂], -NH-C(=NH)-NH[C(CH₃)₃],
 -NH-C(=NH)-N(CH₃)₂, -NH-C(=NH)-N(C₂H₅)₂, -NH-C(=NH)-N(C₃H₇)₂,
 -NH-C(=NH)-N(cyclo-C₃H₅)₂, -O-CO-NHC₃H₇, -NH-C(=NH)-N[CH(CH₃)₂]₂,
 35 -NH-C(=NH)-N[C(CH₃)₃]₂, -O-CO-NH₂, -O-CO-NHCH₃, -O-CO-NHC₂H₅,
 -O-CO-NH[C(CH₃)₃], -O-CO-N(CH₃)₂, -O-CO-N(C₂H₅)₂, -O-CO-N(C₃H₇)₂,
 -O-CO-N(cyclo-C₃H₅)₂, -O-CO-N[CH(CH₃)₂]₂, -O-CO-N[C(CH₃)₃]₂, -O-CO-OCH₃,
 -O-CO-OC₂H₅, -O-CO-OC₃H₇, -O-CO-O-cyclo-C₃H₅, -O-CO-OCH(CH₃)₂,

- $-\text{O}-\text{CO}-\text{OC}(\text{CH}_3)_3$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{CH}_2-\text{CH}_2\text{F}$, $-\text{CH}_2-\text{CHF}_2$,
 $-\text{CH}_2-\text{CF}_3$, $\text{cyclo-C}_8\text{H}_{15}$, $-\text{Ph}$, $-\text{CH}_2-\text{Ph}$, $-\text{CH}_2-\text{CH}_2-\text{Ph}$, $-\text{CH}=\text{CH}-\text{Ph}$,
 $-\text{CPh}_3$, $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{C}_4\text{H}_9$, $-\text{CH}_2-\text{CH}(\text{CH}_3)_2$,
 $-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)_3$, $-\text{C}_5\text{H}_{11}$, $-\text{CH}(\text{CH}_3)-\text{C}_3\text{H}_7$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$,
5 $-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{C}(\text{CH}_3)_3$, $-\text{CH}(\text{C}_2\text{H}_5)_2$,
 $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)_2$, $-\text{C}_6\text{H}_{13}$, $-\text{C}_7\text{H}_{15}$, $-\text{C}_8\text{H}_{17}$, $-\text{C}_3\text{H}_6-\text{CH}(\text{CH}_3)_2$, $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$,
 $-\text{CH}(\text{CH}_3)-\text{C}_4\text{H}_9$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{CH}(\text{CH}_3)_2$,
 $-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$,
 $-\text{C}(\text{CH}_3)_2-\text{C}_3\text{H}_7$, $-\text{C}(\text{CH}_3)_2-\text{CH}(\text{CH}_3)_2$, $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)_3$, $-\text{CH}(\text{CH}_3)-\text{C}(\text{CH}_3)_3$,
10 $-\text{CH}=\text{CH}_2$, $-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}_2$,
 $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{CH}=\text{CH}-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}$,
 $-\text{CH}=\text{C}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_3$, $-\text{CH}=\text{CH}-\text{CH}=\text{CH}_2$, $-\text{C}_3\text{H}_6-\text{CH}=\text{CH}_2$,
 $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{CH}_2-\text{CH}=\text{CH}-\text{C}_2\text{H}_5$, $-\text{CH}=\text{CH}-\text{C}_3\text{H}_7$,
 $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}_2$,
15 $-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)_2$, $-\text{CH}_2-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_3$,
 $-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{CH}=\text{CH}-\text{CH}(\text{CH}_3)_2$, $-\text{CH}=\text{C}(\text{CH}_3)-\text{C}_2\text{H}_5$,
 $-\text{C}(\text{CH}_3)=\text{CH}-\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)=\text{C}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2-\text{CH}=\text{CH}_2$,
 $-\text{CH}(\text{CH}_3)-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{C}_4\text{H}_8-\text{CH}=\text{CH}_2$, $-\text{C}_3\text{H}_6-\text{CH}=\text{CH}-\text{CH}_3$,
 $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{CH}=\text{CH}-\text{C}_3\text{H}_7$, $-\text{CH}=\text{CH}-\text{C}_4\text{H}_9$, $-\text{C}_3\text{H}_6-\text{C}(\text{CH}_3)=\text{CH}_2$,
20 $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}_2$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{CH}=\text{C}(\text{CH}_3)_2$,
 $-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_4-\text{CH}=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_3$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}-\text{CH}_3$,
 $-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}(\text{CH}_3)_2$,
 $-\text{CH}_2-\text{CH}=\text{C}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{C}(\text{CH}_3)=\text{CH}-\text{C}_2\text{H}_5$, $-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}-\text{C}_2\text{H}_5$,
 $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}(\text{CH}_3)_2$, $-\text{CH}=\text{CH}-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{CH}=\text{C}(\text{CH}_3)-\text{C}_3\text{H}_7$,
25 $-\text{C}(\text{CH}_3)=\text{CH}-\text{C}_3\text{H}_7$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{C}[\text{C}(\text{CH}_3)_3]=\text{CH}_2$,
 $-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}_2$,
 $-\text{CH}=\text{CH}-\text{C}_2\text{H}_4-\text{CH}=\text{CH}_2$, $-\text{C}(\text{CH}_3)_2-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{CH}_2-\text{C}(\text{CH}_3)=\text{C}(\text{CH}_3)_2$,
 $-\text{CH}(\text{CH}_3)-\text{CH}=\text{C}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_3$,
 $-\text{CH}(\text{CH}_3)-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_3$, $-\text{CH}=\text{C}(\text{CH}_3)-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}(\text{CH}_3)_2$,
30 $-\text{C}(\text{CH}_3)=\text{C}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{CH}=\text{CH}-\text{C}(\text{CH}_3)_3$, $-\text{C}(\text{CH}_3)_2-\text{C}(\text{CH}_3)=\text{CH}_2$,
 $-\text{CH}(\text{C}_2\text{H}_5)-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{C}(\text{CH}_3)(\text{C}_2\text{H}_5)-\text{CH}=\text{CH}_2$, $-\text{CH}(\text{CH}_3)-\text{C}(\text{C}_2\text{H}_5)=\text{CH}_2$,
 $-\text{CH}_2-\text{C}(\text{C}_3\text{H}_7)=\text{CH}_2$, $-\text{CH}_2-\text{C}(\text{C}_2\text{H}_5)=\text{CH}-\text{CH}_3$, $-\text{CH}(\text{C}_2\text{H}_5)-\text{CH}=\text{CH}-\text{CH}_3$,
 $-\text{C}(\text{C}_4\text{H}_9)=\text{CH}_2$, $-\text{C}(\text{C}_3\text{H}_7)=\text{CH}-\text{CH}_3$, $-\text{C}(\text{C}_2\text{H}_5)=\text{CH}-\text{C}_2\text{H}_5$, $-\text{C}(\text{C}_2\text{H}_5)=\text{C}(\text{CH}_3)_2$,
 $-\text{C}[\text{CH}(\text{CH}_3)(\text{C}_2\text{H}_5)]=\text{CH}_2$, $-\text{C}[\text{CH}_2-\text{CH}(\text{CH}_3)_2]=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{CH}=\text{CH}_2$,
35 $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{C}_3\text{H}_6-\text{C}\equiv\text{C}-\text{CH}_3$, $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{CH}_3$,
 $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{C}_2\text{H}_5$, $-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{C}\equiv\text{CH}$, $-\text{CH}(\text{CH}_3)-\text{C}\equiv\text{C}-\text{CH}_3$,
 $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{C}\equiv\text{CH}$, $-\text{CH}=\text{CH}-\text{CH}=\text{C}(\text{CH}_3)_2$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{C}\equiv\text{CH}$,
 $-\text{CH}=\text{CH}-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_3$, $-\text{CH}=\text{C}(\text{CH}_3)-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}\equiv\text{CH}$,



a, c, e, g are independently of each other selected from 0, 1, 2, 3

15 b, d, f are independently of each other 0 or 1

n is an integer selected from 1, 2, 3, 4, 5, 6, 7 or 8,

m is an integer selected from 0, 1, 2, 3, 4, 5 or 6,

p is an integer selected from 1, 2, 3, 4, 5, 6, 7 or 8

20 and enantiomers, stereoisomeric forms, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, solvates, acid salt forms, tautomers, and racemates of the above mentioned compounds and pharmaceutically acceptable salts thereof.

Prodrugs of the compounds related to formula (I) are also within the scope of this
25 invention. These derivatives may have little or no pharmacological activity themselves. The term "prodrug" as used herein describes a precursor of the active ingredient according to general formula (I), wherein said precursor comprises groups which can be cleaved under physiological conditions so that the active agent of formula (I) is formed. Information on the use of prodrugs may be found for example in "Pro-drugs as
30 Novel Drug Delivery Systems" by T. Higuchi and W. Stella, ACS Symposium Series Vol. 14, 1975(ISBN13: 9780841202917).

A person skilled in the art can synthesize prodrugs for example by replacing a functional group in the compounds according to formula (I) with certain moieties. Examples for prodrugs of a compound according to formula (I) containing a primary or
35 secondary amino functionality include but are not limited to moieties like amides, carbamates or alkyl derivatives thereof. More information on the use of prodrugs for amines may be found for example in *Molecules* 2008, 13, 519-547 (A.L. Simplicio et

al.) or "Prodrugs of Amines" by J.P. Krise and R. Oliyai (Biotechnology: Pharmaceutical Aspects, 2007, Volume V, Part III, 801-831).

The expression tautomer is defined as an organic compound that is interconvertible by a chemical reaction called tautomerization. Tautomerization can be catalyzed preferably by bases or acids or other suitable compounds.

Preferred are compounds of general formula (I), wherein

R^3 represents $-OH$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-I$, $-CN$, $-OR^{11}$, $-CO-O-R^{11}$, $-NR^{11}-CO-OR^{12}$, $-NHR^{11}$, $-NR^{11}R^{12}$, $-CONR^{11}R^{12}$, $-O-CO-NR^{11}R^{12}$, $-O-CO-OR^{11}$, $-CH_3$, $-NR^{11}-CO-NR^{12}R^{13}$, $-SO_2NR^{11}R^{12}$, $-C(=NR^{11})-NR^{12}R^{13}$, $-C(R^{12})=NR^{11}$, $-N=CR^{11}R^{12}$, $-N=S(=O)R^{11}R^{12}$, $-CR^{11}R^{12}R^{13}$, $-CR^{11}=CR^{12}R^{13}$, $-C\equiv CR^{11}$, $-NR^{11}-C(=NR^{12})-NR^{13}R^{14}$, $-SR^{11}$, $-S(=O)R^{11}$, $-NR^{11}-S(=O)R^{12}$, $-O-S(=O)R^{11}$, $-SO_2-R^{11}$, $-NR^{11}-SO_2-R^{12}$, $-O-SO_2-R^{11}$, $-SO(=NR^{11})-R^{12}$, $-CO-R^{11}$, $-O-CO-R^{11}$, $-NR^{11}-CO-R^{12}$, $-CH_2F$, $-CHF_2$, $-CF_3$, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, imidazolyl, furyl, dihydrofuryl, tetrahydrofuryl, thienyl, dihydrothienyl, tetrahydrothienyl, 1,3-oxazolyl, dihydro-1,3-oxazolyl, 1,3-oxazolidinyl, isoxazolyl, dihydro-isoxazolyl, isoxazolidinyl, pyrrolyl, dihydropyrrolyl, pyrrolidinyl, imidazolyl, dihydroimidazolyl, imidazolidinyl, triazolyl, dihydrotriazolyl, triazolidinyl, pyrazolyl, dihydropyrazolyl, pyrazolidinyl, oxadiazolyl, dihydrooxadiazolyl, oxadiazolidinyl, thiadiazolyl, dihydrothiadiazolyl, thiadiazolidinyl, 1,3-thiazolyl, dihydro-1,3-thiazolyl, 1,3-thiazolidinyl, isothiazolyl, dihydroisothiazolyl, isothiazolidinyl, tetrazolyl, dihydrotetrazolyl, tetrazolidinyl, aziridinyl, azirenyl, oxiranyl, thiranyl, azetidyl, oxetanyl, thietanyl, cyclopentanonyl, cyclohexanonyl, pyrrolidinonyl, pyrrolidindionyl, piperidinonyl, piperidindionyl, 1-oxid-thiopyranyl, 1,1-dioxid-thiopyranyl, dihydro-1-oxid-thiopyranyl, dihydro-1,1-dioxid-thiopyranyl, tetrahydro-1-oxid-thiopyranyl, tetrahydro-1,1-dioxid-thiopyranyl, morpholinyl, thiomorpholinyl, 1,2-dioxanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,2-dioxolanyl, 1,3-dioxolanyl, 1,4-dioxolanyl, piperazinyl, 2-oxo-azetidyl, 2-oxo-pyrrolidinyl, 2-oxo-piperidinyl, 2-oxo-oxazolidinyl, 2-oxo-imidazolidinyl, 2-oxo-1,3-oxazinanyl, or 2-oxo-tetrahydropyrimidinyl, wherein the aforementioned ring systems can be substituted with one to four substituents selected from Z^1 , Z^2 , Z^3 and Z^4 ;

R^8 represents 4-membered heterocyclyl, 5-membered heterocyclyl, 6-membered heterocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, 6-membered carbocyclyl, azaspiro[3,3]heptyl, azaspiro[3,4]octyl, azaspiro[3,5]nonyl, azaspiro[3,6]decyl, azaspiro[4,4]nonyl, azaspiro[4,5]decyl, azaspiro[4,6]undecyl, azaspiro[5,5]undecyl, azaspiro[5,6]dodecyl, azaspiro[6,6]tridecyl,

diazaspiro[3,3]heptyl, diazaspiro[3,4]octyl, diazaspiro[3,5]nonyl, diazaspiro[3,6]decyl, diazaspiro[4,4]nonyl, diazaspiro[4,5]decyl, diazaspiro[4,6]undecyl, diazaspiro[5,5]undecyl, diazaspiro[5,6]dodecyl, diazaspiro[6,6]tridecyl, triazaspiro[3,5]nonyl, triazaspiro[3,6]decyl, triazaspiro[4,5]decyl, triazaspiro[4,6]undecyl, triazaspiro[5,5]undecyl, triazaspiro[5,6]dodecyl, triazaspiro[6,6]tridecyl, oxazaspiro[3,3]heptyl, oxazaspiro[3,4]octyl, oxazaspiro[3,5]nonyl, oxazaspiro[3,6]decyl, oxazaspiro[4,4]nonyl, oxazaspiro[4,5]decyl, oxazaspiro[4,6]undecyl, oxazaspiro[5,5]undecyl, oxazaspiro[5,6]dodecyl, oxazaspiro[6,6]tridecyl, oxadiazaspiro[3,5]nonyl, oxadiazaspiro[3,6]decyl, oxadiazaspiro[4,5]decyl, oxadiazaspiro[4,6]undecyl, oxadiazaspiro[5,5]undecyl, oxadiazaspiro[5,6]dodecyl, or oxadiazaspiro[6,6]tridecyl, wherein the afore-mentioned carbocyclyl, heterocyclyl, azaspiro, diazaspiro, triazaspiro, oxazaspiro, oxadiazaspiro residues are linked through a ring carbon atom and wherein the afore-mentioned carbocyclyl, heterocyclyl, azaspiro, diazaspiro, triazaspiro, oxazaspiro, oxadiazaspiro residues are substituted with one to three substituents selected from Z^5 , Z^6 and Z^7 ;

Z^5 and Z^6 if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z^5 and Z^6 are attached;

R^9 represents 4-membered nitrogenheterocyclyl, 5-membered nitrogenheterocyclyl, 6-membered nitrogenheterocyclyl, 5-membered dinitrogenheterocyclyl, 6-membered dinitrogenheterocyclyl, spiro[2,3]heterohexyl, spiro[2,4]heteroheptyl, spiro[2,5]heterooctyl, spiro[2,7]heterononyl, spiro[3,3]heteroheptyl, spiro[3,4]heterooctyl, spiro[3,5]heterononyl, spiro[3,6]heterodecyl, spiro[4,4]heterononyl, spiro[4,5]heterodecyl, spiro[4,6]heteroundecyl, spiro[5,5]heteroundecyl, spiro[5,6]heterododecyl, or spiro[6,6]heterotridecyl, wherein the afore-mentioned nitrogenheterocyclyl, dinitrogenheterocyclyl and spiro residues are linked through the or a ring nitrogen atom and wherein the afore-mentioned nitrogenheterocyclyl, dinitrogenheterocyclyl and spiro residues are substituted with one to three substituents selected from Z^5 , Z^6 and Z^7 ;

Z^5 and Z^6 if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z^5 and Z^6 are attached; and

the residues R^1 , R^2 , $R^4 - R^7$, $R^{10} - R^{17}$, a, b, c, d, e, f, g, m, n, p, Q, G^1 , G^2 and $Z^1 - Z^{15}$ have the meanings as defined herein.

Further preferred compounds of general formula (I) are these compounds, wherein

R^2 represents $-R^8$, $-Q-R^8$, $-R^9$, $-Q-(CH_2)_n-R^8$, $-Q-(CH_2)_n-R^9$, $-(CH_2)_n-R^9$,
 $-(CH_2)_n-NH-R^8$, $-(CH_2)_m-NH-(CH_2)_n-R^9$, $-CO-NH-(CH_2)_n-NH_2$,
 $-CO-NH-(CH_2)_n-R^9$, $-CO-NR^{10}-(CH_2)_n-R^9$, $-CO-R^9$, $-SO-R^9$, $-Q-R^{10}$,
 $-(CH_2)_n-NR^{10}-R^8$, $-(CH_2)_m-NR^{10}-(CH_2)_n-R^9$, $-(Q)_b-(CH_2)_m-(G^1)_d-(CH_2)_e-R^8$,
 5 $-(Q)_b-(CH_2)_m-(G^1)_d-(CH_2)_n-R^9$, $-Q-CH(COOR^{10})-R^8$, or $-Q-CH(R^{10})-R^8$,

Q , represents $-O-$, $-S-$, $-NR^{15}-$, $-SO-$, $-SO_2-$, $-(CH_2)_m-NR^{15}-$, bridging carbocyclyl, bridging heterocyclyl, bridging spirocarbocyclyl, or bridging spiroheterocyclyl;

10

$R^4 - R^7$ represent independently of each other $-H$ or $-F$; and

the residues R^1 , R^3 , $R^8 - R^{17}$, a , b , c , d , e , f , g , m , n , p , G^1 , G^2 and $Z^1 - Z^{15}$ have the meanings as defined herein.

15

It was surprisingly found that the substituent R^3 being a residue different from hydrogen is essential in order to obtain the desired activity and selectivity of the compounds of general formula (I). Consequently, the possibility that R^3 is hydrogen is excluded from the scope of the present invention. The other substituents $R^4 - R^7$ can be hydrogen or
 20 any other of the substituents defined herein for these groups. Further, R^1 is limited to hydrogen or methyl in order to best obtain the surprising effects of the compounds of the present invention.

Moreover, it is particularly advantageous if R^1 represents hydrogen.

25

R^2 represents preferably a moiety containing a group able to form hydrogen bridges such as $-NH_2$, or a secondary or tertiary amino group [such as $-NH-(\text{carbon linked substituent})$, $-N(\text{carbon linked substituent1})(\text{carbon linked substituent2})$, $-NH-(\text{sulfur linked substituent})$ or $-N(\text{sulfur linked substituent1})(\text{carbon linked substituent2})$],
 30 wherein the carbon or sulfur linked substituents are the C_1-C_8 -alkylamines, carbocyclyl, heterocyclyl, nitrogenheterocyclyl, spirocarbocyclyl, spiroheterocyclyl, C_1-C_8 -alkyl, C_3-C_8 -cycloalkyl, C_1-C_8 -fluoroalkyl, C_6-C_{14} -aryl, C_7-C_{20} -alkylaryl, C_8-C_{20} -alkenylaryl, C_2-C_8 -alkenyl, C_2-C_8 -alkynyl, C_2-C_8 -alkoxyalkyl, $CO-C_1-C_8$ -alkyl, $SO_2-C_1-C_8$ -alkyl, $SO-C_1-C_8$ -alkyl and C_2-C_8 -fluoroalkoxyalkyl residues as
 35 defined herein for the substituents R^8 , R^9 , R^{10} and R^{15} . Further, the group which is able to form hydrogen bridges is preferably linked through a linker to the pyrazolo[1,5-a][1,3,5]triazine ring system. Furthermore, the group which is able to form hydrogen bridges can also be part of a cyclic ring preferably a nitrogen heterocyclic ring

(=nitrogenheterocyclyl) such as the nitrogen in piperidinyl, piperazinyl, hexahydropyrimidinyl, morpholinyl, hexahydropyridazinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, 1,3-oxazolidinyl, isoxazolidinyl or can be part of a spiro residue preferably a nitrogen spiro residue (=spironitrogencyclyl) such as the nitrogen in azaspiro, diazaspiro, triazaspiro, oxazaspiro or oxadiazaspiro residues. Also, the group which is able to form hydrogen bridges, especially in case it is an amino group is further preferably attached to a carbocyclic or heterocyclic ring. Examples for such residues are aminocyclohexyl, aminocyclopentyl, aminocyclobutyl, aminopiperidinyl, or an amino spiro residue, amino azaspiro residue, amino diazaspiro residue, amino triazaspiro residue, amino oxazaspiro residue or amino oxadiazaspiro residue.

Thus, it is preferred that R^2 represents $-Q-R^8$, $-R^9$, $-Q-(CH_2)_n-R^9$, $-(CH_2)_n-R^9$, $-(CH_2)_n-NH-R^8$, $-(CH_2)_n-NH-(CH_2)_m-R^9$, $-CO-NH-R^8$, $-CO-R^9$, $-(CH_2)_n-NR^{15}-R^8$, $-(CH_2)_n-NR^{15}-(CH_2)_m-R^9$, $-CO-NR^{15}-R^8$, $-CO-NR^{15}-(CH_2)_n-N(R^{16})(R^{17})$, or $-CO-NR^{15}-(CH_2)_n-R^9$, and it is more preferred that R^2 represents $-Q-R^8$, $-R^9$, $-Q-(CH_2)_n-R^9$, $-(CH_2)_n-R^9$, $-(CH_2)_n-NH-R^8$, $-(CH_2)_n-NH-(CH_2)_m-R^9$, $-CO-NH-R^8$, $-CO-R^9$, $-(CH_2)_n-NR^{15}-R^8$, or $-(CH_2)_n-NR^{15}-(CH_2)_m-R^9$, and it is most preferred that R^2 represents $-Q-R^8$, $-R^9$, $-Q-(CH_2)_n-R^9$, $-(CH_2)_n-R^9$, $-(CH_2)_n-NH-R^8$, $-(CH_2)_n-NH-(CH_2)_m-R^9$, or $-CO-NH-R^8$, wherein

n is an integer selected from 1, 2, 3, 4, 5, 6, 7 or 8,

m is an integer selected from 0, 1, 2, 3, 4, 5 or 6.


Q represents preferably $-O-$, $-S-$, $-NR^{15}-$, $-SO-$, $-NR^{15}-SO-$, $-SO-NR^{15}-$, $-SO_2-$, $-O-SO_2-$, $-SO_2-O-$, $-SO_2-NR^{15}-$, $-NR^{15}-SO_2-$, $-O-CO-$, $-O-CO-O-$, $-CO-$, $-CO-NR^{15}-$, $-NR^{15}-CO-$, $-NR^{15}-CO-NR^{15}-$, $-NR^{15}-CO-O-$, $-O-CO-NR^{15}-$, $-CO-O-$, $-(CH_2)_m-NR^{15}-$, bridging carbocyclyl, bridging heterocyclyl, bridging spirocarbocyclyl, bridging spiroheterocyclyl;

n is an integer selected from 1, 2, 3, 4, 5, 6, 7 or 8,

m is an integer selected from 0, 1, 2, 3, 4, 5 or 6,

More preferably, **Q** represents $-O-$, $-S-$, $-NR^{15}-$, $-SO-$, $-SO_2-$, $-O-CO-$, $-CO-$, $-CO-NR^{15}-$, $-NR^{15}-CO-$, $-CO-O-$, $-(CH_2)_m-NR^{15}-$, and even more preferably **Q** represents $-O-$, $-S-$, $-NR^{15}-$, $-SO-$, $-SO_2-$, $-(CH_2)_m-NR^{15}-$, and most preferably **Q** represents $-O-$, $-NH-$, $-SO-$, $-CO-NR^{15}-$ or $-(CH_2)_m-NR^{15}-$.

The substituent $-Q-R^{10}$ represents preferably $-S-R^{10}$. More preferably $-R^{10}$ in $-S-R^{10}$ is selected from $-CH_3$, $-C_2H_5$, $-C_3H_7$, $-CH(CH_3)_2$, $-CH_2F$, $-CHF_2$, $-CF_3$,



cyclo-C₃H₅, cyclo-C₄H₇, cyclo-C₅H₉, cyclo-C₆H₁₁, cyclo-C₇H₁₃,

-C₄H₉, -CH₂-CH(CH₃)₂, -CH(CH₃)-C₂H₅, -C(CH₃)₃, -C₅H₁₁, -CH(CH₃)-C₃H₇,
 -CH₂-CH(CH₃)-C₂H₅, -CH(CH₃)-CH(CH₃)₂, -C(CH₃)₂-C₂H₅, -CH₂-C(CH₃)₃,
 -CH(C₂H₅)₂, -C₂H₄-CH(CH₃)₂, -C₆H₁₃, -Ph, -CH₂-Ph, -CH₂-CH₂-Ph,
 -CH₂-CH=CH₂, -C(CH₃)=CH₂, -C₂H₄-CH=CH₂, or -CH₂-CH=CH-CH₃.

5


In one embodiment of the compounds of the present invention **R**² represents a linking moiety -(CH₂)_a-(Q)_b-(CH₂)_c-(G¹)_d-(CH₂)_e-(G²)_f-(CH₂)_g-R⁸ or -(CH₂)_a-(Q)_b-(CH₂)_c-(G¹)_d-(CH₂)_e-(G²)_f-CH₂-R⁹, with R⁸ and R⁹ as defined herein and **Q** is defined as discloses herein and **G**¹ and **G**² represent independently of each other:


10

bifunctional carbocyclic or heterocyclic 4-, 5-, 6- or 7-membered ring, wherein the term "bifunctional" refers to the fact that this ring is within the chain or carbon chain and consequently is linked through two ring atoms and is thus a "diyl" residue. Preferred residues for **Q**, **G**¹ and/or **G**² and especially for **G**¹ and/or **G**² are:

15

piperidindiyl, piperazindiyl, pyrimidindiyl, morpholindiyl, pyrrolidindiyl, pyrazolidinyl, and even more preferably at least G¹ or G² represents independently one of the following linking structures, wherein the lines are not methyl groups and indicate the linking bonds:





a, c, e, g are independently of each other selected from 0, 1, 2, 3

b, d, f are independently of each other 0 or 1

n is an integer selected from 1, 2, 3, 4, 5, 6, 7 or 8,

m is an integer selected from 0, 1, 2, 3, 4, 5 or 6,

5 p is an integer selected from 1, 2, 3, 4, 5, 6, 7 or 8;

R^3 represents $-OH$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-I$, $-CN$, $-OR^{11}$, $-CO-O-R^{11}$,
 $-NR^{11}-CO-OR^{12}$, $-NHR^{11}$, $-NR^{11}R^{12}$, $-CONR^{11}R^{12}$, $-O-CO-NR^{11}R^{12}$,
 $-O-CO-OR^{11}$, $-NR^{11}-CO-NR^{12}R^{13}$, $-SO_2NR^{11}R^{12}$, $-C(=NR^{11})-NR^{12}R^{13}$,
 10 $-C(R^{12})=NR^{11}$, $-N=CR^{11}R^{12}$, $-CR^{11}R^{12}R^{13}$, $-CR^{11}=CR^{12}R^{13}$, $-C\equiv CR^{11}$,
 $-NR^{11}-C(=NR^{12})-NR^{13}R^{14}$, $-SR^{11}$, $-S(=O)R^{11}$, $-N=S(=O)R^{11}R^{12}$, $-NR^{11}-S(=O)R^{12}$,
 $-O-S(=O)R^{11}$, $-SO_2-R^{11}$, $-NR^{11}-SO_2-R^{12}$, $-O-SO_2-R^{11}$,
 $-SO(=NR^{11})-R^{12}$, $-CO-R^{11}$, $-O-CO-R^{11}$, $-NR^{11}-CO-R^{12}$,

3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6-
 15 membered heterocyclyl, monounsaturated 4-membered heterocyclyl,
 monounsaturated 5-membered heterocyclyl, monounsaturated 6-membered
 heterocyclyl, 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered
 carbocyclyl, 6-membered carbocyclyl, 6-membered aryl, 5-membered heteroaryl,
 6-membered heteroaryl,

20 and

wherein all afore-mentioned ring systems can be substituted with 1 to 4 substituents
 selected from Z^1 , Z^2 , Z^3 and Z^4 , wherein Z^1 and Z^2 if attached to the same carbon atom
 can together represent $=O$ to form a carbonyl group with the carbon atom to which Z^1 and
 Z^2 are attached. That means, the afore-mentioned ring systems can comprise a
 25 carbonyl group in the ring system, namely where Z^1 and Z^2 are attached to the same ring
 carbon atom and form together an oxygen ($=O$) in addition to two further substituents Z^3
 and Z^4 which are not defined as a carbonyl group together. The same definition applies
 where Z^5 and Z^6 or where Z^8 and Z^9 can form together a carbonyl group.


30 Preferably the residue R^3 represents independently of each other $-OR^{11}$, $-F$, $-Cl$,
 pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, imidazolyl, furyl, dihydrofuryl,
 tetrahydrofuryl, thienyl, dihydrothienyl, tetrahydrothienyl, 1,3-oxazolyl, dihydro-1,3-
 oxazolyl, 1,3-oxazolidinyl, isoxazolyl, dihydro-isoxazolyl, isoxazolidinyl, pyrrolyl,

dihydropyrrolyl, pyrrolidinyl, imidazolyl, dihydroimidazolyl, imidazolidinyl, triazolyl,
 dihydrotriazolyl, triazolidinyl, pyrazolyl, dihydropyrazolyl, pyrazolidinyl, oxadiazolyl,
 dihydrooxadiazolyl, oxadiazolidinyl, thiadiazolyl, dihydrothiadiazolyl, thiadiazolidinyl,
 1,3-thiazolyl, dihydro-1,3-thiazolyl, 1,3-thiazolidinyl, isothiazolyl, dihydroisothiazolyl,
 5 isothiazolidinyl, tetrazolyl, dihydrotetrazolyl, tetrazolidinyl, aziridinyl, azirenyl, oxiranyl,
 thiiranyl, azetidiny, oxetanyl, thietanyl, cyclopentanonyl, cyclohexanonyl,
 pyrrolidinonyl, pyrrolidindionyl, piperidinonyl, piperidinyl, 1-oxid-thiopyranyl, 1,1-dioxid-
 thiopyranyl, dihydro-1-oxid-thiopyranyl, dihydro-1,1-dioxid-thiopyranyl, tetrahydro-1-oxid-
 thiopyranyl, tetrahydro-1,1-dioxid-thiopyranyl, morpholinyl, thiomorpholinyl, 1,2-
 10 dioxanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,2-dioxolanyl, 1,3-dioxolanyl, 1,4-dioxolanyl,
 piperaziny, 2-oxo-azetidiny, 2-oxo-pyrrolidinyl, 2-oxo-piperidinyl, 2-oxo-oxazolidinyl, 2-
 oxo-imidazolidinyl, 2-oxo-1,3-oxazinanyl, 2-oxo-tetrahydropyrimidinyl, wherein the afore-
 mentioned ring systems can be substituted with one to four substituents selected from Z^1 ,
 Z^2 , Z^3 and Z^4 . More preferably the afore-mentioned ring systems can be substituted with
 15 one to three substituents selected from Z^1 , Z^2 and Z^3 and most preferably the afore-
 mentioned ring systems can be substituted with one or two substituents selected from Z^1
 and Z^2 .

OR¹¹ is preferably selected from $-OCH_3$, $-OC_2H_5$, and, $-OCF_3$,

20

Further preferred substituents R^3 are the following nitrogen heteroaromatic residues:





Further, it is also possible that the substituents R^{11} and R^{12} are not single substituent
 25 and that R^{11} together with R^{12} can form a carbocyclic or heterocyclic ring, preferably 4-,

5- or 6-membered ring, more preferably a 5- or 6-membered heterocyclic ring, and that 4-, 5- or 6-membered ring can be saturated or unsaturated and can be substituted with 1 to 8 substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} , Z^{12} , Z^{13} , Z^{14} and Z^{15} , wherein Z^8 and Z^9 if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z^8 and Z^9 are attached. That means, the aforementioned ring systems can comprise a carbonyl group in the ring system, namely where Z^8 and Z^9 are attached to the same ring carbon atom and form together an oxygen (=O) in addition to six further substituents Z^{10} , Z^{11} , Z^{12} , Z^{13} , Z^{14} and Z^{15} which are not defined as a carbonyl group together.


Specifically in one preferred embodiment, wherein the substituents R^{11} and R^{12} are attached to different atoms and R^3 represents one of the residues $-C(R^{12})=NR^{11}$, $-CR^{11}=CR^{12}R^{13}$, $-NR^{11}-S(=O)R^{12}$, $-NR^{11}-SO_2-R^{12}$, $-SO(=NR^{11})-R^{12}$, or $-NR^{11}-CO-R^{12}$

the substituents R^{11} and R^{12} can be joined together and represent one of the following ring fragments:





Also in another preferred embodiment, wherein the substituents $\mathbf{R}^{11}$ and $\mathbf{R}^{12}$ are attached to different atoms and $\mathbf{R}^3$ represents one of the substituents $\text{--NR}^{11}\text{--CO--OR}^{12}$, $\text{--NR}^{11}\text{--CO--NR}^{12}\mathbf{R}^{13}$, $\text{--C(=NR}^{11}\text{)--NR}^{12}\mathbf{R}^{13}$ or $\text{--NR}^{11}\text{--C(=NR}^{12}\text{)--NR}^{13}\mathbf{R}^{14}$, $\mathbf{R}^{11}$ and $\mathbf{R}^{12}$ can be joined together and represent one of the following ring fragments:




$-\text{NR}^{14}-\text{CZ}^9\text{Z}^{10}-$, $-\text{CZ}^8\text{Z}^9-\text{NR}^{14}-$, $-\text{N}=\text{CZ}^8-$, $-\text{N}=\text{CZ}^8-$, $-\text{NR}^{14}-\text{CO}-\text{NR}^{14}-$,
 $-\text{O}-\text{CO}-\text{NR}^{14}-$, $-\text{NR}^{14}-\text{CO}-\text{O}-$, or $-\text{NH}-\text{C}(=\text{NR}^{14})-\text{NR}^{14}-$.

Specifically in one preferred embodiment, wherein the substituents R^{11} and R^{12} are
 5 attached to the same atom, in that R^3 represents one of the residues $-\text{NR}^{11}\text{R}^{12}$,
 $-\text{CONR}^{11}\text{R}^{12}$, $-\text{O}-\text{CO}-\text{NR}^{11}\text{R}^{12}$, $-\text{SO}_2\text{NR}^{11}\text{R}^{12}$, $-\text{N}=\text{CR}^{11}\text{R}^{12}$, $-\text{N}=\text{S}(=\text{O})\text{R}^{11}\text{R}^{12}$,
 $-\text{CR}^{11}\text{R}^{12}\text{R}^{13}$, the substituents R^{11} and R^{12} can be joined together and represent one of
 the following ring fragments:

10 $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CZ}^{12}\text{Z}^{13}-$, $-\text{CZ}^8=\text{CZ}^9-\text{CZ}^{10}=\text{CZ}^{11}-$, $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CZ}^{12}\text{Z}^{13}-\text{CZ}^{14}\text{Z}^{15}-$,
 $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}=\text{CZ}^{11}-$, $-\text{CZ}^8=\text{CZ}^9-\text{CZ}^{10}\text{Z}^{11}-$, $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CZ}^{12}=\text{CZ}^{13}-$,
 $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}=\text{CZ}^{11}-\text{CZ}^{12}\text{Z}^{13}-$, $-\text{CZ}^8=\text{CZ}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CZ}^{12}\text{Z}^{13}-$, $-\text{CZ}^8\text{Z}^9-\text{O}-\text{CZ}^{10}\text{Z}^{11}-$,
 $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{O}-\text{CZ}^{12}\text{Z}^{13}-$, $-\text{CZ}^8\text{Z}^9-\text{O}-\text{CZ}^{10}\text{Z}^{11}-\text{CZ}^{12}\text{Z}^{13}-$, $-\text{CZ}^8=\text{CZ}^9-\text{O}-\text{CZ}^{10}\text{Z}^{11}-$,
 $-\text{CZ}^8\text{Z}^9-\text{O}-\text{CZ}^{10}=\text{CZ}^{11}-$, $-\text{O}-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-$, $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{O}-$, $-\text{O}-\text{CZ}^8=\text{CZ}^9-$,
 $-\text{CZ}^8=\text{CZ}^9-\text{O}-$, $-\text{O}-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CZ}^{12}\text{Z}^{13}-$, $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CZ}^{12}\text{Z}^{13}-\text{O}-$,
 15 $-\text{O}-\text{CZ}^8=\text{CZ}^9-\text{CZ}^{10}\text{Z}^{11}-$, $-\text{O}-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}=\text{CZ}^{11}-$, $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}=\text{CZ}^{11}-\text{O}-$,
 $-\text{CZ}^8=\text{CZ}^9-\text{CZ}^{10}\text{Z}^{11}-\text{O}-$, $-\text{CO}-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-$, $-\text{CZ}^8\text{Z}^9-\text{CO}-\text{CZ}^{10}\text{Z}^{11}-$,
 $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CO}-$, $-\text{CO}-\text{CZ}^8=\text{CZ}^9-$, $-\text{CZ}^8=\text{CZ}^9-\text{CO}-$,
 $-\text{CO}-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CZ}^{12}\text{Z}^{13}-$, $-\text{CZ}^8\text{Z}^9-\text{CO}-\text{CZ}^{10}\text{Z}^{11}-\text{CZ}^{12}\text{Z}^{13}-$,
 $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CO}-\text{CZ}^{12}\text{Z}^{13}-$, $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CZ}^{12}\text{Z}^{13}-\text{CO}-$,
 20 $-\text{CO}-\text{CZ}^8=\text{CZ}^9-\text{CZ}^{10}\text{Z}^{11}-$, $-\text{CZ}^8\text{Z}^9-\text{CO}-\text{CZ}^{10}=\text{CZ}^{11}-$, $-\text{CZ}^8=\text{CZ}^9-\text{CO}-\text{CZ}^{10}\text{Z}^{11}-$,
 $-\text{CZ}^8=\text{CZ}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CO}-$, $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}=\text{CZ}^{11}-\text{CO}-$, $-\text{CO}-\text{O}-\text{CZ}^8\text{Z}^9-$,
 $-\text{CZ}^8\text{Z}^9-\text{CO}-\text{O}-$, $-\text{CO}-\text{O}-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-$, $-\text{CZ}^8\text{Z}^9-\text{CO}-\text{O}-\text{CZ}^{10}\text{Z}^{11}-$,
 $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{CO}-\text{O}-$, $-\text{CO}-\text{O}-\text{CZ}^8=\text{CZ}^9-$, $-\text{CZ}^8=\text{CZ}^9-\text{CO}-\text{O}-$, $-\text{O}-\text{CO}-\text{CZ}^8\text{Z}^9-$,
 $-\text{CZ}^8\text{Z}^9-\text{O}-\text{CO}-$, $-\text{O}-\text{CO}-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-$, $-\text{CZ}^8\text{Z}^9-\text{O}-\text{CO}-\text{CZ}^{10}\text{Z}^{11}-$,
 25 $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{O}-\text{CO}-$, $-\text{O}-\text{CO}-\text{CZ}^8=\text{CZ}^9-$, $-\text{CZ}^8=\text{CZ}^9-\text{O}-\text{CO}-$,
 $-\text{CO}-\text{NR}^{14}-\text{CZ}^9\text{Z}^{10}-$, $-\text{CO}-\text{CZ}^8\text{Z}^9-\text{NR}^{14}-$, $-\text{CO}-\text{N}=\text{CZ}^8-$, $-\text{CO}-\text{CZ}^8=\text{N}-$,
 $-\text{CO}-\text{NZ}^8-\text{CZ}^9\text{Z}^{10}-\text{CZ}^{11}\text{Z}^{12}-$, $-\text{CO}-\text{CZ}^8\text{Z}^9-\text{NR}^{14}-\text{CZ}^{11}\text{Z}^{12}-$,
 $-\text{CO}-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{NR}^{14}-$, $-\text{CO}-\text{NR}^{14}-\text{CZ}^9=\text{CZ}^{10}-$, $-\text{CO}-\text{CZ}^8=\text{CZ}^9-\text{NR}^{14}-$,
 $-\text{CO}-\text{N}=\text{CZ}^8-\text{CZ}^9\text{Z}^{10}-$, $-\text{CO}-\text{CZ}^8=\text{N}-\text{CZ}^9\text{Z}^{10}-$, $-\text{CO}-\text{CZ}^8\text{Z}^9-\text{N}=\text{CZ}^{10}-$,
 30 $-\text{CO}-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}=\text{N}-$, $-\text{NR}^{14}-\text{CO}-\text{CZ}^9\text{Z}^{10}-$, $-\text{NR}^{14}-\text{CZ}^9\text{Z}^{10}-\text{CO}-$, $-\text{N}=\text{CZ}^8-\text{CO}-$,
 $-\text{NR}^{14}-\text{CO}-\text{CZ}^9\text{Z}^{10}-\text{CZ}^{11}\text{Z}^{12}-$, $-\text{NR}^{14}-\text{CZ}^9\text{Z}^{10}-\text{CO}-\text{CZ}^{11}\text{Z}^{12}-$,
 $-\text{NR}^{14}-\text{CZ}^9\text{Z}^{10}-\text{CZ}^{11}\text{Z}^{12}-\text{CO}-$, $-\text{NR}^{14}-\text{CO}-\text{CZ}^9=\text{CZ}^{10}-$, $-\text{NR}^{14}-\text{CZ}^9=\text{CZ}^{10}-\text{CO}-$,
 $-\text{N}=\text{CZ}^8-\text{CO}-\text{CZ}^9\text{Z}^{10}-$, $-\text{N}=\text{CZ}^8-\text{CZ}^{10}\text{Z}^{11}-\text{CO}-$, $-\text{NR}^{14}-\text{CO}-\text{O}-\text{CZ}^9\text{Z}^{10}-$,
 $-\text{NR}^{14}-\text{CZ}^9\text{Z}^{10}-\text{CO}-\text{O}-$, $-\text{CO}-\text{O}-\text{NR}^{14}-\text{CZ}^9\text{Z}^{10}-$, $-\text{N}=\text{CZ}^8-\text{CO}-\text{O}-$, $-\text{CO}-\text{O}-\text{N}=\text{CZ}^8-$,
 35 $-\text{NR}^{14}-\text{O}-\text{CO}-\text{CZ}^9\text{Z}^{10}-$, $-\text{NR}^{14}-\text{CZ}^9\text{Z}^{10}-\text{O}-\text{CO}-$, $-\text{O}-\text{CO}-\text{NR}^{14}-\text{CZ}^9\text{Z}^{10}-$, $-\text{NR}^{14}-\text{O}-$
 $\text{CZ}^9\text{Z}^{10}-\text{CO}-$, $-\text{N}=\text{CZ}^8-\text{O}-\text{CO}-$, $-\text{O}-\text{CO}-\text{N}=\text{CZ}^8-$, $-\text{NR}^{14}-\text{CZ}^9\text{Z}^{10}-\text{CZ}^{11}\text{Z}^{12}-$,
 $-\text{CZ}^8\text{Z}^9-\text{NR}^{14}-\text{CZ}^{11}\text{Z}^{12}-$, $-\text{CZ}^8\text{Z}^9-\text{CZ}^{10}\text{Z}^{11}-\text{NR}^{14}-$, $-\text{NR}^{14}-\text{CZ}^9=\text{CZ}^{10}-$,
 $-\text{CZ}^8=\text{CZ}^9-\text{NR}^{14}-$, $-\text{N}=\text{CZ}^8-\text{CZ}^9\text{Z}^{10}-$, $-\text{CZ}^8\text{Z}^9-\text{N}=\text{CZ}^{10}-$,

$-CZ^8Z^9-CZ^{10}=N-$, $-NR^{14}-CZ^9=CZ^{10}-$, $-CZ^8=CZ^9-NR^{14}-$,
 $-NR^{14}-CZ^9Z^{10}-CZ^{11}Z^{12}-CZ^{13}Z^{14}-$, $-CZ^8Z^9-NR^{14}-CZ^{11}Z^{12}-CZ^{13}Z^{14}-$,
 $-CZ^8Z^9-CZ^{10}Z^{11}-NR^{14}-CZ^{13}Z^{14}-$, $-CZ^8Z^9-CZ^{10}Z^{11}-CZ^{12}Z^{13}-NR^{14}-$,
 $-NR^{14}-CZ^9=CZ^{10}-CZ^{11}Z^{12}-$, $-CZ^8Z^9-NR^{14}-CZ^{11}=CZ^{12}-$, $-CZ^8=CZ^9-NR^{14}-CZ^{11}Z^{12}-$,
 $-CZ^8=CZ^9-CZ^{10}Z^{11}-NR^{14}-$, $-CZ^8Z^9-CZ^{10}=CZ^{11}Z^{12}-NR^{14}-$,
 $-N=CZ^8-CZ^9Z^{10}-CZ^{11}Z^{12}-$, $-CZ^8Z^9-N=CZ^{10}-CZ^{11}Z^{12}-$, $-CZ^8Z^9-CZ^{10}Z^{11}-N=CZ^{12}-$,
 $CZ^8Z^9-CZ^{10}Z^{11}-CZ^{12}=N-$, $-CZ^8=N-CZ^9=CZ^{10}-$, $-CZ^8=CZ^9-N=CZ^{10}-$,
 $-CZ^8=CZ^9-CZ^{10}=N-$, $-NR^{13}-CO-NR^{14}-$, $-NR^{13}-CO-NR^{14}-CZ^{10}Z^{11}-$,
 $-CZ^8Z^9-NR^{13}-CO-NR^{14}-$, $-NR^{14}-CO-N=CZ^9-$, $-CZ^8=N-CO-NR^{14}-$,
 $-NR^{13}-CZ^9Z^{10}-CO-NR^{14}-$, $-NR^{13}-CO-CZ^9Z^{10}-NR^{14}-$, $-N=CZ^8-CO-NR^{14}-$,
 $-O-CO-NR^{14}-$, $-CO-O-NR^{14}-$, $-NR^{14}-O-CO-$, $-NR^{14}-CO-O-$, $-CO-NR^{14}-O-$,
 $-O-CO-NR^{14}-CZ^9Z^{10}-$, $-O-CO-CZ^8Z^9-NR^{14}-$, $-CO-O-NR^{14}-CZ^9Z^{10}-$,
 $-CO-O-CZ^8Z^9-NR^{14}-$, $-CZ^8Z^9-NR^{14}-O-CO-$, $-CZ^8Z^9-NR^{14}-CO-O-$,
 $-NH-C(=NR^{13})-NR^{14}-$, $-O-CO-N=CZ^8-$, $-CH_2-CZ^8Z^9-CZ^{10}Z^{11}-CZ^{12}Z^{13}-$, $-CH_2-$
 $CZ^8=CZ^9-CZ^{10}=CZ^{11}-$, $-CH_2-CZ^8Z^9-CZ^{10}Z^{11}-CZ^{12}Z^{13}-CZ^{14}Z^{15}-$, $-CH_2-CZ^8Z^9-$
 $CZ^{10}=CZ^{11}-$, $-CH_2-CZ^8=CZ^9-CZ^{10}Z^{11}-$, $-CH_2-CZ^8Z^9-CZ^{10}Z^{11}-CZ^{12}=CZ^{13}-$, $-CH_2-$
 $CZ^8Z^9-CZ^{10}=CZ^{11}-CZ^{12}Z^{13}-$, $-CH_2-CZ^8=CZ^9-CZ^{10}Z^{11}-CZ^{12}Z^{13}-$, $-CH_2-CZ^8Z^9-O-$
 $CZ^{10}Z^{11}-$, $-CH_2-CZ^8Z^9-CZ^{10}Z^{11}-O-CZ^{12}Z^{13}-$, $-CH_2-CZ^8Z^9-O-CZ^{10}Z^{11}-CZ^{12}Z^{13}-$,
 $-CH_2-CZ^8=CZ^9-O-CZ^{10}Z^{11}-$, $-CH_2-CZ^8Z^9-O-CZ^{10}=CZ^{11}-$, $-CH_2-O-CZ^8Z^9-CZ^{10}Z^{11}-$,
 $-CH_2-CZ^8Z^9-CZ^{10}Z^{11}-O-$, $-CH_2-O-CZ^8=CZ^9-$, $-CH_2-CZ^8=CZ^9-O-$, $-CH_2-O-$
 $CZ^8Z^9-CZ^{10}Z^{11}-CZ^{12}Z^{13}-$, $-CH_2-CZ^8Z^9-CZ^{10}Z^{11}-CZ^{12}Z^{13}-O-$, $-CH_2-O-CZ^8=CZ^9-$
 $CZ^{10}Z^{11}-$, $-CH_2-O-CZ^8Z^9-CZ^{10}=CZ^{11}-$, $-CH_2-CZ^8Z^9-CZ^{10}=CZ^{11}-O-$, $-CH_2-$
 $CZ^8=CZ^9-CZ^{10}Z^{11}-O-$, $-CH_2-CO-CZ^8Z^9-CZ^{10}Z^{11}-$, $-CH_2-CZ^8Z^9-CO-CZ^{10}Z^{11}-$,
 $-CH_2-CZ^8Z^9-CZ^{10}Z^{11}-CO-$, $-CH_2-CO-CZ^8=CZ^9-$, $-CH_2-CZ^8=CZ^9-CO-$,
 $-CH_2-CO-CZ^8Z^9-CZ^{10}Z^{11}-CZ^{12}Z^{13}-$, $-CH_2-CZ^8Z^9-CO-CZ^{10}Z^{11}-CZ^{12}Z^{13}-$, $-CH_2-$
 $CZ^8Z^9-CZ^{10}Z^{11}-CO-CZ^{12}Z^{13}-$, $-CH_2-CZ^8Z^9-CZ^{10}Z^{11}-CZ^{12}Z^{13}-CO-$, $-CH_2-CO-$
 $CZ^8=CZ^9-CZ^{10}Z^{11}-$, $-CH_2-CZ^8Z^9-CO-CZ^{10}=CZ^{11}-$, $-CH_2-CZ^8=CZ^9-CO-CZ^{10}Z^{11}-$,
 $-CH_2-CZ^8=CZ^9-CZ^{10}Z^{11}-CO-$, $-CH_2-CZ^8Z^9-CZ^{10}=CZ^{11}-CO-$, $-CH_2-CO-O-CZ^8Z^9-$,
 $-CH_2-CZ^8Z^9-CO-O-$, $-CH_2-CO-O-CZ^8Z^9-CZ^{10}Z^{11}-$, $-CH_2-CZ^8Z^9-CO-O-CZ^{10}Z^{11}-$,
 $-CH_2-CZ^8Z^9-CZ^{10}Z^{11}-CO-O-$, $-CH_2-CO-O-CZ^8=CZ^9-$, $-CH_2-CZ^8=CZ^9-CO-O-$,
 $-CH_2-O-CO-CZ^8Z^9-$, $-CH_2-CZ^8Z^9-O-CO-$, $-CH_2-O-CO-CZ^8Z^9-CZ^{10}Z^{11}-$,
 $-CH_2-CZ^8Z^9-O-CO-CZ^{10}Z^{11}-$, $-CH_2-CO-N=CZ^8-$, $-CH_2-CZ^8Z^9-CZ^{10}Z^{11}-O-CO-$,
 $-CH_2-O-CO-CZ^8=CZ^9-$, $-CH_2-CZ^8=CZ^9-O-CO-$, $-CH_2-CO-NR^{14}-CZ^9Z^{10}-$,
 $-CH_2-CO-CZ^8Z^9-NR^{14}-$, $-CH_2-CO-CZ^8=N-$, $-CH_2-CO-NZ^8-CZ^9Z^{10}-CZ^{11}Z^{12}-$,
 $-CH_2-CO-CZ^8Z^9-NR^{14}-CZ^{11}Z^{12}-$, $-CH_2-CO-CZ^8Z^9-CZ^{10}Z^{11}-NR^{14}-$, $-CH_2-CO-$
 $NR^{14}-CZ^9=CZ^{10}-$, $-CH_2-NR^{14}-CO-CZ^9=CZ^{10}-$, $-CH_2-NR^{14}-CZ^9=CZ^{10}-CO-$,
 $-CH_2-CO-CZ^8=CZ^9-NR^{14}-$, $-CH_2-CO-N=CZ^8-CZ^9Z^{10}-$, $-CH_2-CO-CZ^8=N-CZ^9Z^{10}-$,
 $-CH_2-CO-CZ^8Z^9-N=CZ^{10}-$, $-CH_2-CO-CZ^8Z^9-CZ^{10}=N-$, $-CH_2-NR^{14}-CO-CZ^9Z^{10}-$

-CH₂-NR¹⁴-CZ⁹Z¹⁰-CO-, -CH₂-N=CZ⁸-CO-, -CH₂-NR¹⁴-CO-CZ⁹Z¹⁰-CZ¹¹Z¹²-,
-CH₂-NR¹⁴-CZ⁹Z¹⁰-CO-CZ¹¹Z¹²-, -CH₂-NR¹⁴-CZ⁹Z¹⁰-CZ¹¹Z¹²-CO-, -CH₂-N=CZ⁸-
CO-CZ⁹Z¹⁰-, -CH₂-N=CZ⁸-CZ¹⁰Z¹¹-CO-, -CH₂-NR¹⁴-CO-O-CZ⁹Z¹⁰-, -CH₂-
NR¹⁴-CZ⁹Z¹⁰-CO-O-, -CH₂-CO-O-NR¹⁴-CZ⁹Z¹⁰-, -CH₂-N=CZ⁸-CO-O-, -CH₂-
5 CO-O-N=CZ⁸-, -CH₂-NR¹⁴-O-CO-CZ⁹Z¹⁰-, -CH₂-NR¹⁴-CZ⁹Z¹⁰-O-CO-,
-CH₂-O-CO-NR¹⁴-CZ⁹Z¹⁰-, -CH₂-NR¹⁴-O-CZ⁹Z¹⁰-CO-, -CH₂-N=CZ⁸-O-CO-,
-CH₂-O-CO-N=CZ⁸-, -CH₂-NR¹⁴-CZ⁹Z¹⁰-CZ¹¹Z¹²-, -CH₂-CZ⁸Z⁹-NR¹⁴-CZ¹¹Z¹²-,
-CH₂-CZ⁸Z⁹-CZ¹⁰Z¹¹-NR¹⁴-, -CH₂-NR¹⁴-CZ⁹=CZ¹⁰-, -CH₂-CZ⁸=CZ⁹-NR¹⁴-,
-CH₂-N=CZ⁸-CZ⁹Z¹⁰-, -CH₂-CZ⁸Z⁹-N=CZ¹⁰-, -CH₂-CZ⁸Z⁹-CZ¹⁰=N-,
10 -CH₂-NR¹⁴-CZ⁹=CZ¹⁰-, -CH₂-CZ⁸=CZ⁹-NR¹⁴-, -CH₂-NR¹⁴-CZ⁹Z¹⁰-CZ¹¹Z¹²-,
CZ¹³Z¹⁴-, -CH₂-CZ⁸Z⁹-NR¹⁴-CZ¹¹Z¹²-CZ¹³Z¹⁴-, -CH₂-CZ⁸Z⁹-CZ¹⁰Z¹¹-NR¹⁴-CZ¹³Z¹⁴-,
-CH₂-CZ⁸Z⁹-CZ¹⁰Z¹¹-CZ¹²Z¹³-NR¹⁴-, -CH₂-NR¹⁴-CZ⁹=CZ¹⁰-CZ¹¹Z¹²-, -CH₂-CZ⁸Z⁹-
NR¹⁴-CZ¹¹=CZ¹²-, -CH₂-CZ⁸=CZ⁹-NR¹⁴-CZ¹¹Z¹²-, -CH₂-CZ⁸=CZ⁹-CZ¹⁰Z¹¹-NR¹⁴-,
-CH₂-CZ⁸Z⁹-CZ¹⁰=CZ¹¹Z¹²-NR¹⁴-, -CH₂-N=CZ⁸-CZ⁹Z¹⁰-CZ¹¹Z¹²-, -CH₂-CZ⁸Z⁹-
15 N=CZ¹⁰-CZ¹¹Z¹²-, -CH₂-N=CZ⁸-CO-NR¹⁴-, -CH₂-CZ⁸Z⁹-CZ¹⁰Z¹¹-N=CZ¹²-,
-CH₂-CZ⁸Z⁹-CZ¹⁰Z¹¹-CZ¹²=N-, -CH₂-CZ⁸=N-CZ⁹=CZ¹⁰-, -CH₂-CZ⁸=CZ⁹-N=CZ¹⁰-,
-CH₂-CZ⁸=CZ⁹-CZ¹⁰=N-, -CH₂-NR¹³-CO-NR¹⁴-, -CH₂-NR¹³-CO-NR¹⁴-CZ¹⁰Z¹¹-,
-CH₂-CZ⁸Z⁹-NR¹³-CO-NR¹⁴-, -CH₂-NR¹⁴-CO-N=CZ⁹-, -CH₂-CZ⁸=N-CO-NR¹⁴-,
-CH₂-NR¹³-CZ⁹Z¹⁰-CO-NR¹⁴-, -CH₂-O-CO-NR¹⁴-, -CH₂-NR¹³-CO-CZ⁹Z¹⁰-NR¹⁴-,
20 -CH₂-CO-O-NR¹⁴-, -CH₂-NR¹⁴-O-CO-, -CH₂-NR¹⁴-CO-O-, -CH₂-CO-
NR¹⁴-O-, -CH₂-O-CO-NR¹⁴-CZ⁹Z¹⁰-, -CH₂-O-CO-CZ⁸Z⁹-NR¹⁴-,
-CH₂-CO-O-NR¹⁴-CZ⁹Z¹⁰-, -CH₂-CO-O-CZ⁸Z⁹-NR¹⁴-, -CH₂-CZ⁸Z⁹-NR¹⁴-O-CO-,
-CH₂-CZ⁸Z⁹-NR¹⁴-CO-O-, -CH₂-NH-C(=NR¹³)-NR¹⁴-, -CH₂-O-CO-N=CZ⁸-,
-CZ⁸Z⁹-CZ¹⁰Z¹¹-CZ¹²Z¹³-CH₂-, -CZ⁸=CZ⁹-CZ¹⁰=CZ¹¹-CH₂-, -CZ⁸Z⁹-CZ¹⁰Z¹¹-
25 CZ¹²Z¹³-CZ¹⁴Z¹⁵-CH₂-, -CZ⁸Z⁹-CZ¹⁰=CZ¹¹-CH₂-, -CZ⁸=CZ⁹-CZ¹⁰Z¹¹-CH₂-,
-CZ⁸Z⁹-CZ¹⁰Z¹¹-CZ¹²=CZ¹³-CH₂-, -CZ⁸Z⁹-CZ¹⁰=CZ¹¹-CZ¹²Z¹³-CH₂-, -CZ⁸=CZ⁹-
CZ¹⁰Z¹¹-CZ¹²Z¹³-CH₂-, -CZ⁸Z⁹-O-CZ¹⁰Z¹¹-CH₂-, -CZ⁸Z⁹-CZ¹⁰Z¹¹-O-CZ¹²Z¹³-CH₂-,
-CZ⁸Z⁹-O-CZ¹⁰Z¹¹-CZ¹²Z¹³-CH₂-, -CZ⁸=CZ⁹-O-CH₂-, -CZ⁸=CZ⁹-O-CZ¹⁰Z¹¹-CH₂-,
-CZ⁸Z⁹-O-CZ¹⁰=CZ¹¹-CH₂-, -O-CZ⁸Z⁹-CZ¹⁰Z¹¹-CH₂-, -CZ⁸Z⁹-CZ¹⁰Z¹¹-O-CH₂-,
30 -O-CZ⁸=CZ⁹-CH₂-, -O-CZ⁸Z⁹-CZ¹⁰Z¹¹-CZ¹²Z¹³-CH₂-, -CZ⁸Z⁹-CZ¹⁰Z¹¹-CZ¹²Z¹³-
O-CH₂-, -O-CZ⁸=CZ⁹-CZ¹⁰Z¹¹-CH₂-, -O-CZ⁸Z⁹-CZ¹⁰=CZ¹¹-CH₂-, -CZ⁸Z⁹-
CZ¹⁰=CZ¹¹-O-CH₂-, -CZ⁸Z⁹-CZ¹⁰Z¹¹-CO-CH₂-, -CO-CZ⁸=CZ⁹-CH₂-,
-CZ⁸=CZ⁹-CZ¹⁰Z¹¹-O-CH₂-, -CO-CZ⁸Z




35 If R^{11} and R^{12} are joined together, they form a ring system and especially a four-membered, five-membered or a six-membered ring system together with the atoms to which they are attached. Preferred ring systems are five-membered cyclocarbamates, five-membered cyclic ureas, five-membered cyclic guanidines, six-membered

cyclocarbamates, six-membered cyclic ureas, six-membered cyclic guanidines, pyrrolidones, pyridones, piperidinones, imidazoles, imidazolines, pyrrolines, imidazolidin-2-ones.

- 5 R^3 together with R^4 can form a carbocyclic or heterocyclic 4-, 5-, 6- or 7-membered ring with the two carbon atoms of the benzo ring to which R^3 and R^4 are attached and that 4-, 5-, 6- or 7-membered ring can be partly saturated or unsaturated and can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 . Z^1 and Z^2 if attached to the same carbon atom can together represent =O to form a carbonyl group with the
10 carbon atom to which Z^1 and Z^2 are attached, so that so a ring has one carbonyl group and may comprise one or two further residues which are not allowed to form a carbonyl group together.


- Partly saturated as used herein means that the ring system additionally formed by joining
15 R^3 with R^4 when taken alone already bears one double bond originated in the phenyl ring to which R^3 and R^4 are attached. Thus, since R^3 and R^4 are attached to a phenyl ring a double bond equivalent exists between the two carbon atoms that bear R^3 and R^4 , respectively. Therefore, the person skilled in the art will understand that the ring system formed when R^3 and R^4 are joined together can not be a saturated ring system, but a
20 partly saturated ring system when the moiety introduces at least one saturated atom or two subsequent saturated bonds.

- Preferably R^{10} , R^{16} and R^{17} are selected from the following group of substituents: -H,
25 -CH₃, -C₂H₅, -C₃H₇, -CF₃,



cyclo-C₃H₅, cyclo-C₄H₇, cyclo-C₅H₉, cyclo-C₆H₁₁, cyclo-C₇H₁₃,


- CH(CH₃)₂, -C₄H₉, -CH₂-CH(CH₃)₂, -CH(CH₃)-C₂H₅, -C(CH₃)₃, -C₅H₁₁,
-CH(CH₃)-C₃H₇, -CH₂-CH(CH₃)-C₂H₅, -CH(CH₃)-CH(CH₃)₂, -C(CH₃)₂-C₂H₅,
-CH₂-C(CH₃)₃, -CH(C₂H₅)₂, -C₂H₄-CH(CH₃)₂, -C₆H₁₃, -C₇H₁₅, -C₈H₁₇, -Ph,
-CH₂-Ph, -CH₂-CH₂-Ph, -CH₂-CH=CH₂, -C(CH₃)=CH₂, -C₂H₄-CH=CH₂,
30 -CH₂-CH=CH-CH₃, -CH₂-C(CH₃)=CH₂, -CH(CH₃)-CH=CH₂, -C(CH₃)=CH-CH₃,
-CH₂-C≡CH, -C₂H₄-C≡CH, -CH₂-C≡C-CH₃, -C₂H₄-OCF₃, -C₃H₆-OCF₃,
-C₂H₄-OCH₃, -C₃H₆-OCH₃, -CH₂-OC₂H₅, -C₃H₆-OC₂H₅,
and also preferably from the following group of substituents: -C₂H₅,



cyclo-C₃H₅, cyclo-C₄H₇, cyclo-C₅H₉, cyclo-C₆H₁₁, -C₃H₇, -CF₃,


$-\text{CH}(\text{CH}_3)_2$, $-\text{C}_4\text{H}_9$, $-\text{CH}_2-\text{CH}(\text{CH}_3)_2$, $-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)_3$, $-\text{C}_5\text{H}_{11}$,
 $-\text{CH}(\text{CH}_3)-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{CH}=\text{CH}_2$,
 $-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}$, $-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_3$,
 $-\text{CH}_2-\text{C}\equiv\text{CH}$, and more preferably from the following group of substituents: $-\text{C}_2\text{H}_5$,

5 $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{C}_4\text{H}_9$, $-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)_3$,



cyclo- C_3H_5 , cyclo- C_4H_7 , cyclo- C_5H_9 , cyclo- C_6H_{11} ,

$-\text{CH}(\text{CH}_3)-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{CH}=\text{CH}_2$,
 $-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}$, $-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_3$, $-\text{CH}_2-\text{C}\equiv\text{CH}$, and still more
 preferably from the following group of substituents: $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$,
 $-\text{CH}(\text{CH}_3)_2$, $-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)_3$, cyclo- C_4H_7 , cyclo- C_5H_9 , cyclo- C_6H_{11} ,



$-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}$, $-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_3$,

10 and even still more preferably from the following group of substituents: $-\text{C}_2\text{H}_5$,
 $-\text{CH}(\text{CH}_3)_2$, $-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)_3$, cyclo- C_4H_7 , cyclo- C_5H_9 , cyclo- C_6H_{11} ,
 $-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$, and most preferably from the following group of substituents:
 $-\text{CH}(\text{CH}_3)_2$, cyclo- C_4H_7 , cyclo- C_5H_9 .

15 $\text{R}^4 - \text{R}^7$ represent independently of each other $-\text{H}$, $-\text{F}$, $-\text{Cl}$, $-\text{CH}_3$; preferably $-\text{H}$ or $-\text{F}$.

R^8 represents preferably $-(\text{CH}_2)_p-\text{NH}_2$, $-(\text{CH}_2)_p-\text{N}(\text{R}^{16}\text{R}^{17})$, C_3-C_8 -cycloalkyl,
 C_7-C_{16} -spiroalkyl, C_1-C_9 -heterocyclyl, C_5-C_{14} -spiroheterocyclyl, wherein the
 20 afore-mentioned residues are linked through a ring carbon atom and can be substituted
 with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 ;

R^8 represents more preferably C_3-C_8 -cycloalkyl, substituted C_3-C_8 -cycloalkyl,
 C_7-C_{16} -spiroalkyl, substituted C_7-C_{16} -spiroalkyl, C_1-C_9 -heterocyclyl, substituted
 25 C_1-C_9 -heterocyclyl, C_5-C_{14} -spiroheterocyclyl, substituted C_5-C_{14} -spiroheterocyclyl,
 wherein the afore-mentioned substituted residues are linked through a ring carbon
 atom and can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 ,

R^8 represents most preferably piperidinyl, morpholinyl, piperazinyl, pyranlyl,
 30 pyrrolidinyl, iminopropylenyl, pyridyl and cyclohexyl, wherein the afore-mentioned
 substituted residues are linked through a ring carbon atom and can be substituted with
 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 .

R^9 represents preferably $-R^8$, C_1-C_9 -nitrogenheterocyclyl, C_5-C_{14} -spironitrogenheterocyclyl, wherein the afore-mentioned nitrogenheterocyclyl and spironitrogenheterocyclyl residues are linked through a ring nitrogen atom and can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 .

5

R^9 represents more preferably C_1-C_9 -nitrogenheterocyclyl, substituted C_1-C_9 -nitrogenheterocyclyl, C_5-C_{14} -spironitrogenheterocyclyl, substituted C_5-C_{14} -spironitrogenheterocyclyl, wherein the afore-mentioned nitrogenheterocyclyl and spironitrogenheterocyclyl residues are linked through a ring nitrogen atom and can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 .

10

R^9 represents most preferably piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl and iminopropylenyl, wherein the afore-mentioned nitrogenheterocyclyl and spironitrogenheterocyclyl residues are linked through a ring nitrogen atom and can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 .

15

In another preferred embodiment of the present invention substituent R^2 represents $-Q-(CH_2)_n-R^8$, $-(CH_2)_m-NH-(CH_2)_n-R^8$, $-(CH_2)_m-NH-(CH_2)_n-R^9$, $-Q-(CH_2)_n-R^8$, $-(CH_2)_n-R^8$, $-CO-NH-(CH_2)_n-R^8$, $-(CH_2)_m-NR^{10}-(CH_2)_n-R^8$, $-CO-NR^{10}-(CH_2)_n-R^8$, $-R^8$, $-Q-R^8$, $-R^9$, $-Q-(CH_2)_n-R^9$, $-(CH_2)_n-R^9$, $-(CH_2)_n-NH-R^8$, $-(CH_2)_m-NH-(CH_2)_n-R^9$, $-CO-NH-(CH_2)_n-NH_2$, $-CO-NH-(CH_2)_n-R^9$, $-CO-R^9$, $-SO-R^9$, $-(CH_2)_n-NR^{10}-R^8$, $-(CH_2)_m-NR^{10}-(CH_2)_n-R^9$, $-CO-NR^{10}-(CH_2)_n-R^9$, $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$, $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$; and more preferably R^2 represents $-Q-(CH_2)_n-R^8$, $-(CH_2)_m-NH-(CH_2)_n-R^8$, $-(CH_2)_m-NH-(CH_2)_n-R^9$, $-Q-(CH_2)_n-R^8$, $-(CH_2)_n-R^8$, $-CO-NH-(CH_2)_n-R^8$, $-(CH_2)_m-NR^{10}-(CH_2)_n-R^8$, $-CO-NR^{10}-(CH_2)_n-R^8$, $-R^8$, $-Q-R^8$, $-R^9$, $-Q-(CH_2)_n-R^9$, $-(CH_2)_n-R^9$, $-(CH_2)_n-NH-R^8$, $-(CH_2)_m-NH-(CH_2)_n-R^9$, $-CO-NH-(CH_2)_n-NH_2$, $-CO-NH-(CH_2)_n-R^9$, $-CO-R^9$, $-SO-R^9$, $-(CH_2)_n-NR^{10}-R^8$, $-(CH_2)_m-NR^{10}-(CH_2)_n-R^9$, $-CO-NR^{10}-(CH_2)_n-R^9$.

20

25

30

This is especially the case, if substituent R^9 does not include the substituent R^8 .

R^{11} , R^{12} , R^{13} , R^{14} and R^{15} represent independently of each other $-H$, linear or branched C_1-C_8 -alkyl, C_3-C_8 -cycloalkyl, C_1-C_9 -heterocyclyl, linear or branched C_2-C_8 -alkenyl, linear or branched C_2-C_8 -alkynyl, C_6-C_{14} -aryl, C_1-C_{10} -heteroaryl, wherein the afore-mentioned residues can be substituted with 1 to 5 substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} .

35

R^{11} , R^{12} , R^{13} , R^{14} and R^{15} preferably represent independently of each other -H, methyl, isopropyl and pyrrolidinyl.

As used herein **linear C_1-C_8 -alkyl** refers to $-CH_3$, $-C_2H_5$, $-C_3H_7$, $-C_4H_9$, $-C_5H_{11}$, $-C_6H_{13}$, $-C_7H_{15}$, $-C_8H_{17}$, $-CH_2-Ph$, $-CH_2-CH_2-Ph$, wherein these residues can be substituted with 1 to 5 substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . However it is clear to a skilled person that the term "can be substituted" refers to the replacement of a hydrogen atom by one of the substituents Z^8 , Z^9 , Z^{10} , Z^{11} or Z^{12} . Moreover it is clear to a skilled person that only these hydrogen atoms which are present in the residue can be replaced by the substituents Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . Thus, since the methyl group has only three hydrogen atoms, only three hydrogen atoms can be replaced by three substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . For the definitions used herein the alkylaryl group $-CH_2-Ph$ (benzyl group) and the $-CH_2-CH_2-Ph$ group should fall under the definition "linear C_1-C_8 -alkyl".

The term "substituted" as used herein further indicates that the substituted residue like "substituted linear C_1-C_8 -alkyl" does definitely have at least one substituent (at least one Z substituent) while the residue without the term "substituted" like "linear C_1-C_8 -alkyl" can have at least one substituent. Consequently, if the term "substituted" is not used in relation to a residue this does not indicate that this residue is unsubstituted.

Examples of preferred substituted linear C_1-C_8 -alkyl residues are $-CH_2-OH$, $-CH_2-O-CH_3$, $-CH_2-OCF_3$, $-CF_3$, $-CH_2Cl$, $-CH_2CH_2Cl$, $-CH_2CH_2-OCF_3$, and $-CH_2-Ph$.

As used herein **branched C_1-C_8 -alkyl** or preferably branched C_3-C_8 -alkyl refers to $-CH(CH_3)_2$, $-CH_2-CH(CH_3)_2$, $-CH(CH_3)-C_2H_5$, $-C(CH_3)_3$, $-CH(CH_3)-C_3H_7$, $-CH_2-CH(CH_3)-C_2H_5$, $-CH(CH_3)-CH(CH_3)_2$, $-C(CH_3)_2-C_2H_5$, $-CH_2-C(CH_3)_3$, $-CH(C_2H_5)_2$, $-C_2H_4-CH(CH_3)_2$, $-C_3H_6-CH(CH_3)_2$, $-C_2H_4-CH(CH_3)-C_2H_5$, $-CH(CH_3)-C_4H_9$, $-CH_2-CH(CH_3)-C_3H_7$, $-CH(CH_3)-CH_2-CH(CH_3)_2$, $-CH(CH_3)-CH(CH_3)-C_2H_5$, $-CH_2-CH(CH_3)-CH(CH_3)_2$, $-CH_2-C(CH_3)_2-C_2H_5$, $-C(CH_3)_2-C_3H_7$, $-C(CH_3)_2-CH(CH_3)_2$, $-C_2H_4-C(CH_3)_3$, $-CH(CH_3)-C(CH_3)_3$, $-C_4H_8-CH(CH_3)_2$, $-C_3H_6-CH(CH_3)-C_2H_5$, $-C_3H_6-CH(CH_3)-C_2H_5$, $-C_2H_4-CH(CH_3)-C_3H_7$, $-CH_2-CH(CH_3)-C_4H_9$, $-CH(CH_3)-C_5H_{11}$, $-CH(C_2H_5)-C_4H_9$, $-C_2H_4-CH(CH_3)-C_3H_7$, $-CH_2-CH(C_2H_5)-C_3H_7$, $-CH_2-CH(CH_3)-C_4H_9$, $-CH_2-CH(CH_3)-CH_2-CH(CH_3)_2$, $-CH(C_2H_5)-CH_2-CH(CH_3)_2$, $-CH(CH_3)-C_2H_4-CH(CH_3)_2$, $-CH(CH_3)-CH_2-CH(CH_3)-C_2H_5$, $-CH_2-CH(CH_3)-CH(CH_3)-C_2H_5$, $-CH(CH_3)-CH_2-CH(CH_3)-C_2H_5$.

- $-\text{CH}(\text{CH}_3)-\text{CH}(\text{C}_2\text{H}_5)-\text{C}_2\text{H}_5$, $-\text{CH}(\text{C}_2\text{H}_5)-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)-\text{C}_3\text{H}_7$,
 $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2-\text{CH}(\text{C}_2\text{H}_5)-\text{CH}(\text{CH}_3)_2$,
 $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$,
 $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{C}(\text{CH}_3)(\text{C}_2\text{H}_5)_2$, $-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{C}_3\text{H}_7$,
5 $-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{C}_3\text{H}_7$, $-\text{C}(\text{CH}_3)(\text{C}_2\text{H}_5)-\text{C}_3\text{H}_7$, $-\text{C}(\text{CH}_3)_2-\text{C}_4\text{H}_9$,
 $-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)(\text{C}_2\text{H}_5)-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2-\text{CH}_2-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2-\text{C}(\text{CH}_3)_3$,
 $-\text{C}(\text{CH}_3)_2-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_6-\text{C}(\text{CH}_3)_3$,
 $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}(\text{CH}_3)_3$, $-\text{CH}(\text{C}_2\text{H}_5)-\text{C}(\text{CH}_3)_3$,
 $-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{C}(\text{CH}_3)_3$, $-\text{CH}(\text{CH}_3)-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$, $-\text{C}_5\text{H}_{10}-\text{CH}(\text{CH}_3)_2$,
10 $-\text{C}_4\text{H}_8-\text{C}(\text{CH}_3)_3$, $-\text{C}_4\text{H}_8-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{C}_4\text{H}_8-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$,
 $-\text{C}_3\text{H}_6-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_6-\text{CH}(\text{C}_2\text{H}_5)-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_6-\text{CH}(\text{CH}_3)-\text{C}_3\text{H}_7$,
 $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)_2-\text{C}_3\text{H}_7$, $-\text{C}_2\text{H}_4-\text{CH}(\text{C}_2\text{H}_5)-\text{C}_3\text{H}_7$, $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{C}_4\text{H}_9$,
 $-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{C}_4\text{H}_9$, $-\text{CH}_2-\text{CH}(\text{C}_2\text{H}_5)-\text{C}_4\text{H}_9$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}_5\text{H}_{11}$,
 $-\text{C}(\text{CH}_3)_2-\text{C}_5\text{H}_{11}$, $-\text{CH}(\text{CH}_3)-\text{C}_6\text{H}_{13}$, $-\text{CH}(\text{C}_3\text{H}_7)-\text{C}_4\text{H}_9$,
15 $-\text{CH}(\text{C}_2\text{H}_5)-\text{C}_5\text{H}_{11}$, $-\text{CH}_2-\text{C}(\text{CH}_3)(\text{C}_2\text{H}_5)-\text{C}_3\text{H}_7$, $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{CH}(\text{CH}_3)_2$,
 $-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{CH}_2-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2-\text{CH}(\text{C}_2\text{H}_5)-\text{CH}_2-\text{CH}(\text{CH}_3)_2$,
 $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{C}(\text{CH}_3)_3$,
 $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)(\text{C}_2\text{H}_5)-\text{CH}_2-\text{CH}(\text{CH}_3)_2$,
 $-\text{CH}(\text{C}_3\text{H}_7)-\text{CH}_2-\text{CH}(\text{CH}_3)_2$, $-\text{CH}(\text{C}_2\text{H}_5)-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)_2$,
20 $-\text{CH}(\text{C}_2\text{H}_5)-\text{CH}_2-\text{C}(\text{CH}_3)_3$, $-\text{CH}(\text{C}_2\text{H}_5)-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$,
 $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)_2$, $-\text{CH}(\text{C}_2\text{H}_5)-\text{C}_2\text{H}_4-$
 $\text{CH}(\text{CH}_3)_2$, $-\text{CH}(\text{CH}_3)-\text{C}_3\text{H}_6-\text{CH}(\text{CH}_3)_2$, $-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)_3$, $-\text{CH}(\text{CH}_3)-$
 $\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)_2-\text{CH}_2-$
 $\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$,
25 $-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}_3\text{H}_7$, $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{C}(\text{CH}_3)_2-$
 $\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{CH}(\text{C}_2\text{H}_5)-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}_2-\text{CH}(\text{CH}_3)-$
 C_2H_5 , $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{CH}(\text{CH}_3)-\text{CH}(\text{C}_2\text{H}_5)_2$, $-\text{C}_3\text{H}_6-$
 $\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)_2$, $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)_2-\text{CH}(\text{CH}_3)_2$, $-\text{C}_2\text{H}_4-\text{CH}(\text{C}_2\text{H}_5)-\text{CH}(\text{CH}_3)_2$,
 $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{C}(\text{CH}_3)_3$, $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_6-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$,
30 $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)_2-\text{C}_3\text{H}_7$, $-\text{CH}_2-\text{C}(\text{CH}_3)(\text{C}_2\text{H}_5)_2$, $-\text{C}_2\text{H}_4-\text{C}(\text{C}_2\text{H}_5)_3$, $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)_2-$
 C_3H_7 , $-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{C}_4\text{H}_9$, $-\text{C}(\text{C}_2\text{H}_5)_2-\text{C}_3\text{H}_7$, $-\text{C}(\text{CH}_3)(\text{C}_3\text{H}_7)-\text{C}_3\text{H}_7$,
 $-\text{C}(\text{CH}_3)(\text{C}_2\text{H}_5)-\text{C}_4\text{H}_9$, $-\text{C}(\text{CH}_3)(-\text{C}_2\text{H}_5)-\text{C}_4\text{H}_9$, $-\text{C}(\text{CH}_3)_2-\text{C}_5\text{H}_{11}$, $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)_2-$
 $\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{C}(\text{CH}_3)_3$, $-\text{C}(\text{C}_2\text{H}_5)_2-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)(\text{C}_3\text{H}_7)-$
 $\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)(\text{C}_2\text{H}_5)-\text{C}(\text{CH}_3)_3$, $-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{CH}_2-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2-$
35 $\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2-\text{CH}_2-\text{C}(\text{CH}_3)_3$, $-\text{CH}_2-\text{C}(\text{CH}_3)_2-\text{C}(\text{CH}_3)_3$, $-\text{C}_4\text{H}_8-\text{C}(\text{CH}_3)_3$,
 $-\text{C}_3\text{H}_6-\text{C}(\text{CH}_3)_2-\text{C}_2\text{H}_5$, $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)_2-\text{C}_3\text{H}_7$, $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{C}(\text{CH}_3)_3$, $-\text{CH}_2-$
 $\text{C}(\text{CH}_3)_2-\text{C}(\text{CH}_3)_3$, wherein these residues can be substituted with 1 to 5 substituents
selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . However it is clear to a skilled person that the term

“can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^8 , Z^9 , Z^{10} , Z^{11} or Z^{12} . The carbon atom number of C_1-C_8 refers only to the carbon atoms of the alkyl residue and does not include the carbon atoms of the substituents Z^8 to Z^{12} .

5

Examples of preferred substituted branched C_1-C_8 -alkyl or preferably branched C_3-C_8 -alkyl residues are $-CH(CH_2Cl)_2$, $-CH(CH_3)-C_2H_4-OCF_3$, $-C(CH_3)_2-CF_3$, $-COCH_3(CH_3)_2$, $-CHCH_3Cl$, $-CH_2-CHCH_3NH_2$, $-CClCH_3-C_2H_5$, $-C(CH_3)_2OH$, $-CClCH_3-C_3H_7$, $-CH_2-C(OH)(CH_3)-C_2H_5$, $-CH(CH_3)-CHCH_3Cl$, $-C(CH_3)_2-C_2H_4NH_2$, $-CH_2-C(CH_3)_2OH$, $-CNH_2(C_2H_5)_2$, $-C_2H_4-COH(CH_3)_2$, $-C_3H_6-COH(CH_3)_2$.

10

As defined above, the term “substituted” in “substituted branched C_3-C_8 -alkyl” indicated that definitely at least one substituent is present while the term “branched C_3-C_8 -alkyl” only defines that the carbon chain is branched but does not exclude further substituents. Consequently it is stated above that the “branched C_3-C_8 -alkyl” residues can be substituted with 1 to 5 substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . Thus, for instance, the “substituted branched C_3-C_8 -alkyl” residues are a subgroup of the “branched C_3-C_8 -alkyl” residues. The same applies to the other residues which are mentioned with the term “substituted” and without the term “substituted”.


15


20

As used herein, **C_3-C_8 -cycloalkyl** refers to cyclo- C_3H_5 , cyclo- C_4H_7 , cyclo- C_5H_9 , cyclo- C_6H_{11} , cyclo- C_7H_{13} , and cyclo- C_8H_{15} , wherein these residues can be substituted with 1 to 5 substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^8 , Z^9 , Z^{10} , Z^{11} or Z^{12} . The carbon atom number of **C_3-C_8** refers only to the carbon atoms of the cycloalkyl residue and does not include the carbon atoms of the substituents Z^8 to Z^{12} .


25

Examples of preferred substituted C_3-C_8 -cycloalkyl residues are





As used herein, the term “**linear or branched C₂–C₈–alkenyl**” refers to –CH=CH₂,






$-\text{C}_3\text{H}_6-\text{C}(\text{C}_2\text{H}_5)=\text{CH}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{CH}(\text{C}_2\text{H}_5)-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{C}(\text{C}_4\text{H}_9)=\text{CH}_2$,
 $-\text{C}_2\text{H}_4-\text{C}(\text{C}_3\text{H}_7)=\text{CH}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{C}(\text{C}_2\text{H}_5)=\text{CH}-\text{C}_2\text{H}_5$, $-\text{C}_2\text{H}_4-\text{C}(\text{C}_2\text{H}_5)=\text{C}(\text{CH}_3)_2$,
 $-\text{C}_2\text{H}_4-\text{C}[\text{C}(\text{CH}_3)_3]=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{C}[\text{CH}(\text{CH}_3)(\text{C}_2\text{H}_5)]=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{C}[\text{CH}_2-\text{CH}(\text{CH}_3)_2]=\text{CH}_2$,
 $-\text{C}_4\text{H}_8-\text{CH}=\text{CH}-\text{CH}=\text{CH}_2$, $-\text{C}_3\text{H}_6-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{C}_2\text{H}_4-\text{CH}=\text{CH}_2$,
 $-\text{C}_3\text{H}_6-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{C}_2\text{H}_5$,
 $-\text{C}_3\text{H}_6-\text{CH}=\text{CH}-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{C}_3\text{H}_6-\text{CH}=\text{C}(\text{CH}_3)-\text{CH}=\text{CH}_2$, $-\text{C}_3\text{H}_6-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}=\text{CH}_2$,
 $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}-\text{CH}=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{CH}_2-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}_2$,
 $-\text{C}_2\text{H}_4-\text{CH}=\text{C}(\text{CH}_3)-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}_2$,
 $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{CH}=\text{C}(\text{CH}_3)_2$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{CH}=\text{C}(\text{CH}_3)-\text{CH}=\text{CH}-\text{CH}_3$,
 $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{CH}=\text{C}(\text{CH}_3)-\text{C}(\text{CH}_3)=\text{CH}_2$,
 $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)=\text{CH}-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)=\text{C}(\text{CH}_3)-\text{CH}=\text{CH}_2$, $-\text{CH}=\text{CH}-\text{Ph}$ and
 $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{CH}=\text{CH}_2$,


wherein these residues can be substituted with 1 to 5 substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . However it is clear to a skilled person that the term "can be substituted" refers to the replacement of a hydrogen atom by one of the substituents Z^8 , Z^9 , Z^{10} , Z^{11} or Z^{12} . Moreover, it is clear to a skilled person that only these hydrogen atoms which are present in the residue can be replaced by the substituents Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . Thus, since the vinyl group has only three hydrogen atoms, only three hydrogen atoms can be replaced by three substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . The carbon atom number of C_2-C_8 refers only to the carbon atoms of the alkenyl residue and does not include the carbon atoms of the substituents Z^8 to Z^{12} . For the definitions used herein, the group $-\text{CH}=\text{CH}-\text{Ph}$ should fall under the term "linear or branched C_2-C_8 -alkenyl".

Preferred are $-\text{CH}=\text{CH}_2$, $-\text{CH}_2-\text{CH}=\text{CH}_2$, $-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}=\text{CH}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}_2$, $-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_3$. Especially preferred are $-\text{CH}=\text{CH}_2$, $-\text{CH}_2-\text{CH}=\text{CH}_2$, and $-\text{CH}=\text{CH}-\text{CH}_3$.

Examples of preferred substituted linear or branched C_2-C_8 -alkenyl residues are
 $-\text{CF}=\text{CF}_2$, $-\text{CCl}=\text{Cl}_2$, $-\text{CH}=\text{CH}-\text{OH}$, $-\text{CH}=\text{CH}-\text{NH}_2$, $-\text{CH}=\text{CH}-\text{Cl}$, $-\text{CH}=\text{CH}-\text{CF}_3$,
 $-\text{C}(\text{CH}_3)=\text{CH}-\text{NH}_2$, $-\text{C}(\text{CH}_3)=\text{CH}-\text{OH}$, $-\text{C}(\text{CH}_3)=\text{CH}-\text{CF}_3$, $-\text{C}(\text{CH}_3)=\text{CH}-\text{Cl}$,
 $-\text{CH}_2-\text{CH}=\text{CF}_2$, $-\text{CF}_2-\text{CH}=\text{CH}_2$, $-\text{CH}(\text{OH})-\text{CH}=\text{CH}_2$, $-\text{CH}(\text{NH}_2)-\text{CH}=\text{CH}_2$,
 $-\text{CHCl}-\text{CH}=\text{CH}_2$, $-\text{CH}(\text{CF}_3)-\text{CH}=\text{CH}_2$, $-\text{CH}=\text{CCl}-\text{CH}_3$, $-\text{CH}=\text{C}(\text{OH})-\text{CH}_3$,
 $-\text{CH}=\text{C}(\text{NH}_2)-\text{CH}_3$, $-\text{CH}=\text{C}(\text{CF}_3)-\text{CH}_3$, $-\text{C}(\text{OH})=\text{CH}-\text{CH}_3$, $-\text{CCl}=\text{CH}-\text{CH}_3$,
 $-\text{C}(\text{NH}_2)=\text{CH}-\text{CH}_3$, $-\text{C}(\text{CF}_3)=\text{CH}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{OH}$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{NH}_2$,
 $-\text{C}_2\text{H}_4-\text{CH}=\text{CHCl}$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CH}-\text{CF}_3$, $-\text{C}_2\text{H}_4-\text{C}(\text{OH})=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{CCl}=\text{CH}_2$,
 $-\text{C}_2\text{H}_4-\text{C}(\text{NH}_2)=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{C}(\text{CF}_3)=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{CH}=\text{CF}_2$, $-\text{C}_2\text{H}_4-\text{CF}=\text{CF}_2$,
 $-\text{C}_2\text{H}_4-\text{CCl}=\text{CH}_2$, $-\text{C}_2\text{H}_4-\text{CCl}=\text{CCl}_2$, $-\text{CH}_2-\text{COH}=\text{CH}-\text{CH}_3$, $-\text{CH}_2-\text{CCl}=\text{CH}-\text{CH}_3$,



As used herein, the term “**linear or branched C₂–C₈–alkynyl**” refers to $-\text{C}\equiv\text{CH}$,





- $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{CH}(\text{CH}_3)-\text{C}\equiv\text{CH}$, $-\text{C}_2\text{H}_4-\text{CH}(\text{C}_3\text{H}_7)-\text{C}\equiv\text{CH}$, $-\text{C}_2\text{H}_4-\text{C}(\text{CH}_3)(\text{C}_2\text{H}_5)-\text{C}\equiv\text{CH}$,
 $-\text{C}_4\text{H}_8-\text{C}\equiv\text{C}-\text{C}\equiv\text{CH}$, $-\text{C}_3\text{H}_6-\text{C}\equiv\text{C}-\text{CH}_2-\text{C}\equiv\text{CH}$, $-\text{C}_2\text{H}_4-\text{C}\equiv\text{C}-\text{C}_2\text{H}_4-\text{C}\equiv\text{CH}$,
 $-\text{C}_3\text{H}_6-\text{C}\equiv\text{C}-\text{C}\equiv\text{C}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{C}\equiv\text{C}-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_3$, $-\text{C}_2\text{H}_4-\text{C}\equiv\text{C}-\text{C}\equiv\text{C}-\text{C}_2\text{H}_5$,
 $-\text{C}_2\text{H}_4-\text{C}\equiv\text{C}-\text{CH}(\text{CH}_3)-\text{C}\equiv\text{CH}$, $-\text{C}\equiv\text{C}-\text{Ph}$, $-\text{C}_2\text{H}_4-\text{CH}(\text{CH}_3)-\text{C}\equiv\text{C}-\text{C}\equiv\text{CH}$,
 $-\text{C}_2\text{H}_4-\text{CH}(\text{C}\equiv\text{CH})-\text{CH}_2-\text{C}\equiv\text{CH}$, $-\text{C}_2\text{H}_4-\text{C}(\text{C}\equiv\text{CH})_2-\text{CH}_3$, $-\text{C}_3\text{H}_6-\text{CH}(\text{C}\equiv\text{CH})_2$,
 $-\text{C}_2\text{H}_4-\text{CH}(\text{C}\equiv\text{CH})-\text{C}\equiv\text{C}-\text{CH}_3$, wherein these residues can be substituted with 1 to 5
substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . However it is clear to a skilled person
that the term "can be substituted" refers to the replacement of a hydrogen atom by one of
the substituents Z^8 , Z^9 , Z^{10} , Z^{11} or Z^{12} . Moreover it is clear to a skilled person that only
these hydrogen atoms which are present in the residue can be replaced by the
substituents Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . Thus, since the acetylenyl group has only one
hydrogen atom, only one hydrogen atom can be replaced by one substituent selected
from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . The carbon atom number of C_2-C_8 refers only to the carbon
atoms of the alkynyl residue and does not include the carbon atoms of the substituents Z^8
to Z^{12} . For the definitions used herein, the group $-\text{C}\equiv\text{C}-\text{Ph}$ should fall under the term
"linear or branched C_2-C_8 -alkynyl".


Preferred are $-\text{C}\equiv\text{CH}$, $-\text{C}\equiv\text{C}-\text{CH}_3$.


- Examples of preferred substituted linear or branched C_2-C_8 -alkynyl residues are
 $-\text{C}\equiv\text{C}-\text{OH}$, $-\text{C}\equiv\text{C}-\text{Cl}$, $-\text{C}\equiv\text{C}-\text{NH}_2$, $-\text{C}\equiv\text{C}-\text{CF}_3$, $-\text{C}\equiv\text{C}-\text{CH}_2\text{Cl}$, $-\text{C}\equiv\text{C}-\text{CHCl}_2$,
 $-\text{C}\equiv\text{C}-\text{CCl}_3$, $-\text{C}\equiv\text{C}-\text{CF}_3$, $-\text{CH}_2-\text{C}\equiv\text{C}-\text{CO}-\text{CH}_3$,


- As used herein, the term " **C_1-C_9 -heterocyclyl**" covers saturated or partly unsaturated
heterocyclic residues with 1 to 9 ring carbon atoms, but not aromatic residues and
covers also bicyclic saturated or partly unsaturated residues with 1 to 9 ring carbon
atoms, but preferably not fully aromatic residues which are aromatic throughout the
bicyclic system but may comprise partly aromatic ring systems, wherein one ring of the
bicyclic ring system is aromatic. Preferably " **C_1-C_9 -heterocyclyl**" refers to













wherein these residues can be substituted with 1 to 5 substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^8 , Z^9 , Z^{10} , Z^{11} or Z^{12} . Moreover it is clear to a skilled person that only these hydrogen atoms which are present in the residue can be replaced by the substituents Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . Thus, since the oxirane group (also named as ethylene oxide group) has only three hydrogen atoms, only three hydrogen atoms can be replaced by three substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . The carbon atom number of C_1 – C_9 refers only to the carbon

atoms of the heterocyclic ring system (heterocyclyl) and does not include the carbon atoms of the substituents Z^8 to Z^{12} .


The term "**heterocyclyl**" as used herein refers to C_1 – C_9 –heterocyclyl, 3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6-membered heterocyclyl, monounsaturated 4-membered heterocyclyl, monounsaturated 5-membered heterocyclyl, and monounsaturated 6-membered heterocyclyl.


10 Examples of preferred substituted C_1 – C_9 –heterocyclyl residues are







As used herein, the term “**C₁–C₁₀–heteroaryl**” refers to aromatic residues with one or more heteroatoms such as O, S, N and especially N and refers preferably to











































wherein these residues can be substituted with 1 to 5 substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^8 , Z^9 , Z^{10} , Z^{11} or

Z^{12} . Moreover it is clear to a skilled person that only these hydrogen atoms which are present in the residue can be replaced by the substituents Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . Thus, since the oxadiazole group has only one hydrogen atom, only one hydrogen atom can be replaced by one substituent selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} . The carbon atom number of **C**₁–**C**₁₀ refers only to the carbon atoms of the heteroaromatic ring system (heteroaryl) and does not include the carbon atoms of the substituents Z^8 to Z^{12} .

Examples of preferred substituted **C**₁–**C**₁₀–heteroaryl residues are




















As used herein, the term “**C₆–C₁₄–aryl**” refers to aromatic residues or more specific to aromatic carbocyclic residues with one, two or three aromatic rings and refers preferably to phenyl and naphthyl, wherein these phenyl and naphthyl residues can be substituted with 1 to 5 substituents selected from Z⁸, Z⁹, Z¹⁰, Z¹¹ and Z¹². However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z⁸, Z⁹, Z¹⁰, Z¹¹ or Z¹². The carbon atom number of **C₆–C₁₄** refers only to the carbon atoms of the aromatic ring system (aryl) and does not include the carbon atoms of the substituents Z⁸ to Z¹².

Examples of preferred C₆–C₁₄–aryl groups and substituted C₆–C₁₄–aryl residues are









As used herein, the term “**C₇–C₁₆–spiroalkyl**” refers to spirocarbocyclic residues, wherein these spirocarbocyclic residues can be substituted with 1 to 3 substituents selected from Z⁵, Z⁶ and Z⁷. However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z⁵, Z⁶ and Z⁷. It is also possible that two of the substituents Z⁵, Z⁶ and Z⁷ represent together an oxygen atom and form together with the carbon atom of the spiroalkyl residue to which they are both attached a carbonyl moiety. The carbon atom number of **C₇–C₁₆** refers only to the carbon atoms of the spiro ring system and does not include the carbon atoms of the substituents. Thus a spiro[4,5]decyl residue is counted as a C₁₀–spiroalkyl regardless if this spiro residue carries five pentyl substituents.

Examples of preferred C₇–C₁₆–spiroalkyl groups and substituted C₇–C₁₆–spiroalkyl groups are







preferred substituents Z^5 , Z^6 and Z^7 are $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OC}_2\text{H}_5$, $-\text{OC}_3\text{H}_7$, $-\text{NH}_2$, $-\text{N}(\text{CH}_3)_2$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{CN}$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{OCHF}_2$, $-\text{OCF}_3$.


As used herein, the term “**C₅–C₁₄–spiroheterocyclyl**” refers to spiro residues with one, two or three heteroatoms such as O, S, N in the spiro ring system, wherein these spiroheterocyclic residues can be substituted with 1 to 3 substituents selected from Z⁵, Z⁶ and Z⁷. However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z⁵, Z⁶ and Z⁷. The carbon atom number of **C₅–C₁₄** refers only to the carbon atoms of the spiro ring system and does not include the carbon atoms of the substituents. Thus a azaspiro[4,5]decyl residue is counted as a C₉–spiroalkyl regardless if this azaspiro[4,5]decyl residue carries five isopropyl substituents.


10


Examples of preferred C₅–C₁₄–spiroheterocyclyl groups and substituted C₅–C₁₄–spiroheterocyclyl groups are











wherein Y and X represent independently of each other $-O-$, $-NH-$, $-NR^{11}-$, $-SO-$, or $-SO_2-$, preferably $-NH-$ and $-NR^{11}-$ and Z⁵ and Z⁶ represent independently of each other $-CH_3$, $-C_2H_5$, $-C_3H_7$, $-CH(CH_3)_2$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OC_3H_7$, $-NH_2$, $-N(CH_3)_2$, $-F$, $-Cl$, $-Br$, $-I$, $-CN$, $-CH_2F$, $-CHF_2$, $-CF_3$, $-OCHF_2$, or $-OCF_3$.


5

As used herein, the term “**3-membered heterocyclyl**” refers to a substituted or non substituted ring system of three atoms including at least one heteroatom such as O, S, SO, SO₂, N, NO, wherein these 3-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z¹, Z², Z³ and Z⁴. However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z¹, Z², Z³ or Z⁴. Moreover it is clear to a skilled person that only these hydrogen atoms which are present in the 3-membered heterocyclic group can be replaced by the substituents Z¹, Z², Z³ and Z⁴. Thus, since the diazirene group has only one hydrogen atom, only one hydrogen atom can be replaced by one substituent selected

10


- from Z^1 , Z^2 , Z^3 and Z^4 . It is also possible that two of the substituents Z^1 , Z^2 , Z^3 and Z^4 represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with the ring sulphur atom to which they are attached. If the 3-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z^1 , Z^2 , Z^3 and Z^4 , said Z substituent represents R^{11} . If the 3-membered heterocyclic residue contains two nitrogen atoms which are both substituted by one of the substituents Z^1 , Z^2 , Z^3 and Z^4 , the first Z substituent represents R^{11} and the second Z substituent represents R^{12} .

Examples of preferred 3-membered heterocyclic groups and substituted 3-membered heterocyclic groups are



- 15 Preferably Z^1 to Z^4 represent independently of each other $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OC}_2\text{H}_5$, $-\text{OC}_3\text{H}_7$, $-\text{NH}_2$, $-\text{N}(\text{CH}_3)_2$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{CN}$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{OCHF}_2$, or $-\text{OCF}_3$.

Preferably R^{11} represents $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$,




cyclo- C_3H_5 , cyclo- C_4H_7 , cyclo- C_5H_9 , cyclo- C_6H_{11} , cyclo- C_7H_{13} ,

- 20 $-\text{C}_4\text{H}_9$, $-\text{CH}_2\text{CH}(\text{CH}_3)_2$, $-\text{CH}(\text{CH}_3)\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)_3$, $-\text{C}_5\text{H}_{11}$, $-\text{CH}(\text{CH}_3)\text{C}_3\text{H}_7$, $-\text{CH}_2\text{CH}(\text{CH}_3)\text{C}_2\text{H}_5$, $-\text{CH}(\text{CH}_3)\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2\text{C}_2\text{H}_5$, $-\text{CH}_2\text{C}(\text{CH}_3)_3$, $-\text{CH}(\text{C}_2\text{H}_5)_2$, $-\text{C}_2\text{H}_4\text{CH}(\text{CH}_3)_2$, $-\text{C}_6\text{H}_{13}$, $-\text{C}_7\text{H}_{15}$, $-\text{C}_8\text{H}_{17}$, $-\text{Ph}$, $-\text{CH}_2\text{Ph}$, $-\text{CH}_2\text{CH}_2\text{Ph}$, $-\text{CH}=\text{CHPh}$, $-\text{CH}=\text{CH}_2$, $-\text{CH}_2\text{CH}=\text{CH}_2$, $-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}=\text{CHCH}_3$, $-\text{C}_2\text{H}_4\text{CH}=\text{CH}_2$, $-\text{CH}_2\text{CH}=\text{CHCH}_3$, $-\text{CH}=\text{CHC}_2\text{H}_5$,
 25 $-\text{CH}_2\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}(\text{CH}_3)\text{CH}=\text{CH}_2$, $-\text{CH}=\text{C}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)=\text{CHCH}_3$, $-\text{C}\equiv\text{CH}$, $-\text{C}\equiv\text{CCH}_3$, $-\text{CH}_2\text{C}\equiv\text{CH}$, $-\text{C}_2\text{H}_4\text{C}\equiv\text{CH}$, $-\text{CH}_2\text{C}\equiv\text{CCH}_3$, $-\text{C}\equiv\text{CC}_2\text{H}_5$, $-\text{CH}_2\text{OCF}_3$, $-\text{C}_2\text{H}_4\text{OCF}_3$, $-\text{C}_3\text{H}_6\text{OCF}_3$, $-\text{CH}_2\text{OCH}_3$, $-\text{C}_2\text{H}_4\text{OCH}_3$, $-\text{C}_3\text{H}_6\text{OCH}_3$, $-\text{CH}_2\text{OC}_2\text{H}_5$, $-\text{C}_2\text{H}_4\text{OC}_2\text{H}_5$, or $-\text{C}_3\text{H}_6\text{OC}_2\text{H}_5$;


As used herein for the substituent R^3 , the term “**4-membered heterocyclyl**” refers to a substituted or non substituted ring system of four atoms including at least one heteroatom such as O, S, SO, SO_2 , N, NO, wherein these 4-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 . It is also possible that two of the substituents Z^1 , Z^2 , Z^3 and Z^4 represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with the ring sulphur atom to which they are attached. If the 4-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z^1 , Z^2 , Z^3 and Z^4 , said Z substituent represents R^{11} . If the 4-membered heterocyclic residue contains two nitrogen atoms which are both substituted by one of the substituents Z^1 , Z^2 , Z^3 and Z^4 , the first Z substituent represents R^{11} and the second Z substituent represents R^{12} . The same definition applies for the substituent R^8 with the only difference that the optional substituents of the 4-membered heterocyclyl residue are Z^5 to Z^7 instead of Z^1 to Z^4 . Thus for R^8 the optional substituent Z^1 is replaced by Z^5 , Z^2 is replaced by Z^6 , Z^3 is replaced by Z^7 , and Z^4 is hydrogen.

Examples of preferred 4-membered heterocyclic groups and substituted 4-membered heterocyclic groups for R^3 are



Preferably Z^1 to Z^4 represent independently of each other $-CH_3$, $-C_2H_5$, $-C_3H_7$, $-CH(CH_3)_2$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OC_3H_7$, $-NH_2$, $-N(CH_3)_2$, $-F$, $-Cl$, $-Br$, $-I$, $-CN$, $-CH_2F$, $-CHF_2$, $-CF_3$, $-OCHF_2$, and $-OCF_3$.

Preferred substituents for R^{11} are $-CH_3$, $-C_2H_5$, $-C_3H_7$, $-CH(CH_3)_2$, $-CH_2F$, $-CHF_2$, $-CF_3$,




cyclo-C₃H₅, cyclo-C₄H₇, cyclo-C₅H₉, cyclo-C₆H₁₁, cyclo-C₇H₁₃,

-C₄H₉, -CH₂-CH(CH₃)₂, -CH(CH₃)-C₂H₅, -C(CH₃)₃, -C₅H₁₁, -CH(CH₃)-C₃H₇,
 -CH₂-CH(CH₃)-C₂H₅, -CH(CH₃)-CH(CH₃)₂, -C(CH₃)₂-C₂H₅, -CH₂-C(CH₃)₃,
 -CH(C₂H₅)₂, -C₂H₄-CH(CH₃)₂, -C₆H₁₃, -C₇H₁₅, -C₈H₁₇, -Ph, -CH₂-Ph,
 -CH₂-CH₂-Ph, -CH=CH-Ph, -CH=CH₂, -CH₂-CH=CH₂, -C(CH₃)=CH₂,
 5 -CH=CH-CH₃, -C₂H₄-CH=CH₂, -CH₂-CH=CH-CH₃, -CH=CH-C₂H₅,
 -CH₂-C(CH₃)=CH₂, -CH(CH₃)-CH=CH₂, -CH=C(CH₃)₂, -C(CH₃)=CH-CH₃,
 -C≡CH, -C≡C-CH₃, -CH₂-C≡CH, -C₂H₄-C≡CH, -CH₂-C≡C-CH₃,
 -C≡C-C₂H₅, -CH₂-OCF₃, -C₂H₄-OCF₃, -C₃H₆-OCF₃, -CH₂-OCH₃,
 -C₂H₄-OCH₃, -C₃H₆-OCH₃, -CH₂-OC₂H₅, -C₂H₄-OC₂H₅, and -C₃H₆-OC₂H₅.


10

Preferred 4-membered heterocyclyl groups are



As used herein, the term “**5-membered heterocyclyl**” refers to a substituted or non substituted ring system of five atoms including at least one heteroatom such as O, S, SO, SO₂, N, NO, wherein these 5-membered heterocyclic residues can be substituted
 15 with 1 to 4 substituents selected from Z¹, Z², Z³ and Z⁴. It is also possible that two of the substituents Z¹, Z², Z³ and Z⁴ represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with
 20 the ring sulphur atom to which they are attached. If the 5-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z¹, Z², Z³ and Z⁴, said Z substituent represents R¹¹. If the 5-membered heterocyclic residue contains two nitrogen atoms which are both substituted by one of the substituents Z¹, Z², Z³ and Z⁴, the first Z substituent represents R¹¹ and the second Z substituent
 25 represents R¹². The same definition applies for the substituent R⁸ with the only difference that the optional substituents of the 5-membered heterocyclyl residue are Z⁵ to Z⁷ instead of Z¹ to Z⁴. Thus for R⁸ the optional substituent Z¹ is replaced by Z⁵, Z² is replaced by Z⁶, Z³ is replaced by Z⁷, and Z⁴ is hydrogen.


30 Examples of preferred 5-membered heterocyclic groups and substituted 5-membered heterocyclic groups for R³ are




wherein the afore-mentioned 5-membered heterocyclic groups can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 .

As used herein, the term “**6-membered heterocyclyl**” refers to a substituted or non substituted ring system of six atoms including at least one heteroatom such as O, S, SO, SO₂, N, NO, wherein these 6-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z¹, Z², Z³ and Z⁴. It is also possible that two of the substituents Z¹, Z², Z³ and Z⁴ represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with the ring sulphur atom to which they are attached. If the 6-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z¹, Z², Z³ and Z⁴, said Z substituent represents R¹¹. If the 6-membered heterocyclic residue contains two nitrogen atoms which are both substituted by one of the substituents Z¹, Z², Z³ and Z⁴, the first Z substituent represents R¹¹ and the second Z substituent represents R¹². The same definition applies for the substituent R⁸ with the only difference that the optional substituents of the 6-membered heterocyclyl residue are Z⁵ to Z⁷ instead of Z¹ to Z⁴. Thus for R⁸ the optional substituent Z¹ is replaced by Z⁵, Z² is replaced by Z⁶, Z³ is replaced by Z⁷, and Z⁴ is hydrogen.

Examples of preferred 6-membered heterocyclic groups and substituted 6-membered heterocyclic groups for R³ are





wherein the afore-mentioned 6-membered heterocyclic groups can be substituted with 1 to 4 substituents selected from Z¹, Z², Z³ and Z⁴. Preferred residues for the substituents Z¹ to Z⁴ are disclosed above.

5


As used herein, the term “**monounsaturated 4-membered heterocyclyl**” refers to a substituted or non substituted ring system of four atoms including at least one heteroatom such as O, S, SO, SO₂, N, NO, and one double bond, wherein these monounsaturated 4-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z¹, Z², Z³ and Z⁴. However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z¹, Z², Z³ or Z⁴. Moreover it is clear to a skilled person that only these hydrogen atoms which are present in the monounsaturated 4-membered heterocyclic residue can be replaced by the substituents Z¹, Z², Z³ and Z⁴. It is also possible that two of the substituents Z¹, Z², Z³ and Z⁴ represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together

10

15

- with the ring sulphur atom to which they are attached. If the monounsaturated 4-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z^1 , Z^2 , Z^3 and Z^4 , said Z substituent represents R^{11} . If the monounsaturated 4-membered heterocyclic residue contains two nitrogen atoms which are both substituted by one of the substituents Z^1 , Z^2 , Z^3 and Z^4 , the first Z substituent represents R^{11} and the second Z substituent represents R^{12} .


Examples of preferred monounsaturated 4-membered heterocyclic groups and substituted 4-membered heterocyclic groups for R^3 are



10

Preferably Z^1 to Z^4 represent independently of each other $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OC}_2\text{H}_5$, $-\text{OC}_3\text{H}_7$, $-\text{NH}_2$, $-\text{N}(\text{CH}_3)_2$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{CN}$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{OCHF}_2$, and $-\text{OCF}_3$.

Preferred substituents for R^{11} are $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$,



$-\text{CF}_3$, cyclo- C_3H_5 , cyclo- C_4H_7 , cyclo- C_5H_9 , cyclo- C_6H_{11} , cyclo- C_7H_{13} ,


- 15 $-\text{C}_4\text{H}_9$, $-\text{CH}_2\text{CH}(\text{CH}_3)_2$, $-\text{CH}(\text{CH}_3)\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)_3$, $-\text{C}_5\text{H}_{11}$, $-\text{CH}(\text{CH}_3)\text{C}_3\text{H}_7$, $-\text{CH}_2\text{CH}(\text{CH}_3)\text{C}_2\text{H}_5$, $-\text{CH}(\text{CH}_3)\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2\text{C}_2\text{H}_5$, $-\text{CH}_2\text{C}(\text{CH}_3)_3$, $-\text{CH}(\text{C}_2\text{H}_5)_2$, $-\text{C}_2\text{H}_4\text{CH}(\text{CH}_3)_2$, $-\text{C}_6\text{H}_{13}$, $-\text{C}_7\text{H}_{15}$, $-\text{C}_8\text{H}_{17}$, $-\text{Ph}$, $-\text{CH}_2\text{Ph}$, $-\text{CH}_2\text{CH}_2\text{Ph}$, $-\text{CH}=\text{CHPh}$, $-\text{CH}=\text{CH}_2$, $-\text{CH}_2\text{CH}=\text{CH}_2$, $-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}=\text{CHCH}_3$, $-\text{C}_2\text{H}_4\text{CH}=\text{CH}_2$, $-\text{CH}_2\text{CH}=\text{CHCH}_3$, $-\text{CH}=\text{CHC}_2\text{H}_5$,


$-\text{CH}_2-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}(\text{CH}_3)-\text{CH}=\text{CH}_2$, $-\text{CH}=\text{C}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_3$,
 $-\text{C}\equiv\text{CH}$, $-\text{C}\equiv\text{C}-\text{CH}_3$, $-\text{CH}_2-\text{C}\equiv\text{CH}$, $-\text{C}_2\text{H}_4-\text{C}\equiv\text{CH}$, $-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_3$,
 $-\text{C}\equiv\text{C}-\text{C}_2\text{H}_5$, $-\text{CH}_2-\text{OCF}_3$, $-\text{C}_2\text{H}_4-\text{OCF}_3$, $-\text{C}_3\text{H}_6-\text{OCF}_3$, $-\text{CH}_2-\text{OCH}_3$,
 $-\text{C}_2\text{H}_4-\text{OCH}_3$, $-\text{C}_3\text{H}_6-\text{OCH}_3$, $-\text{CH}_2-\text{OC}_2\text{H}_5$, $-\text{C}_2\text{H}_4-\text{OC}_2\text{H}_5$, and $-\text{C}_3\text{H}_6-\text{OC}_2\text{H}_5$.


5

As used herein, the term “**monounsaturated 5-membered heterocyclyl**” refers to a substituted or non substituted ring system of five atoms including at least one heteroatom such as O, S, SO, SO₂, N, NO, and one double bond, wherein these monounsaturated 5-membered heterocyclic residues can be substituted with 1 to 4
 10 substituents selected from Z¹, Z², Z³ and Z⁴. It is also possible that two of the substituents Z¹, Z², Z³ and Z⁴ represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with
 15 the ring sulphur atom to which they are attached. If the monounsaturated 5-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z¹, Z², Z³ and Z⁴, said Z substituent represents R¹¹. If the monounsaturated 5-membered heterocyclic residue contains two nitrogen atoms which are both substituted by one of the substituents Z¹, Z², Z³ and Z⁴, the first Z substituent
 20 represents R¹¹ and the second Z substituent represents R¹².

Examples of preferred monounsaturated 5-membered heterocyclic groups and substituted 5-membered heterocyclic groups for R³ are









wherein the afore-mentioned monounsaturated 5-membered heterocyclic groups can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 .


5 Preferably Z^1 to Z^4 represent independently of each other $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OC}_2\text{H}_5$, $-\text{OC}_3\text{H}_7$, $-\text{NH}_2$, $-\text{N}(\text{CH}_3)_2$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{CN}$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{OCHF}_2$, and $-\text{OCF}_3$.


As used herein, the term “**monounsaturated 6-membered heterocyclyl**” refers to a substituted or non substituted ring system of six atoms including at least one heteroatom such as O, S, SO, SO₂, N, NO, and one double bond, wherein these monounsaturated 6-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z¹, Z², Z³ and Z⁴. It is also possible that two of the substituents Z¹, Z², Z³ and Z⁴ represent together an oxygen atom and form together with the ring carbon atom of the heterocyclic ring to which they are both attached a carbonyl moiety or a sulfoxide moiety together with the ring sulphur atom to which they are attached or both Z substituents represent oxygen and form a sulfone moiety together with the ring sulphur atom to which they are attached. If the monounsaturated 6-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z¹, Z², Z³ and Z⁴, said Z substituent represents R¹¹. If the monounsaturated 6-membered heterocyclic residue contains two nitrogen atoms which are both substituted by one of the substituents Z¹, Z², Z³ and Z⁴, the first Z substituent represents R¹¹ and the second Z substituent represents R¹².


Examples of preferred monounsaturated 6-membered heterocyclic groups and substituted 6-membered heterocyclic groups for R³ are















wherein the afore-mentioned monounsaturated 6-membered heterocyclic groups can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 .

5 Preferably Z^1 to Z^4 represent independently of each other $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OC}_2\text{H}_5$, $-\text{OC}_3\text{H}_7$, $-\text{NH}_2$, $-\text{N}(\text{CH}_3)_2$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{CN}$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{OCHF}_2$, and $-\text{OCF}_3$.

Preferred substituents for R^{11} are $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$,




–CF₃, cyclo-C₃H₅, cyclo-C₄H₇, cyclo-C₅H₉, cyclo-C₆H₁₁, cyclo-C₇H₁₃,

–C₄H₉, –CH₂–CH(CH₃)₂, –CH(CH₃)–C₂H₅, –C(CH₃)₃, –C₅H₁₁, –CH(CH₃)–C₃H₇,
 –CH₂–CH(CH₃)–C₂H₅, –CH(CH₃)–CH(CH₃)₂, –C(CH₃)₂–C₂H₅, –CH₂–C(CH₃)₃,
 –CH(C₂H₅)₂, –C₂H₄–CH(CH₃)₂, –C₆H₁₃, –C₇H₁₅, –C₈H₁₇, –Ph, –CH₂–Ph,
 –CH₂–CH₂–Ph, –CH=CH–Ph, –CH=CH₂, –CH₂–CH=CH₂, –C(CH₃)=CH₂,
 5 –CH=CH–CH₃, –C₂H₄–CH=CH₂, –CH₂–CH=CH–CH₃, –CH=CH–C₂H₅,
 –CH₂–C(CH₃)=CH₂, –CH(CH₃)–CH=CH₂, –CH=C(CH₃)₂, –C(CH₃)=CH–CH₃,
 –C≡CH, –C≡C–CH₃, –CH₂–C≡CH, –C₂H₄–C≡CH, –CH₂–C≡C–CH₃,
 –C≡C–C₂H₅, –CH₂–OCF₃, –C₂H₄–OCF₃, –C₃H₆–OCF₃, –CH₂–OCH₃,
 –C₂H₄–OCH₃, –C₃H₆–OCH₃, –CH₂–OC₂H₅, –C₂H₄–OC₂H₅, and –C₃H₆–OC₂H₅.

10


The term “**carbocyclyl**” as used herein refers to C₃–C₈–cycloalkyl, 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, and 6-membered carbocyclyl.

As used herein for the substituent R³,
 the term “**3-membered carbocyclyl**” refers to




15

As used herein for the substituent R³,
 the term “**4-membered carbocyclyl**” refers to




The same definition applies for the substituent R⁸ with the only difference that the optional substituents of the 4-membered carbocyclyl residue are Z⁵ to Z⁷ instead of Z¹ to Z⁴. Thus for R⁸ the optional substituent Z¹ is replaced by Z⁵, Z² is replaced by Z⁶, Z³ is replaced by Z⁷, and Z⁴ is hydrogen.

As used herein for the substituent R³,
 the term “**5-membered carbocyclyl**” refers to



20 The same definition applies for the substituent R⁸ with the only difference that the optional substituents of the 5-membered carbocyclyl residue are Z⁵ to Z⁷ instead of Z¹ to Z⁴. Thus for R⁸ the optional substituent Z¹ is replaced by Z⁵, Z² is replaced by Z⁶, Z³ is replaced by Z⁷, and Z⁴ is hydrogen.


As used herein for the substituent R^3 ,
the term “**6-membered carbocyclyl**” refers to



The same definition applies for the substituent R^8 with the only difference that the optional substituents of the 6-membered carbocyclyl residue are Z^5 to Z^7 instead of Z^1 to Z^4 . Thus for R^8 the optional substituent Z^1 is replaced by Z^5 , Z^2 is replaced by Z^6 , Z^3 is replaced by Z^7 , and Z^4 is hydrogen.

5


As used herein, the term “**6-membered aryl**” refers to phenyl, substituted phenyl as well as to benzo residues where a non aromatic ring is condensed to a benzo ring such as a benzodioxol:



wherein the afore-mentioned 6-membered aryl groups can be substituted with 1 to 4
substituents selected from Z^1 , Z^2 , Z^3 and Z^4 .

10

As used herein, the term “**naphthyl**” refers to





As used herein, the term “**5-membered heteroaryl**” refers to a substituted or non substituted aromatic ring system of five atoms including at least one heteroatom such as O, S, SO, SO₂, N, NO, wherein these aromatic 5-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 . However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^1 , Z^2 , Z^3 or Z^4 . Moreover it is clear to a skilled person that only these hydrogen atoms which are present in the aromatic 5-membered heterocyclic group can be replaced by the substituents Z^1 , Z^2 , Z^3 and Z^4 . Thus, since the tetrazole group has only one hydrogen atom, only one hydrogen atom can be replaced by one substituent selected from Z^1 , Z^2 , Z^3 and Z^4 . If the aromatic 5-membered heterocyclic residue contains a nitrogen atom which is substituted by one of the substituents Z^1 , Z^2 , Z^3 and Z^4 , said Z substituent represents R^{11} .


15

20

Examples of preferred aromatic 5-membered heterocyclic groups and substituted aromatic 5-membered heterocyclic groups are








wherein the afore-mentioned 5-membered heteroaryl groups can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 .

- 5 Preferably Z^1 to Z^4 represent independently of each other $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OC}_2\text{H}_5$, $-\text{OC}_3\text{H}_7$, $-\text{NH}_2$, $-\text{N}(\text{CH}_3)_2$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{CN}$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{OCHF}_2$, and $-\text{OCF}_3$.

10 As used herein, the term “**6-membered heteroaryl**” refers to a substituted or non substituted aromatic ring system of six atoms including at least one heteroatom such as O, S, SO, SO₂, N, NO, wherein these aromatic 6-membered heterocyclic residues can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 . However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a

hydrogen atom by one of the substituents Z^1 , Z^2 , Z^3 or Z^4 . Moreover it is clear to a skilled person that only these hydrogen atoms which are present in the aromatic 6-membered heterocyclic group can be replaced by the substituents Z^1 , Z^2 , Z^3 and Z^4 . Thus, since the triazine group has only two hydrogen atoms, only two hydrogen atoms can be replaced by two substituents selected from Z^1 , Z^2 , Z^3 and Z^4 .

Examples of preferred aromatic 6-membered heterocyclic groups and substituted aromatic 6-membered heterocyclic groups are



wherein the afore-mentioned 6-membered heteroaryl groups can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 .

It is also possible that the substituents R^3 and R^4 are not single substituent and that R^3 together with R^4 can form a carbocyclic or heterocyclic 4-, 5-, 6- or 7-membered ring with the two carbon atoms of the benzo ring to which R^3 and R^4 are attached and that 4-, 5-, 6- or 7-membered ring can be aromatic or non aromatic and can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 .

The term "carbocyclic 4-membered ring" is used synonymic for the term "4-membered carbocyclyl". In case R^{11} and R^{12} together with the atoms to which they are attached represent a "carbocyclic 4-membered ring", the optional substituents Z^1 to Z^4 are replaced by the optional substituents Z^8 to Z^{13} .

The term "carbocyclic 5-membered ring" is used synonymic for the term "5-membered carbocyclyl". In case R^{11} and R^{12} together with the atoms to which they are attached represent a "carbocyclic 5-membered ring", the optional substituents Z^1 to Z^4 are replaced by the optional substituents Z^8 to Z^{15} .

The term "carbocyclic 6-membered ring" is used synonymic for the term "6-membered carbocyclyl". In case R^{11} and R^{12} together with the atoms to which they are attached represent a "carbocyclic 6-membered ring", the optional substituents Z^1 to Z^4 are replaced by the optional substituents Z^8 to Z^{15} .

The term “carbocyclic 7-membered ring” is used synonymic for the term “7-membered carbocyclyl”.


The term “heterocyclic 4-membered ring” is used synonymic for the term “4-membered heterocyclyl”. In case R^{11} and R^{12} together with the atoms to which they are attached represent a “heterocyclic 4-membered ring”, the optional substituents Z^1 to Z^4 are replaced by the optional substituents Z^8 to Z^{13} .

The term “heterocyclic 5-membered ring” is used synonymic for the term “5-membered heterocyclyl”. In case R^{11} and R^{12} together with the atoms to which they are attached represent a “heterocyclic 5-membered ring”, the optional substituents Z^1 to Z^4 are replaced by the optional substituents Z^8 to Z^{15} .


The term “heterocyclic 6-membered ring” is used synonymic for the term “6-membered heterocyclyl”. In case R^{11} and R^{12} together with the atoms to which they are attached represent a “heterocyclic 6-membered ring”, the optional substituents Z^1 to Z^4 are replaced by the optional substituents Z^8 to Z^{15} .


The term “heterocyclic 7-membered ring” is used synonymic for the term “7-membered heterocyclyl”.

Thus if R^3 and R^4 form together with the two carbon atoms of the phenyl group to which they are attached a fused ring system so that the moiety



represents a bicyclic moiety, the following ring fragments are preferred:






wherein the afore-mentioned 5-membered or 6-membered moieties or the afore-mentioned ring fragments consisting of 3 or 4 ring fragment atoms can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 . However it is clear to a skilled person that the term "can be substituted" refers to the replacement of a hydrogen atom by one of the substituents Z^1 , Z^2 , Z^3 or Z^4 . Moreover it is clear to a skilled person that only these hydrogen atoms which are present in the afore-mentioned carbocyclic or heterocyclic 4-, 5-, 6- or 7-membered rings or in the afore-mentioned ring fragments can be replaced by the substituents Z^1 , Z^2 , Z^3 and Z^4 . Thus, since the ring fragment =N-O-N= does not have any hydrogen atoms, no substitution is possible at this 3 atom ring fragment.

Thus, it is preferred that the phenyl group together with R^3 and R^4 form the following bicyclic systems which can be further substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 and Z^4 on the ring formed by R^3 and R^4 as well as with R^5 , R^6 and R^7 on the phenyl group which is the benzo group in the bicyclic ring:

1*H*-indolyl, 2*H*-isoindolyl, 1-benzo-thiophenyl, 1-benzofuranyl, 2-benzofuranyl, 2-benzothiophenyl, 1*H*-indazolyl, 1*H*-benz-imidazolyl, 1,3-benzoxazolyl, 1,3-benzothiazolyl, 1,2-benzisoxazolyl, 2,1-benzisoxazolyl, 2,1,3-benzoxadiazolyl, 1,2-benzisothiazolyl, 2,1-benzisothiazolyl, 2,1,3-benzothiadiazolyl, 2*H*-indazolyl, 1*H*-1,2,3-benzotriazolyl, 1,2,3-benzoxadiazolyl, 1,2,3-benzothiadiazolyl, naphthyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, indolinyl, isoindolinyl, 2,3-dihydro-1-benzofuranyl, 2,3-dihydro-1-benzothiophenyl, 1,2,3,4-tetrahydronaphthyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydrophthalazinyl, and 3,4-dihydroquinazolin-2(1*H*)-onyl.

As used herein, the term "**carbocyclyl**" refers preferably to a **C₃–C₈–cycloalkyl** as disclosed above. Moreover the carbocyclyl residues can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 . Thus, the above-mentioned C₃–C₈–cycloalkyl residues are examples for carbocyclyl residues which can be substituted with one, two or three substituents selected from Z^5 , Z^6 and Z^7 . Further, it is clear to a skilled person that the term "can be substituted" refers to the replacement of a hydrogen atom by one of the substituents Z^5 , Z^6 and Z^7 . Moreover it is clear to a skilled person that only these hydrogen atoms which are present in the carbocyclic group can be replaced by the substituents Z^5 , Z^6 and Z^7 . Further, as used herein the term "**carbocyclyl**" refers to carbocyclic residues with 3 to 8 ring carbon atoms which may also be partly unsaturated but not aromatic such as. Thus, the term "carbocyclyl" refers for example to cyclohexadienyl (–C₆H₇), but not to phenyl (–C₆H₅).

Examples of preferred carbocyclic residues are:





wherein these residues can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 , and Z^7 .

5

Preferably Z^5 , Z^6 and Z^7 represent independently of each other $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OC}_2\text{H}_5$, $-\text{OC}_3\text{H}_7$, $-\text{NH}_2$, $-\text{N}(\text{CH}_3)_2$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{CN}$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{OCHF}_2$, and $-\text{OCF}_3$.

Examples of preferred substituted carbocyclic residues are





The term „**bridging carbocyclyl**“ refers to a carbocyclyl residue as disclosed herein, which is further bonded to a second substituent independent from any optional substitution with substituents Z^1 , Z^2 , Z^3 or Z^4 . Thus, in a “bridging carbocyclyl” two hydrogen atoms are replaced by residues rendering the „bridging carbocyclyl” a di-yl moiety. Further, the „bridging carbocyclyl” binds the two different residues with two different carbon atoms, thereby preventing a substitution pattern wherein the two residues are bonded to the same carbon atom. The „bridging carbocyclyl” can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 or Z^4 . It is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^1 , Z^2 , Z^3 or Z^4 . Further, it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^1 , Z^2 , Z^3 or Z^4 . Moreover, it is clear to a skilled person that only these hydrogen atoms which are present in the „bridging carbocyclyl” group can be replaced by the substituents Z^1 , Z^2 , Z^3 and Z^4 .

The person skilled in the art will understand that when R^2 being $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$ and for example Q represents “a bridging carbocyclyl” ($b=1$), then this “bridging carbocyclyl” is attached to a first part of R^2 , for example $-CH_2-$ in case $a=1$ and a second part of R^2 , for instance $-CH_2-R^8$ in case $c=1$ and d , e , f and g are 0. Thus, “a bridging carbocyclyl” is attached to two different residues rendering it a di-yl residue.

As used herein, the term “**heterocyclyl**” refers preferably to a **C₁–C₉–heterocyclyl** as disclosed above. Moreover the heterocyclyl residues can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 . Thus, the above-mentioned **C₁–C₉–heterocyclyl** residues are examples for heterocyclyl residues which can be substituted with one, two or three substituents selected from Z^5 , Z^6 and Z^7 . The number of 1 to 9 carbon atoms (**C₁–C₉**) refers to the number of ring carbon atoms and does not include any carbon atoms probably present in the substituents Z^5 to Z^7 .

As used herein, the term “**C₁–C₉–nitrogenheterocyclyl**” refers to cyclic substituents with 1 to 9 carbon atoms and at least one nitrogen atom and optionally further heteroatoms such as N, S, O, S=O, SO₂ in the cyclus and refers preferably to the **C₁–C₉–heterocyclyl** residues as disclosed above, wherein one heteroatom is nitrogen. The **C₁–C₉–nitrogenheterocyclyl** residue is linked through the at least one nitrogen ring atom to the rest of the molecule. Moreover the **C₁–C₉–nitrogenheterocyclyl** residue can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 .

The term „**bridging heterocyclyl**“ refers to a heterocyclyl residue as disclosed above, which is further bonded to a second substituent independent from any optional substitution with substituents Z^1 , Z^2 , Z^3 or Z^4 . Thus, in a “bridging heterocyclyl” two hydrogen atoms are replaced by residues rendering the „bridging heterocyclyl” a di-yl moiety. Further, the „bridging heterocyclyl” binds the two different residues with two different atoms of the heterocyclyl skeleton, thereby preventing a substitution pattern wherein the two residues are bonded to the same atom. The „bridging heterocyclyl” can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 or Z^4 . It is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^1 , Z^2 , Z^3 or Z^4 . Further, it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^1 , Z^2 , Z^3 or Z^4 . Moreover, it is clear to a skilled person that only these hydrogen atoms which are present in the „bridging heterocyclyl” group can be replaced by the substituents Z^1 , Z^2 , Z^3 and Z^4 .

The person skilled in the art will understand that when R^2 being $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$ and for example G^1 represents “a bridging heterocyclyl” ($d=1$), then this “bridging heterocyclyl” is attached to a first residue of R^2 , for example $-C_3H_6-$ in case $a=3$ and $b=c=0$ and a second residue of R^2 , for example $-CH_2-O-CH_2-$ R^8 in case $e=f=g=1$ and $G^2 = -O-$. Thus, “a bridging heterocyclyl” is attached to two different residues rendering it a di-yl residue.

As used herein, the term “**spirocarbocyclyl**” refers also to the **C₇–C₁₆–spiroalkyl** residues as disclosed above but is not limited to these C₇–C₁₆–spiroalkyl residues. Moreover the spirocarbocyclyl residues can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 . Thus, the above-mentioned C₇–C₁₆–spiroalkyl residues are examples for spirocarbocyclyl residues which can be substituted with one, two or three substituents selected from Z^5 , Z^6 and Z^7 . However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^5 , Z^6 or Z^7 . It is also possible that two of the substituents Z^5 , Z^6 and Z^7 represent together an oxygen atom and form together with the carbon atom of the spirocarbocyclyl residue to which they are both attached a carbonyl moiety. The carbon atom number of **C₇–C₁₆** refers only to the carbon atoms of the spiro residue (spiroalkyl) and does not include the carbon atoms of the substituents Z^5 to Z^7 .

R^8 represents preferably the following spirocarbocyclyl residues: spiro[2,3]hexyl, spiro[2,4]heptyl, spiro[2,5]octyl, spiro[2,7]nonyl, spiro[3,3]heptyl, spiro[3,4]octyl, spiro[3,5]nonyl, spiro[3,6]decyl, spiro[4,4]nonyl, spiro[4,5]decyl, spiro[4,6]undecyl,

spiro[5,5]undecyl, spiro[5,6]dodecyl, spiro[6,6]tridecyl, wherein the afore-mentioned spirocarbocyclyl residues can be substituted with one to three substituents selected from Z^5 , Z^6 and Z^7 .

- 5 The term „**bridging spirocarbocyclyl**“ refers to a spirocarbocyclyl residue as disclosed above, which is further bonded to a second substituent independent from any optional substitution with substituents Z^1 , Z^2 , Z^3 or Z^4 . Thus, in a “bridging spirocarbocyclyl” two hydrogen atoms are replaced by residues rendering the „bridging spirocarbocyclyl” a di-yl moiety. Further, the „bridging spirocarbocyclyl” binds the two different residues with
- 10 two different atoms of the spirocarbocyclyl skeleton, thereby preventing a substitution pattern wherein the two residues are bonded to the same atom. The „bridging spirocarbocyclyl” can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 or Z^4 . It is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^1 , Z^2 , Z^3 or Z^4 . Further, it is
- 15 clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^1 , Z^2 , Z^3 or Z^4 . Moreover, it is clear to a skilled person that only these hydrogen atoms which are present in the „bridging spirocarbocyclyl” group can be replaced by the substituents Z^1 , Z^2 , Z^3 and Z^4 .
- The person skilled in the art will understand that when R^2 being $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$ and for example G^2 represents “a bridging spirocarbocyclyl” ($f=1$), then this “bridging spirocarbocyclyl” is attached to a first part of R^2 , for example $-CH_2-CO-C_2H_4-$ in case $a=b=c=e=1$, $d=0$, $Q=-CO-$, and a second residue of R^2 , for instance $-C_2H_4-R^8$ in case $g=2$. Thus, “a bridging spirocarbocyclyl” is attached to two different residues rendering it a di-yl residue.

25

- As used herein, the term “**spiroheterocyclyl**” refers to $C_5-C_{14}/N_0-N_2/O_0-O_2/S_0-S_1$ -**spiroheterocyclyl** residues comprising or including the C_5-C_{14} -**spiroheterocyclyl** residues as disclosed above. Moreover the $C_5-C_{14}/N_0-N_2/O_0-O_2/S_0-S_1$ -**spiroheterocyclyl** residues or the C_5-C_{14} -**spiroheterocyclyl** residues can be
- 30 substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 . Thus, the above-mentioned C_5-C_{14} -spiroheterocyclyl residues are examples for $C_5-C_{14}/N_0-N_2/O_0-O_2/S_0-S_1$ -**spiroheterocyclyl** residues which can be substituted with one, two or three substituents selected from Z^5 , Z^6 and Z^7 . However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the
- 35 substituents Z^5 , Z^6 or Z^7 . It is also possible that two of the substituents Z^5 , Z^6 and Z^7 represent together an oxygen atom and form together with the carbon atom of the spiroheterocyclyl residue to which they are both attached a carbonyl moiety. Moreover, the $C_5-C_{14}/N_0-N_2/O_0-O_2/S_0-S_1$ -**spiroheterocyclyl** residues are characterized by that

the spiroheterocyclyl residue is linked through a carbon atom of the spiro ring system and not through the hetero atom, i.e. the nitrogen atom of the spiro ring system. If the spiroheterocyclyl residue contains a nitrogen atom which is substituted by one of the substituents Z^5 , Z^6 and Z^7 , said Z substituent represents R^{12} . Thus the indication "N₁"

- 5 refers to the group >N-R^{12} of the spiro ring system. If the spiroheterocyclyl residue contains two nitrogen atoms which are both substituted by one of the substituents Z^5 , Z^6 and Z^7 , the first Z substituent represents R^{11} and the second Z substituent represents R^{12} . Thus the indication "N₂" refers to the groups >N-R^{11} and >N-R^{12} of the spiro ring system. The indication "S₁" refers to the group -S- or -SO- or -SO₂- of the spiro ring system. The indication "S₀" means that no sulfur is present in the spiroheterocyclyl residue. The indication "O₁" refers to the group -O- and the indication "O₂" to two groups -O- which are not directly linked to each other, while "O₀" indicates that no oxygen is present in the spiro ring system. Thus the **C₅-C₁₄/N₀-N₂/O₀-O₂/S₀-S₁-spiroheterocyclyl** residues can contain up to two nitrogen atoms and up to two oxygen atoms and one sulfur atom while in total not more than 3 hetero atoms should be present in the spiro ring system. Moreover, it is preferred that the heteroatoms in the spiro ring system are not directly bond to each other. The numbers of atoms "**C₅-C₁₄/N₀-N₂/O₀-O₂/S₀-S₁**" do not include C, N, O and/or S atoms from the substituents Z^5 to Z^7 .
- 10
15
20 Preferred is the presence of one nitrogen atom or two nitrogen atoms or one sulfur atom or one sulfoxide moiety or one sulphone moiety or one oxygen atom or two oxygen atoms or one oxygen and one nitrogen atom in the spiro ring system.

- As used herein, the term "**C₅-C₁₄-spironitrogenheterocyclyl**" refers to spiro substituents with 5 to 14 carbon atoms and at least one nitrogen atom and optionally further heteroatoms such as N, S, O, S=O, SO₂ in the spiro cyclus and refers preferably to the **C₅-C₁₄-spiroheterocyclyl** residues as disclosed above, wherein one heteroatom is nitrogen. The C₅-C₁₄-spironitrogenheterocyclyl residue is linked through the at least one nitrogen spiro cyclus atom to the rest of the molecule.
- 25
30 Moreover the C₅-C₁₄-spironitrogenheterocyclyl residue can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 .

- The term „**bridging spiroheterocyclyl**“ refers to a spiroheterocyclyl residue as disclosed above, which is further bonded to a second substituent independent from any optional substitution with substituents Z^1 , Z^2 , Z^3 or Z^4 . Thus, in a “bridging spiroheterocyclyl” two hydrogen atoms are replaced by residues rendering the „bridging
- 35

spiroheterocyclyl“ a di-yl moiety. Further, the „bridging spiroheterocyclyl“ binds the two different residues with two different atoms of the spiroheterocyclyl skeleton, thereby preventing a substitution pattern wherein the two residues are bonded to the same atom. The „bridging spiroheterocyclyl“ can be substituted with 1 to 4 substituents selected from Z^1 , Z^2 , Z^3 or Z^4 . It is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^1 , Z^2 , Z^3 or Z^4 . Further, it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z^1 , Z^2 , Z^3 or Z^4 . Moreover, it is clear to a skilled person that only these hydrogen atoms which are present in the „bridging spiroheterocyclyl“ group can be replaced by the substituents Z^1 , Z^2 , Z^3 and Z^4 .

The person skilled in the art will understand that when R^2 being $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$ and for example G^1 represents “a bridging spiroheterocyclyl” ($d=1$), then this “bridging spiroheterocyclyl” is attached to a first part of R^2 , for instance $-NR^{15}-CH_2-$ in case $a=0$, $b=c=1$, $Q = -NR^{15}-$, and a second part of R^2 , for instance $-C_4H_8-R^9$ in case $f=0$ and $e=3$. Thus, “a bridging spiroheterocyclyl” is attached to two different residues rendering it a di-yl residue.

R^8 represents preferably the following spiroheterocyclyl or $C_5-C_{14}/N_0-N_2/O_0-O_2/S_0-S_1$ -spiroheterocyclyl residues: spiro[2,3]heterohexyl, spiro[2,4]heteroheptyl, spiro[2,5]heterooctyl, spiro[2,7]heterononyl, spiro[3,3]heteroheptyl, spiro[3,4]heterooctyl, spiro[3,5]heterononyl, spiro[3,6]heterodecyl, spiro[4,4]heterononyl, spiro[4,5]heterodecyl, spiro[4,6]heteroundecyl, spiro[5,5]heteroundecyl, spiro[5,6]heterododecyl, spiro[6,6]heterotridecyl, wherein the afore-mentioned spiroheterocyclyl or $C_5-C_{14}/N_0-N_2/O_0-O_2/S_0-S_1$ -spiroheterocyclyl residues are linked through a ring carbon atom to the rest of the molecule and wherein the afore-mentioned spiroheterocyclyl or $C_5-C_{14}/N_0-N_2/O_0-O_2/S_0-S_1$ -spiroheterocyclyl residues are optionally substituted with one to three substituents selected from Z^5 , Z^6 and Z^7 . The heteroatom in the afore-mentioned spiroheterocyclyl or $C_5-C_{14}/N_0-N_2/O_0-O_2/S_0-S_1$ -spiroheterocyclyl residues is preferably selected from $-O-$, $-NH-$, $-NR^{11}-$, $-SO-$, and $-SO_2-$.

More preferably R^8 represents preferably the following spiroheterocyclyl or $C_5-C_{14}/N_0-N_2/O_0-O_2/S_0-S_1$ -spiroheterocyclyl residues: azaspiro[3,3]heptyl, azaspiro[3,4]octyl, azaspiro[3,5]nonyl, azaspiro[3,6]decyl, azaspiro[4,4]nonyl, azaspiro[4,5]decyl, azaspiro[4,6]undecyl, azaspiro[5,5]undecyl, azaspiro[5,6]dodecyl, azaspiro[6,6]tridecyl, diazaspiro[3,3]heptyl, diazaspiro[3,4]octyl, diazaspiro[3,5]nonyl, diazaspiro[3,6]decyl, diazaspiro[4,4]nonyl, diazaspiro[4,5]decyl,

- diazaspiro[4,6]undecyl, diazaspiro[5,5]undecyl, diazaspiro[5,6]dodecyl,
 diazaspiro[6,6]tridecyl, triazaspiro[3,5]nonyl, triazaspiro[3,6]decyl,
 triazaspiro[4,5]decyl, triazaspiro[4,6]undecyl, triazaspiro[5,5]undecyl,
 triazaspiro[5,6]dodecyl, triazaspiro[6,6]tridecyl, oxazaspiro[3,3]heptyl,
 5 oxazaspiro[3,4]octyl, oxazaspiro[3,5]nonyl, oxazaspiro[3,6]decyl,
 oxazaspiro[4,4]nonyl, oxazaspiro[4,5]decyl, oxazaspiro[4,6]undecyl,
 oxazaspiro[5,5]undecyl, oxazaspiro[5,6]dodecyl, oxazaspiro[6,6]tridecyl,
 oxadiazaspiro[3,5]nonyl, oxadiazaspiro[3,6]decyl, oxadiazaspiro[4,5]decyl,
 oxadiazaspiro[4,6]undecyl, oxadiazaspiro[5,5]undecyl, oxadiazaspiro[5,6]dodecyl,
 10 oxadiazaspiro[6,6]tridecyl, wherein the afore-mentioned spiroheterocyclyl or C₅–
 C₁₄/N₀–N₂/O₀–O₂/S₀–S₁–spiroheterocyclyl residues are linked through a ring carbon
 atom to the rest of the molecule and wherein the afore-mentioned spiroheterocyclyl or
 C₅–C₁₄/N₀–N₂/O₀–O₂/S₀–S₁–spiroheterocyclyl residues are optionally substituted with
 one to three substituents selected from Z⁵, Z⁶ and Z⁷.
 15
- Also, R⁸ represents more preferably the following residues: –(CH₂)_p–NH₂, –(CH₂)_p–
 NR¹⁶R¹⁷, substituted or unsubstituted 4-membered carbocyclyl, substituted or
 unsubstituted 5-membered carbocyclyl, substituted or unsubstituted 6-membered
 carbocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6-membered
 20 heterocyclyl, substituted 4-membered heterocyclyl, substituted 5-membered
 heterocyclyl, substituted 6-membered heterocyclyl, 4-membered nitrogenheterocyclyl,
 5-membered nitrogenheterocyclyl, 6-membered nitrogenheterocyclyl, substituted 4-
 membered nitrogenheterocyclyl, substituted 5-membered nitrogenheterocyclyl,
 substituted 6-membered nitrogenheterocyclyl, spiro[2,3]heterohexyl,
 25 spiro[2,4]heteroheptyl, spiro[2,5]heterooctyl, spiro[2,7]heterononyl,
 spiro[3,3]heteroheptyl, spiro[3,4]heterooctyl, spiro[3,5]heterononyl,
 spiro[3,6]heterodecyl, spiro[4,4]heterononyl, spiro[4,5]heterodecyl,
 spiro[4,6]heteroundecyl, spiro[5,5]heteroundecyl, spiro[5,6]heterododecyl,
 spiro[6,6]heterotridecyl,
 30 substituted spiro[2,3]heterohexyl, substituted spiro[2,4]heteroheptyl, substituted
 spiro[2,5]heterooctyl, substituted spiro[2,7]heterononyl, substituted
 spiro[3,3]heteroheptyl, substituted spiro[3,4]heterooctyl, substituted
 spiro[3,5]heterononyl, substituted spiro[3,6]heterodecyl, substituted
 spiro[4,4]heterononyl, substituted spiro[4,5]heterodecyl, substituted
 35 spiro[4,6]heteroundecyl, substituted spiro[5,5]heteroundecyl, substituted
 spiro[5,6]heterododecyl, substituted spiro[6,6]heterotridecyl,


azaspiro[3,3]heptyl, azaspiro[3,4]octyl, azaspiro[3,5]nonyl, azaspiro[3,6]decyl,
 azaspiro[4,4]nonyl, azaspiro[4,5]decyl, azaspiro[4,6]undecyl, azaspiro[5,5]undecyl,
 azaspiro[5,6]dodecyl, azaspiro[6,6]tridecyl,
 substituted azaspiro[3,3]heptyl, substituted azaspiro[3,4]octyl, substituted
 5 azaspiro[3,5]nonyl, substituted azaspiro[3,6]decyl, substituted azaspiro[4,4]nonyl,
 substituted azaspiro[4,5]decyl, substituted azaspiro[4,6]undecyl, substituted
 azaspiro[5,5]undecyl, substituted azaspiro[5,6]dodecyl, substituted
 azaspiro[6,6]tridecyl,
 diazaspiro[3,3]heptyl, diazaspiro[3,4]octyl, diazaspiro[3,5]nonyl, diazaspiro[3,6]decyl,
 10 diazaspiro[4,4]nonyl, diazaspiro[4,5]decyl, diazaspiro[4,6]undecyl,
 diazaspiro[5,5]undecyl, diazaspiro[5,6]dodecyl, diazaspiro[6,6]tridecyl,
 substituted diazaspiro[3,3]heptyl, substituted diazaspiro[3,4]octyl, substituted
 diazaspiro[3,5]nonyl, substituted diazaspiro[3,6]decyl, substituted
 diazaspiro[4,4]nonyl, substituted diazaspiro[4,5]decyl, substituted
 15 diazaspiro[4,6]undecyl, substituted diazaspiro[5,5]undecyl, substituted
 diazaspiro[5,6]dodecyl, substituted diazaspiro[6,6]tridecyl,
 triazaspiro[3,5]nonyl, triazaspiro[3,6]decyl, triazaspiro[4,5]decyl,
 triazaspiro[4,6]undecyl, triazaspiro[5,5]undecyl, triazaspiro[5,6]dodecyl,
 triazaspiro[6,6]tridecyl,
 20 substituted triazaspiro[3,5]nonyl, substituted triazaspiro[3,6]decyl, substituted
 triazaspiro[4,5]decyl, substituted triazaspiro[4,6]undecyl, substituted
 triazaspiro[5,5]undecyl, substituted triazaspiro[5,6]dodecyl, or substituted
 triazaspiro[6,6]tridecyl,
 oxazaspiro[3,3]heptyl, oxazaspiro[3,4]octyl, oxazaspiro[3,5]nonyl,
 25 oxazaspiro[3,6]decyl, oxazaspiro[4,4]nonyl, oxazaspiro[4,5]decyl,
 oxazaspiro[4,6]undecyl, oxazaspiro[5,5]undecyl, oxazaspiro[5,6]dodecyl,
 oxazaspiro[6,6]tridecyl,
 substituted oxazaspiro[3,3]heptyl, substituted oxazaspiro[3,4]octyl, substituted
 oxazaspiro[3,5]nonyl, substituted oxazaspiro[3,6]decyl, substituted
 30 oxazaspiro[4,4]nonyl, substituted oxazaspiro[4,5]decyl, substituted
 oxazaspiro[4,6]undecyl, substituted oxazaspiro[5,5]undecyl, substituted
 oxazaspiro[5,6]dodecyl, substituted oxazaspiro[6,6]tridecyl,
 oxadiazaspiro[3,5]nonyl, oxadiazaspiro[3,6]decyl, oxadiazaspiro[4,5]decyl,
 oxadiazaspiro[4,6]undecyl, oxadiazaspiro[5,5]undecyl, oxadiazaspiro[5,6]dodecyl,
 35 oxadiazaspiro[6,6]tridecyl,
 substituted oxadiazaspiro[3,5]nonyl, substituted oxadiazaspiro[3,6]decyl, substituted
 oxadiazaspiro[4,5]decyl, substituted oxadiazaspiro[4,6]undecyl, substituted

oxadiazaspiro[5,5]undecyl, substituted oxadiazaspiro[5,6]dodecyl, or substituted oxadiazaspiro[6,6]tridecyl,

wherein the afore-mentioned substituted or non-substituted spiroheterocyclyl or C₅–C₁₄/N₀–N₂/O₀–O₂/S₀–S₁–spiroheterocyclyl residues are linked through a ring carbon atom to the rest of the molecule and wherein the afore-mentioned substituted or non-substituted spiroheterocyclyl or C₅–C₁₄/N₀–N₂/O₀–O₂/S₀–S₁–spiroheterocyclyl residues are optionally substituted with one to three substituents selected from Z⁵, Z⁶ and Z⁷. The heteroatom in the afore-mentioned substituted or non-substituted spiroheterocyclyl or C₅–C₁₄/N₀–N₂/O₀–O₂/S₀–S₁–spiroheterocyclyl residues is preferably selected from –O–, –NH–, –NR¹¹–, –SO–, and –SO₂–.

Preferably Z⁵, Z⁶ and Z⁷ represent independently of each other –CH₃, –C₂H₅, –C₃H₇, –CH(CH₃)₂, –OH, –OCH₃, –OC₂H₅, –OC₃H₇, –NH₂, –N(CH₃)₂, –F, –Cl, –Br, –I, –CN, –CH₂F, –CHF₂, –CF₃, –OCHF₂, and –OCF₃.

Preferred substituents for R¹¹ are –CH₃, –C₂H₅, –C₃H₇, –CH(CH₃)₂, –CH₂F, –CHF₂,



–CF₃, cyclo-C₃H₅, cyclo-C₄H₇, cyclo-C₅H₉, cyclo-C₆H₁₁, cyclo-C₇H₁₃,

–C₄H₉, –CH₂–CH(CH₃)₂, –CH(CH₃)–C₂H₅, –C(CH₃)₃, –C₅H₁₁, –CH(CH₃)–C₃H₇, –CH₂–CH(CH₃)–C₂H₅, –CH(CH₃)–CH(CH₃)₂, –C(CH₃)₂–C₂H₅, –CH₂–C(CH₃)₃, –CH(C₂H₅)₂, –C₂H₄–CH(CH₃)₂, –C₆H₁₃, –C₇H₁₅, –C₈H₁₇, –Ph, –CH₂–Ph, –CH₂–CH₂–Ph, –CH=CH–Ph, –CH=CH₂, –CH₂–CH=CH₂, –C(CH₃)=CH₂, –CH=CH–CH₃, –C₂H₄–CH=CH₂, –CH₂–CH=CH–CH₃, –CH=CH–C₂H₅, –CH₂–C(CH₃)=CH₂, –CH(CH₃)–CH=CH₂, –CH=C(CH₃)₂, –C(CH₃)=CH–CH₃, –C≡CH, –C≡C–CH₃, –CH₂–C≡CH, –C₂H₄–C≡CH, –CH₂–C≡C–CH₃, –C≡C–C₂H₅, –CH₂–OCF₃, –C₂H₄–OCF₃, –C₃H₆–OCF₃, –CH₂–OCH₃, –C₂H₄–OCH₃, –C₃H₆–OCH₃, –CH₂–OC₂H₅, –C₂H₄–OC₂H₅, and –C₃H₆–OC₂H₅.


The term “4-membered nitrogenheterocyclyl” refers to the residue “4-membered heterocyclyl” as defined above, wherein at least one heteroatom is a nitrogen atom and the residue is linked through the at least one nitrogen ring atom to the rest of the molecule and wherein Z¹ is replaced by Z⁵, Z² is replaced by Z⁶, Z³ is replaced by Z⁷, and Z⁴ is hydrogen.


The term “5-membered nitrogenheterocyclyl” refers to the residue “5-membered heterocyclyl” as defined above, wherein at least one heteroatom is a nitrogen atom and the residue is linked through the at least one nitrogen ring atom to the rest of the molecule and wherein Z¹ is replaced by Z⁵, Z² is replaced by Z⁶, Z³ is replaced by Z⁷, and Z⁴ is hydrogen.


The term “6-membered nitrogenheterocyclyl” refers to the residue “6-membered heterocyclyl” as defined above, wherein at least one heteroatom is a nitrogen atom and the residue is linked through the at least one nitrogen ring atom to the rest of the molecule and wherein Z^1 is replaced by Z^5 , Z^2 is replaced by Z^6 , Z^3 is replaced by Z^7 , and Z^4 is hydrogen.


5


Still more preferably R^8 represents the following residues: $-(CH_2)_p-NH_2$, $-(CH_2)_p-N(R^{16}R^{17})$,




















wherein Y represents $-\text{O}-$, $-\text{NH}-$, $-\text{NR}^{11}-$, $-\text{SO}-$, or $-\text{SO}_2-$, preferably $-\text{NH}-$ and $-\text{NR}^{11}-$ and wherein the substituents Z^5 , Z^6 and Z^7 have the meanings as defined herein.

As used herein, the term “**spironitrogencycyl**” refers to the **C₅–C₁₄/N₁–N₃–spironitrogencycyl** residues comprising or including the **C₅–C₁₄–spiroheterocycyl** residues as disclosed above, wherein the heteroatom is nitrogen, i.e. Y is NH or NR¹¹.

The term “C₅–C₁₄/N₁–N₃” means that the spiro ring system consists of 5 to 14 carbon atoms and 1 to 3 nitrogen atoms. Moreover the **spironitrogencycyl** residues can be substituted with 1 to 3 substituents selected from Z⁵, Z⁶ and Z⁷. However it is clear to a skilled person that the term “can be substituted” refers to the replacement of a hydrogen atom by one of the substituents Z⁵, Z⁶ or Z⁷. It is also possible that two of the substituents Z⁵, Z⁶ and Z⁷ represent together an oxygen atom and form together with the carbon atom of the spironitrogencycyl residue to which they are both attached a carbonyl moiety. Moreover the **C₅–C₁₄/N₁–N₃–spironitrogencycyl** residues are characterized in that the spironitrogencycyl residue is linked through a nitrogen atom of the spiro ring system and not through a carbon atom of the spiro ring system. This means in regard to the above-mentioned C₅–C₁₄–spiroheterocycyl residue that the heteroatom Y is nitrogen and that this C₅–C₁₄–spiroheterocycyl residue is linked to the rest of the molecule through this nitrogen atom (which is Y). If the **C₅–C₁₄/N₁–N₃–spironitrogencycyl** residue contains a second nitrogen atom which is substituted by one of the substituents Z⁵, Z⁶ and Z⁷, said Z substituent represents R¹². Thus the indication “N₂” refers to a first nitrogen atom through which the **spironitrogencycyl**

residue is linked and to the group >N-R^{12} of the spiro ring system. If the spironitrogencycyl residue contains a third nitrogen atom and both nitrogen atoms are substituted by one of the substituents Z⁵, Z⁶ and Z⁷, the first Z substituent on the second nitrogen atom represents R¹² and the second Z substituent on the third nitrogen atom represents R¹¹. Thus the indication “N₃” refers to a first nitrogen atom through

which the **spironitrogencycyl** residue is linked and to the groups >N-R^{11} and >N-R^{12} of the spiro ring system. Thus the **C₅–C₁₄/N₁–N₃–spironitrogencycyl** residue can contain one, two or three nitrogen atoms in the spiro ring system. The numbers of atoms “C₅–C₁₄/N₁–N₂” do not include C and N atoms from the substituents Z⁵ to Z⁷.

As used herein, the term “**nitrogenheterocycyl**” refers to **C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁–nitrogenheterocycyl** residues comprising or including the **C₅–C₁₄–spiroheterocycyl** residues as disclosed above, wherein the heteroatom is nitrogen, i.e. Y is NH or NR¹¹.

The term “C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁” means that the spiro ring system consists of 5 to 14 carbon atoms and 1 to 3 nitrogen atoms, 0 to 2 oxygen atoms and 0 or 1 sulfur

atom. Moreover the **nitrogenheterocyclyl** residues can be substituted with 1 to 3 substituents selected from Z^5 , Z^6 and Z^7 . However it is clear to a skilled person that the term "can be substituted" refers to the replacement of a hydrogen atom by one of the substituents Z^5 , Z^6 or Z^7 . It is also possible that two of the substituents Z^5 , Z^6 and Z^7 represent together an oxygen atom and form together with the carbon atom of the **nitrogenheterocyclyl** residue to which they are both attached a carbonyl moiety. Moreover the **C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁–nitrogenheterocyclyl** residues are characterized by that the **nitrogenheterocyclyl** residue is linked through a nitrogen atom of the spiro ring system and not through a carbon atom of the spiro ring system. This means in regard to the above-mentioned C₅–C₁₄–spiroheterocyclyl residue that the heteroatom Y is nitrogen and that this C₅–C₁₄–spiroheterocyclyl residue is linked to the rest of the molecule through this nitrogen atom (which is Y). If the **C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁–nitrogenheterocyclyl** residue contains a second nitrogen atom which is substituted by one of the substituents Z^5 , Z^6 and Z^7 , said Z substituent represents R¹². Thus, the indication "N₂" refers to a first nitrogen atom through which the

nitrogenheterocyclyl residue is linked and to the group >N-R^{12} of the spiro ring system. If the **nitrogenheterocyclyl** residue contains a third nitrogen atom and both nitrogen atoms are substituted by one of the substituents Z^5 , Z^6 and Z^7 , the first Z substituent on the second nitrogen atom represents R¹² and the second Z substituent on the third nitrogen atom represents R¹¹. Thus, the indication "N₃" refers to a first nitrogen atom through which the **nitrogenheterocyclyl** residue is linked and to the groups >N-R^{11} and >N-R^{12} of the spiro ring system. The indication "S₁" refers to the group –S– or –SO– or –SO₂– of the spiro ring system. The indication "S₀" means that no sulfur is present in the **nitrogenheterocyclyl** residue. The indication "O₁" refers to the group –O– and the indication "O₂" to two groups –O– which are not directly linked to each other, while "O₀" indicates that no oxygen is present in the spiro ring system. Thus, the **C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁–nitrogenheterocyclyl** residue can contain in total 6 hetero atoms while in total not more than 3 hetero atoms should be present in the spiro ring system. Moreover it is preferred that the heteroatoms in the spiro ring system are not directly bond to each other. The numbers of atoms "C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁" do not include C, O, S and N atoms from the substituents Z^5 to Z^7 .

Preferred is the presence of one nitrogen atom or two nitrogen atoms or one nitrogen atom and one sulfur atom or one nitrogen atom and one sulfoxide moiety or one nitrogen atom and one sulphone moiety or one nitrogen atom and one oxygen atom or one nitrogen atom and two oxygen atoms or one oxygen atom and two nitrogen atoms in the spiro ring system.


R⁹ represents preferably the following **spironitrogencycyl**, **nitrogenheterocycyl**, **C₅–C₁₄/N₁–N₃–spironitrogencycyl** or **C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁–nitrogenheterocycyl** residues: 4-membered nitrogenheterocycyl, 5-membered nitrogenheterocycyl, 6-membered nitrogenheterocycyl, 5-membered dinitrogenheterocycyl, 6-membered dinitrogenheterocycyl, spiro[2,3]heterohexyl, spiro[2,4]heteroheptyl, spiro[2,5]heterooctyl, spiro[2,7]heterononyl, spiro[3,3]heteroheptyl, spiro[3,4]heterooctyl, spiro[3,5]heterononyl, spiro[3,6]heterodecyl, spiro[4,4]heterononyl, spiro[4,5]heterodecyl, spiro[4,6]heteroundecyl, spiro[5,5]heteroundecyl, spiro[5,6]heterododecyl, spiro[6,6]heterotridecyl, wherein the afore-mentioned spironitrogencycyl, nitrogenheterocycyl, C₅–C₁₄/N₁–N₃–spironitrogencycyl or C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁–nitrogenheterocycyl residues are linked through a ring nitrogen atom to the rest of the molecule and wherein the afore-mentioned spironitrogencycyl, nitrogenheterocycyl, C₅–C₁₄/N₁–N₃–spironitrogencycyl or C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁–nitrogenheterocycyl residues are optionally substituted with one to three substituents selected from Z⁵, Z⁶ and Z⁷.

The term “5-membered dinitrogenheterocycyl” refers to the residue “5-membered heterocycyl” as defined above, wherein two heteroatoms are nitrogen atoms and the residue is linked through a nitrogen ring atom to the rest of the molecule and wherein Z¹ is replaced by Z⁵, Z² is replaced by Z⁶, Z³ is replaced by Z⁷, and Z⁴ is hydrogen.

The term “6-membered dinitrogenheterocycyl” refers to the residue “6-membered heterocycyl” as defined above, wherein two heteroatoms are nitrogen atoms and the residue is linked through a nitrogen ring atom to the rest of the molecule and wherein Z¹ is replaced by Z⁵, Z² is replaced by Z⁶, Z³ is replaced by Z⁷, and Z⁴ is hydrogen.

Moreover the afore-mentioned spironitrogencycyl, nitrogenheterocycyl, C₅–C₁₄/N₁–N₃–spironitrogencycyl or C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁–nitrogenheterocycyl residues contain at least one nitrogen atom through which these residues are linked to the rest of the molecule and may contain one or two further moieties selected from oxygen (–O–), sulfoxide (–SO–), sulfone (–SO₂–), carbonyl (–CO–) and nitrogen (–NR¹¹–).

Preferable substituents Z⁵, Z⁶ and Z⁷ represent independently of each other –CH₃, –C₂H₅, –C₃H₇, –CH(CH₃)₂, –OH, –OCH₃, –OC₂H₅, –OC₃H₇, –NH₂, –NHCH₃, –N(CH₃)₂, –F, –Cl, –Br, –I, –CN, –CH₂F, –CHF₂, –CF₃, –OCHF₂, and –OCF₃. If present, R¹¹ and R¹² are preferably selected from: –CH₃, –C₂H₅, –C₃H₇, –CH(CH₃)₂, –CH₂F, –CHF₂, –CF₃,



cyclo-C₃H₅, cyclo-C₄H₇, cyclo-C₅H₉, cyclo-C₆H₁₁, cyclo-C₇H₁₃,

-C₄H₉, -CH₂-CH(CH₃)₂, -CH(CH₃)-C₂H₅, -C(CH₃)₃, -C₅H₁₁, -CH(CH₃)-C₃H₇,
 -CH₂-CH(CH₃)-C₂H₅, -CH(CH₃)-CH(CH₃)₂, -C(CH₃)₂-C₂H₅, -CH₂-C(CH₃)₃,
 -CH(C₂H₅)₂, -C₂H₄-CH(CH₃)₂, -C₆H₁₃, -C₇H₁₅, -C₈H₁₇, -Ph, -CH₂-Ph,
 -CH₂-CH₂-Ph, -CH=CH-Ph, -CH=CH₂, -CH₂-CH=CH₂, -C(CH₃)=CH₂,
 5 -CH=CH-CH₃, -C₂H₄-CH=CH₂, -CH₂-CH=CH-CH₃, -CH=CH-C₂H₅,
 -CH₂-C(CH₃)=CH₂, -CH(CH₃)-CH=CH₂, -CH=C(CH₃)₂, -C(CH₃)=CH-CH₃,
 -C≡CH, -C≡C-CH₃, -CH₂-C≡CH, -C₂H₄-C≡CH, -CH₂-C≡C-CH₃,
 -C≡C-C₂H₅, -CH₂-OCF₃, -C₂H₄-OCF₃, -C₃H₆-OCF₃, -CH₂-OCH₃,
 -C₂H₄-OCH₃, -C₃H₆-OCH₃, -CH₂-OC₂H₅, -C₂H₄-OC₂H₅, -C₃H₆-OC₂H₅.

10

More preferably R⁹ represents the following spironitrogencycyl, nitrogenheterocycyl,
 C₅-C₁₄/N₁-N₃-spironitrogencycyl or C₅-C₁₄/N₁-N₃/O₀-O₂/S₀-S₁-nitrogenheterocycyl
 residues: 4-membered nitrogenheterocycyl linked through the nitrogen atom to the
 rest of the molecule, 5-membered nitrogenheterocycyl linked through the nitrogen
 15 atom to the rest of the molecule, 6-membered nitrogenheterocycyl linked through the
 nitrogen atom, substituted 4-membered nitrogenheterocycyl linked through the
 nitrogen atom, substituted 5-membered nitrogenheterocycyl linked through the
 nitrogen atom, substituted 6-membered nitrogenheterocycyl linked through the
 nitrogen atom, 5-membered dinitrogenheterocycyl linked through a nitrogen atom, 6-
 20 membered dinitrogenheterocycyl linked through a nitrogen atom, substituted 5-
 membered dinitrogenheterocycyl linked through a nitrogen atom, substituted 6-
 membered dinitrogenheterocycyl linked through a nitrogen atom to the rest of the
 molecule, wherein the afore-mentioned spironitrogencycyl, nitrogenheterocycyl, C₅-
 C₁₄/N₁-N₃-spironitrogencycyl or C₅-C₁₄/N₁-N₃/O₀-O₂/S₀-S₁-nitrogenheterocycyl
 25 residues are optionally substituted with one to three substituents selected from Z⁵, Z⁶ and
 Z⁷.

Still more preferably R⁹ represents the following spironitrogencycyl,
 nitrogenheterocycyl, C₅-C₁₄/N₁-N₃-spironitrogencycyl or C₅-C₁₄/N₁-N₃/O₀-O₂/S₀-S₁-
 30 nitrogenheterocycyl residues:

azaspiro[3,3]heptyl linked through the nitrogen atom, azaspiro[3,4]octyl linked through
 the nitrogen atom, azaspiro[3,5]nonyl linked through the nitrogen atom,
 azaspiro[3,6]decyl linked through the nitrogen atom, azaspiro[4,4]nonyl linked through
 the nitrogen atom, azaspiro[4,5]decyl linked through the nitrogen atom,
 35 azaspiro[4,6]undecyl linked through the nitrogen atom, azaspiro[5,5]undecyl linked

through the nitrogen atom, azaspiro[5,6]dodecyl linked through the nitrogen atom, azaspiro[6,6]tridecyl linked through the nitrogen atom,

substituted azaspiro[3,3]heptyl linked through the nitrogen atom, substituted azaspiro[3,4]octyl linked through the nitrogen atom, substituted azaspiro[3,5]nonyl

5 linked through the nitrogen atom, substituted azaspiro[3,6]decyl linked through the nitrogen atom, substituted azaspiro[4,4]nonyl linked through the nitrogen atom, substituted azaspiro[4,5]decyl linked through the nitrogen atom, substituted azaspiro[4,6]undecyl linked through the nitrogen atom, substituted azaspiro[5,5]undecyl linked through the nitrogen atom, substituted
10 azaspiro[5,6]dodecyl linked through the nitrogen atom, substituted azaspiro[6,6]tridecyl linked through the nitrogen atom,

diazaspiro[3,3]heptyl linked through a nitrogen atom, diazaspiro[3,4]octyl linked through a nitrogen atom, diazaspiro[3,5]nonyl linked through a nitrogen atom, diazaspiro[3,6]decyl linked through a nitrogen atom, diazaspiro[4,4]nonyl linked
15 through a nitrogen atom, diazaspiro[4,5]decyl linked through a nitrogen atom, diazaspiro[4,6]undecyl linked through a nitrogen atom, diazaspiro[5,5]undecyl linked through a nitrogen atom, diazaspiro[5,6]dodecyl linked through a nitrogen atom, diazaspiro[6,6]tridecyl linked through a nitrogen atom,

substituted diazaspiro[3,3]heptyl linked through a nitrogen atom, substituted
20 diazaspiro[3,4]octyl linked through a nitrogen atom, substituted diazaspiro[3,5]nonyl linked through a nitrogen atom, substituted diazaspiro[3,6]decyl linked through a nitrogen atom, substituted diazaspiro[4,4]nonyl linked through a nitrogen atom, substituted diazaspiro[4,5]decyl linked through a nitrogen atom, substituted diazaspiro[4,6]undecyl linked through a nitrogen atom, substituted
25 diazaspiro[5,5]undecyl linked through a nitrogen atom, substituted diazaspiro[5,6]dodecyl linked through a nitrogen atom, substituted diazaspiro[6,6]tridecyl linked through a nitrogen atom,

triazaspiro[3,5]nonyl linked through a nitrogen atom, triazaspiro[3,6]decyl linked through a nitrogen atom, triazaspiro[4,5]decyl linked through a nitrogen atom, triazaspiro[4,6]undecyl linked through a nitrogen atom, triazaspiro[5,5]undecyl linked
30 through a nitrogen atom, triazaspiro[5,6]dodecyl linked through a nitrogen atom, triazaspiro[6,6]tridecyl linked through a nitrogen atom,

substituted triazaspiro[3,5]nonyl linked through a nitrogen atom, substituted triazaspiro[3,6]decyl linked through a nitrogen atom, substituted triazaspiro[4,5]decyl
35 linked through a nitrogen atom, substituted triazaspiro[4,6]undecyl linked through a nitrogen atom, substituted triazaspiro[5,5]undecyl linked through a nitrogen atom, substituted triazaspiro[5,6]dodecyl linked through a nitrogen atom, substituted triazaspiro[6,6]tridecyl linked through a nitrogen atom,

oxazaspiro[3,3]heptyl linked through a nitrogen atom, oxazaspiro[3,4]octyl linked through a nitrogen atom, oxazaspiro[3,5]nonyl linked through a nitrogen atom, oxazaspiro[3,6]decyl linked through a nitrogen atom, oxazaspiro[4,4]nonyl linked through a nitrogen atom, oxazaspiro[4,5]decyl linked through a nitrogen atom,

5 oxazaspiro[4,6]undecyl linked through a nitrogen atom, oxazaspiro[5,5]undecyl linked through a nitrogen atom, oxazaspiro[5,6]dodecyl linked through a nitrogen atom, oxazaspiro[6,6]tridecyl linked through a nitrogen atom, substituted oxazaspiro[3,3]heptyl linked through a nitrogen atom, substituted oxazaspiro[3,4]octyl linked through a nitrogen atom, substituted oxazaspiro[3,5]nonyl

10 linked through a nitrogen atom, substituted oxazaspiro[3,6]decyl linked through a nitrogen atom, substituted oxazaspiro[4,4]nonyl linked through a nitrogen atom, substituted oxazaspiro[4,5]decyl linked through a nitrogen atom, substituted oxazaspiro[4,6]undecyl linked through a nitrogen atom, substituted oxazaspiro[5,5]undecyl linked through a nitrogen atom, substituted

15 oxazaspiro[5,6]dodecyl linked through a nitrogen atom, substituted oxazaspiro[6,6]tridecyl linked through a nitrogen atom, oxadiazaspiro[3,5]nonyl linked through a nitrogen atom, oxadiazaspiro[3,6]decyl linked through a nitrogen atom, oxadiazaspiro[4,5]decyl linked through a nitrogen atom, oxadiazaspiro[4,6]undecyl linked through a nitrogen atom, oxadiazaspiro[5,5]undecyl

20 linked through a nitrogen atom, oxadiazaspiro[5,6]dodecyl linked through a nitrogen atom, oxadiazaspiro[6,6]tridecyl linked through a nitrogen atom, substituted oxadiazaspiro[3,5]nonyl linked through a nitrogen atom, substituted oxadiazaspiro[3,6]decyl linked through a nitrogen atom, substituted oxadiazaspiro[4,5]decyl linked through a nitrogen atom, substituted


25 oxadiazaspiro[4,6]undecyl linked through a nitrogen atom, substituted oxadiazaspiro[5,5]undecyl linked through a nitrogen atom, substituted oxadiazaspiro[5,6]dodecyl linked through a nitrogen atom, substituted oxadiazaspiro[6,6]tridecyl linked through a nitrogen atom, wherein the afore-mentioned substituted spironitrogencycyl, substituted nitrogenheterocycyl, substituted C₅–C₁₄/N₁–N₃–spironitrogencycyl or substituted C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁–nitrogenheterocycyl


30 residues are optionally substituted with one to three substituents selected from Z⁵, Z⁶ and Z⁷. Moreover the afore-mentioned substituted or non-substituted spironitrogencycyl, substituted or non-substituted nitrogenheterocycyl, substituted or non-substituted C₅–C₁₄/N₁–N₃–spironitrogencycyl or substituted or non-substituted C₅–C₁₄/N₁–N₃/O₀–O₂/S₀–S₁–nitrogenheterocycyl


35 residues contain at least one nitrogen atom through which these residues are linked through the rest of the molecule and may contain one or two further moieties selected from oxygen (–O–), sulfoxide (–SO–), sulfone (–SO₂–), carbonyl (–CO–) and nitrogen (–NR¹²–).


Still more preferably R^9 represents the following spironitrogencycyl, nitrogenheterocycyl, C_5-C_{14}/N_1-N_3 -spironitrogencycyl or $C_5-C_{14}/N_1-N_3/O_0-O_2/S_0-S_1$ -nitrogenheterocycyl residues:


5












wherein Y represents $-\text{O}-$, $-\text{NH}-$, $-\text{NR}^{11}-$, $-\text{SO}-$, or $-\text{SO}_2-$, preferably $-\text{NH}-$ and $-\text{NR}^{11}-$ and wherein the substituents Z^5 , Z^6 and Z^7 have the meanings as defined herein.

- 5 Preferably Z^5 , Z^6 and Z^7 represent independently of each other $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{OH}$, $-\text{OCH}_3$, $-\text{OC}_2\text{H}_5$, $-\text{OC}_3\text{H}_7$, $-\text{NH}_2$, $-\text{NH}(\text{CH}_3)$, $-\text{N}(\text{CH}_3)_2$, $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{CN}$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{OCHF}_2$, and $-\text{OCF}_3$, more preferably $-\text{NH}_2$, $-\text{NH}(\text{CH}_3)$, $-\text{N}(\text{CH}_3)_2$.

- 10 If present, R^{11} and R^{12} is preferably selected from: $-\text{CH}_3$, $-\text{C}_2\text{H}_5$, $-\text{C}_3\text{H}_7$, $-\text{CH}(\text{CH}_3)_2$, $-\text{CH}_2\text{F}$, $-\text{CHF}_2$, $-\text{CF}_3$,



cyclo- C_3H_5 , cyclo- C_4H_7 , cyclo- C_5H_9 , cyclo- C_6H_{11} , cyclo- C_7H_{13} ,

- 15 $-\text{C}_4\text{H}_9$, $-\text{CH}_2\text{CH}(\text{CH}_3)_2$, $-\text{CH}(\text{CH}_3)\text{C}_2\text{H}_5$, $-\text{C}(\text{CH}_3)_3$, $-\text{C}_5\text{H}_{11}$, $-\text{CH}(\text{CH}_3)\text{C}_3\text{H}_7$, $-\text{CH}_2\text{CH}(\text{CH}_3)\text{C}_2\text{H}_5$, $-\text{CH}(\text{CH}_3)\text{CH}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)_2\text{C}_2\text{H}_5$, $-\text{CH}_2\text{C}(\text{CH}_3)_3$, $-\text{CH}(\text{C}_2\text{H}_5)_2$, $-\text{C}_2\text{H}_4\text{CH}(\text{CH}_3)_2$, $-\text{C}_6\text{H}_{13}$, $-\text{C}_7\text{H}_{15}$, $-\text{C}_8\text{H}_{17}$, $-\text{Ph}$, $-\text{CH}_2\text{Ph}$, $-\text{CH}_2\text{CH}_2\text{Ph}$, $-\text{CH}=\text{CHPh}$, $-\text{CH}=\text{CH}_2$, $-\text{CH}_2\text{CH}=\text{CH}_2$, $-\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}=\text{CHCH}_3$, $-\text{C}_2\text{H}_4\text{CH}=\text{CH}_2$, $-\text{CH}_2\text{CH}=\text{CHCH}_3$, $-\text{CH}=\text{CHC}_2\text{H}_5$, $-\text{CH}_2\text{C}(\text{CH}_3)=\text{CH}_2$, $-\text{CH}(\text{CH}_3)\text{CH}=\text{CH}_2$, $-\text{CH}=\text{C}(\text{CH}_3)_2$, $-\text{C}(\text{CH}_3)=\text{CHCH}_3$, $-\text{C}\equiv\text{CH}$, $-\text{C}\equiv\text{CCH}_3$, $-\text{CH}_2\text{C}\equiv\text{CH}$, $-\text{C}_2\text{H}_4\text{C}\equiv\text{CH}$, $-\text{CH}_2\text{C}\equiv\text{CCH}_3$, $-\text{C}\equiv\text{CC}_2\text{H}_5$, $-\text{CH}_2\text{OCF}_3$, $-\text{C}_2\text{H}_4\text{OCF}_3$, $-\text{C}_3\text{H}_6\text{OCF}_3$, $-\text{CH}_2\text{OCH}_3$, $-\text{C}_2\text{H}_4\text{OCH}_3$, $-\text{C}_3\text{H}_6\text{OCH}_3$, $-\text{CH}_2\text{OC}_2\text{H}_5$, $-\text{C}_2\text{H}_4\text{OC}_2\text{H}_5$, $-\text{C}_3\text{H}_6\text{OC}_2\text{H}_5$.
- 20

In a further aspect of the present invention, the novel compounds according to the general formula (I) represent chiral compounds. The novel compounds according to the general formula (I) represent a racemate, or a S or a R enantiomer or a mixture of isomers.

5

In yet another preferred embodiment of the present invention, the compound according to the general formula (I) is selected from the group of compounds depicted in the following Table 1.

10

Table 1:

compound	name
(VII-01)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-02)	(R)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-03)	(R)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-04)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(2-azaspiro[3.3]heptan-6-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-05)	2-(1-oxa-8-azaspiro[4.5]decan-3-yloxy)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-06)	N-(1-(2-(1H-pyrazol-1-yl)phenyl)ethyl)-8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-07)	(R)-N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-08)	(R)-N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-09)	N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-10)	8-isopropyl-N-((S)-1-(2-methoxyphenyl)ethyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-11)	8-isopropyl-N-((S)-1-(2-methoxyphenyl)ethyl)-2-((R)-pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-12)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-13)	(R)-8-isopropyl-2-(pyrrolidin-3-yloxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-14)	8-isopropyl-2-(piperidin-4-yloxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-15)	(S)-8-isopropyl-N-(1-(2-methoxyphenyl)ethyl)-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-16)	(R)-N-(2-isopropoxybenzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-17)	N-(2-isopropoxybenzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-18)	(R)-N-(2-isopropoxybenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-19)	N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(VII-20)	(R)-N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-21)	(R)-N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-22)	N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-23)	(R)-8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-24)	8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-25)	(R)-8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-26)	(R)-N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-27)	(R)-N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-28)	N-((S)-1-(2-chlorophenyl)ethyl)-8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-29)	(R)-8-isopropyl-N-(2-(1-methyl-1H-tetrazol-5-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-30)	(R)-5-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)quinoline 1-oxide
(VII-31)	(R)-8-isopropyl-N-(isoquinolin-8-ylmethyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-32)	(R)-8-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)isoquinoline 2-oxide
(VII-33)	(R)-8-isopropyl-N-((1-methyl-1H-indazol-4-yl)methyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-34)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyridin-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-35)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(quinolin-8-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-36)	(R)-N-((1H-indazol-4-yl)methyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-37)	(R)-8-isopropyl-N-(2-(2-methyl-2H-tetrazol-5-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-38)	(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)-N,N-dimethylbenzenesulfonamide
(VII-39)	(R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)pyrrolidin-2-one
(VII-40)	(R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)azetidin-2-one
(VII-41)	(R)-N-(5-fluoro-2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-42)	(R)-N-(3-fluoro-2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-43)	(R)-N-(4-fluoro-2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-44)	(R)-N-(2-fluoro-6-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-45)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-(pyridin-3-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(VII-46)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyridin-3-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-47)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-phenoxybenzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-48)	(R)-8-isopropyl-N-(2-phenoxybenzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-49)	(R)-8-isopropyl-N-(2-(oxazol-2-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-50)	(R)-N-(2-(furan-2-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-51)	(R)-N-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)acetamide
(VII-52)	(R)-N-(2-(4-chloro-1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-53)	8-isopropyl-N-(2-methylbenzyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-54)	N-(2-(dimethylamino)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-55)	2-(((8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzonitrile
(VII-56)	N-(2-fluorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-57)	N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-58)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-(trifluoromethyl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-59)	N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-60)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-morpholinobenzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-61)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(naphthalen-1-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-62)	N-(2-chloro-6-methylbenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-63)	N-(2,6-dichlorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-64)	N-(2,6-difluorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-65)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-66)	N-(2-isopropoxybenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-67)	(S)-8-isopropyl-N-(1-(2-methoxyphenyl)ethyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-68)	N-(2-chlorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-69)	(S)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(1-(naphthalen-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-70)	N-(2-ethoxybenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-71)	8-isopropyl-N-(2-methoxybenzyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(VII-72)	N-(2-(difluoromethoxy)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-73)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-74)	N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-75)	8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-76)	N-(2-(difluoromethoxy)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-77)	methyl 2-(((2-(2-(dimethylamino)ethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzoate
(VII-78)	2-((6-aminospiro[3.3]heptan-2-yl)oxy)-8-isopropyl-N-(quinolin-5-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-79)	8-isopropyl-2-(2-(piperidin-4-yl)ethoxy)-N-(quinolin-5-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-80)	N-(2-aminobenzyl)-2-(azetidin-3-ylmethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine
(VII-89)	tert-butyl 2-(((8-isopropyl-2-(2-(piperidin-1-yl)ethoxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)carbamate
(VII-90)	N-(2-(((2-(2-(2-(dimethylamino)ethoxy)ethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methanesulfonamide
(VII-91)	N-(2-(((2-(2-(2-(dimethylamino)ethyl)(methyl)amino)ethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methanesulfonamide
(VIII-01)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine
(VIII-02)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.4]octan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-03)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[4.4]nonan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-04)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,6-diazaspiro[3.5]nonan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-05)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.5]nonan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-06)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[4.5]decan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-07)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.4]octan-6-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-08)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,6-diazaspiro[3.3]heptan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-09)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-10)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.3]heptan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-11)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-12)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[3.5]nonan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-13)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[4.4]nonan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-14)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,8-diazaspiro[5.5]undecan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine

	yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-15)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,8-diazaspiro[5.5]undecan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-16)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[3.5]nonan-7-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-17)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[4.4]nonan-7-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-18)	8-isopropyl-N-(2-(1-methyl-1H-tetrazol-5-yl)benzyl)-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-19)	8-isopropyl-N-(2-(2-methyl-2H-tetrazol-5-yl)benzyl)-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-20)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[3.5]nonan-7-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-21)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,9-diazaspiro[5.5]undecan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-22)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,8-diazaspiro[4.5]decan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-23)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,9-diazaspiro[5.5]undecan-9-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-24)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(4-(dimethylamino)piperidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-25)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(4-(methylamino)piperidin-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-26)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(3,9-diazaspiro[5.5]undecan-3-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-27)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[4.5]decan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-28)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,6-diazaspiro[3.4]octan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-31)	8-isopropyl-N4-((S)-1-(2-methoxyphenyl)ethyl)-N2-((R)-piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine
(VIII-32)	(R)-N4-(2-isopropoxybenzyl)-8-isopropyl-N2-(piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine
(VIII-33)	(R)-N4-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-N2-(piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine
(VIII-34)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[3.5]nonan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-35)	2-(((8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)-N,N-dimethylbenzenesulfonamide
(VIII-36)	N-(benzo[c][1,2,5]oxadiazol-4-ylmethyl)-8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-37)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,8-diazaspiro[4.5]decan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(VIII-38)	1-(2-(((8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)pyrrolidin-2-one
(X-1)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(X-2)	8-isopropyl-2-(piperidin-4-ylsulfinyl)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(X-3)	N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(X-4)	N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(X-5)	8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
(XII-1)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-(piperidin-4-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide
(XII-2)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-N-(azetidin-3-ylmethyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxamide
(XII-3)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-(pyrrolidin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide
(XII-4)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-(piperidin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide
(XII-5)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-N-(4-aminobutyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxamide

(R)-N-(4-chloro-2-methylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(R)-N-(2-bromobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

5 (R)-8-isopropyl-N-(2-(morpholinosulfonyl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyridin-2-yloxy)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine

10 (R)-N-(2-cyclobutoxybenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzamide

(R)-N-(2-(cyclopentyloxy)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

15 (R)-N-(2,4-dichlorobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

8-isopropyl-N-(4-methyl-2-((tetrahydrofuran-3-yl)oxy)benzyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

20 (R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzyl)pyrrolidin-2-one

N-(2-(((8-isopropyl-2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methanesulfonamide

4-(benzyloxy)-8-isopropyl-2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazine
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2-(piperazin-1-yl)ethoxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

25 N-(2-(1H-pyrazol-1-yl)benzyl)-2-((1R,5S)-3-azabicyclo[3.2.0]heptan-6-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine

2-((1,4-oxazepan-6-yl)oxy)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine

2-(1-oxa-8-azaspiro[4.5]decan-3-yloxy)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-
 isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((1,2,3,6-tetrahydropyridin-3-
 yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 5 (R)-N-(2-(cyclopentylthio)benzyl)-8-isopropyl-2-(piperidin-3-
 yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 (R)-8-isopropyl-N-(2-(methylthio)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-
 a][1,3,5]triazin-4-amine
 (R)-8-isopropyl-2-(piperidin-3-yloxy)-N-((2',3',4',5'-tetrahydro-[1,1'-biphenyl]-
 10 2-yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 (R)-N-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-6-yl)methyl)-8-isopropyl-2-
 (piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 (R)-N-(2-isobutoxy-4-methylbenzyl)-8-isopropyl-2-(piperidin-3-
 yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 15 (R)-1-ethyl-3-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-
 a][1,3,5]triazin-4-yl)amino)methyl)phenyl)urea
 (R)-1-benzyl-3-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-
 a][1,3,5]triazin-4-yl)amino)methyl)phenyl)urea
 (R)-1-cyclohexyl-3-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-
 20 a][1,3,5]triazin-4-yl)amino)methyl)phenyl)urea
 (R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)phenyl)-3-phenylurea
 (R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)phenyl)-3-propylurea
 25 N-(but-3-yn-2-yl)-2-(((8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-
 a][1,3,5]triazin-4-yl)amino)methyl)benzamide
 (R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)-N-methylbenzamide
 (R)-8-isopropyl-N-(2-((4-methylpiperazin-1-yl)sulfonyl)benzyl)-2-(piperidin-3-
 30 yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 (R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyrrolidin-1-
 ylsulfonyl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 (R)-N-isopropyl-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-
 a][1,3,5]triazin-4-yl)amino)methyl)benzenesulfonamide
 35 (R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)-N-methylbenzenesulfonamide
 (R)-N-(2,3-dichlorobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-
 a][1,3,5]triazin-4-amine
 (R)-N-(4-chloro-2-(trifluoromethyl)benzyl)-8-isopropyl-2-(piperidin-3-
 40 yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

N-(2-(1H-pyrazol-1-yl)benzyl)-2-(2-azabicyclo[2.2.1]heptan-5-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine

N-(2-iodobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

5 N-(2-(((8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)-2-methylpropane-2-sulfonamide

(R)-isobutyl (2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)carbamate

(R)-N-(2-((1H-pyrazol-1-yl)methyl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

10 (R)-N-(2,5-dichlorobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyrrolidin-1-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine

15 (R)-8-isopropyl-N-(2-(piperidin-1-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

azetidin-3-yl (2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl)(methyl)carbamate

20 N-(2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl)-3-(dimethylamino)-N-methylpropane-1-sulfonamide

N-(2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl)-N-methylpiperidine-4-sulfonamide

25 2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl azetidin-3-ylcarbamate

2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)-N-(pyrrolidin-3-yl)ethanesulfonamide

N-(2-(1H-pyrazol-1-yl)benzyl)-2-(8-azabicyclo[3.2.1]octan-3-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine

30 N-(2-(1H-pyrazol-1-yl)benzyl)-2-(2-azaspiro[3.3]heptan-5-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine

N-(2-(1H-pyrazol-1-yl)benzyl)-2-((4-aminocyclohexyl)oxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine

(R)-N-(2-cyclobutylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(R)-N-(2-cyclopentylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

N-(2-cyclopropylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

40 (R)-N-(2-cyclohexylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl acetate

(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl ethylcarbamate

(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl methanesulfonate

2-(((8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl 2-methylpropane-2-sulfinate

(R)-isobutyl (2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl) carbonate

(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenol

(R)-8-isopropyl-N-(2-(methylsulfonyl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

8-isopropyl-N-(2-(methylsulfinyl)benzyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

N-(2-(cyclopentylsulfinyl)benzyl)-8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine

N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(3-aminopropyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(2-(pyrrolidin-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

N-(2-(1H-pyrazol-1-yl)benzyl)-2-(3-(3,3-difluoropyrrolidin-1-yl)azetidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine

N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(2-morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(pyrrolidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(3-morpholinopropyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(2-(pyrrolidin-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(2-morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

1-(1-(4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)azetidin-3-yl)pyrrolidin-2-one

N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(2-(2-aminoethoxy)ethyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(3-(piperidin-1-yl)propyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

N-(2-(1H-pyrazol-1-yl)benzyl)-2-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine

N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(2-aminoethyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

5 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(pyrrolidin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

N-(2-(1H-pyrazol-1-yl)benzyl)-2-(3-aminopiperidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine

10 N-(2-(1H-pyrazol-1-yl)benzyl)-2-(3-aminopyrrolidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine

methyl 2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-3-aminopropanoate

N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(2-amino-1-phenylethyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

15 N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(azetidin-3-ylmethyl)-8-isopropyl-N2-methylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(2-morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

20 N-(2-(1H-pyrazol-1-yl)benzyl)-2-(4-aminopiperidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine

N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(4-aminocyclohexyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine

N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((R)-((R)-piperidin-3-yl)sulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine

25 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylsulfonyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(R)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-ylthio)pyrazolo[1,5-a][1,3,5]triazin-4-amine

30 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylthio)pyrazolo[1,5-a][1,3,5]triazin-4-amine

(4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)(2,6-diazaspiro[3.3]heptan-2-yl)methanone

4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-methyl-N-(2-morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide

35 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide

(4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)(piperazin-1-yl)methanone

40 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-N-(3-aminopropyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxamide

(4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)(4-aminopiperidin-1-yl)methanone
 N1-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)methyl)ethane-1,2-diamine
 5 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(((3-morpholinopropyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((methyl(2-(pyrrolidin-1-yl)ethyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(((2-(pyrrolidin-1-yl)ethyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 10 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(((2-morpholinoethyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((methyl(3-(piperidin-1-yl)propyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 15 N-(2-(1H-pyrazol-1-yl)benzyl)-2-((3-(3,3-difluoropyrrolidin-1-yl)azetidin-1-yl)methyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine
 1-(1-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)methyl)azetidin-3-yl)pyrrolidin-2-one
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((4-(2-methoxyethyl)piperazin-1-yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 20 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((pyrrolidin-3-ylamino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperazin-1-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 25 N-(2-(1H-pyrazol-1-yl)benzyl)-2-(((azetidin-3-ylmethyl)(methyl)amino)methyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine
 N-(2-(2-(((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)methyl)amino)ethoxy)ethyl)-2-(pyrrolidin-1-yl)acetamide
 30 N-(2-(1H-pyrazol-1-yl)benzyl)-2-((4-aminopiperidin-1-yl)methyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine
 1-methylpyrrolidin-3-yl 4-((2-(1H-pyrazol-1-yl)benzyl) amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxylate
 8-isopropyl-N-(2-(S-methylsulfonimidoyl)benzyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 35 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo [1,5-a][1,3,5]triazin-2-ol
 N-(2-(1H-pyrazol-1-yl)benzyl)-2-bromo-8-isopropylpyrazolo [1,5-a][1,3,5]triazin-4-amine
 40 tert-butyl 2-(1H-pyrazol-1-yl)benzyl(2-bromo-8-isopropyl pyrazolo[1,5-a][1,3,5]triazin-4-yl)carbamate

N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine
 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(2-morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine
 5 N-(2-(1H-pyrazol-1-yl)benzyl)-2-(4-aminopiperidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine
 N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(4-aminocyclohexyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine
 N-(2-(2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)ethoxy)ethyl)-2-(pyrrolidin-1-yl)acetamide
 10 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(2-(piperazin-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine
 N-(2-(1H-pyrazol-1-yl)benzyl)-2-(azetidin-3-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine
 15


The compounds of the present invention may form salts with organic or inorganic acids or bases. Examples of suitable acids for such acid addition salt formation are hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, acetic acid, citric acid, oxalic acid, malonic acid, salicylic acid, p-aminosalicylic acid, malic acid, fumaric acid, succinic acid, ascorbic acid, maleic acid, sulfonic acid, phosphonic acid, perchloric acid, nitric acid, formic acid, propionic acid, gluconic acid, lactic acid, tartaric acid, hydroxymaleic acid, pyruvic acid, phenylacetic acid, benzoic acid, p-aminobenzoic acid, p-hydroxybenzoic acid, methanesulfonic acid, ethanesulfonic acid, nitrous acid, hydroxyethanesulfonic acid, ethylenesulfonic acid, p-toluenesulfonic acid, naphthylsulfonic acid, sulfanilic acid, camphorsulfonic acid, china acid, mandelic acid, o-methylmandelic acid, hydrogen-benzenesulfonic acid, picric acid, adipic acid, d-o-tolyltartaric acid, tartronic acid, (o, m, p)-toluic acid, naphthylamine sulfonic acid, trifluoroacetic acid, and other mineral or carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner.

In the case the inventive compounds bear acidic groups, salts could also be formed with inorganic or organic bases. Examples for suitable inorganic or organic bases are, for example, NaOH, KOH, NH₄OH, tetraalkylammonium hydroxide, lysine or arginine and the like. Salts may be prepared in a conventional manner using methods well known in the art, for example by treatment of a solution of the compound of the general formula (I) with a solution of an acid, selected out of the group mentioned above.

Synthesis of Compounds


The inventive pyrazolo[1,5-a][1,3,5]triazines according to the present invention can be prepared by methods known to one skilled in the art. The synthesis is preferably carried out according to the general synthetic sequences, shown in schemes 3 and 4. This enables those skilled in the art to introduce to intermediate (IV) any suitable amine R²-NH₂ that is commercially available or can be synthesized according to or in analogy to literature procedures. Further, after introduction of a methylsulfoxide leaving group by oxidation of the thioatom in (V) compounds with this formed methylsulfoxide group provide the basis to react with many classes of C-, S-, N- or O-nucleophiles that are available either commercially or by synthetic means. Therefore, the synthetic approach according to schemes 3 and 4 enables the synthesis of any of the pyrazolo[1,5-a][1,3,5]triazines disclosed in the present invention. However a person skilled in the art can also prepare these compounds following to other synthetic sequences.

In the following schemes occurring abbreviations mean DCM (dichloromethane); DIPEA (N-ethyl-N,N-diisopropylamine); DMF (dimethylformamide); DMSO (dimethyl sulfoxide); EtOAc (ethyl acetate); EtOH (ethanol); mCPBA (3-chlorobenzoperoxoic acid); MeOH (methanol); MeCN (acetonitrile); TFA (trifluoroacetic acid), PhNEt₂ (dimethyl phenyl amine), Boc (tert-butyloxycarbonyl), Ph (phenyl), Ts (tosylate, *p*-toluenesulfonyl group), Mes (mesylate, methanesulfonyl group).




scheme 1


As depicted in scheme 1 in a first step 4-isopropyl-1H-pyrazol-5-amine was reacted with ethoxycarbonyl isothiocyanate to give a thiourea derivative that was cyclized to 2-mercaptopyrazolo[1,5-a][1,3,5]triazin-4-ol (II). The thiol (II) is then methylated by standard procedure to yield intermediate methylthioether (III).

**scheme 2**

Starting from (III) two further intermediate compounds can be derived as depicted in
 5 scheme 2. Firstly, after said methylation of the mercapto group in (II) 4-chloro-2-(
 (methylthio)pyrazolo[1,5-a][1,3,5]triazine (IV) was obtained by chlorination of (III) with
 phosphoryl trichloride in the presence of N,N-diethylaniline. Secondly, by oxidation of
 (III) the sulfone derivative (XVII) can be synthesized. Both, intermediate (IV) and (XVII)
 can be used for synthesis of the compounds of the present invention of the general
 10 formula (I) via various synthetic routes.

**scheme 3**


The residue A^1 can be introduced by nucleophilic substitution reaction of (IV) with amines of the formula A^1NH_2 , and DIPEA as a base yielding 4-amino-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazines (V) as shown in scheme 3, wherein A^1 represents the upper benzyl building block of the compounds of the general formula (I)



5

Compounds (V) were then oxidized with 3-chlorobenzoperoxoic acid to 4-amino-2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazines (VI) that could be substituted by reaction with compounds of the general formula R^2-H yielding the compounds of the present invention of the general formula (I), wherein R^2 and A^1 represent residues as defined herein.

10



scheme 4


An alternative synthesis to the route outlined in scheme 3 is depicted in scheme 4 starting from intermediate (XVII). As one synthetic option the reaction of a nucleophile (R^2-H) for introduction of the residue R^2 takes place before the incorporation of the amine A^1NH_2 (upper pathway). In addition as a second synthetic option it is possible to obtain chloride (XX) and subsequently substitute said chloride before the sulfone is replaced by R^2 . The synthetic approach for the compounds of the general formula (I) according to scheme 4 has the advantage that the oxidation step for generating a sulfone from a thioether (here (III) converts to (XVII)) takes place before the introduction of the upper building block A^1 by reaction with the amine A^1NH_2 . Accordingly, moieties A^1 being sensitive to oxidative reaction conditions can also be introduced, thereby broadening the scope of the compounds of the present invention significantly.

Conveniently, many ortho-substituted benzylamines A^1NH_2 as these are useful starting materials for the synthesis of the compounds of the general formula (I) are commercially available. Additional derivatives can be prepared by a person skilled in the art following known synthetic procedures that are disclosed in patent or non-patent literature.

In principle, following any approach for the preparation of the compounds with the general formula A^1-NH_2 and thereby for the compounds of the present invention with the general formula (I) two aspects have to be considered. Firstly, the generation of the benzylic amino group in A^1NH_2 and secondly, the introduction of the desired substitution pattern as represented by R^3-R^7 .


Commonly used syntheses for said aminomethylphenyl derivatives are shown in scheme 5. Suitable starting materials include aryl halogenides, sulfonates, nitriles, oximes, halogenomethans and related precursors.

Depending on the target molecule with its specific substitution pattern (as represented by R^3-R^7) a person skilled in the art of organic chemistry will plan the synthetic approach for each benzylamine (XIII) individually and decide at which point the aminomethyl group and their related precursors will be synthesized. Also, scheme 5 shows merely exemplary synthetic methods for the preparation of compounds (XIII) which is only a specific embodiment of the moiety A^1 , wherein R^1 is hydrogen. However, the person skilled in the art will understand that the below synthetic routes are also suitable for the preparation of amines A^1-NH_2 with any residue R^1 as defined herein.




scheme 5

- 5 According to the present invention ortho-substituent R^3 in compounds of the general formula (I) is different from hydrogen. Starting from a wide range of commercially available materials many synthetic approaches can be applied to introduce the moieties at the respective position to yield compounds of the formula (I) and are well known to a person skilled in the art of synthesis.
- 10 For example, R^3 in formula (I) can derive from a nucleophile. In such a case it can be introduced for example via reaction with a 2-fluorobenzonitrile derivative (XIV, scheme 6). Subsequently, ortho-substituted benzylamines (XVI) can be obtained by reduction of the corresponding nitrile (XV). Examples for nucleophiles represented by NuH are alcohols, amines, thiols or 5-membered heteroaromatics such as pyrazole or triazole derivatives. If necessary, compounds of formula (XV) or (XVI) can be further modified in various positions before or after being used as building block ($\text{A}^1\text{-NH}_2$) according to schemes 3 and 4.
- 15

**scheme 6**

Other examples for aromatic substitutions of aryl halides, triflates or boronates are copper mediated Ullman-type or palladium catalyzed Buchwald-Hartwig reactions with N-, O- or S-nucleophiles.

Further, there is also a huge number of reactions that enable a person skilled in the art of organic chemistry attaching R^3 in compounds of the general formula (I) via a carbon-carbon bond. These reactions include but are not limited to catalyzed (e.g. by palladium, nickel, copper or iron species) cross-coupling reactions of an appropriate aryl halides or sulfonate with an alkyl, aryl or heteroaryl boron-, zinc-, magnesium-, tin- or silicon-reagent. Alternatively, for introduction of the substituent R^3 it is possible to transform an aryl halide or sulfonate (e.g. triflate) into one of the above mentioned metal species that can be used in a cross-coupling reaction with for example alkyl, aryl or heteroaryl halide R^3 -X. Further on scheme 3, synthetic options are presented for the rather general introduction of the residue R^2 in the following schemes 7-9:


**scheme 7**

For example intermediate (VI) can be reacted with different nucleophiles to give derivatives (VII)-(IX) that all bear different residues A^2 to A^7 at the afore-mentioned R^2 position in (I) in scheme 3.

In one embodiment in the synthesis of the compounds of the present invention amides of formula (XII) were synthesized via introduction of a cyanide group, transforming the resulting nitriles into imidoesters (XI) which underwent a subsequent nucleophilic attack with primary or secondary amines A^3A^4NH and hydrolysis to yield said related amides (scheme 7). In such embodiment the residue R^2 is represented by the amide group $-CO-NA^3A^4$. For example, for A^3 being R^{15} and A^4 being R^8 the case R^2 being $-Q-R^8$ with $Q = -CO-NR^{15}$ is realized. Examples of the residue $-CO-NA^3A^4$ as represented by R^2 are $-Q-R^8$ with $Q = -CO-$, $-CO-NH-(CH_2)_n-NH_2$, $-CO-NH-(CH_2)_n-R^9$, $-CO-NR^{10}-(CH_2)_n-R^9$, $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$, $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$ which can be synthesized according to the synthetic pathway as depicted in scheme 7.

Specifically, for $R^2 = -Q-R^8$ and $Q = -CO-NR^{15}-$, then $A^3 = R^{15}$ and A^4 represents R^8 . For $R^2 = -CO-NH-(CH_2)_n-NH_2$, $-CO-NH-(CH_2)_n-R^9$, $A^3 = H$ and A^4 represents $(CH_2)_n-NH_2$, or $(CH_2)_n-R^9$. For $R^2 = -CO-NR^{10}-(CH_2)_n-R^9$, $A^3 = R^{10}$ and A^4 represents $(CH_2)_n-R^9$. For $R^2 = -(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$, $a = 0$, $b = 1$, and $Q = -CO-NR^{15}-$, then $A^3 = R^{15}$ and A^4 represents $(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$, wherein G^1 , G^2 , c , d , e , f , g , n , R^8 and R^9 are as defined herein.


For $R^2 = -(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$, $a = 0$, $b = 1$, and $Q = -CO-NR^{15}-$, then $A^3 = R^{15}$ and A^4 represents $(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$, wherein G^1 , G^2 , c , d , e , f , g , n , R^8 and R^9 are as defined herein.



scheme 8

In another embodiment it is possible to introduce the moiety A^5 by conversion of a sulfone (e.g. (VI)) with the mercaptan A^5SH furnishing the thioether (IX) which can

optionally be oxidized to the sulfoxide (X) as shown in scheme 8. By introduction of A^5 via reaction with A^5SH examples for $-S-A^5$ or $-SO-A^5$ as represented by R^2 are $-Q-R^8$ with $Q = -S-$ or $-SO-$, $-Q-(CH_2)_n-R^8$ with $Q = -S-$ or $-SO-$, $-Q-(CH_2)_n-R^9$ with $Q = -S-$ or $-SO-$, $-SO-R^9$, $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$, $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$ are obtainable, wherein Q can be $-S-$ or $-SO-$, $a = 0$, $b = 1$ and G , c , d , e , f , g , n , R^8 and R^9 are as defined herein. Therefore, A^5 can be selected from the group consisting of $-R^8$, $-(CH_2)_n-R^8$, $-(CH_2)_n-R^9$, $-R^9$, $-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$ and $-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$, wherein G , c , d , e , f , g , n , R^8 and R^9 are as defined herein for the respective examples of R^2 as specified above for scheme 8.



scheme 9

In another embodiment it is possible to introduce the moiety A^2 by conversion of a sulfone (e.g. (VI)) with the alcohol A^2OH furnishing the ether (VII). By introduction of A^2 via reaction with A^2OH examples for $-O-A^2$ as represented by R^2 are $-Q-R^8$ with $Q = -O-$, $-Q-(CH_2)_n-R^8$ with $Q = -O-$, $-Q-(CH_2)_n-R^9$ with $Q = -O-$, $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$, $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$ are obtainable, wherein Q can be $-O-$, $a = 0$, $b = 1$ and G , c , d , e , f , g , n , R^8 and R^9 are as defined herein. Therefore, A^2 can be selected from the group consisting of $-R^8$, $-(CH_2)_n-R^8$, $-(CH_2)_n-R^9$, $-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$ and $-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$, wherein G , c , d , e , f , g , n , R^8 and R^9 are as defined herein for the respective examples of R^2 as specified above for scheme 9.

Yet in another embodiment it is possible to introduce the moiety $-NA^6A^7$ by conversion of a sulfone (e.g. (VI)) with the amine of the formula HNA^6A^7 furnishing compound (VIII). By introduction of $-NA^6A^7$ via reaction with HNA^6A^7 . Examples for $-NA^6A^7$ as represented by R^2 are $-Q-R^8$ with $Q = -NR^{15}-$, $-NR^{15}-SO-$, $-NR^{15}-SO_2-$, $-NR^{15}-CO-$, $-NR^{15}-CO-NR^{15}-$, $-NR^{15}-CO-O-$, $-Q-(CH_2)_n-R^8$ with $Q = -NR^{15}-$, $-NR^{15}-$

SO-, $-\text{NR}^{15}-\text{SO}_2-$, $-\text{NR}^{15}-\text{CO}-$, $-\text{NR}^{15}-\text{CO}-\text{NR}^{15}-$, $-\text{NR}^{15}-\text{CO}-\text{O}-$, $-\text{Q}-(\text{CH}_2)_n-\text{R}^9$
 with Q = $-\text{NR}^{15}-$, $-\text{NR}^{15}-\text{SO}-$, $-\text{NR}^{15}-\text{SO}_2-$, $-\text{NR}^{15}-\text{CO}-$, $-\text{NR}^{15}-\text{CO}-\text{NR}^{15}-$, $-\text{NR}^{15}-$
 $\text{CO}-\text{O}-$, $-(\text{CH}_2)_m-\text{NH}-(\text{CH}_2)_n-\text{R}^9$, $-(\text{CH}_2)_m-\text{NR}^{10}-(\text{CH}_2)_n-\text{R}^9$,

$-(\text{CH}_2)_a-(\text{Q})_b-(\text{CH}_2)_c-(\text{G}^1)_d-(\text{CH}_2)_e-(\text{G}^2)_f-(\text{CH}_2)_g-\text{R}^8$,

5 $-(\text{CH}_2)_a-(\text{Q})_b-(\text{CH}_2)_c-(\text{G}^1)_d-(\text{CH}_2)_e-(\text{G}^2)_f-\text{CH}_2-\text{R}^9$ are obtainable.

Specifically, for R^2 being $-\text{Q}-\text{R}^8$, then Q can be selected from the group consisting of
 $-\text{NR}^{15}-$, $-\text{NR}^{15}-\text{SO}-$, $-\text{NR}^{15}-\text{SO}_2-$, $-\text{NR}^{15}-\text{CO}-$, $-\text{NR}^{15}-\text{CO}-\text{NR}^{15}-$, $-\text{NR}^{15}-\text{CO}-\text{O}-$
 and $-(\text{CH}_2)_m-\text{NR}^{15}-$ with $m = 0$, and then A^6 represents R^{15} and A^7 is selected from the
 10 group consisting of $-\text{R}^8$, $-\text{SO}_2-\text{R}^8$, $-\text{CO}-\text{R}^8$, $-\text{CO}-\text{NR}^{15}-\text{R}^8$ and $-\text{CO}-\text{O}-\text{R}^8$, wherein
 R^8 is as defined herein.

For R^2 being $-\text{Q}-(\text{CH}_2)_n-\text{R}^8$, then Q can be selected from the group consisting of
 $-\text{NR}^{15}-$, $-\text{NR}^{15}-\text{SO}-$, $-\text{NR}^{15}-\text{SO}_2-$, $-\text{NR}^{15}-\text{CO}-$, $-\text{NR}^{15}-\text{CO}-\text{NR}^{15}-$, $-\text{NR}^{15}-\text{CO}-\text{O}-$
 15 and $-(\text{CH}_2)_m-\text{NR}^{15}-$ with $m = 0$, and then A^6 represents R^{15} and A^7 is selected from the
 group consisting of $-(\text{CH}_2)_n-\text{R}^8$, $-\text{SO}_2-(\text{CH}_2)_n-\text{R}^8$, $-\text{CO}-(\text{CH}_2)_n-\text{R}^8$, $-\text{CO}-\text{NR}^{15}-$
 $(\text{CH}_2)_n-\text{R}^8$ and $-\text{CO}-\text{O}-(\text{CH}_2)_n-\text{R}^8$, wherein R^8 is as defined herein.

For R^2 being $-\text{Q}-(\text{CH}_2)_n-\text{R}^9$, then Q can be selected from the group consisting of
 $-\text{NR}^{15}-$, $-\text{NR}^{15}-\text{SO}-$, $-\text{NR}^{15}-\text{SO}_2-$, $-\text{NR}^{15}-\text{CO}-$, $-\text{NR}^{15}-\text{CO}-\text{NR}^{15}-$, $-\text{NR}^{15}-\text{CO}-\text{O}-$
 20 and $-(\text{CH}_2)_m-\text{NR}^{15}-$ with $m = 0$, and then A^6 represents R^{15} and A^7 is selected from the
 group consisting of $-(\text{CH}_2)_n-\text{R}^9$, $-\text{SO}_2-(\text{CH}_2)_n-\text{R}^9$, $-\text{CO}-(\text{CH}_2)_n-\text{R}^9$, $-\text{CO}-\text{NR}^{15}-$
 $(\text{CH}_2)_n-\text{R}^9$ and $-\text{CO}-\text{O}-(\text{CH}_2)_n-\text{R}^9$, wherein R^9 is as defined herein.

For R^2 being $-(\text{CH}_2)_m-\text{NH}-(\text{CH}_2)_n-\text{R}^9$, then $m = 0$ and then A^6 represents H and A^7 is
 selected from the group consisting of $-(\text{CH}_2)_n-\text{R}^9$, wherein R^9 is as defined herein.

For R^2 being $-(\text{CH}_2)_m-\text{NR}^{10}-(\text{CH}_2)_n-\text{R}^9$, then $m = 0$ and then A^6 represents R^{10} and A^7
 is selected from the group consisting of $-(\text{CH}_2)_n-\text{R}^9$, wherein R^9 and R^{10} are as defined
 herein.

For R^2 being $-(\text{CH}_2)_a-(\text{Q})_b-(\text{CH}_2)_c-(\text{G}^1)_d-(\text{CH}_2)_e-(\text{G}^2)_f-(\text{CH}_2)_g-\text{R}^8$, then $a = 0$ and $b = 1$
 and Q can be selected from the group consisting of
 $-\text{NR}^{15}-$, $-\text{NR}^{15}-\text{SO}-$, $-\text{NR}^{15}-\text{SO}_2-$, $-\text{NR}^{15}-\text{CO}-$, $-\text{NR}^{15}-\text{CO}-\text{NR}^{15}-$, $-\text{NR}^{15}-\text{CO}-\text{O}-$
 and $-(\text{CH}_2)_m-\text{NR}^{15}-$ with $m = 0$, and then A^6 represents R^{15} and A^7 is selected from the
 35 group consisting of $-(\text{CH}_2)_c-(\text{G}^1)_d-(\text{CH}_2)_e-(\text{G}^2)_f-(\text{CH}_2)_g-\text{R}^8$, $-\text{SO}_2-(\text{CH}_2)_c-(\text{G}^1)_d-$
 $(\text{CH}_2)_e-(\text{G}^2)_f-(\text{CH}_2)_g-\text{R}^8$, $-\text{CO}-(\text{CH}_2)_c-(\text{G}^1)_d-(\text{CH}_2)_e-(\text{G}^2)_f-(\text{CH}_2)_g-\text{R}^8$, $-\text{CO}-\text{NR}^{15}-$
 $(\text{CH}_2)_c-(\text{G}^1)_d-(\text{CH}_2)_e-(\text{G}^2)_f-(\text{CH}_2)_g-\text{R}^8$ and $-\text{CO}-\text{O}-(\text{CH}_2)_c-(\text{G}^1)_d-(\text{CH}_2)_e-(\text{G}^2)_f-$
 $(\text{CH}_2)_g-\text{R}^8$, wherein c, d, e, f, g, G^1 , G^2 and R^8 is as defined herein.

For R^2 being $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$, then $a = 0$ and $b = 1$ and Q can be selected from the group consisting of $-NR^{15}-$, $-NR^{15}-SO-$, $-NR^{15}-SO_2-$, $-NR^{15}-CO-$, $-NR^{15}-CO-NR^{15}-$, $-NR^{15}-CO-O-$ and $-(CH_2)_m-NR^{15}-$ with $m = 0$, and then A^6 represents R^{15} and A^7 is selected from the group consisting of $-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$, $-SO_2-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$, $-CO-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$, $-CO-NR^{15}-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$ and $-CO-O-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$, wherein c , d , e , f , g , G^1 , G^2 and R^8 is as defined herein.

Several compounds of formula (I) may be derivatized by converting substituents which are attached to any position using standard reactions which are known to the person skilled in the art. For example, a nitro group can be reduced to an amino group, such an amino group can be converted to a sulfonamide by reaction with a sulfonyl chloride, to a carboxamide by reaction with a carbonyl chloride or another activated derivative of a carboxylic acid, to an urea by reaction with an isocyanate. Carbamate substituents may be cleaved to amino groups, in particular *tert*-butyl carbamates by reaction with acids like trifluoroacetic acid or hydrochloric acid. Formyl groups may be converted to aminomethyl groups by reaction with primary amines under conditions of a reductive amination.

Indications

In a further aspect of the present invention, the novel compounds according to the general formula (I) are used as pharmaceutically active agent.

Further aspects of the present invention relate to the use of the compounds of general formula (I) for the preparation of a pharmaceutical composition useful for prophylaxis and/or treatment of infectious diseases including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke.

Infectious diseases including opportunistic infections

In yet another aspect of the present invention, the compounds according to the general formula (I) are for the preparation of a pharmaceutical composition for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases and opportunistic infections. The term "infectious diseases" comprises infections caused by viruses, bacteria, prions, fungi, and/or parasites.

Especially, virally induced infectious diseases, including opportunistic diseases are addressed. In a preferred embodiment of this aspect, the virally induced infectious diseases, including opportunistic diseases, are caused by retroviruses, human
 5 endogenous retroviruses (HERVs), hepadnaviruses, herpesviruses, flaviviridae, and/or adenoviruses. Preferably, the retroviruses are selected from lentiviruses or oncoretroviruses, wherein the lentivirus is preferably selected from the group comprising: HIV-1, HIV-2, feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), simian immunodeficiency viruses (SIVs), chimeras of HIV
 10 and SIV (SHIV), caprine arthritis encephalitis virus (CAEV), visna/maedi virus (VMV) or equine infectious anemia virus (EIAV), preferably HIV-1 and HIV-2, and the oncoretrovirus is preferably selected from HTLV-I, HTLV-II or bovine leukemia virus (BLV), preferably HTLV-I and HTLV-II.

15 The hepadnavirus is preferably selected from HBV, ground squirrel hepatitis virus (GSHV) or woodchuck hepatitis virus (WHV), preferably HBV, the herpesvirus is selected from the group comprising: Herpes simplex virus I (HSV I), herpes simplex virus II (HSV II), Epstein-Barr virus (EBV), varicella zoster virus (VZV), human cytomegalovirus (HCMV) or human herpesvirus 8 (HHV-8), preferably HCMV, and the
 20 flaviviridae is selected from HCV, West Nile or Yellow Fever.

It is to be understood, that all the viruses mentioned above, also comprise drug resistant virus strains.

Examples of infectious diseases are AIDS, Alveolar Hydatid Disease (AHD, Echinococcosis), Amebiasis (Entamoeba histolytica Infection), Angiostrongylus Infection, Anisakiasis, Anthrax, Babesiosis (Babesia Infection), Balantidium Infection (Balantidiasis), Baylisascaris Infection (Raccoon Roundworm), Bilharzia (Schistosomiasis), Blastocystis hominis Infection (Blastomycosis), Boreliosis, Botulism, Brainerd Diarrhea, Brucellosis, BSE (Bovine Spongiform Encephalopathy),
 25 Candidiasis, Capillariasis (Capillaria Infection), CFS (Chronic Fatigue Syndrome), Chagas Disease (American Trypanosomiasis), Chickenpox (Varicella-Zoster virus), Chlamydia pneumoniae Infection, Cholera, Chronic Fatigue Syndrome, CJD (Creutzfeldt-Jakob Disease), Clonorchiasis (Clonorchis Infection), CLM (Cutaneous Larva Migrans, Hookworm Infection), Coccidioidomycosis, Conjunctivitis,
 30 Coxsackievirus A16 (Hand, Foot and Mouth Disease), Cryptococcosis, Cryptosporidium Infection (Cryptosporidiosis), Culex mosquito (Vector of West Nile Virus), Cutaneous Larva Migrans (CLM), Cyclosporiasis (Cyclospora Infection), Cysticercosis (Neurocysticercosis), Cytomegalovirus Infection, Dengue / Dengue Fever, Dipylidium Infection (Dog and Cat Flea Tapeworm), Ebola Virus Hemorrhagic

Fever, Echinococcosis (Alveolar Hydatid Disease), Encephalitis, Entamoeba coli
 Infection, Entamoeba dispar Infection, Entamoeba hartmanni Infection, Entamoeba
 histolytica Infection (Amebiasis), Entamoeba polecki Infection, Enterobiasis (Pinworm
 Infection), Enterovirus Infection (Non-Polio), Epstein-Barr Virus Infection, Escherichia
 coli Infection, Foodborne Infection, Foot and mouth Disease, Fungal Dermatitis,
 5 Gastroenteritis, Group A streptococcal Disease, Group B streptococcal Disease,
 Hansen's Disease (Leprosy), Hantavirus Pulmonary Syndrome, Head Lice Infestation
 (Pediculosis), Helicobacter pylori Infection, Hematologic Disease, Hendra Virus
 Infection, Hepatitis (HCV, HBV), Herpes Zoster (Shingles), HIV Infection, Human
 10 Ehrlichiosis, Human Parainfluenza Virus Infection, Influenza, Isosporiasis (Isospora
 Infection), Lassa Fever, Leishmaniasis, Kala-azar (Kala-azar, Leishmania Infection),
 Leprosy, Lice (Body lice, Head lice, Pubic lice), Lyme Disease, Malaria, Marburg
 Hemorrhagic Fever, Measles, Meningitis, mycobacteria-induced meningitis,
 Mosquito-borne Diseases, Mycobacterium avium Complex (MAC) Infection, Naegleria
 15 Infection, Nosocomial Infections, Nonpathogenic Intestinal Amebae Infection,
 Onchocerciasis (River Blindness), Opisthorciasis (Opisthorcis Infection), Parvovirus
 Infection, Plague, PCP (Pneumocystis carinii Pneumonia), Polio, Q Fever, Rabies,
 Respiratory Syncytial Virus (RSV) Infection, Rheumatic Fever, Rift Valley Fever,
 River Blindness (Onchocerciasis), Rotavirus Infection, Roundworms Infection,
 20 Salmonellosis, Salmonella Enteritidis, Scabies, Shigellosis, Shingles, Sleeping
 Sickness, Smallpox, Streptococcal Infection, Tapeworm Infection (Taenia Infection),
 Tetanus, Toxic Shock Syndrome, Tuberculosis, Ulcers (Peptic Ulcer Disease), Valley
 Fever, Vibrio parahaemolyticus Infection, Vibrio vulnificus Infection, Viral
 Hemorrhagic Fever, Warts, Waterborne infectious Diseases, West Nile Virus Infection
 25 (West Nile Encephalitis), Whooping Cough, Yellow Fever.

Immunological diseases

Another aspect of the present invention is directed to the use of at least one compound
 of the general formula (I) and/or pharmaceutically acceptable salts thereof for
 30 prophylaxis and/or treatment of immunological diseases, neuroimmunological diseases,
 and autoimmune diseases.

Immunological diseases are, for instance, asthma and diabetes, rheumatic and
 autoimmune diseases, AIDS, rejection of transplanted organs and tissues (cf. below),
 35 rhinitis, chronic obstructive pulmonary diseases, osteoporosis, ulcerative colitis,
 sinusitis, lupus erythematosus, recurrent infections, atopic dermatitis / eczema and
 occupational allergies, food allergies, drug allergies, severe anaphylactic reactions,
 anaphylaxis, and other manifestations of allergic disease, as well as uncommon
 problems such as primary immunodeficiencies, including antibody deficiency states,

cell mediated immunodeficiencies (e.g., severe combined immunodeficiency, DiGeorge syndrome, Hyper-IgE syndrome, Wiskott-Aldrich syndrome, ataxia- telangiectasia), immune mediated cancers, and white cell defects.

5 In autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis (RA), multiple sclerosis (MS), immune-mediated or type 1 diabetes mellitus, immune mediated glomerulonephritis, scleroderma, pernicious anemia, alopecia, pemphigus, pemphigus vulgaris, myasthenia gravis, inflammatory bowel diseases, Crohn's disease, psoriasis, autoimmune thyroid diseases, and Hashimoto's disease, dermatomyositis,
10 goodpasture syndrome, myasthenia gravis pseudoparalytica, ophtalmia sympathica, phakogene uveitis, chronicl agressivce hepatitis, primary billiary cirrhosis, autoimmune hemolytic anemy, Werlof disease, specific cells uncontrollably attack the body's own tissues and organs (autoimmunity), producing inflammatory reactions and other serious symptoms and diseases.

15 Hashimoto's thyroiditis is one of the most common autoimmune diseases. "Autoimmune disease" refers to a category of more than 80 chronic illnesses, that can affect everything from the endocrine glands (like the thyroid) to organs like the kidneys, as well as to the digestive system.

20 There are many different autoimmune diseases, and they can each affect the body in different ways. For example, the autoimmune reaction is directed against the brain in multiple sclerosis and the gut in Crohn's disease. In other autoimmune diseases such as systemic lupus erythematosus (lupus), affected tissues and organs may vary among
25 individuals with the same disease. One person with lupus may have affected skin and joints whereas another may have affected skin, kidney, and lungs. Ultimately, damage to certain tissues by the immune system may be permanent, as with destruction of insulin-producing cells of the pancreas in type 1 diabetes mellitus.

30 **Cardiovascular diseases**

The inventive compounds are also useful for prophylaxis and/or treatment of cardiovascular diseases such as cardiac hypertrophy, adult congenital heart disease, aneurysm, stable angina, unstable angina, angina pectoris, angioneurotic edema, aortic valve stenosis, aortic aneurysm, arrhythmia, arrhythmogenic right ventricular
35 dysplasia, arteriosclerosis, arteriovenous malformations, atrial fibrillation, Behcet syndrome, bradycardia, cardiac tamponade, cardiomegaly, congestive cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, cardiovascular disease prevention, carotid stenosis, cerebral hemorrhage, Churg-Strauss syndrome, diabetes, Ebstein's Anomaly, Eisenmenger complex, cholesterol embolism, bacterial

endocarditis, fibromuscular dysplasia, congenital heart defects, heart diseases, congestive heart failure, heart valve diseases, heart attack, epidural hematoma, hematoma, subdural, Hippel-Lindau disease, hyperemia, hypertension, pulmonary hypertension, hypertrophic growth, left ventricular hypertrophy, right ventricular hypertrophy, hypoplastic left heart syndrome, hypotension, intermittent claudication, ischemic heart disease, Klippel-Trenaunay-Weber syndrome, lateral medullary syndrome, long QT syndrome mitral valve prolapse, moyamoya disease, mucocutaneous lymph node syndrome, myocardial infarction, myocardial ischemia, myocarditis, pericarditis, peripheral vascular diseases, phlebitis, polyarteritis nodosa, pulmonary atresia, Raynaud disease, restenosis, Sneddon syndrome, stenosis, superior vena cava syndrome, syndrome X, tachycardia, Takayasu's arteritis, hereditary hemorrhagic telangiectasia, telangiectasis, temporal arteritis, tetralogy of fallot, thromboangiitis obliterans, thrombosis, thromboembolism, tricuspid atresia, varicose veins, vascular diseases, vasculitis, vasospasm, ventricular fibrillation, Williams syndrome, peripheral vascular disease, varicose veins and leg ulcers, deep vein thrombosis, Wolff-Parkinson-White syndrome.

Preferred are cardiac hypertrophy, adult congenital heart disease, aneurysms, angina, angina pectoris, arrhythmias, cardiovascular disease prevention, cardiomyopathies, congestive heart failure, myocardial infarction, pulmonary hypertension, hypertrophic growth, restenosis, stenosis, thrombosis and arteriosclerosis.

Proliferative disease

The term "proliferative diseases" as used herein refers also to tumors, cancer, malignancies and their metastases. Additionally it refers also to benign proliferative diseases, which may be harmful producing a "mass effect" (compression of vital organs or closure of hollow organs such as blood vessels), or benign tumors of endocrine tissues, which may overproduce certain hormones.

The proliferation disorders and cancers are preferably selected from the group comprising or consisting of adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, desmoid tumor, bladder cancer, bronchial carcinoma, estrogen dependent and independent breast cancer, Burkitt's lymphoma, corpus cancer, CUP-syndrome (carcinoma of unknown primary), colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear, nose and throat tumors, hematologic neoplasias, hairy cell leukemia, urethral cancer, skin cancer, skin testis cancer, brain

tumors (gliomas), brain metastases, testicle cancer, hypophysis tumor, carcinoids, Kaposi's sarcoma, laryngeal cancer, germ cell tumor, bone cancer, colorectal carcinoma, head and neck tumors (tumors of the ear, nose and throat area), colon carcinoma, craniopharyngiomas, oral cancer (cancer in the mouth area and on lips),

5 cancer of the central nervous system, liver cancer, liver metastases, leukemia, eyelid tumor, lung cancer, lymph node cancer (Hodgkin's/Non-Hodgkin's lymphomas), lymphomas, stomach cancer, malignant melanoma, malignant neoplasia, malignant tumors gastrointestinal tract, breast carcinoma, rectal cancer, medulloblastomas, melanoma, meningiomas, Hodgkin's disease, mycosis fungoides, nasal cancer,

10 neurinoma, neuroblastoma, kidney cancer, renal cell carcinomas, non-Hodgkin's lymphomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcomas, ovarian carcinoma, pancreatic carcinoma, penile cancer, plasmocytoma, prostate cancer, pharyngeal cancer, rectal carcinoma, retinoblastoma, vaginal cancer, thyroid carcinoma, Schneeberger disease, esophageal

15 cancer, spinaliomas, T-cell lymphoma (mycosis fungoides), thymoma, tube carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial carcinoma, vulva cancer, wart appearance, soft tissue tumors, soft tissue sarcoma, Wilm's tumor, cervical carcinoma, tongue cancer, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, lobular carcinoma in situ, small-cell lung carcinoma, non-small-cell

20 lung carcinoma, bronchial adenoma, pleuropulmonary blastoma, mesothelioma, brain stem glioma, hypophtalmic glioma, cerebellar astrocytoma, cerebral astrocytoma, neuroectodermal tumours, pineal tumors, sarcoma of the uterus, salivary gland cancers, anal gland adenocarcinomas, mast cell tumors, pelvis tumours, ureter tumours, hereditary papillary renal cancers, sporadic papillary renal cancers,

25 intraocular melanoma, hepatocellular carcinoma (liver cell carcinomas with or without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct carcinoma), mixed hepatocellular cholangiocarcinoma, squamous cell carcinoma, malignant melanoma, Merkel cell skin cancer, non-melanoma skin cancer, hypopharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer, oral cavity cancer, squamous cell

30 cancer, oral melanoma, AIDS-related lymphoma, cutaneous T-cell lymphoma, lymphoma of the central nervous system, malignant fibrous histiocytooma, lymphosarcoma, rhabdomyosarcoma, malignant histiocytosis, fibrosarcoma, hemangiosarcoma, hemangiopericytoma, leiomyosarcoma., canine mammary carcinoma, and feline mammary carcinoma.

35

In yet another preferred embodiment, the cell proliferative disease is cancer. Preferred are the following cancer types: Leukemias including but not limited to chronic lymphocytic leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia,

acute myeloid leukemia, mixed lineage leukemia, bladder cancer, breast cancer, breast carcinoma, cancer of the central nervous system, colon carcinoma, gastric cancer, lung cancer, kidney cancer, melanoma, head and neck tumors (tumors of the ear, nose and throat area), ovarian cancer, ovarian carcinoma, cervical cancer, cervix, cervical carcinoma, glioblastomas, pancreatic cancer, pancreatic carcinoma, prostate cancer, stomach cancer, skin cancer, skin testis cancer, Hodgkin's lymphoma, liver cancer, liver metastases and renal cell carcinomas.

Inflammation

In yet another preferred embodiment, said inflammation is mediated preferably by the cytokines TNF- α , IL-1 β , GM-CSF, IL-6 and/or IL-8.

As described above, the compounds according to general formula (I) are pharmaceutically active agents for prophylaxis and/or treatment of inflammatory diseases. Thus, these compounds are used for the manufacture of a pharmaceutical formulation for prophylaxis and/or treatment of inflammations and inflammatory diseases in mammals, including humans.

Inflammatory diseases can emanate from infectious and non-infectious inflammatory conditions which may result from infection by an invading organism or from irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic causes as shown in the following list.

I. Acute infections

- | | | |
|----|----------|--------------|
| 25 | A. Viral | B. Bacterial |
|----|----------|--------------|

II. Noninfectious causes

III. Chronic (granulomatous) diseases

- | | | |
|----|---------------------|----------------|
| 30 | A. Bacterial | B. Spirochetal |
| | C. Mycotic (Fungal) | D. Idiopathic |

IV. Allergic, immune, and idiopathic disorders

- | | |
|----|------------------------------------|
| 35 | A. Hypersensitivity reactions |
| | B. Immune and idiopathic disorders |

V. Miscellaneous inflammatory conditions

- | | |
|----|---|
| 40 | A. Parasitic infections |
| | B. Inhalation causes: - Acute (thermal) injury |
| | - Pollution and inhalant allergy |

- Carcinogens
- C. Radiation injury: - Radionecrosis

Thus, the compounds disclosed herein can be used for prophylaxis and/or treatment of inflammations caused by invading organisms such as viruses, bacteria, prions, and parasites as well as for prophylaxis and/or treatment of inflammations caused by irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic reasons.

Consequently, the disclosed compounds are useful for prophylaxis and/or treatment of inflammatory diseases which are initiated or caused by viruses, parasites, and bacteria which are connected to or involved in inflammations.

The following bacteria are known to cause inflammatory diseases: mycoplasma pulmonis (causes e.g. chronic lung diseases (CLD), murine chronic respiratory disease), ureaplasma urealyticum (causes pneumonia in newborns), mycoplasma pneumoniae and chlamydia pneumoniae (cause chronic asthma), C. pneumoniae (causes atherosclerosis, pharyngitis to pneumonia with empyema, human coronary heart disease), Helicobacter pylori (human coronary heart disease, stomach ulcers).

The following viruses are known to cause inflammatory diseases: herpesviruses especially cytomegalovirus (causes human coronary heart disease).

The compounds disclosed herein are useful for prophylaxis and/or treatment of inflammatory diseases caused and/or induced and/or initiated and/or enhanced by the afore-mentioned bacteria or viruses.

Furthermore, the compounds of formula (I) are useful for prophylaxis and/or treatment of inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, inflammatory diseases of the larynx.

Examples for inflammatory diseases of the central nervous system (CNS) are algal disorders, protothecosis, bacterial disorders, abscessation, bacterial meningitis, idiopathic inflammatory disorders, eosinophilic meningoencephalitis, feline polioencephalomyelitis, granulomatous meningoencephalomyelitis, meningitis, steroid responsive meningitis-arteritis, miscellaneous meningitis / meningoencephalitis, meningoencephalitis in greyhounds, necrotizing encephalitis, pyogranulomatous meningoencephalomyelitis, shaker dog disease, mycotic diseases of the CNS, parasitic encephalomyelitis, prion protein induced diseases, feline spongiform

encephalopathy, protozoal encephalitis-encephalomyelitis, toxoplasmosis, neosporosis, sarcocystosis, encephalitozoonosis, trypanosomiasis, acanthamebiasis, babesiosis, leishmaniasis, rickettsial disorders, rocky mountain spotted fever, canine ehrlichiosis, salmon poisoning, viral disorders, aujeszky's disease, borna disease, canine herpes virus encephalomyelitis, canine distemper encephalomyelitis, canine distemper encephalomyelitis in immature animals, chronic relapsing encephalomyelitis, post-vaccinal canine distemper encephalitis, feline immunodeficiency virus, feline infectious peritonitis, feline leukemia virus, infectious canine hepatitis, La Crosse virus encephalitis, parvovirus encephalitis, rabies, post-vaccinal rabies.

Examples for inflammatory rheumatic diseases are rheumatoid arthritis, scleroderma, lupus, polymyositis, dermatomyositis, psoriatic arthritis, ankylosing spondylitis, Reiters's syndrome, juvenile rheumatoid arthritis, bursitis, tendinitis (tendonitis), and fibromyositis.

Examples for inflammatory diseases of blood vessels are vasculitis, autoantibodies in vasculitis, microscopic polyangiitis, giant cell arteritis, Takayasu's arteritis, vasculitis of the central nervous system, thromboangiitis obliterans (Buerger's Disease), vasculitis secondary to bacterial, fungal, and parasitic infection, vasculitis and rheumatoid arthritis, vasculitis in systemic lupus erythematosus, vasculitis in the idiopathic inflammatory myopathies, relapsing polychondritis, systemic vasculitis in sarcoidosis, vasculitis and malignancy, and drug-induced vasculitis.

Examples for inflammatory diseases of the middle ear are acute suppurative otitis media, bullous myringitis, granular myringitis, and chronic suppurative otitis media, which can manifest as mucosal disease, cholesteatoma, or both.

Examples for inflammatory bowel diseases are ulcerative colitis, Crohn's disease.

Examples for inflammatory diseases of the skin are acute inflammatory dermatoses, urticaria (hives), spongiotic dermatitis, allergic contact dermatitis, irritant contact dermatitis, atopic dermatitis, erythema multiforme (EM minor), Stevens-Johnson syndrome (SJS, EM major), toxic epidermal necrolysis (TEN), chronic inflammatory dermatoses, psoriasis, lichen planus, discoid lupus erythematosus, and acne vulgaris.

Uveitis are inflammations located in and/or on the eye and may be associated with inflammation elsewhere in the body. In most circumstances, patients who have uveitis

as part of a disease elsewhere in the body are aware of that illness. The majority of patients with uveitis do not have an apparent associated systemic illness. Causes of uveitis can be infectious causes, masquerade syndromes, suspected immune-mediated diseases, and/or syndromes confined primarily to the eye.

5

The following viruses are associated with inflammations: human immunodeficiency virus-I, herpes simplex virus, herpes zoster virus, and cytomegalovirus.

10 Bacterial or spirochetal caused, induced, initiated and/or enhanced inflammations are tuberculosis, leprosy, propionobacterium, syphilis, Whipple's disease, leptospirosis, brucellosis, and lyme disease.

15 Parasitic (protozoan or helminthic) caused, induced, initiated and/or enhanced inflammations are toxoplasmosis, acanthameba, toxocariasis, cysticercosis, onchocerciasis.

Examples of inflammatory diseases caused, induced, initiated and/or enhanced by fungi are histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, sporotrichosis, blastomycosis, and cryptococcosis.

20 Masquerade syndromes are, for instance, leukemia, lymphoma, retinitis pigmentosa, and retinoblastoma.

Suspected immune-mediated diseases can be selected from the group comprising ankylosing spondylitis, Behcet's disease, Crohn's disease, drug or hypersensitivity reaction, interstitial nephritis, juvenile rheumatoid arthritis, Kawasaki's disease, 25 multiple sclerosis, psoriatic arthritis, Reiter's syndrome, relapsing polychondritis, sarcoidosis, Sjogren's syndrome, systemic lupus erythematosus, ulcerative colitis, vasculitis, vitiligo, Vogt Koyanagi Harada syndrome.

30 Syndromes confined primarily to the eye are, for instance, acute multifocal placoid pigmentary epitheliopathy, acute retinal necrosis, birdshot choroidopathy, Fuch's heterochromic cyclitis, glaucomatocyclitic crisis, lens-induced uveitis, multifocal choroiditis, pars planitis, serpiginous choroiditis, sympathetic ophthalmia, and trauma.

35 Examples for inflammatory diseases of the larynx are gastroesophageal (laryngopharyngeal) reflux disease, pediatric laryngitis, acute laryngeal infections of adults, chronic (granulomatous) diseases, allergic, immune, and idiopathic disorders and miscellaneous inflammatory conditions.

Pediatric laryngitis is known as acute (viral or bacterial) infection such as laryngotracheitis (croup), supraglottitis (epiglottitis), diphtheria, and noninfectious causes are for example spasmodic croup and traumatic laryngitis.

- 5 Acute laryngeal infections of adults are, for instance, viral laryngitis, common upper respiratory infection, laryngotracheitis, herpes simplex, bacterial laryngitis, supraglottitis, laryngeal abscess, and gonorrhea.

- 10 Chronic (granulomatous) diseases can be selected from the group comprising bacterial diseases, tuberculosis, leprosy, scleroma, actinomycosis, tularemia, glanders, spirochetal (syphilis) diseases, mycotic (fungal) diseases, candidiasis, blastomycosis, histoplasmosis, coccidiomycosis, aspergillosis, idiopathic diseases, sarcoidosis, and Wegener's granulomatosis.

- 15 Allergic, immune, and idiopathic disorders are, for example, hypersensitivity reactions, angioedema, Stevens-Johnson syndrome, immune and idiopathic disorders, infections of the immunocompromised host, rheumatoid arthritis, systemic lupus erythematosus, cicatricial pemphigoid, relapsing polychondritis, Sjogren's syndrome, and amyloidosis.

- 20 Miscellaneous inflammatory conditions are, for instance, parasitic infections, trichinosis, leishmaniasis, schistosomiasis, syngamus laryngeus, inhalation laryngitis, acute (thermal) injury, pollution and inhalant allergy, carcinogens, radiation injury, radiation laryngitis, radionecrosis, vocal abuse, vocal-cord hemorrhage, 25 muscle tension dysphonias, and contact ulcer and granuloma.

Stroke

The inventive compounds according to the general formula (I) as well as pharmaceutically acceptable salts thereof are also useful for treatment of stroke.

- 30 In another aspect of the present invention, the compounds according to the general formula (I) as well as pharmaceutically acceptable salts thereof are used as an inhibitor for a protein kinase, preferably as an inhibitor for a cellular protein kinase.

- In a preferred embodiment of this aspect said cellular protein kinase consists of Cyclin- 35 dependent protein kinases (CDKs).

The cyclin-dependent protein kinase can be selected from the group comprising: CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CrkRS (Crk7, CDC2-related protein kinase 7), CDKL1 (cyclin-dependent kinase-like 1); KKIALRE, CDKL2 (cyclin-dependent kinase-like 2), KKIAMRE, CDKL3 (cyclin-

dependent kinase-like 3), NKIAMRE, CDKL4, similar to cyclin-dependent kinase-like 1, CDC2L1 (cell division cycle 2-like 1), PITSLRE B, CDC2L1 (cell division cycle 2-like 1), PITSLRE A, CDC2L5 (cell division cycle 2-like 5), PCTK1 (PCTAIRE protein kinase 1), PCTK2 (PCTAIRE protein kinase 2), PCTK3 (PCTAIRE protein kinase 3) or PFTK1 (PFTAIRE protein kinase 1).

In a further preferred embodiment said cyclin-dependent protein kinase is CDK7. Thus, the compounds according to the general formula (I) as well as pharmaceutically acceptable salts thereof are used as an inhibitor for CDK7.

Surprisingly it turned out that the compounds according to the general formula (I) as well as pharmaceutically acceptable salts thereof selectively inhibit CDK7 in comparison to other protein kinases and in comparison to other cyclin-dependent protein kinases. Thus, the compounds according to the general formula (I) as well as pharmaceutically acceptable salts thereof are used as selective inhibitors for CDK7.

As used herein, a kinase "inhibitor" refers to any compound capable of downregulating, decreasing, suppressing or otherwise regulating the amount and/or activity of a kinase. Inhibition of these kinases can be achieved by any of a variety of mechanisms known in the art, including, but not limited to binding directly to the kinase polypeptide, denaturing or otherwise inactivating the kinase, or inhibiting the expression of the gene (e.g., transcription to mRNA, translation to a nascent polypeptide, and/or final polypeptide modifications to a mature protein), which encodes the kinase. Generally, kinase inhibitors may be proteins, polypeptides, nucleic acids, small molecules, or other chemical moieties.

As used herein the term "inhibiting" or "inhibition" refers to the ability of a compound to downregulate, decrease, reduce, suppress, inactivate, or inhibit at least partially the activity of an enzyme, or the expression of an enzyme or protein and/or the virus replication.

In a further aspect of the present invention, a method for preventing and/or treating infectious diseases, including opportunistic diseases, in a mammal, especially in a human, is provided, which method comprises administering to the mammal an amount of at least one compound according to the general formula (I), effective to prevent and/or treat said infectious diseases, including opportunistic diseases. In a preferred embodiment of this method, the infectious diseases, including opportunistic diseases, are virally induced infectious diseases. The virally induced infectious diseases, including opportunistic diseases, are caused by retroviruses, hepadnaviruses, herpesviruses, flaviviridae, and/or adenoviruses. In a further preferred embodiment of

this method, the retroviruses are selected from lentiviruses or oncoretroviruses, wherein the lentivirus is selected from the group comprising: HIV-1, HIV-2, FIV, BIV, SIVs, SHIV, CAEV, VMV or EIAV, preferably HIV-1 or HIV-2 and wherein the oncoretrovirus is selected from the group consisting of: HTLV-I, HTLV-II or BLV. In a further preferred embodiment of this method, the hepadnavirus is selected from HBV, GSHV or WHV, preferably HBV, the herpesvirus is selected from the group comprising: HSV I, HSV II, EBV, VZV, HCMV or HHV 8, preferably HCMV and the flaviviridae is selected from HCV, West Nile or Yellow Fever.

In a further aspect of the present invention, methods for preventing and/or treating infectious diseases including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke in a mammal, especially in a human, are provided, which methods comprise administering to the mammal an amount of at least one compound according to the general formula (I) and/or pharmaceutically acceptable salts thereof, effective to prevent and/or treat said infectious diseases including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke.

In further preferred embodiments, the specific diseases addressed as infectious diseases including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke are selected from the groups disclosed above.

The compounds enlisted explicitly in Table 1 are preferred to be used within the methods or indications disclosed herein. Another aspect of the present invention is that at least one compound according to the general formula (I) used as a pharmaceutically active agent may be administered in combination with further therapeutic compounds.

For the indication HIV compounds according to the general formula (I) may be administered in combination with anti-retroviral drugs, selected from the following five classes:

- 1) Nucleoside reverse transcriptase inhibitors (NRTIs),
- 2) Non-nucleoside reverse transcriptase inhibitors (NNRTIs),
- 3) Protease inhibitors (PIs),
- 4) Fusion inhibitors or
- 5) Immune stimuli.

Thus, another aspect of the present invention relates to drug combinations comprising at least one inventive compound according to general formula (I) and/or pharmaceutically acceptable salts thereof together with at least one anti-retroviral drug, especially at least one of the drugs mentioned above.

Thus, the compounds of the present invention are used for the manufacture of a pharmaceutical formulation for prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke.

The pharmaceutical compositions or formulations according to the present invention comprise at least one compound according to the present invention as an active ingredient together with at least one pharmaceutically acceptable (i.e. non-toxic) carrier, excipient and/or diluent. The pharmaceutical compositions of the present invention can be prepared in a conventional solid or liquid carrier or diluent and a conventional pharmaceutically-made adjuvant at suitable dosage level in a known way. The preferred preparations are adapted for oral application. These administration forms include, for example, pills, tablets, film tablets, coated tablets, capsules, powders and deposits.

Furthermore, the present invention also includes pharmaceutical preparations for parenteral application, including dermal, intradermal, intragastral, intracutan, intravasal, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal, percutan, rectal, subcutaneous, sublingual, topical, or transdermal application, which preparations in addition to typical vehicles and/or diluents contain at least one compound according to the present invention and/or a pharmaceutical acceptable salt thereof as active ingredient.

The pharmaceutical compositions according to the present invention containing at least one compound according to the present invention and/or a pharmaceutical acceptable salt thereof as active ingredient will typically be administered together with suitable carrier materials selected with respect to the intended form of administration, i.e. for oral administration in the form of tablets, capsules (either solid filled, semi-solid filled or liquid filled), powders for constitution, gels, elixirs, dispersible granules, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices. For example, for oral administration in the form of tablets or capsules, the active drug component may be combined with any oral non-toxic pharmaceutically acceptable carrier, preferably with an inert carrier like lactose, starch, sucrose, cellulose,

magnesium stearate, dicalcium phosphate, calcium sulfate, talc, mannitol, ethyl alcohol (liquid filled capsules) and the like. Moreover, suitable binders, lubricants, disintegrating agents and coloring agents may also be incorporated into the tablet or capsule. Powders and tablets may contain about 5 to about 95-weight % of the pyrazolo[1,5-a][1,3,5]triazine derivatives according to the general formula (I) or analogues compound thereof or the respective pharmaceutically active salt as active ingredient.

Suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. Among suitable lubricants there may be mentioned boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Suitable disintegrants include starch, methylcellulose, guar gum, and the like. Sweetening and flavoring agents as well as preservatives may also be included, where appropriate. The disintegrants, diluents, lubricants, binders etc. are discussed in more detail below.

Moreover, the pharmaceutical compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimise the therapeutic effect(s), e.g. antihistaminic activity and the like. Suitable dosage forms for sustained release include tablets having layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.

Liquid form preparations include solutions, suspensions, and emulsions. As an example, there may be mentioned water or water/propylene glycol solutions for parenteral injections or addition of sweeteners and opacifiers for oral solutions, suspensions, and emulsions. Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be present in combination with a pharmaceutically acceptable carrier such as an inert, compressed gas, e.g. nitrogen.

For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides like cocoa butter is melted first, and the active ingredient is then dispersed homogeneously therein e.g. by stirring. The molten, homogeneous mixture is then poured into conveniently sized moulds, allowed to cool, and thereby solidified.

Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions, and emulsions.

5 The compounds according to the present invention may also be delivered transdermally. The transdermal compositions may have the form of a cream, a lotion, an aerosol and/or an emulsion and may be included in a transdermal patch of the matrix or reservoir type as is known in the art for this purpose.

10 The term capsule as recited herein refers to a specific container or enclosure made e.g. of methylcellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredient(s). Capsules with hard shells are typically made of blended of relatively high gel strength gelatins from bones or pork skin. The capsule itself may contain small amounts of dyes, opaquing agents,
15 plasticisers and/or preservatives.

Under tablet a compressed or moulded solid dosage form is understood which comprises the active ingredients with suitable diluents. The tablet may be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation,
20 or by compaction well known to a person of ordinary skill in the art.

Oral gels refer to the active ingredients dispersed or solubilised in a hydrophilic semi-solid matrix.

25 Powders for constitution refers to powder blends containing the active ingredients and suitable diluents which can be suspended e.g. in water or in juice.

Suitable diluents are substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose,
30 sucrose, mannitol, and sorbitol, starches derived from wheat, corn rice, and potato, and celluloses such as microcrystalline cellulose. The amount of diluent in the composition can range from about 5 to about 95 % by weight of the total composition, preferably from about 25 to about 75 weight %, and more preferably from about 30 to about 60 weight %.

35 The term disintegrants refers to materials added to the composition to support break apart (disintegrate) and release the pharmaceutically active ingredients of a medicament. Suitable disintegrants include starches, "cold water soluble" modified starches such as sodium carboxymethyl starch, natural and synthetic gums such as
40 locust bean, karaya, guar, tragacanth and agar, cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose, microcrystalline celluloses, and cross-linked microcrystalline celluloses such as sodium croscarmellose, alginates

such as alginic acid and sodium alginate, clays such as bentonites, and effervescent mixtures. The amount of disintegrant in the composition may range from about 2 to about 20 weight % of the composition, more preferably from about 5 to ca. 10 weight %.

Binders are substances which bind or "glue" together powder particles and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength already available in the diluent or bulking agent. Suitable binders include sugars such as sucrose, starches derived from wheat corn rice and potato, natural gums such as acacia, gelatin and tragacanth, derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate, cellulose materials such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose, polyvinylpyrrolidone, and inorganic compounds such as magnesium aluminum silicate. The amount of binder in the composition may range from about 2 to about 20 weight % of the composition, preferably from about 3 to about 10 weight %, and more preferably from about 3 to about 6 weight %.

Lubricants refer to a class of substances which are added to the dosage form to enable the tablet granules etc. after being compressed to release from the mould or die by reducing friction or wear. Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate, or potassium stearate, stearic acid, high melting point waxes, and other water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and D,L-leucine. Lubricants are usually added at the very last step before compression, since they must be present at the surface of the granules. The amount of lubricant in the composition may range from about 0.2 to about 5 weight % of the composition, preferably from about 0.5 to about 2 weight %, and more preferably from about 0.3 to about 1.5 weight % of the composition.

Glidants are materials that prevent caking of the components of the pharmaceutical composition and improve the flow characteristics of granulate so that flow is smooth and uniform. Suitable glidants include silicon dioxide and talc. The amount of glident in the composition may range from about 0.1 to about 5 weight % of the final composition, preferably from about 0.5 to about 2 weight %.

Coloring agents are excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent may vary from about 0.1 to about 5 weight % of the composition, preferably from about 0.1 to about 1 weight %.

Examples


Preparation of compounds:

Abbreviations used in the present description have the following meanings:

CDCl₃ (deuterated chloroform); cHex (cyclohexane); DCM (dichloromethane); DIPEA (N-ethyl-N,N-diisopropylamine); DMF (dimethylformamide); DMSO (dimethyl sulfoxide); eq (equivalent); ES (electrospray); EtOAc (ethyl acetate); EtOH (ethanol); mCPBA (3-chlorobenzoperoxoic acid); MeOH (methanol); MeCN (acetonitrile); MS (mass spectrometry); NMR (nuclear magnetic resonance); Pd(dppf)Cl₂ ([1,1'-bis(diphenylphosphino)ferrocene]dichloro palladium(II) complex with dichloromethane); iPrOH (iso-propanol); RT (room temperature); sat. aq. (saturated aqueous); SiO₂ (silica gel); TFA (trifluoroacetic acid); THF (tetrahydrofuran), KHMDS (potassium hexamethyldisilazide), FRET-signal (fluorescence resonance energy transfer), MBP substrat (myelin basic protein), ATP (adenosine triphosphate), HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), EGTA (ethylene glycol tetraacetic acid), EDTA (ethylenediaminetetraacetic acid), (DTT (dithiothreitol), CycH (cyclin-H). CycA (cyclin-A), MAT1 (mating type gene 1),), PYBOP (benzotriazole-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate), NMP (N-Methyl-2-pyrrolidone), Pd-PEPPSI-IPent (dichloro[1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II)).

Preparative Examples

Intermediate (II): 8-isopropyl-2-thioxo-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one




To a chilled solution of 4-isopropyl-1H-pyrazol-5-amine (2.5 g, 20 mmol) in 20 ml DCM ethoxycarbonyl isothiocyanate (2.6 g, 20 mmol) dissolved in 10 ml DCM were added dropwise. The resulting suspension was further diluted with 30 ml DCM and stirred for 2 h. The product was collected, washed with DCM and dried. 2.0 g (7.8 mmol) of this

raw material together with 3.2 g (23.4 mmol) were then refluxed in 15 ml MeCN for 2 h. After careful neutralization with acetic acid the solvent was removed *in vacuo*. The remaining solid was suspended in water. The product was collected, washed with water and dried to yield title compound (II) as colorless powder.

- 5 $^1\text{H-NMR}$ (400MHz, $\text{d}_6\text{-DMSO}$, 300K) δ 1.14 (d, $J = 6.8$ Hz, 6H), 3.12 (h, $J = 6.8$ Hz, 1H), 7.88 (s, 1H), 12.60 (s, broad, 1H), 13.34 (s, broad, 1H); MS (ES) $\text{C}_8\text{H}_{10}\text{N}_4\text{OS}$, requires 210.06, found 211.3 ($\text{M}+\text{H}$) $^+$.


10 **Intermediate (III): 8-isopropyl-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4(3H)-one**



4.0 g (19.1 mmol) starting material (II) were dissolved in 60 ml ethanol and 19.1 ml 2 M NaOH. The solution was cooled in an ice bath and MeI (0.67 g, 4.76 mmol) was added dropwise within 20 minutes. After stirring over night the solution was acidified with 6 M HCl and the solvent was removed under reduced pressure. The remaining solid was suspended in water. The product was collected, washed with water and dried to yield title compound (III) as colorless powder.


- 15 $^1\text{H-NMR}$ (400MHz, $\text{d}_6\text{-DMSO}$, 300K) δ 1.27 (d, $J = 7.0$ Hz, 6H), 2.55 (s, 3H), 3.02 (h, $J = 7.0$ Hz, 1H), 7.92 (s, 1H), 12.73 (s, broad, 1H); MS (ES) $\text{C}_9\text{H}_{12}\text{N}_4\text{OS}$ requires 224.07, found 225.1 ($\text{M}+\text{H}$) $^+$.
- 20

Intermediate (IV): 4-chloro-8-isopropyl-2-(methylthio)pyrazolo[1,5-a][1,3,5]-triazine



- 25 25.0 g (0.111 mol) intermediate (III) and 53 ml (0.334 mol) N,N-diethylaniline in 300 ml POCl_3 were stirred at 90 °C for 3 h. The volatiles were removed under reduced pressure and the remaining oil was used without any further purification. MS (ES) $\text{C}_9\text{H}_{11}\text{ClN}_4\text{S}$ requires 242.04, found 243.0 ($\text{M}+\text{H}$) $^+$.


- 30 **Intermediate (XXI): 4-(benzyloxy)-8-isopropyl-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazine**



To a solution of intermediate (IV) (raw, prepared from 15 g intermediate (III)) in 10.5 ml (0.101 mol) benzyl alcohol and 20 ml MeCN 46.7 ml of DIPEA (0.268 mmol) were added and the reaction mixture was stirred over night. Additional 7.0 ml of the alcohol and 23.4 ml of DIPEA were added as the reaction was not completed. The reaction mixture was stirred for another 4 h, diluted with ethyl acetate and washed with 2M NaOH. The aqueous phase was extracted twice with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO₄, filtered and evaporated. The product was purified by column chromatography using 330g silica gel and a cyclohexane / ethyl acetate gradient to give the desired product as reddish oil.

¹H-NMR (400MHz, d₆-DMSO, 300K) δ 1.25 (d, J = 6.92 Hz, 6H), 2.52 (s, 3H), 3.05 (h, J = 6.92 Hz, 1H), 5.63 (s, 2H), 7.37 – 7.42 (m, 3H), 7.50 – 7.53 (m, 2H), 8.01 (s, 1H); MS (ES) C₁₆H₁₈N₄OS requires 314.12, found 314.9 (M+H)⁺.

Intermediate (XXII): 4-(benzyloxy)-8-isopropyl-2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazine



8.9 g (28.3 mmol) thioether (XXI) were dissolved in 200ml DCM and 8.9 g of mCPBA (51 mmol) were added. After 1 h 4.5 g mCPBA were added. The reaction mixture was stirred for another hour, diluted with ethyl acetate and washed with 2M NaOH. The aqueous phase was extracted twice with ethyl acetate. The combined organic phases were washed with brine, dried over MgSO₄, filtered and evaporated. The product was purified by column chromatography using 330g silica gel and a cyclohexane / ethyl acetate gradient to give the desired product as reddish oil.


¹H-NMR (400MHz, d₆-DMSO, 300K) δ 1.29 (d, J = 6.92 Hz, 6H), 3.18 (h, J = 6.92 Hz, 1H), 3.41 (s, 3H), 5.79 (s, 2H), 7.41 – 7.46 (m, 3H), 7.57 – 7.59 (m, 2H), 8.35 (s, 1H); MS (ES) C₁₆H₁₈N₄O₃S requires 346.11, found 347.3 (M+H)⁺.

5

Method A: nucleophilic aromatic substitution of chloride (IV) with amines A¹-NH₂

Intermediate (V-a): N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(methylthio)-pyrazolo[1,5-a][1,3,5]triazin-4-amine

10



A solution of 13.4 g (60 mmol) intermediate (III) in 47 ml (520 mmol) POCl₃ and 27.1 ml (179 mmol) PhNEt₂ was stirred at 90 °C for 1.5 h. Volatiles were removed under reduced pressure and heating. The remaining oil (crude intermediate (IV)) was added to a solution of 25 g (120 mmol) (2-(1H-pyrazol-1-yl)phenyl)methanamine and 52 ml DIPEA in acetonitrile and stirred at 50 °C over night. The solution was concentrated, diluted with ethyl acetate and washed with 2 N NaOH and brine. The organic phase was dried over MgSO₄, filtered and evaporated. The crude product was purified by column chromatography (silica, elution with cyclohexane/ethyl acetate).

15

¹H-NMR (400MHz, d₆-DMSO, 300K) δ 1.27 (d, J = 7.2 Hz, 6H), 2.40 (s, 3H), 3.04 (h, J = 7.2 Hz, 1H), 4.66 (d, J = 4.8 Hz, 2H), 6.56 (m, 1H), 7.37-7.46 (m, 4H), 7.81 (m, 1H), 7.96 (s, 1H), 8.18 (m, 1H), 9.09 (broad, 1H); MS (ES) C₁₉H₂₁N₇S requires 379.48, found 379.9 (M+H)⁺.













20













Intermediates (V-b) – (V-ae)













Title compounds (V-b) – (V-ae) were prepared similar to method A typically on a 1 mmol scale.













25













intermediate	A ¹ -NH ₂	formula	exact mass	MS(ES) [M+H] ⁺	structure
--------------	---------------------------------	---------	------------	------------------------------	-----------

(V-b)		C ₂₂ H ₂₃ N ₅ S	389.17	390.3	
(V-c)		C ₁₈ H ₂₃ N ₅ OS	357.16	358.3	
(V-d)		C ₂₀ H ₂₁ N ₅ S ₂	395.12	396.1	
(V-e)		C ₁₉ H ₂₅ N ₅ OS	371.18	372.3	
(V-f)		C ₁₉ H ₂₁ N ₇ S	379.16	380.3	
(V-g)		C ₁₈ H ₂₀ N ₈ S	380.15	380.9	

(V-h)		C ₂₀ H ₂₃ N ₇ S	393.17	394.2	
(V-i)		C ₁₇ H ₂₀ ClN ₅ S	361.11	362.2	
(V-j)		C ₁₈ H ₂₁ N ₉ S	395.16	396.4	
(V-k)		C ₁₉ H ₂₀ N ₆ S	364.15	364.9	
(V-l)		C ₁₉ H ₂₀ N ₆ S	364.15	364.9	
(V-m)		C ₁₈ H ₂₁ N ₇ S	367.16	368.0	


(V-n)		C ₂₁ H ₂₂ N ₆ S	390.16	391.1	
(V-o)		C ₁₉ H ₂₀ N ₆ S	364.15	365.0	
(V-p)		C ₁₆ H ₁₇ N ₇ OS	355.12	356.2	
(V-q)		C ₁₇ H ₁₉ N ₇ S	353.14	354.2	
(V-r)		C ₂₀ H ₂₄ N ₆ OS	396.17	397.0	
(V-s)		C ₂₀ H ₂₃ N ₇ S	393.17	395.0	

(V-t)		C18H24N6O2 S2	420.14	421.1	
(V-u)		C19H22N6OS	382.16	383.2	
(V-v)		C19H20FN7S	397.15	398.3	
(V-w)		C19H20FN7S	397.15	398.3	
(V-x)		C19H20FN7S	397.15	398.2	
(V-y)		C19H20FN7S	397.15	398.1	

(V-z)		C ₂₁ H ₂₂ N ₆ S	390.16	391.2	
(V-aa)		C ₂₂ H ₂₃ N ₅ OS	405.16	406.0	
(V-ab)		C ₁₉ H ₂₀ N ₆ OS	380.14	380.8	
(V-ac)		C ₂₀ H ₂₁ N ₅ OS	379.15	379.9	
(V-ad)		C ₁₈ H ₂₂ N ₆ OS	370.16	371.1	
(V-ae)		C ₁₉ H ₂₀ ClN ₇ S	413.12	414.2	

Method B: oxidation of thioethers (V)

Intermediate (VI-a): N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine




Thioether (V-a) (17.4 g; 45.9 mmol) was dissolved in 300 ml DCM and 23.9 g (138 mmol) mCPBA were added in small portions to keep the temperature below 30 °C. After 4 h the reaction mixture was washed with 2 N NaOH and brine, dried (MgSO₄) and evaporated to dryness. The crude product was chromatographed on silica using ethyl acetate and cyclohexane.

¹H-NMR (400MHz, d₆-DMSO, 300K) δ 1.30 (d, J = 7.2 Hz, 6H), 3.15 (h, J = 7.2 Hz, 1H), 3.24 (s, 3H), 4.75 (s, 2H), 6.55 (m, 1H), 7.41-7.56 (m, 4H), 7.80 (m, 1H), 8.21 (m, 1H), 8.28 (s, broad, 1H), 9.73 (broad, 1H); MS (ES) C₁₉H₂₁N₇O₂S requires 411.2, found 412.3 (M+H)⁺.

Method H: substitution of chloride (XX) with amines A¹NH₂

Intermediate (VI-ag): N-(2-(((8-isopropyl-2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methanesulfonamide




1.2 g (4.69 mmol) intermediate (XVII) were stirred in 12.8 ml (141 mmol) POCl₃ and 2.1 ml (14.1 mmol) N,N-diethylaniline at 100 °C for 1.5h. Volatiles were removed under reduced pressure. The remaining oil was dissolved in acetonitrile and evaporated three times. Crude chloride (XX) was diluted to 9 ml with acetonitrile and used in 1.5 ml (0.782 mmol) aliquots. One aliquot of this stock solution was added to 233 mg (0.938 mmol) N-(2-(aminomethyl)phenyl)methanesulfonamide hydrochloride and 409 µl (2.35 mmol) DIPEA in 2 ml acetonitrile. The reaction mixture was stirred at room temperature over night, diluted with ethyl acetate and washed with saturated aqueous NaHCO₃.

solution. The organic phase was dried over MgSO_4 and concentrated *in vacuo*. Title compound (VI-ag) was obtained after chromatography on silica using ethyl acetate and cyclohexane gradient.

$^1\text{H-NMR}$ (400MHz, $\text{d}_6\text{-DMSO}$, 300K) δ 1.31 (d, $J = 6.9$ Hz, 6H), 3.06 (s, 3H), 3.15 (h, $J = 6.9$ Hz, 1H), 3.28 (s, 3H), 4.89 (d, $J = 6.2$ Hz, 2H), 7.21-7.45 (m, 4H), 8.29 (s, 1H), 9.3 (s, 1H), 9.73 (t, $J = 6.2$ Hz, 1H); MS (ES) $\text{C}_{17}\text{H}_{22}\text{N}_6\text{O}_4\text{S}_2$ requires 438.11, found 439.4 ($\text{M}+\text{H}$) $^+$.

Method I: substitution of ether (XXII) with amines A^1NH_2

Intermediate (VI-ak): N-(2-(((8-isopropyl-2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methanesulfonamide









30.0 mg (0.087 mmol) intermediate (XXII) and 15.3 mg (0.087 mmol) (2,4-dichlorophenyl)methanamine were heated in 0.5 ml NMP at 120 °C for 40 min. Ethyl acetate was added and the mixture was washed with 2 M aqueous NaOH solution and brine. The organic phase was dried over MgSO_4 and concentrated under reduced pressure. Title compound (VI-ak) was obtained after chromatography on 12 g silica gel using ethyl acetate and cyclohexane gradient.







MS (ES) $\text{C}_{16}\text{H}_{17}\text{Cl}_2\text{N}_5\text{O}_2\text{S}$ requires 413.05, found 414.2 ($\text{M}+\text{H}$) $^+$.

Intermediates (VI-b – VI-bs)







Title compounds (VI-b) – (VI-af) were prepared from the related thioethers similar to method B in about 0.1 - 1 mmol scale. Compounds (VI-ag)-(VI-aj) were synthesized similar to method H. Compounds (VI-al)-(VI-bs) were synthesized similar to method I (if A^1NH_2 were used as hydrochlorides, DIEPA was added).







intermediate	formula	exact mass	MS(ES) [$\text{M}+\text{H}$] $^+$	from intermediate	structure
--------------	---------	------------	--	----------------------	-----------







(VI-b)	C ₂₂ H ₂₃ N ₅ O ₂ S	421.16	422.3	(V-b)	
(VI-c)	C ₁₈ H ₂₃ N ₅ O ₃ S	389.15	390.3	(V-c)	
(VI-d)	C ₂₀ H ₂₁ N ₅ O ₂ S ₂	427.11	428.2	(V-d)	
(VI-e)	C ₁₉ H ₂₅ N ₅ O ₃ S	403.17	404.3	(V-e)	
(VI-f)	C ₁₉ H ₂₁ N ₇ O ₂ S	411.15	412.3	(V-f)	
(VI-g)	C ₁₈ H ₂₀ N ₈ O ₂ S	412.14	413.1	(V-g)	







(VI-h)	C ₂₀ H ₂₃ N ₇ O ₂ S	425.16	426.3	(V-h)	
(VI-i)	C ₁₇ H ₂₀ ClN ₅ O ₂ S	393.10	394.2	(V-i)	
(VI-j)	C ₁₈ H ₂₁ N ₉ O ₂ S	427.15	428.3	(V-j)	
(VI-k)	C ₁₉ H ₂₀ N ₆ O ₃ S	412.13	413.3	(V-k)	
(VI-l)	C ₁₉ H ₂₀ N ₆ O ₂ S	396.14	397.2	(V-l)	
(VI-m)	C ₁₉ H ₂₀ N ₆ O ₃ S	412.13	413.2	(V-l)	

(VI-n)	C ₁₉ H ₂₀ N ₆ O ₃ S	399.15	400.3	(V-m)	
(VI-o)	C ₁₈ H ₂₁ N ₇ O ₂ S	422.15	423.0	(V-n)	
(VI-p)	C ₂₁ H ₂₂ N ₆ O ₂ S	396.14	397.1	(V-o)	
(VI-q)	C ₁₉ H ₂₀ N ₆ O ₂ S	387.11	388.3	(V-p)	
(VI-r)	C ₁₆ H ₁₇ N ₇ O ₃ S	385.13	386.2	(V-q)	
(VI-s)	C ₂₀ H ₂₄ N ₆ O ₃ S	428.16	429.3	(V-r)	







(VI-t)	C ₁₈ H ₂₁ N ₉ O ₂ S	427.15	428.3	(V-s)	
(VI-u)	C ₁₈ H ₂₄ N ₆ O ₄ S ₂	452.13	453.3	(V-t)	
(VI-v)	C ₁₉ H ₂₂ N ₆ O ₃ S	414.15	415.2	(V-u)	
(VI-w)	C ₁₉ H ₂₀ FN ₇ O ₂ S	429.14	430.3	(V-v)	
(VI-x)	C ₁₉ H ₂₀ FN ₇ O ₂ S	429.14	430.2	(V-w)	
(VI-y)	C ₁₉ H ₂₀ FN ₇ O ₂ S	429.14	430.3	(V-x)	

(VI-z)	C ₁₉ H ₂₀ FN ₇ O ₂ S	429.14	430.3	(V-y)	
(VI-aa)	C ₂₁ H ₂₂ N ₆ O ₂ S	422.15	423.3	(V-z)	
(VI-ab)	C ₂₂ H ₂₃ N ₅ O ₃ S	437.15	438.0	(V-aa)	
(VI-ac)	C ₁₉ H ₂₀ N ₆ O ₃ S	412.13	413.6	(V-ab)	
(VI-ad)	C ₂₀ H ₂₁ N ₅ O ₃ S	411.14	412.6	(V-ac)	
(VI-ae)	C ₁₈ H ₂₂ N ₆ O ₃ S	402.15	403.2	(V-ad)	

(VI-af)	C ₁₉ H ₂₀ ClN ₇ O ₂ S	445.11	446.1	(V-ae)	
(VI-ag)	C ₁₇ H ₂₂ N ₆ O ₄ S ₂	438.11	439.4	(XX)	
(VI-ah)	C ₁₈ H ₂₁ N ₅ O ₄ S	403.13	404.3	(XX)	
(VI-ai)	C ₂₁ H ₂₈ N ₆ O ₄ S	460.19	461.6	(XX)	
(VI-aj)	C ₁₉ H ₂₀ N ₆ O ₂ S	396.14	397.4	(XX)	
(VI-al)	C ₂₁ H ₂₆ N ₆ O ₃ S	442.18	443.4	(XXII)	

(VI-am)	C ₂₁ H ₂₇ N ₅ O ₄ S	445.18	446.4	(XXII)	
(VI-an)	C ₂₁ H ₂₇ N ₅ O ₃ S	429.18	430.3	(XXII)	
(VI-ao)	C ₁₇ H ₂₀ N ₆ O ₃ S	388.13	389.2	(XXII)	
(VI-ap)	C ₂₀ H ₂₅ N ₅ O ₃ S	415.17	416.4	(XXII)	
(VI-aq)	C ₂₁ H ₂₂ N ₆ O ₃ S	438.15	439.3	(XXII)	
(VI-ar)	C ₂₀ H ₂₆ N ₆ O ₅ S ₂	494.14	495.3	(XXII)	

(VI-as)	C ₁₆ H ₁₈ BrN ₅ O ₂ S	423.04	424.2	(XXII)	
(VI-at)	C ₁₇ H ₂₀ ClN ₅ O ₂ S	393.10	394.2	(XXII)	
(VI-au)	C ₁₇ H ₁₇ ClF ₃ N ₅ O ₂ S	447.07	448.2	(XXII)	
(VI-av)	C ₁₆ H ₁₇ Cl ₂ N ₅ O 2S	413.05	414.1	(XXII)	
(VI-aw)	C ₁₇ H ₂₂ N ₆ O ₄ S ₂	438.11	439.3	(XXII)	
(VI-ax)	C ₁₉ H ₂₆ N ₆ O ₄ S ₂	466.15	467.3	(XXII)	

(VI-ay)	C ₂₀ H ₂₆ N ₆ O ₄ S ₂	478.15	479.3	(XXII)	
(VI-az)	C ₂₁ H ₂₉ N ₇ O ₄ S ₂	507.17	508.0	(XXII)	
(VI-ba)	C ₁₇ H ₂₁ N ₅ O ₂ S ₂	391.11	392.3	(XXII)	
(VI-bb)	C ₁₈ H ₂₂ N ₆ O ₃ S	402.15	403.3	(XXII)	
(VI-bc)	C ₂₁ H ₂₄ N ₆ O ₃ S	440.16	441.3	(XXII)	
(VI-bd)	C ₂₀ H ₂₇ N ₇ O ₃ S	445.19	446.4	(XXII)	


(VI-be)	C ₂₃ H ₂₅ N ₇ O ₃ S	479.17	480.2	(XXII)	
(VI-bf)	C ₂₃ H ₃₁ N ₇ O ₃ S	485.22	490.4	(XXII)	
(VI-bg)	C ₂₄ H ₂₇ N ₇ O ₃ S	493.19	494.4	(XXII)	
(VI-bh)	C ₁₉ H ₂₅ N ₇ O ₃ S	431.17	432.3	(XXII)	
(VI-bi)	C ₂₁ H ₂₇ N ₅ O ₂ S ₂	445.16	446.0	(XXII)	
(VI-bj)	C ₂₁ H ₂₉ N ₅ O ₃ S	431.20	431.9	(XXII)	

(VI-bk)	C ₁₉ H ₂₃ N ₅ O ₄ S	417.15	417.9	(XXII)	
(VI-bl)	C ₂₂ H ₂₇ N ₅ O ₂ S	425.19	426.3	(XXII)	
(VI-bm)	C ₁₇ H ₂₁ N ₅ O ₂ S ₂	391.11	392.3	(XXII)	
(VI-bn)	C ₂₃ H ₂₅ N ₅ O ₃ S	451.17	452.4	(XXII)	
(VI-bo)	C ₁₆ H ₁₈ N ₅ O ₂ S	471.02	472.2	(XXII)	
(VI-bp)	C ₂₀ H ₂₃ N ₇ O ₂ S	425.16	426.2	(XXII)	

(VI-bq)	C ₁₆ H ₁₇ Cl ₂ N ₅ O 2S	413.05	414.2	(XXII)	
(VI-br)	C ₂₀ H ₂₆ N ₆ O ₂ S	414.18	415.3	(XXII)	
(VI-bs)	C ₂₁ H ₂₈ N ₆ O ₂ S	428.20	429.2	(XXII)	

Method C: nucleophilic substitution of sulfones (VI) with O-nucleophiles

- 5 **compound (VII-1): N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine**




- 10 25 mg (0.061 mmol) methylsulfone (VI-a) were added to a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (37 mg, 0.183 mmol) and KHMDS (0.183 mmol) in DMF and stirred over night at 70 °C. The reaction mixture was diluted with ethyl acetate, washed with 10% aqueous NaHCO₃ and brine, dried with MgSO₄, filtered and concentrated in vacuo. The Boc-protecting group was removed in TFA and the pure

compound (VII-1) was obtained after RP-HPLC using a water/acetonitrile (0.1 % TFA) gradient.

$^1\text{H-NMR}$ (400MHz, $\text{d}_6\text{-DMSO}$, 300K) δ 1.26 (d, $J = 6.8$ Hz, 6H), 1.84 (m, broad, 2H), 2.07 (m, broad, 2H), 2.98 (h, $J = 6.8$ Hz, 1H), 3.10 (m, broad, 2H), 3.20 (m, broad, 2H), 4.66 (d, $J = 6.4$ Hz, 2H), 5.06 (m, 1H), 6.57 (dd, $J^1 = J^2 = 2.4$ Hz, 1H), 7.43 (m, 4H), 7.81 (d, $J = 2.4$ Hz, 1H), 7.96 (s, 1H), 8.20 (d, $J = 2.4$ Hz, 1H), 9.15 (t, $J = 6.4$ Hz, 1H); MS (ES) $\text{C}_{23}\text{H}_{28}\text{N}_8\text{O}$ requires 432.24, found 433.2 ($\text{M}+\text{H}$) $^+$.


Intermediate (XVII): 8-isopropyl-2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazin-4-ol



7.3 g (42.7 mmol) mCPBA were added in portions to 3.0 g (13.4 mmol) thioether (III) in 300 ml DCM. After the conversion to the sulfone was complete the reaction mixture was extracted with 2 M aqueous NaOH/brine (1:1). The aqueous phase was brought to pH = 1 and extracted with ethyl acetate. The combined organic phases were dried (MgSO_4), filtered and concentrated under reduced pressure. The crude product was purified by silica column chromatography (gradient elution using cyclohexane/ethyl acetate).

$^1\text{H-NMR}$ (400MHz, $\text{d}_6\text{-DMSO}$, 300K) δ 1.25 (d, $J = 6.9$ Hz, 6 H), 3.02 (h, $J = 6.9$ Hz, 1H), 3.19 (s, 3H), 7.73 (s, 1H); MS (ES) $\text{C}_9\text{H}_{12}\text{N}_4\text{O}_3\text{S}$ requires 256.06, found 257.1 ($\text{M}+\text{H}$) $^+$.

Intermediate (XVIII): 8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5] triazin-4-ol




2.7 g (10.6 mmol) methylsulfone (XVII) in 10 ml DMF were added to a solution of 3.6 g (31.6 mmol) 1-methylpiperidin-4-ol and 0.76 g (31.6 mmol) NaH in 5 ml DMF. The reaction mixture was heated to 60 °C for 30 minutes, diluted with methanol, neutralized with 2 M aqueous HCl and absorbed on silica gel. Title compound (XVIII) was obtained after purification by column chromatography (silica gel, gradient elution with cyclohexane/ethyl acetate).

¹H-NMR (400MHz, d₆-DMSO, 300K) δ 1.23 (d, J = 6.9 Hz), 6H), 2.00-2.10 (m, broad, 2H), 2.17-2.27 (m, broad, 2H), 2.67 (s, 3H), 2.89 (h, J = 6.9 Hz, 1H), 3.10-3.26 (m, broad, 4H), 5.13 (m, broad, 1H), 7.75 (s, 1H); MS (ES) C₁₄H₂₁N₅O₂ requires 291.17, found 292.1 (M+H)⁺.

5

Intermediate (XIX): 4-chloro-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazine




0.30 g (1.03 mmol) intermediate (XVIII), 4.7 g (30.9 mmol) POCl₃ and 0.46 g (3.09 mmol) N,N-diethylaniline were mixed and stirred at 80 °C for 2h. Volatiles were removed under reduced pressure and the crude product was used in aliquots. MS (ES) C₁₄H₂₀ClN₅O requires 309.14, found 310.3 (M+H)⁺.

10

Method G: nucleophilic substitution of chloride (XIX) with amines A¹NH₂

15

compound (VII-56): N-(2-fluorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine



To 0.103 mmol intermediate (XIX) in 0.5 ml acetonitrile at 0°C were added 66 µl DIPEA and 24 mg (0.19 mmol) (2-fluorophenyl)methanamine. The mixture was stirred at 40°C for 1 h. compound (VII-56) was obtained after purification by RP-HPLC (gradient using water/acetonitrile containing 0.1% TFA).

20

¹H-NMR (400MHz, d₆-DMSO, 300K) δ 1.25 (d, J = 6.8 Hz, 6H), 1.71-2.2 (m, 4H), 2.79 (m, 3H), 2.97 (h, J = 6.8 Hz, 1H), 3.11 (m, broad, 2H), 3.29-3.48 (m, broad, 2H), 4.70 (m, 2H), 5.00 (m, 1H), 7.12-7.20 (m, 4H), 7.96 (s, 1H), 9.29 (m, 1H); MS (ES) C₂₁H₂₇FN₆O requires 398.22, found 399.5 (M+H)⁺.

25







compounds (VII-01) – (VII-141)

Title compounds (VII-2) – (VII-52), (VII-77) – (VII-126) and (VII-129)–(VII-141) were prepared from related methylsulfones (VI) similar to method C (in some cases NaH was used as base instead of KHMDS). Compounds (VII-53)–(VII-76) and (VII-127)–(VII-128)

5 were synthesized similar to method G.

Compound	formula	calculated	MS(ES) [M+H] ⁺	Starting material	name	structure
(VII-01)	C ₂₃ H ₂₈ N ₈ O	432.24	433.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-02)	C ₂₂ H ₂₆ N ₈ O	418.22	418.9	(VI-a)	(R)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-03)	C ₂₃ H ₂₈ N ₈ O	432.24	433.3	(VI-a)	(R)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
VII-04)	C ₂₄ H ₂₈ N ₈ O	444.24	445.7	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(2-azaspiro[3.3]heptan-6-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-05)	C ₂₆ H ₃₂ N ₈ O ₂	488.26	489.4	(VI-a)	2-(1-oxa-8-azaspiro[4.5]decan-3-yloxy)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-06)	C ₂₄ H ₃₀ N ₈ O	446.25	447.4	(VI-a)	N-(1-(2-(1H-pyrazol-1-yl)phenyl)ethyl)-8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-07)	C ₂₆ H ₃₀ N ₆ O	442.25	443.5	(VI-b)	(R)-N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-08)	C ₂₅ H ₂₈ N ₆ O	428.23	429.2	(VI-b)	(R)-N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-09)	C ₂₆ H ₃₀ N ₆ O	442.25	443.3	(VI-b)	N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-10)	C ₂₂ H ₃₀ N ₆ O ₂	410.24	411.4	(VI-c)	8-isopropyl-N-((S)-1-(2-methoxyphenyl)ethyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-11)	C ₂₁ H ₂₈ N ₆ O ₂	396.23	397.4	(VI-c)	8-isopropyl-N-((S)-1-(2-methoxyphenyl)ethyl)-2-((R)-pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	







(VII-12)	C ₂₄ H ₂₈ N ₆ O ₂ S	448.20	449.3	(VI-d)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-13)	C ₂₃ H ₂₆ N ₆ O ₂ S	434.19	435.3	(VI-d)	(R)-8-isopropyl-2-(pyrrolidin-3-yloxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-14)	C ₂₄ H ₂₈ N ₆ O ₂ S	448.20	449.1	(VI-d)	8-isopropyl-2-(piperidin-4-yloxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-15)	C ₂₂ H ₃₀ N ₆ O ₂	410.24	411.3	(VI-c)	(S)-8-isopropyl-N-(1-(2-methoxyphenyl)ethyl)-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-16)	C ₂₂ H ₃₀ N ₆ O ₂	410.24	411.1	(VI-e)	(R)-N-(2-isopropoxybenzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-17)	C ₂₃ H ₃₂ N ₆ O ₂	424.26	425.4	(VI-e)	N-(2-isopropoxybenzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	







(VII-18)	C ₂₃ H ₃₂ N ₆ O ₂	424.26	425.3	(VI-e)	(R)-N-(2-isopropoxybenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-19)	C ₂₃ H ₂₈ N ₈ O	432.24	433.4	(VI-f)	N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-20)	C ₂₂ H ₂₇ N ₉ O	433.23	434.3	(VI-g)	(R)-N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-21)	C ₂₁ H ₂₅ N ₉ O	419.22	419.8	(VI-g)	(R)-N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-22)	C ₂₂ H ₂₇ N ₉ O	433.23	434.0	(VI-g)	N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-23)	C ₂₄ H ₃₀ N ₈ O	446.25	447.2	(VI-h)	(R)-8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-24)	C ₂₄ H ₃₀ N ₈ O	446.25	447.3	(VI-h)	8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-25)	C ₂₃ H ₂₈ N ₈ O*2C ₂ H ₃ F ₃ O ₂	432.24	433.3	(VI-h)	(R)-8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-26)	C ₂₃ H ₂₈ N ₈ O	432.24	433.2	(VI-f)	(R)-N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-27)	C ₂₂ H ₂₆ N ₈ O*2C ₂ H ₃ F ₃ O ₂	418.22	419.3	(VI-f)	(R)-N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-28)	C ₂₁ H ₂₇ ClN ₆ O	414.19	415.4	(VI-i)	N-((S)-1-(2-chlorophenyl)ethyl)-8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-29)	C ₂₂ H ₂₈ N ₁₀ O	448.24	449.3	(VI-j)	(R)-8-isopropyl-N-(2-(1-methyl-1H-tetrazol-5-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-30)	C23H27N7O2	433.22	434.1	(VI-k)	(R)-5-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)quinoline 1-oxide	
(VII-31)	C23H27N7O	417.23	418.3	(VI-l)	(R)-8-isopropyl-N-(isoquinolin-8-ylmethyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-32)	C23H27N7O2	433.22	434.0	(VI-m)	(R)-8-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)isoquinoline 2-oxide	
(VII-33)	C22H28N8O	420.24	421.4	(VI-n)	(R)-8-isopropyl-N-((1-methyl-1H-indazol-4-yl)methyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-34)	C25H29N7O	443.24	444.4	(VI-o)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyridin-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-35)	C23H27N7O	417.23	418.3	(VI-p)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(quinolin-8-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-36)	C ₂₁ H ₂₆ N ₈ O	406.22	407.3	(VI-r)	(R)-N-((1H-indazol-4-yl)methyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-37)	C ₂₂ H ₂₈ N ₁₀ O	448.24	449.5	(VI-t)	(R)-8-isopropyl-N-(2-(2-methyl-2H-tetrazol-5-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-38)	C ₂₂ H ₃₁ N ₇ O ₃ S	473.22	474.4	(VI-u)	(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)-N,N-dimethylbenzenesulfonamide	
(VII-39)	C ₂₄ H ₃₁ N ₇ O ₂	449.25	450.5	(VI-s)	(R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)pyrrolidin-2-one	
(VII-40)	C ₂₃ H ₂₉ N ₇ O ₂	435.238 273	436.4	(VI-v)	(R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)azetidin-2-one	
(VII-41)	C ₂₃ H ₂₇ FN ₈ O	450.23	451.5	(VI-w)	(R)-N-(5-fluoro-2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-42)	C23H27FN8O	450.23	451.4	(VI-x)	(R)-N-(3-fluoro-2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-43)	C23H27FN8O	450.23	451.4	(VI-y)	(R)-N-(4-fluoro-2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-44)	C23H27FN8O	450.23	451.5	(VI-z)	(R)-N-(2-fluoro-6-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-45)	C26H31N7O	457.26	458.3	(VI-aa)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-(pyridin-3-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-46)	C25H29N7O	443.24	444.3	(VI-aa)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyridin-3-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-47)	C27H32N6O2	472.26	472.9	(VI-ab)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-phenoxybenzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-48)	C ₂₆ H ₃₀ N ₆ O ₂	458.24	459.0	(VI-ab)	(R)-8-isopropyl-N-(2-phenoxybenzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-49)	C ₂₃ H ₂₇ N ₇ O ₂	433.22	434.7	(VI-ac)	(R)-8-isopropyl-N-(2-(oxazol-2-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-50)	C ₂₄ H ₂₈ N ₆ O ₂	432.23	433.6	(VI-ad)	(R)-N-(2-(furan-2-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-51)	C ₂₂ H ₂₉ N ₇ O ₂	423.24	424.3	(VI-ae)	(R)-N-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)acetamide	
(VII-52)	C ₂₃ H ₂₇ ClN ₈ O	466.20	467.3	(VI-af)	(R)-N-(2-(4-chloro-1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-53)	C ₂₂ H ₃₀ N ₆ O	394.25	395.47	(XIX)	8-isopropyl-N-(2-methylbenzyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-54)	C23H33N7O	423.27	424.46	(XIX)	N-(2-(dimethylamino)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-55)	C22H27N7O	405.23	406.3	(XIX)	2-(((8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzo nitrile	
(VII-56)	C21H27FN6O	398.22	399.4	(XIX)	N-(2-fluorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-57)	C27H32N6O	456.26	457.09	(XIX)	N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-58)	C22H27F3N6O	448.22	449.18	(XIX)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-(trifluoromethyl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-59)	C24H30N8O	446.25	447.49	(XIX)	N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	






(VII-60)	C ₂₅ H ₃₅ N ₇ O ₂	465.29	466.36	(XIX)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-morpholinobenzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-61)	C ₂₅ H ₃₀ N ₆ O	430.25	431.21	(XIX)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(naphthalen-1-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-62)	C ₂₂ H ₂₉ ClN ₆ O	428.21	429.19	(XIX)	N-(2-chloro-6-methylbenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-63)	C ₂₁ H ₂₆ Cl ₂ N ₆ O	448.15	449.14	(XIX)	N-(2,6-dichlorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-64)	C ₂₁ H ₂₆ F ₂ N ₆ O	416.21	417.19	(XIX)	N-(2,6-difluorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-65)	C ₂₅ H ₃₀ N ₆ OS	462.22	463.43	(XIX)	8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-66)	C ₂₄ H ₃₄ N ₆ O ₂	438.27	439.09	(XIX)	N-(2-isopropoxybenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-67)	C ₂₃ H ₃₂ N ₆ O ₂	424.26	425.25	(XIX)	(S)-8-isopropyl-N-(1-(2-methoxyphenyl)ethyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-68)	C ₂₁ H ₂₇ ClN ₆ O	414.19	415.35	(XIX)	N-(2-chlorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-69)	C ₂₆ H ₃₂ N ₆ O	444.26	445.39	(XIX)	(S)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(1-(naphthalen-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-70)	C ₂₃ H ₃₂ N ₆ O ₂	424.26	425.17	(XIX)	N-(2-ethoxybenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-71)	C ₂₂ H ₃₀ N ₆ O ₂	410.24	411.07	(XIX)	8-isopropyl-N-(2-methoxybenzyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-72)	C ₂₂ H ₂₈ F ₂ N ₆ O ₂	446.22	447.08	(XIX)	N-(2-(difluoromethoxy)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-73)	C ₂₄ H ₃₀ N ₈ O	446.25	447.00	(XIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-74)	C ₂₃ H ₂₉ N ₉ O	447.25	447.94	(XIX)	N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-75)	C ₂₅ H ₃₂ N ₈ O*2C ₂ H ₅ F ₃ O ₂	460.27	461.35	(XIX)	8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-76)	C ₂₂ H ₂₇ F ₃ N ₆ O ₂	464.21	464.97	(XIX)	N-(2-(difluoromethoxy)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-77)	C ₂₁ H ₂₈ N ₆ O ₃	412.22	413.6	(VI-ah)	methyl 2-(((2-(2-(dimethylamino)ethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzoate	

(VII-78)	C ₂₅ H ₂₉ N ₇ O	443.24	444.7	(VI-aj)	2-((6-aminospiro[3.3]heptan-2-yl)oxy)-8-isopropyl-N-(quinolin-5-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-79)	C ₂₅ H ₃₁ N ₇ O	445.26	446.6	(VI-aj)	8-isopropyl-2-(2-(piperidin-4-yl)ethoxy)-N-(quinolin-5-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-80)	C ₁₉ H ₂₅ N ₇ O	367.21	368.5	(VI-ai)	N-(2-aminobenzyl)-2-(azetidin-3-ylmethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-89)	C ₂₇ H ₃₉ N ₇ O ₃	509.31	510.7	(VI-ai)	tert-butyl (2-(((8-isopropyl-2-(2-(piperidin-1-yl)ethoxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)carbamate	
(VII-90)	C ₂₂ H ₃₃ N ₇ O ₄ S	491.23	492.6	(VI-ag)	N-(2-(((2-(2-(dimethylamino)ethoxy)ethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methanesulfonamide	
(VII-91)	C ₂₃ H ₃₆ N ₈ O ₃ S	504.26	505.5	(VI-ag)	N-(2-(((2-(2-(dimethylamino)ethyl)(methyl)amino)ethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methanesulfonamide	

(VII-92)	C ₂₅ H ₃₃ N ₇ O ₂	463.27	464.4	(VI-al)	(R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzyl)pyrrolidin-2-one	
(VII-93)	C ₂₅ H ₃₄ N ₆ O ₃	466.27	467.4	(VI-am)	8-isopropyl-N-(4-methyl-2-((tetrahydrofuran-3-yl)oxy)benzyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-94)	C ₂₀ H ₂₄ Cl ₂ N ₆ O	434.14	435.3	(VI-ak)	(R)-N-(2,4-dichlorobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-95)	C ₂₅ H ₃₄ N ₆ O ₂	450.27	451.4	(VI-an)	(R)-N-(2-(cyclopentyloxy)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-96)	C ₂₁ H ₂₇ N ₇ O ₂	409.22	410.4	(VI-ao)	(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzamide	

(VII-97)	C ₂₄ H ₃₂ N ₆ O ₂	436.26	437.4	(VI-ap)	(R)-N-(2-cyclobutoxybenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-98)	C ₂₅ H ₂₉ N ₇ O ₂	459.24	460.4	(VI-aq)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyridin-2-yloxy)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-99)	C ₂₄ H ₃₃ N ₇ O ₄ S	515.23	516.4	(VI-ar)	(R)-8-isopropyl-N-(2-(morpholinosulfonyl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-100)	C ₂₀ H ₂₅ BrN ₆ O	444.13	445.3	(VI-as)	(R)-N-(2-bromobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-101)	C ₂₁ H ₂₇ ClN ₆ O	414.19	415.3	(VI-at)	(R)-N-(4-chloro-2-methylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-102)	C ₂₁ H ₂₄ ClF ₃ N ₆ O	468.17	469.3	(VI-au)	(R)-N-(4-chloro-2-(trifluoromethyl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-103)	C ₂₀ H ₂₄ Cl ₂ N ₆ O	434.14	435.3	(VI-av)	(R)-N-(2,3-dichlorobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-104)	C ₂₁ H ₂₉ N ₇ O ₃ S	459.21	460.4	(VI-aw)	(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)-N-methylbenzenesulfonamide	
(VII-105)	C ₂₃ H ₃₃ N ₇ O ₃ S	487.24	488.4	(VI-ax)	(R)-N-isopropyl-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzenesulfonamide	
(VII-106)	C ₂₄ H ₃₃ N ₇ O ₃ S	499.24	500.4	(VI-ay)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyrrolidin-1-ylsulfonyl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-107)	C25H36N8O3S	528.26	529.4	(VI-az)	(R)-8-isopropyl-N-(2-((4-methylpiperazin-1-yl)sulfonyl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-108)	C22H29N7O2	423.24	424.5	(VI-ba)	(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)-N-methylbenzamide	
(VII-109)	C25H31N7O2	461.25	462.5	(VI-bc)	N-(but-3-yn-2-yl)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzamide	
(VII-110)	C24H34N8O2	466.28	467.5	(VI-bd)	(R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)-3-propylurea	
(VII-111)	C27H32N8O2	500.26	501.4	(VI-be)	(R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)-3-phenylurea	
(VII-112)	C27H38N8O2	506.31	507.5	(VI-bf)	(R)-1-cyclohexyl-3-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)urea	

(VII-113)	C ₂₈ H ₃₄ N ₈ O ₂	514.28	515.4	(VI-bg)	(R)-1-benzyl-3-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)urea	
(VII-114)	C ₂₃ H ₃₂ N ₈ O ₂	452.26	453.5	(VI-bh)	(R)-1-ethyl-3-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)urea	
(VII-115)	C ₂₅ H ₃₆ N ₆ O ₂	452.29	453.4	(VI-bj)	(R)-N-(2-isobutoxy-4-methylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-116)	C ₂₃ H ₃₀ N ₆ O ₃	438.24	439.4	(VI-bk)	(R)-N-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-6-yl)methyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-117)	C ₂₆ H ₃₄ N ₆ O	446.28	447.4	(VI-bl)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-((2',3',4',5'-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-118)	C ₂₁ H ₂₈ N ₆ O _S	412.20	413.3	(VI-bm)	(R)-8-isopropyl-N-(2-(methylthio)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-119)	C ₂₅ H ₃₄ N ₆ O ₂ S	466.25	467.4	(VI-bi)	(R)-N-(2-(cyclopentylthio)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-120)	C ₂₃ H ₂₆ N ₈ O	430.22	453.1 [M+Na] ⁺	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((1,2,3,6-tetrahydropyridin-3-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-121)	C ₂₆ H ₃₂ N ₈ O ₂	488.26	489.2	(VI-a)	2-(1-oxa-8-azaspiro[4.5]decan-3-yloxy)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-122)	C ₂₃ H ₂₈ N ₈ O ₂	448.23	449.2	(VI-a)	2-((1,4-oxazepan-6-yl)oxy)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-123)	C ₂₄ H ₂₈ N ₈ O	444.24	445.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-((1R,5S)-3-azabicyclo[3.2.0]heptan-6-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-124)	C ₂₄ H ₃₁ N ₉ O	461.27	462.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2-(piperazin-1-yl)ethoxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-125)	C ₂₄ H ₂₈ N ₈ O	444.24	445.3	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(2-azabicyclo[2.2.1]heptan-5-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-126)	C ₂₀ H ₂₅ N ₆ O	492.11	493.2	(VI-bo)	N-(2-iodobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-127)	C ₂₅ H ₃₇ N ₇ O ₂ S	499.27	500.3	(XIX)	N-(2-(((8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)-2-methylpropane-2-sulfinamide	
(VII-128)	C ₂₆ H ₃₇ N ₇ O ₃	495.30	496.4	(XIX)	isobutyl (2-(((8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)carbamate	
(VII-129)	C ₂₄ H ₃₀ N ₈ O	446.25	447.2	(VI-bp)	(R)-N-(2-((1H-pyrazol-1-yl)methyl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-130)	C ₂₀ H ₂₄ Cl ₂ N ₆ O	434.1	435.2	(VI-bq)	(R)-N-(2,5-dichlorobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	


(VII-131)	C ₂₄ H ₃₃ N ₇ O	435.2 7	436.3	(VI-br)	(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyrrolidin-1-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-132)	C ₂₅ H ₃₅ N ₇ O	449.2 9	450.4	(VI-bs)	(R)-8-isopropyl-N-(2-(piperidin-1-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-133)	C ₂₅ H ₃₁ N ₉ O ₃	505.2 5	506.2	(VI-a)	azetidin-3-yl (2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl)(methyl) carbamate	
(VII-134)	C ₂₆ H ₃₇ N ₉ O ₃ S	555.2 7	556.1	(VI-a)	N-(2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl)-3-(dimethylamino)-N-methylpropane-1-sulfonamide	
(VII-135)	C ₂₆ H ₃₅ N ₉ O ₃ S	553.2 6	554.0	(VI-a)	N-(2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl)-N-methylpiperidine-4-sulfonamide	

(VII-136)	C ₂₄ H ₂₉ N ₉ O ₃	491.2 4	492.4	(VI-a)	2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl azetidin-3-ylcarbamate	
(VII-137)	C ₂₄ H ₃₁ N ₉ O ₃ S	525.2 3	526.3	(VI-a)	2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)-N-(pyrrolidin-3-yl)ethanesulfonamide	
(VII-138)	C ₂₅ H ₃₀ N ₈ O	458.2 5	459.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(8-azabicyclo[3.2.1]octan-3-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-139)	C ₂₄ H ₂₈ N ₈ O	444.2 4	445.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(2-azaspiro[3.3]heptan-5-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-140)	C ₂₄ H ₃₀ N ₈ O	446.2 5	447.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-((4-aminocyclohexyl)oxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VII-141)	C ₂₁ H ₂₄ N ₈ O	404.2 1	405.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(azetidin-3-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
-----------	--	------------	-------	--------	---	--

Method J: C-C cross couplings with intermediate (XXIII)

- 5 **compound (VII-141): N-(2-cyclobutylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine**



- 10 To a solution of 40 mg (0.068 mmol) iodine (XXIII) (prepared from intermediate (VI-bo) similar to method C without the final Boc-deprotection step) in 0.5 ml toluene 5.4 mg (0.0068 mmol) dichloro[1,3-bis(2,6-di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)-palladium(II) were added. The reaction mixture was degassed with nitrogen and 0.544 ml (0.272 mmol) of a cyclobutylzinc bromide solution (0.5 M in THF) were added dropwise at 0°C. The ice bath was removed and the reaction mixture stirred for
- 15 90 min at room temperature. The intermediate product was purified by column chromatography (12 g silica gel, cyclohexane / ethyl acetate). The Boc-protecting group was removed with 20% TFA/DCM and the pure compound was obtained after RP-HPLC using a water/acetonitril (0.1%TFA) gradient.

MS (ES) C₂₄H₃₂N₆O requires 420.26, found 421.2 (M+H)⁺.

20


compounds (VII-141) – (VII-144)

Compounds (VII-142)-(VII-144) were synthesized similar to method J.

Compound	formula	calculated	MS(ES) [M+H] ⁺	starting material	name	structure
----------	---------	------------	------------------------------	-------------------	------	-----------

(VII-141)	C ₂₄ H ₃₂ N ₆ O	420.26	421.2	(XXIII)	(R)-N-(2-cyclobutylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-142)	C ₂₅ H ₃₄ N ₆ O	434.28	435.2	(XXIII)	(R)-N-(2-cyclopentylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-143)	C ₂₃ H ₃₀ N ₆ O	406.52	407.4	(XXIII)	N-(2-cyclopropylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-144)	C ₂₆ H ₃₆ N ₆ O	448.30	449.4	(XXIII)	(R)-N-(2-cyclohexylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

Intermediate (XXV): (R)-tert-butyl 3-((4-((tert-butoxycarbonyl)(2-hydroxybenzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)piperidine-1-carboxylate



5

To a solution of 483 mg (0.83 mmol) intermediate (XXIV) (prepared from intermediate (VI-bn) similar to method C without the final Boc-deprotection step) in 10 ml DCM were added 543 mg (2.49 mmol) Boc₂O and 20.3 mg (0.083 mmol) DMAP. After the mixture

was stirred at room temperature for 2 h, the same amount of Boc_2O and DMAP was added. After 1 h the solvent was removed under reduced pressure and the crude product was purified by column chromatography (12 g silica gel, cyclohexane / ethyl acetate).


5 MS (ES) $\text{C}_{37}\text{H}_{48}\text{N}_6\text{O}_6$ requires 672.36, found 673.6 ($\text{M}+\text{H}$)⁺.

577 mg (0.86 mmol) of the intermediate benzyl ether were hydrogenated in 25 ml ethanol / ethyl acetate (1:1) (H-Cube: flow 1 ml/min; 10% Pd/C; 60°C). The crude product was purified by column chromatography (12 g silica gel, cyclohexane / ethyl acetate).

10 MS (ES) $\text{C}_{25}\text{H}_{34}\text{N}_6\text{O}_4$ requires 582.32, found 583.6 ($\text{M}+\text{H}$)⁺.

Method K: derivatives of intermediate (XXV)

compound (VII-145): (R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl acetate



3 μL acetyl chloride were added at 0°C to a solution of 20 mg of intermediate (XXV) and 14.2 μL of triethylamine in 0.4 ml DCM. The mixture was stirred at 0°C until the reaction was complete. The reaction mixture was purified by column chromatography (12 g silica gel, cyclohexane / ethyl acetate). The Boc-protecting group was removed with 20 % TFA/DCM and the pure compound was obtained after RP-HPLC using a water/acetonitril (0.1 % TFA) gradient.

20 MS (ES) $\text{C}_{22}\text{H}_{28}\text{N}_6\text{O}_3$ requires 424.22, found 425.4 ($\text{M}+\text{H}$)⁺.

compounds (VII-145) – (VII-150)


Compounds (VII-146)-(VII-150) were synthesized from intermediate (XXV) similar to method K. Depending on the nature of the related electrophile the reaction was also carried out at room temperature.

Compound	formula	calculated	MS(ES) [M+H] ⁺	starting material s	name	structure
----------	---------	------------	------------------------------	---------------------------	------	-----------

(VII-145)	C ₂₂ H ₂₈ N ₆ O ₃	424.22	425.4	(XXV) and acetyl chloride	(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl acetate	
(VII-146)	C ₂₃ H ₃₁ N ₇ O ₃	453.25	454.4	(XXV) and ethyl isocyanate	(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl ethylcarbamate	
(VII-147)	C ₂₁ H ₂₈ N ₆ O ₄ S	460.19	461.3	(XXV) and Methane sulfonyl chloride	(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl methanesulfonate	
(VII-148)	C ₂₄ H ₃₄ N ₆ O ₃ S	486.24	487.4	(XXV) and tert-butyl-sulfinyl chloride	2-(((8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl 2-methylpropane-2-sulfinate	
(VII-149)	C ₂₅ H ₃₄ N ₆ O ₄	482.26	483.4	(XXV) and isobutyl chloroformate	(R)-isobutyl 2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl carbonate	
(VII-150)	LDC191336	382.21	383.3	(XXV)	(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenol	

Method N: sulfoximines from intermediate (XXIII)

compound (VII-151): N-(2-(((8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)-S,S-dimethylsulfoximine




20 mg (0.034 mmol) iodine (XXIII) (prepared from intermediate (VII-bo) similar to method C without the final Boc-deprotection step), 3.7 μl (dimethylsulfinylidene)amine, 1.6 mg CuI and 27.7 mg Cs_2CO_3 were stirred in 0.5 ml toluene at 110 $^\circ\text{C}$ over night. The reaction mixture was diluted with ethyl acetate, washed with brine, dried with MgSO_4 , filtered and concentrated in vacuo. The crude product was purified on silica gel using an ethyl acetate / cyclohexane gradient.

The resulting intermediate was dissolved in 20% TFA/DCM. After the Boc-group was cleaved the title compound was obtained after RP-HPLC using a water/acetonitrile (0.1 % TFA) gradient.

MS (ES) $\text{C}_{22}\text{H}_{31}\text{N}_7\text{O}_2\text{S}$ requires 457.23, found 458.1 ($\text{M}+\text{H}$) $^+$.

Method O: Oxidation of thioethers

compound (VII-152): 8-isopropyl-N-(2-(methylsulfinyl)benzyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine



Boc-protected (VII-118) was obtained as described for (VII-118) but without the deprotection step. The 223 mg (0.436 mmol) thioether were then oxidized in 10 ml DCM at 0 $^\circ\text{C}$ using 83 mg (0.48 mmol) mCPBA. After 1h the reaction mixture was


diluted with ethyl acetate and washed with 2 M NaOH solution and brine. The organic phase was dried over MgSO₄, concentrated under reduced pressure and purified on silica gel using an ethyl acetate / cyclohexane gradient. The resulting intermediate was dissolved in 20% TFA/DCM. After the Boc-group was cleaved the title compound was obtained after RP-HPLC using a water/acetonitrile (0.1 % TFA) gradient.

MS (ES) C₂₁H₂₈N₆O₂S requires 428.20, found 429.2 (M+H)⁺.

compounds (VII-152) – (VII-154)

Compounds (VII-152)-(VII-154) were synthesized similar to method O. In case the related sulfonyl instead of the sulfinyl was desired, additional equivalents of mCPBA were used at elevated temperatures.

Compound	formula	calculated	MS(ES) [M+H] ⁺	name	structure
(VII-154)	C ₂₁ H ₂₈ N ₆ O ₃ S	444.19	445.4	(R)-8-isopropyl-N-(2-(methylsulfonyl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-152)	C ₂₁ H ₂₈ N ₆ O ₂ S	428.20	429.2	8-isopropyl-N-(2-(methylsulfinyl)benzyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VII-153)	C ₂₅ H ₃₄ N ₆ O ₂ S	482.25	483.3	N-(2-(cyclopentylsulfinyl)benzyl)-8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

Method D: substitution of methylsulfones (VI) with N-nucleophiles**Compound (VIII-16):**

- 5 25 mg (0.061 mmol) methylsulfone (VI-a) were added to a solution of tert-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate (28 mg, 0.122 mmol) in NMP and stirred 18 h at 120 °C. The reaction mixture was diluted with ethyl acetate, washed with 10% aqueous NaHCO₃ and brine, dried with MgSO₄, filtered and concentrated in vacuo. The remaining Boc-protecting group was removed in TFA and the pure compound (VIII-16)
- 10 was obtained after RP-HPLC using a water/acetonitrile (0.1 % TFA) gradient.
- ¹H-NMR (400MHz, CDCl₃, 300K) δ 1.18 (d, J = 6.8 Hz, 6H), 2.09 (m, broad, 4H), 3.23 (h, J = 6.8 Hz, 1H), 3.95-4.05 (m, broad, 8H), 4.72 (d, J = 6.0 Hz, 2H), 6.55 (m, 1H), 7.26-7.42 (m, 4H), 7.54 (s, 1H), 7.81 (m, 1H), 7.87 (m, 1H), 9.26 (t, J = 6.0 Hz, 1H), 9.85 (s, broad, 2H); MS (ES) C₂₅H₃₁N₉ requires 457.27, found 458.4 (M+H)⁺.







Compounds (VIII-1) – (VIII-62)

Compounds (VIII-1) – (VIII-62) were prepared from the related methylsulfones (VI) according to method D and as exemplified for compound (VIII-16). In some cases DMF was used as solvent and 4 equivalents NEt₃ were used as additional base.

Compound	formula	calculated	MS(ES) [M+H] ⁺	starting material	name	structure
(VIII-01)	C ₂₃ H ₂₉ N ₉	431.25	432.4	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	







(VIII-02)	C ₂₄ H ₂₉ N ₉	443.25	444.1	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.4]octan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-03)	C ₂₅ H ₃₁ N ₉	457.27	458.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[4.4]nonan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-04)	C ₂₅ H ₃₁ N ₉	457.27	458.3	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,6-diazaspiro[3.5]nonan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-05)	C ₂₅ H ₃₁ N ₉	457.27	458.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.5]nonan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-06)	C ₂₆ H ₃₃ N ₉	471.29	472.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[4.5]decan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-07)	C ₂₄ H ₂₉ N ₉	443.25	444.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.4]octan-6-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VIII-08)	C23H27N9	429.24	530.1	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,6-diazaspiro[3.3]heptan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-09)	C26H33N9	471.29	572.1	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-10)	C23H27N9	429.24	530.0	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.3]heptan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-11)	C26H33N9	471.29	472.4	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-12)	C25H31N9	457.27	458.4	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[3.5]nonan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-13)	C25H31N9	457.27	458.3	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[4.4]nonan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VIII-14)	C27H35N9	485.30	486.5	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,8-diazaspiro[5.5]undecan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-15)	C27H35N9	485.30	486.4	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,8-diazaspiro[5.5]undecan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-16)	C25H31N9	457.27	458.4	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[3.5]nonan-7-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-17)	C25H31N9	457.27	458.5	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[4.4]nonan-7-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-18)	C25H33N11	487.29	488.5	(VI-j)	8-isopropyl-N-(2-(1-methyl-1H-tetrazol-5-yl)benzyl)-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-19)	C25H33N11	487.29	488.5	(VI-t)	8-isopropyl-N-(2-(2-methyl-2H-tetrazol-5-yl)benzyl)-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VIII-20)	C25H31N9	457.27	458.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[3.5]nonan-7-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-21)	C27H35N9	485.30	486.5	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,9-diazaspiro[5.5]undecan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-22)	C26H33N9	471.29	472.3	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,8-diazaspiro[4.5]decan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-23)	C27H35N9	485.30	486.4	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,9-diazaspiro[5.5]undecan-9-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-24)	C25H33N9	459.29	460.3	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(4-(dimethylamino)piperidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	

(VIII-25)	C24H31N9	445.27	446.3	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(4-(methylamino)piperidin-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-26)	C27H35N9	485.30	486.3	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(3,9-diazaspiro[5.5]undecan-3-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-27)	C26H33N9	471.29	472.3	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[4.5]decan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-28)	C24H29N9	443.25	444.3	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,6-diazaspiro[3.4]octan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-31)	C22H31N7O	409.26	409.9	(VI-c)	8-isopropyl-N4-((S)-1-(2-methoxyphenyl)ethyl)-N2-((R)-piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-32)	C23H33N7O	423.28	424.2	(VI-e)	(R)-N4-(2-isopropoxybenzyl)-8-isopropyl-N2-(piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	


(VIII-33)	C22H28N10	432.25	433.4	(VI-g)	(R)-N4-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-N2-(piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-34)	C25H31N9	457.27	458.4	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[3.5]nonan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-35)	C25H36N8O2S	512.26	513.4	(VI-u)	2-(((8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)-N,N-dimethylbenzenesulfonamide	
(VIII-36)	C23H29N9O	447.25	448.4	(VI-q)	N-(benzo[c][1,2,5]oxadiazol-4-ylmethyl)-8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-37)	C26H33N9	471.29	472.5	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,8-diazaspiro[4.5]decan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-38)	C27H36N8O	488.30	489.5	(VI-s)	1-(2-(((8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)pyrrolidin-2-one	

(VIII-39)	C21H27N9	405.24	406.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(3-aminopropyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-40)	C24H31N9	445.27	446.3	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(2-(pyrrolidin-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-41)	C25H29F2N9	493.25	494.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(3-(3,3-difluoropyrrolidin-1-yl)azetidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-4-amine	
(VIII-42)	C25H33N9O	475.28	476.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(2-morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-43)	C22H27N9	417.24	418.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(pyrrolidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-44)	C25H33N9O	475.28	476.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(3-morpholinopropyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	

(VIII-45)	C25H33N9	459.29	460.3	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(2-(pyrrolidin-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-46)	C24H31N9O	461.27	462.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(2-morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-47)	C25H29N9O	471.25	472.1	(VI-a)	1-(1-(4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)azetidin-3-yl)pyrrolidin-2-one	
(VIII-48)	C22H29N9O	435.25	436.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(2-(2-aminoethoxy)ethyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-49)	C27H37N9	487.32	488.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(3-(piperidin-1-yl)propyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-50)	C24H29N9	443.25	444.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	


(VIII-51)	C20H25N9	391.22	392.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(2-aminoethyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-52)	C23H29N9	431.25	432.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(pyrrolidin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-53)	C23H29N9	431.25	432.1	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(3-aminopiperidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-54)	C22H27N9	417.24	418.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(3-aminopyrrolidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-55)	C22H27N9O2	449.23	450.2	(VI-a)	methyl 2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)-3-aminopropanoate	
(VIII-56)	C26H29N9	467.25	468.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(2-amino-1-phenylethyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	

(VIII-57)	C23H29N9	431.25	432.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(azetidin-3-ylmethyl)-8-isopropyl-N2-methylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-58)	C25H33N9O	475.28	476.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(2-morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-59)	C23H29N9	431.25	432.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(4-aminopiperidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(VIII-60)	C24H31N9	445.27	446.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(4-aminocyclohexyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
(VIII-61)	C28H38N10O2	546.32	547.2	(VI-a)	N-(2-(2-((4-(2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)ethoxy)ethyl)-2-(pyrrolidin-1-yl)acetamide	

(VIII-62)	C ₂₄ H ₃₂ N ₁₀	460.28	461.2	(VI-a)	N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(2-(piperazin-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine	
-----------	---	--------	-------	--------	---	---

Method E: substitution of methylsulfones (VI) with S-nucleophiles

Compound (X-2): 8-isopropyl-2-(piperidin-4-ylsulfinyl)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine



30 mg (0.07 mmol) methylsulfone (VI-d) were added to a solution of tert-butyl 4-mercaptopiperidine-1-carboxylate (46 mg, 0.21 mmol) and KHMDS (29 mg, 0.15 mmol) in DMF. The reaction was stirred at room temperature over night, diluted with ethyl acetate and washed with 10% aqueous NaHCO₃ and brine, dried with MgSO₄, filtered and concentrated in vacuo. The crude product was dissolved in DCM and cooled in an ice bath. 14 mg mCPBA (0.081 mmol) were added in three portions during 2 h. The reaction mixture was poured into a solution of 2 M aqueous NaOH and extracted with DCM. The organic layer was separated, washed with 2 M aqueous NaOH and brine, dried with MgSO₄, filtered and concentrated in vacuo. The protecting group was removed in TFA and the pure title compound (X-2) was obtained after RP-HPLC using a water/acetonitrile (0.1 % TFA) gradient.

¹H-NMR (400MHz, d₆-DMSO, 300K) δ 1.30 (d, J = 6.8 Hz, 3H), 1.31 (d, J = 6.8 Hz, 3H), 1.47 (d, broad, J = 12.3 Hz, 1H), 1.76 (m, broad, 2H), 2.07 (d, broad, J = 12.3 Hz, 1H), 2.62 (m, broad, 1H), 2.80 (m, broad, 1H), 2.99 (m, 1H), 3.14 (h, J = 6.8 Hz, 1H), 3.24 (d, broad, 1H), 3.32 (d, broad, 1H), 4.80 (m, 2H), 7.18-7.42 (m, 6H), 7.66 (m, 1H), 8.22 (m, broad, 1H), 8.23 (s, 1H), 8.56 (m, broad, 1H), 9.85 (t, J = 5.9 Hz, 1H). MS (ES) C₂₄H₂₈N₆OS₂ requires 480.18, found 481.7 (M+H)⁺.

compounds (X-1) – (X-9)

Title compounds (X-1) – (X-6) were prepared from the related methylsulfones (VI) according to method E. Sulfone (X-7) was prepared similar to (X-1) at elevated temperature using additional equivalents mCPBA. Thioethers (X-8) and (X-9) were prepared from the related intermediates (IX) using TFA to remove the Boc protecting group.


5

Compound	formula	calculated	MS(ES) [M+H] ⁺	starting material	name	structure
(X-1)	C ₂₃ H ₂₈ N ₈ O ₂ S	464.21	465.1	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(X-2)	C ₂₄ H ₂₈ N ₆ O ₂ S ₂	480.18	481.7	(VI-d)	8-isopropyl-2-(piperidin-4-ylsulfinyl)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(X-3)	C ₂₆ H ₃₀ N ₆ O ₂ S	474.22	475.3	(VI-b)	N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(X-4)	C ₂₂ H ₂₇ N ₉ O ₂ S	465.21	466.0	(VI-g)	N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(X-5)	C ₂₄ H ₃₀ N ₈ O ₂ S	478.23	479.2	(VI-h)	8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(X-6)	C ₂₃ H ₂₈ N ₈ OS	464.21	465.3	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((R)-((R)-piperidin-3-yl)sulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(X-7)	C ₂₃ H ₂₈ N ₈ O ₂ S	480.21	481.1	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylsulfonyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(X-8)	C ₂₃ H ₂₈ N ₈ S	448.22	449.1	(VI-a)	(R)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-ylthio)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(X-9)	C ₂₃ H ₂₈ N ₈ S	448.2	449.2	(VI-a)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylthio)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

Intermediate (XI): Ethyl 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-pyrazolo[1,5-a][1,3,5]triazine-2-carbimidate

5



200 mg (0.49 mmol) (VI-a) and 63 mg (0.97 mmol) KCN in 1 ml NMP were heated at 80 °C for 4 h. The reaction mixture was diluted with ethyl acetate and purified on silica (cyclo hexane/ethylacetate) to yield the intermediate nitrile as colorless solid.


- 5 ¹H-NMR (400MHz, d₆-DMSO, 300K) δ 1.30 (d, J = 6.8 Hz, 6H), 3.13 (h, J = 6.8 Hz, 1H), 4.73 (s, 2H), 6.55 (m, 1H), 7.39-7.45 (m, 4H), 7.80 (m, 1H), 8.19 (m, 1H), 8.28 (s, 1H), 9.67 (s, broad, 1H); MS (ES) C₁₉H₁₈N₈ requires 358.17, found 359.1 (M+H)⁺.

This intermediate was dissolved in 3.2 ml 1.25 M HCl/ethanol and stirred at 60 °C over night. The volatiles were removed under reduced pressure and the title compound (XI) was dried. It was used without any further purification.

MS (ES) C₂₁H₂₄N₈O requires 404.21, found 406.1 (ester, M+H)⁺.

Method F: amides (XII) from ethyl carbimidate (XI)


Compound (XII-1): 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-(piperidin-4-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide



20 mg (0.045 mmol) intermediate (XI) and 0.23 mmol tert-butyl 4-(aminomethyl)piperidine-1-carboxylate in 200 µl ethanol were heated in a sealed tube at 120 °C over night. The reaction mixture was cooled and partitioned between ethyl acetate and brine. The organic phase was dried (MgSO₄), filtered and evaporated to dryness. The Boc-protection group was then removed in TFA at room temperature. The pure title compounds (XII-1) was obtained after RP-HPLC using a water/ acetonitrile (0.1 % TFA) gradient.

MS (ES) C₂₅H₃₁N₉O requires 473.27, found 474.1 (M+H)⁺.


Intermediate (XXVI): ethyl 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxylate



13.16 g (29.85 mmol) of intermediate (XI) were dissolved in 121 ml ethanol and 97.0 ml 3 M HCl. The reaction mixture was stirred at room temperature over night. The mixture was poured into water and extracted three times with dichloromethane. The organic phase was washed with sodium bicarbonate and brine. The organic phase was dried and evaporated. 8.8 g of the title product were obtained.

MS (ES) C₂₁H₂₃N₇O₂ requires 405.19, found 406.1 (M+H)⁺. ¹H-NMR (300 MHz, CDCl₃), δ (ppm): 1.31 (d, J = 6.9 Hz, 6 H), 1.50 (t, J = 7.1 Hz, 3 H), 3.35 (m, 1 H), 4.51 (q, J = 7.0 Hz, 2 H), 4.82 (d, J = 6.4 Hz, 2 H), 6.53 (t, J = 2.2 Hz, 1 H), 7.30-7.43 (m, 3 H), 7.80 (d, J = 2.0 Hz, 1 H), 7.84-7.90 (m, 2 H), 7.94 (s, 1 H), 8.54 (t, J = 6.4 Hz, 1 H).

Intermediate (XXVII): 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo [1,5-a][1,3,5]triazine-2-carboxylic acid




2.5 g (6.17 mmol) of intermediate (XXII) were dissolved in 43 ml THF and 25.6 ml 0.5 M NaOH. The mixture was stirred at room temperature for 5 h. Water was added and the mixture was extracted three times with TBME. The aqueous phase was adjusted to pH 5 using 5 % citric acid and extracted with ethyl acetate. The second organic phase was dried and evaporated. 1.72 g (4.56 mmol) of the title product were obtained.

MS (ES) C₁₉H₁₉N₇O₂ requires 377.16, found 378.1 (M+H)⁺. ¹H-NMR (300 MHz, CDCl₃), δ (ppm): 1.27 (d, J = 6.9 Hz, 6 H), 3.13-3.27 (m, 1 H), 4.78 (d, J = 6.6 Hz, 2 H), 6.48 (t, J = 2.1 Hz, 1 H), 7.25-7.40 (m, 3 H), 7.73 (dd, J = 5.7/2.3 Hz, 2 H), 7.83 (d, J = 1.4 Hz, 1 H), 7.91 (s, 1 H), 8.82 (t, J = 6.0 Hz, 1 H).

5

Method L: amides (XII) from acid (XXVII)

Compound (XII-7): (4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)(2,6-diazaspiro[3.3]heptan-2-yl)methanone



10 50 mg (132 μmol) 8-Isopropyl-4-(2-pyrazol-1-yl-benzylamino)-pyrazolo[1,5-a][1,3,5]triazine-2-carboxylic acid, 20 mg (141 μmol, 1.07 eq) 6-(tert-butoxycarbonyl)-6-aza-2-azoniaspiro[3.3]heptane oxalate and 64 mg (168 μmol, 1.28 eq) HATU were dissolved in 1.8 ml DMF and cooled to 0 °C. 52 mg (512 μmol, 3.89 eq) triethylamine were added. The reaction mixture was stirred over night and allowed to warm to room temperature. The mixture was dissolved in ethyl acetate, washed with saturated sodium bicarbonate solution and brine. The organic phase was dried and evaporated. The residue was purified on silica gel, eluting with 10/30 cyclohexane/ethyl acetate to give the Boc-protected intermediate of (XII-7).

MS (ES) C₂₉H₃₅N₉O₃ requires 557.29, found 558 (M+H)⁺ and 580 (M+Na)⁺.

20 45 mg (80.7 μmol) of the the Boc-protected intermediate of (XII-7) were dissolved in 1 ml dichloromethane at 0 °C. 92 mg (807 μmol, 10 eq) trifluoroacetic acid were added. The reaction mixture was stirred over night. The reaction mixture was evaporated and the residue was purified on silica gel, eluting with 90/10 chloroform/methanol. 34 mg of the title product was obtained.

25 MS (ES) C₂₄H₂₇N₉O requires 457.23, found 458 (M+H)⁺ and 480 (M+Na)⁺.

Compounds (XII-1)-(XII-11)


Compounds (XII-1)-(XII-5) were synthesized similar to method F. Compounds (XII-6)-(XII-11) were synthesized similar to method L.

30

Compound	formula	calculated	MS (ES) [M+H] ⁺	from intermediate	name	structure
(XII-1)	C ₂₅ H ₃₁ N ₉ O	473.27	474.1	(XI)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-(piperidin-4-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide	
(XII-2)	C ₂₃ H ₂₇ N ₉ O	445.23	446.0	(XI)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-N-(azetidin-3-ylmethyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxamide	
(XII-3)	C ₂₄ H ₂₉ N ₉ O	459.25	460.1	(XI)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-(pyrrolidin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide	
(XII-4)	C ₂₅ H ₃₁ N ₉ O	473.27	474.1	(XI)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-(piperidin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide	
(XII-5)	C ₂₃ H ₂₉ N ₉ O	447.25	448.1	(XI)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-N-(4-aminobutyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxamide	
(XII-7)	C ₂₄ H ₂₇ N ₉ O	457.23	458.1	(XXVII)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-yl(2,6-diazaspiro[3.3]heptan-2-yl)methanone	

(XII-6)	C26H33N9O2	503.28	504.3	(XXVII)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-methyl-N-(2-morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide	
(XII-8)	C26H33N9O	487.28	488.2	(XXVII)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-methyl-N-(2-(pyrrolidin-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide	
(XII-9)	C23H27N9O	445.23	446.3	(XXVII)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)(piperazin-1-yl)methanone	
(XII-10)	C22H27N9O	433.23	434.3	(XXVII)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-N-(3-aminopropyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxamide	
(XII-11)	C24H29N9O	459.25	460.3	(XXVII)	4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)(4-aminopiperidin-1-yl)methanone	


Intermediate (XXVIII): 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)methanol



6.0 g (14.8 mmol) of ester (XXVI) were dissolved in 126 ml THF and cooled to 0 °C. A suspension of 1.12 g (29.6 mmol) LiAlH₄ in 30 ml THF was added dropwise. The mixture was stirred for 1 h at 0 °C. After this time saturated ammonium chloride was added and it was extracted with ethyl acetate. The organic phase was dried and evaporated. The residue was purified on silica gel eluting with 90/10 cyclohexane/ethyl acetate. 2.7 g (7.43 mmol) of the title product were obtained.

MS (ES) C₁₉H₂₁N₇O requires 363.18, found 364.2 (M+H)⁺. ¹H-NMR (300 MHz, CDCl₃), δ (ppm): 1.32 (d, J = 6.7 Hz, 1 H), 1.61 (br, 1 H), 3.10-3.26 (m, 1 H), 3.82 (t, J = 4.5 Hz, 1 H), 4.65 (d, J = 4.3 Hz, 2 H), 4.75 (d, J = 6.5 Hz, 2 H), 6.53 (t, J = 2.1 Hz, 1 H), 7.30-7.45 (m, 3 H), 7.69 (dd, J = 7.1/1.6 Hz, 1 H), 7.78 (d, J = 2.0 Hz, 1 H), 7.83 (s, 1 H), 7.89 (dd, J = 1.4 Hz, 1 H), 8.34 (t, J = 6.3 Hz, 1 H).

Intermediate (XXIX): 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carbaldehyde




385 mg (908 μmol) Dess–Martin periodinane were dissolved in 1.5 ml dichloromethane and cooled to 0 °C. 300 mg (0.825 mmol) of intermediate (XXVIII) in 1.5 ml dichloromethane were added dropwise. The mixture was stirred for 3 h at room

temperature. The reaction mixture was neutralized with saturated sodium bicarbonate and extracted with dichloromethane. The organic phase was dried and evaporated. 300 mg of the title product was obtained as crude product and it was used without further purification in the next steps. MS (ES) C₁₉H₁₉N₇O requires 361.17, found 362.2 (M+H)⁺. ¹H-NMR (300 MHz, CDCl₃), δ (ppm): 1.29 (d, J = 6.9 Hz, 6 H), 3.16-3.32 (m, 1 H), 4.77 (d, J = 6.6 Hz, 1 H), 6.47 (t, J = 2.1 Hz, 1 H), 7.23-7.37 (m, 3 H), 8.61 (t, J = 6.4 Hz, 1 H), 9.85 (s, 1 H).

Method M: reductive aminations with aldehyde (XXIX)

Compound (XXX-1): N1-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)methyl)ethane-1,2-diamine



21 mg (133 μmol, 1.2 eq) N-Boc-ethylenediamine, 1 mg (1 mol%) Chloro-(pentamethylcyclopentadienyl)-{5-methoxy-2-{1-[(4-methoxyphenyl)imino-N]ethyl}phenyl-C}-iridium(III) and 40 mg (111 μmol) 8-Isopropyl-4-(2-pyrazol-1-yl-benzylamino)-pyrazolo[1,5-a][1,3,5]triazine-2-carbaldehyde were dissolved in 1 ml MeOH. 111 μl of formic acid – trimethylamine – complex (5:2) were added and the reaction mixture was stirred for 1 h at 80 °C. Water was added and the mixture was extracted with ethyl acetate. The organic phase was washed three times with water, then with brine. The organic phase was dried and the solvent was evaporated off. The residue was purified on silica gel, eluting with 99/1 dichloromethane/methanol. 25 mg of the Boc-protected intermediate were obtained.

MS (ES) C₂₆H₃₅N₉O₂ requires 505.29, found 506 (M+H)⁺ and 528 (M+Na)⁺.

21 mg (42 μmol) of the intermediate were dissolved in 360 μl dichloromethane at 0 °C. 48 mg (416 μmol, 10 eq) trifluoroacetic acid was added. The reaction mixture was stirred over night. The reaction mixture was evaporated and the residue was purified on silica gel, eluting with 90/10 chloroform/methanol.

MS (ES) C₂₁H₂₇N₉ requires 405.24, found 406 (M+H)⁺ and 428 (M+Na)⁺.

Compounds (XXX-1)-(XXX-14)

Compounds (XXX-2)-(XXX-14) were synthesized similar to method M.


Compound	formula	calculated	MS (ES) [M+H] ⁺	from intermediate	name	structure
(XXX-1)	C ₂₁ H ₂₇ N ₉	405.24	406.2	(XXIX)	N1-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)methyl)ethane-1,2-diamine	
(XXX-2)	C ₂₆ H ₃₅ N ₉ O	489.30	490.2	(XXIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(((3-morpholinopropyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(XXX-3)	C ₂₆ H ₃₅ N ₉	473.30	474.3	(XXIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(((methyl(2-(pyrrolidin-1-yl)ethyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(XXX-4)	C ₂₅ H ₃₃ N ₉	459.29	460.2	(XXIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(((2-(pyrrolidin-1-yl)ethyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(XXX-5)	C ₂₅ H ₃₃ N ₉ O	475.28	476.2	(XXIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(((2-morpholinoethyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(XXX-6)	C ₂₈ H ₃₉ N ₉	501.33	502.2	(XXIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(((methyl(3-(piperidin-1-yl)propyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	

(XXX-7)	C26H31F2N9	507.27	508.2	(XXIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-((3-(3,3-difluoropyrrolidin-1-yl)azetidin-1-yl)methyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	
(XXX-8)	C26H31N9O	485.27	486.2	(XXIX)	1-(1-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)methyl)azetidin-3-yl)pyrrolidin-2-one	
(XXX-9)	C26H35N9O	489.30	490.2	(XXIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((4-(2-methoxyethyl)piperazin-1-yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(XXX-10)	C23H29N9	431.25	432.2	(XXIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((pyrrolidin-3-ylamino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(XXX-11)	C23H29N9	431.25	432.2	(XXIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperazin-1-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine	
(XXX-12)	C24H31N9	445.27	446.2	(XXIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-(((azetidin-3-ylmethyl)(methyl)amino)methyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	

(XXX-13)	C29H40N10O2	560.33	561.3	(XXIX)	N-(2-(2-(((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)methyl)amino)ethoxy)ethyl)-2-(pyrrolidin-1-yl)acetamide	
(XXX-14)	C24H31N9	445.27	446.2	(XXIX)	N-(2-(1H-pyrazol-1-yl)benzyl)-2-((4-aminopiperidin-1-yl)methyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine	

Method P: esters (XXXI) from acid (XXVII)

Compound (XXXI-1): 1-methylpyrrolidin-3-yl 4-((2-(1H-pyrazol-1-yl)benzyl) amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxylate




50 mg (132 μ mol) 8-Isopropyl-4-(2-pyrazol-1-yl-benzylamino)-pyrazolo[1,5-a][1,3,5]triazine-2-carboxylic acid were dissolved in 3 ml methanol. 13 mg (132 μ mol) triethylamine were added and the reaction mixture was stirred at room temperature. After 30 min the mixture was evaporated to dryness. The residue was dissolved in 3 ml dichloromethane. 16 mg (159 μ mol) 3-hydroxy-1-methylpyrrolidine and 76 mg (146 μ mol) benzotriazole-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate were added and the reaction mixture was stirred at room temperature over night. The mixture was dissolved in ethyl acetate, washed with saturated sodium bicarbonate solution and brine. The organic phase was dried and evaporated. The residue was purified on silica gel, eluting with 95/5 chloroform/methanol.

MS (ES) C₂₄H₂₈N₈O₂ requires 460.23, found 461 (M+H)⁺ and 483 (M+Na)⁺.


Method Q: sulfoximines from thioethers

compound (XXXII-1): 8-isopropyl-N-(2-(S-methylsulfonylimidoyl)benzyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine



12 mg (0.023 mmol) intermediate Boc-(VII-152), 5.2 mg (0.046 mmol) F_3CCONH_2 , 6.4 mg (0.09 mmol) MnO , 1.0 mg (0.0023 mmol) rhodium(II) acetate and 11.1 mg (0.035 mmol) (diacetoxyiodo)benzene were stirred in 0.5 ml DCM at 40 °C. After 24 h the mixture was purified on silica gel eluting with a cyclohexane / ethyl acetate gradient. The resulting intermediate was dissolved in methanol and stirred with 20 mg K_2CO_3 at 40 °C for 1 h. The mixture was filtered, and the solvent was removed under reduced pressure. After TFA cleavage of the Boc-protecting group, the crude product was purified by RP-HPLC using a water/acetonitrile (0.1 % TFA) gradient. MS (ES) $C_{21}H_{29}N_7O_2S$ requires 443.21, found 444.32 ($M+H$)⁺.

intermediate (XXXIII): 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-ol




14.6 g (35.5 mmol) of (8-isopropyl-2-methanesulfonyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl)-(2-pyrazol-1-yl-benzyl)-amine and lithium hydroxide (2.55 g, 106.4 mmol) were dissolved in 300 mL aqueous 1,4-dioxane (10:1). The mixture was stirred at 60 °C until total consumption of the starting material and then diluted with water. pH was adjusted to 7 by the addition of 6 M hydrochloric acid, and the resulting mixture was extracted

with dichloromethane. The combined organic layers were washed with brine, dried (MgSO₄) and concentrated. 11.5 g (32.9 mmol) of the title compound were obtained.

¹H-NMR (300 MHz, CDCl₃) δ (ppm): 1.26 (d, J = 6.9 Hz, 6 H), 3.00-3.14 (m, 1 H), 4.73 (d, J = 6.0 Hz, 2 H), 6.52 (t, J = 2.1 Hz, 1 H), 7.33-7.44 (m, 3 H), 7.60 (s, 1 H), 7.76-7.83 (m, 2 H), 7.86 (d, J = 1.7 Hz, 1 H), 8.61 (t, J = 5.6 Hz, 1 H), 11.20 (br s, 1 H); MS (ES) C₁₈H₁₉N₇O requires 349.17, found 350.1 (M+H)⁺.


intermediate (XXXIV): N-(2-(1H-pyrazol-1-yl)benzyl)-2-bromo-8-isopropylpyrazolo [1,5-a][1,3,5]triazin-4-amine



100 mg (286 μmol) 8-Isopropyl-4-(2-pyrazol-1-yl-benzylamino)-pyrazolo[1,5-a][1,3,5] triazin-2-ol were dissolved in 1 ml toluene. 123 mg (429 μmol) phosphorus oxybromide and 85 mg (566 μmol) N,N-diethylaniline were added. The reaction mixture was stirred at 100 °C over night. The mixture was poured in ice. The resulting solution was adjusted to pH 3 with 1 M hydrochloride solution and extracted three times with ethyl acetate. The organic phase was dried and evaporated. The residue was purified on silica gel, eluting with 40/10 cyclohexane/ethyl acetate. 64 mg of the title product were obtained.

MS (ES) C₁₈H₁₈BrN₇ requires 411.08, found 411.9/414.4 (M+H)⁺.

intermediate (XXXV): tert-butyl 2-(1H-pyrazol-1-yl)benzyl(2-bromo-8-isopropyl pyrazolo[1,5-a][1,3,5]triazin-4-yl)carbamate




225 mg (546 μ mol) of intermediate (XXXIV) were dissolved in 3.5 ml THF. 14 mg (105 μ mol) DMAP and 155 mg (708 μ mol) di-tert-butyl dicarbonate were added and the mixture was stirred at room temperature over night. The reaction mixture was dissolved in ethyl acetate and washed with water and brine. The organic phase was dried and

5 evaporated. The residue was purified on silica gel, eluting with chloroform. 83 mg of the title product were obtained.

MS (ES) C₂₃H₂₆BrN₇O₂ requires 511.13, found 512.1/ 514.0 (M+H)⁺.

Method R: Cross coupling reactions with bromide (XXXV)

10 **compound (XXXVI-1): N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine**



12 mg (61 μ mol) N-Boc-3-methylenepiperidine and 120 μ l 9-borabicyclo[3.3.1]nonane were added into a flask and refluxed for 7 h. 30 mg (59 μ mol) of intermediate (XXXV) were dissolved in 1 ml DMF and 50 μ l water. 5 mg (3 μ mol) 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride and 11 mg (77 μ mol) potassium carbonate were added. To this solution the above prepared solution was added and the mixture was stirred at 60 °C for 2.5 h. The reaction mixture was

20 quenched with water and adjusted to pH 11 with 1 N NaOH. It was extracted three times with ethyl acetate. The organic phase was washed three times with water and once with brine. The organic phase was dried and evaporated. The residue was purified on silica gel, eluting with 50/50 cyclohexane/ ethyl acetate. 21 mg of the title compound (XXXVI-1) were obtained.

25 MS (ES) C₃₄H₄₆N₈O₄ requires 630.36, found 631.2 (M+H)⁺.

21 mg of the Boc-protected intermediate were dissolved in 500 μ l dichloromethane at 0 °C. 10 equivalents trifluoroacetic acid were added. The reaction mixture was stirred over night. The reaction mixture was evaporated and the residue was purified on silica gel, eluting with 19/1 chloroform/methanol.

30 MS (ES) C₂₄H₃₀N₈ requires 430.26, found 431.3 (M+H)⁺.

Results:**1. Measurement of Binding Affinities to CDKs**

This protocol describes how the Lance Kinase Activity Assay was performed to determine IC₅₀ values of compounds of general formula (I) against CDK/Cyclin complexes. The principle behind this enzymatic assay is based upon the phosphorylation of the ULight-Peptide Substrat. It is detected by using a specific EU-labeled anti-phospho peptide antibody. The binding of the Eu labeled anti-phospho peptide antibody to the phosphorylated ULight® labeled peptide gives rise to a FRET-signal.

Binding of an inhibitor to the kinase prevents phosphorylation of the Ulight-MBP Substrat, resulting in a loss of FRET.

CDK2 Enzymatic Activity Assay**Table 2:** Reagents, stock concentrations and final assay concentrations

Reagents	Stock concentration	Working concentration	Final assay concentration	Supplier
ULight MBP substrate	5 µM	83.33 nM	50 nM	PerkinElmer
Eu-Anti-P-MBP Antibody (AB)	625 nM	4nM	2 nM	PerkinElmer
CDK2 /CycA (135kDa)	2.02 µM	8,33 nM	5 nM	Proqinase
ATP	100mM	15µM	3 µM	Sigma

The compounds of general formula (I) exemplary summarized in Table 1 were diluted from a 10 mM DMSO stock solution 1:10 in a total volume of 15 µl DMSO. This compound predilution was then serial diluted 1:3 over 8 steps in DMSO and briefly spun down. Each compound solution was now diluted 1:20 in Enzymatic Buffer (HEPES: 50 mM, pH: 7.5; MgCl₂: 10 mM; EGTA: 1 mM; DTT: 2mM; Tween®-20: 0.01%), mixed thoroughly and spun down.

For every sample, 2 µl of the diluted compound were mixed with 6 µl CDK2/CycA/substrate working solution (8.33 nM CDK2/CycA; 83.33 nM ULight MBP substrate in enzymatic buffer) and 2 µl ATP working solution (15 µM ATP in enzymatic buffer) in a well of a small volume 384 well plate (Corning Incorporated, Corning, NY, USA; order no. 3673). For negative controls, in each well 2 µl of DMSO working solution (5% DMSO diluted in enzymatic buffer) was mixed with 6 µl substrate working

solution (83.33 nM ULightMBP substrate in enzymatic buffer) and 2 μ l ATP working solution. For positive controls, 2 μ l of DMSO working solution were mixed with 6 μ l CDK2/CycA/substrate working solution and 2 μ l ATP working solution. Positive and negative controls were calculated from at least 8 different wells. The 384 well plates were mixed in a Teleshaker plate mixer (Beckman Coulter, Brea, CA, USA) at 2000 rpm for 40 sec, and incubated for 1h at room temperature before addition of 10 μ l LANCE Detection Buffer (EDTA: 20nM; Eu-Anti-P-MBP: 4nM) per well. Plates were mixed in a Teleshaker plate mixer (Beckman Coulter, Brea, CA, USA) at 2000 rpm for 40 sec, followed by incubation with Detection Buffer for 1 h, and reading. The FRET signal was measured at 340 nm excitation, 665 nm and 615 nm emission (for the ULight MBP substrate and LanthaScreen Eu-AB, respectively) with an Envision spectrophotometer (Perkin Elmer, Waltham, MA, USA) with 90 μ s delay and 20 μ s integration time. IC₅₀ values were determined from the sigmoidal dose response curves with the software Quattro Workflow (Quattro GmbH, Munich, Germany). In case of tight binding of the inhibitors to CDK2/CycA, final assay concentrations were adjusted to 0,25 nM Eu-Anti-MBP AB, 2 nM CDK2 /CycA and 30 μ M ATP, and IC₅₀ values were converted according to the Cheng Prusoff equation to the IC₅₀ values at the original ATP-concentration.

Results are presented in Tables 5, 6 and 7.

CDK7 Enzymatic Activity Assay

Table 3: Reagents, stock concentrations and final assay concentrations

Reagents	Stock concentration	Working concentration	Final assay concentration	Supplier
ULight MBP substrate	5 μ M	83.33 nM	50 nM	PerkinElmer
Eu-Anti-P-MBP AB	625 nM	4nM	2 nM	PerkinElmer
CDK7 /CycH/Mat1 143,2kDa)	1,39 μ M	16.66 nM	10 nM	Carna
ATP	100mM	125 μ M	25 μ M	Sigma

The compounds of general formula (I) exemplary summarized in Table 1 were diluted from a 10 mM DMSO stock solution 1:10 in a total volume of 15 μ l DMSO. This compound predilution was then serial diluted 1:3 over 8 steps in DMSO and briefly spun down. Each compound solution was now diluted 1:20 in Enzymatic Buffer (HEPES: 50 mM, pH: 7.5; MgCl₂: 10 mM; EGTA: 1 mM; DTT: 2mM; Tween®-20: 0.01%), mixed thoroughly and spun down.

For every sample, 2 μ l of the diluted compound were mixed with 6 μ l CDK7 /CycH/Mat1/substrate working solution (16.66 nM CDK7 /CycH/Mat1; 83.33 nM ULight MBP substrate in enzymatic buffer) and 2 μ l ATP working solution (125 μ M ATP in enzymatic buffer) in a well of a small volume 384 well plate (Corning Incorporated, Corning, NY, USA; order no. 3673). For negative controls, in each well 2 μ l of DMSO working solution (5% DMSO diluted in enzymatic buffer) was mixed with 6 μ l substrate working solution (83.33 nM ULightMBP substrate in enzymatic buffer) and 2 μ l ATP working solution. For positive controls, 2 μ l of DMSO working solution were mixed with 6 μ l CDK7/CycH/Mat1/substrate working solution and 2 μ l ATP working solution. Positive and negative controls were calculated from at least 8 different wells. The 384 well plates were mixed in a Teleshaker plate mixer (Beckman Coulter, Brea, CA, USA) at 2000 rpm for 40 sec, and incubated for 1h at room temperature before addition of 10 μ l LANCE Detection Buffer (1X; EDTA: 20nM; Eu-Anti-P-MBP: 4nM) per well. Plates were mixed in a Teleshaker plate mixer (Beckman Coulter, Brea, CA, USA) at 2000 rpm for 40 sec, followed by incubation with Detection Buffer for 1 h, and reading. The FRET signal was measured at 340 nm excitation, 665 nm and 615 nm emission (for the ULight MBP substrate and LanthaScreen Eu-AB, respectively) with an Envision spectrophotometer (Perkin Elmer, Waltham, MA, USA) with 90 μ s delay and 20 μ s integration time. IC₅₀ values were determined from the sigmoidal dose response curves with the software Quattro Workflow (Quattro GmbH, Munich, Germany). In case of tight binding of the inhibitors to CDK7/CycH/Mat1, final assay concentrations were adjusted to 2 nM Eu-Anti-MBP AB, 10 nM CDK7/CycH/Mat1 and 250 μ M ATP; or 2 nM Eu-Anti-MBP AB, 3 nM CDK7/CycH/Mat1 and 2500 μ M ATP, and IC₅₀ values were converted according to the Cheng Prusoff equation to the IC₅₀ values at the original ATP-concentration.

Results are presented in Tables 5, 6 and 7.

CDK9 Enzymatic Activity Assay

Table 4: Reagents, stock concentrations and final assay concentrations

Reagents	Stock concentration	Working concentration	Final assay concentration	Supplier
ULight MBP substrate	5 μ M	83.33 nM	50 nM	PerkinElmer
Eu-Anti-P-MBP AB	625 nM	4nM	2 nM	PerkinElmer
CDK9 /Cyclin T1 (131,7 kDa)	2,67 μ M	16.66 nM	10 nM	Invitrogen
ATP	100mM	125 μ M	25 μ M	Sigma

The compounds of general formula (I) exemplary summarized in Table 1 were diluted from a 10 mM DMSO stock solution 1:10 in a total volume of 15 μ l DMSO. This compound predilution was then serially diluted 1:3 over 8 steps in DMSO and briefly spun down. Each compound solution was now diluted 1:20 in Enzymatic Buffer (HEPES: 50 mM, pH: 7.5; $MgCl_2$: 10 mM; EGTA: 1 mM; DTT: 2mM; Tween®-20: 0.01%), mixed thoroughly and spun down.

For every sample, 2 μ l of the diluted compound were mixed with 6 μ l CDK9 /Cyclin T1/substrate working solution (16.66 nM CDK9/cyclin T1; 83.33 nM ULight MBP substrate in enzymatic buffer) and 2 μ l ATP working solution (125 μ M ATP in enzymatic buffer) in a well of a small volume 384 well plate (Corning Incorporated, Corning, NY, USA; order no. 3673). For negative controls, in each well 2 μ l of DMSO working solution (5% DMSO diluted in enzymatic buffer) was mixed with 6 μ l substrate working solution (83.33 nM ULightMBP substrate in enzymatic buffer) and 2 μ l ATP working solution. For positive controls, 2 μ l of DMSO working solution were mixed with 6 μ l CDK9/cyclin T1/substrate working solution and 2 μ l ATP working solution. Positive and negative controls were calculated from at least 8 different wells. The 384 well plates were mixed in a Teleshaker plate mixer (Beckman Coulter, Brea, CA, USA) at 2000 rpm for 40 sec, and incubated for 1h at room temperature before addition of 10 μ l LANCE Detection Buffer (1X; EDTA: 20nM; Eu-Anti-P-MBP: 4nM) per well. Plates were mixed in a Teleshaker plate mixer (Beckman Coulter, Brea, CA, USA) at 2000 rpm for 40 sec, followed by incubation with Detection Buffer for 1 h, and reading. The FRET signal was measured at 340 nm excitation, 665 nm and 615 nm emission (for the ULight MBP substrate and Lanthascreen Eu-AB, respectively) with an Envision spectrophotometer (Perkin Elmer, Waltham, MA, USA) with 90 μ s delay and 20 μ s integration time. IC_{50} values were determined from the sigmoidal dose response curves with the software Quattro Workflow (Quattro GmbH, Munich, Germany). Results are presented in Tables 5A, 5B, 6 and 7.

For evaluating the CDK7 inhibitory activity of the compounds of the present invention the following ranges for the IC_{50} [nM] were applied:

$IC_{50} \leq 5$ nM	+++
5 nM < $IC_{50} \leq 10$ nM	++
10 nM < $IC_{50} \leq 25$ nM	+
$IC_{50} > 25$ nM	o

Table 5A: CDK7 inhibitory activity of the compounds of general formula (I):

Comp.	CDK7	Comp.	CDK7	Comp.	CDK7
(VII-01)	+++	(VII-26)	+++	(VIII-055)	o
(VII-02)	+++	(VII-27)	+++	(VIII-06)	+++
(VII-03)	+++	(VII-28)	+++	(VIII-07)	+++
(VII-04)	+++	(VII-29)	+++	(VIII-08)	++
(VII-05)	+++	(VII-30)	+++	(VIII-09)	++
(VII-058)	o	(VII-31)	+++	(VIII-10)	++
(VII-06)	+++	(VII-32)	+++	(VIII-11)	+++
(VII-07)	+++	(VII-33)	+++	(VIII-12)	+++
(VII-08)	++	(VII-34)	+++	(VIII-13)	++
(VII-09)	+++	(VII-35)	+++	(VIII-14)	+
(VII-092)	+	(VII-36)	+++	(VIII-15)	+
(VII-093)	o	(VII-37)	+++	(VIII-16)	+++
(VII-095)	o	(VII-38)	+++	(VIII-17)	+++
(VII-096)	+++	(VII-39)	+++	(VIII-18)	+++
(VII-097)	o	(VII-40)	o	(VIII-19)	+++
(VII-098)	+	(VII-41)	+++	(VIII-20)	+++
(VII-099)	+++	(VII-42)	+++	(VIII-21)	++
(VII-10)	+++	(VII-43)	+++	(VIII-22)	+++
(VII-100)	+++	(VII-44)	+++	(VIII-23)	+++
(VII-103)	+	(VII-45)	+++	(VIII-24)	+++
(VII-104)	+++	(VII-46)	+++	(VIII-25)	+++
(VII-105)	o	(VII-47)	+++	(VIII-26)	++
(VII-106)	+++	(VII-48)	+++	(VIII-27)	++

(VII-107)	+++	(VII-49)	+++	(VIII-28)	+++
(VII-108)	+++	(VII-50)	+++	(VIII-31)	++
(VII-109)	+	(VII-51)	+++	(VIII-32)	++
(VII-11)	++	(VII-52)	+++	(VIII-33)	+++
(VII-110)	+++	(VII-53)	++	(VIII-34)	+++
(VII-111)	+	(VII-54)	++	(VIII-35)	+++
(VII-112)	++	(VII-55)	+	(VIII-36)	+++
(VII-113)	+	(VII-56)	++	(VIII-37)	+++
(VII-114)	+++	(XXX-8)	o	(VIII-38)	+++
(VII-115)	o	(VII-58)	+	(X-1)	+++
(VII-116)	+	(VII-59)	+++	(X-2)	+++
(VII-117)	o	(VII-60)	o	(X-3)	+
(VII-118)	++	(VII-61)	++	(X-4)	+++
(VII-119)	o	(VII-62)	+	(X-5)	+++
(VII-12)	+++	(VII-63)	+	(X-7)	+++
(VII-120)	++	(VII-64)	++	(X-8)	+++
(VII-121)	+++	(VII-65)	+++	(X-9)	+
(VII-122)	+	(VII-66)	+++	(XII-06)	o
(VII-123)	+++	(XXX-2)	o	(XII-07)	o
(VII-124)	o	(XXX-9)	o	(XII-1)	+++
(VII-13)	+++	(VII-69)	+++	(XII-10)	o
(VII-14)	+++	(VII-70)	+++	(XII-2)	+++
(VII-141)	+	(XXX-4)	o	(XII-3)	+++
(VII-142)	o	(VII-72)	+++	(XXX-7)	o
(VII-143)	+	(VII-73)	+++	(XII-5)	+++
(VII-145)	+	(VIII-053)	o	(XII-8)	o

(VII-146)	+	(VII-75)	+++	(XII-9)	o
(VII-147)	++	(VII-76)	+++	(VII-71)	+++
(VII-148)	+++	(VIII-01)	+++	(XXX-3)	o
(VII-149)	+	(VIII-052)	o	(VII-68)	+++
(VII-15)	+++	(VIII-039)	o	(XXX-5)	o
(VII-151)	+++	(VIII-04)	+	(VIII-05)	+++
(VII-152)	+	(VIII-040)	o	(XXX-6)	o
(VII-153)	+	(VIII-041)	o	(VII-20)	+++
(VII-154)	+++	(VIII-043)	++	(VIII-054)	o
(VII-16)	+++	(VIII-044)	o	(VII-57)	+++
(VII-17)	+++	(VIII-045)	+	(VIII-051)	++
(VII-18)	+++	(VIII-046)	o	(VIII-02)	+++
(VII-19)	+++	(VIII-047)	o	(VIII-03)	+++
(XXX-4)	o	(VIII-048)	+	(VII-25)	+++
(VII-21)	+++	(VIII-049)	o	(VII-74)	+++
(VII-22)	+++	(XII-4)	+++	(VII-67)	+++
(VII-23)	+++	(VIII-050)	+	(VII-24)	+++

Comp.: Compound

CDK7: IC₅₀ [nM] for CDK7 inhibition (the above defined ranges apply)

5

Correspondingly, for evaluating the simultaneous CDK2 and CDK9 selectivities the following ranges for IC₅₀ [nM] were applied:

10

IC ₅₀ ≤ 50 nM	o
50 nM < IC ₅₀ ≤ 500 nM	+
500 nM < IC ₅₀ ≤ 2500 nM	++
IC ₅₀ > 2500 nM	+++

Table 5B: CDK7 selectivity of the compounds of general formula (I):

Comp.	CDK2	CDK9	Comp.	CDK2	CDK9
(VII-104)	+	+++	(VII-10)	+++	++
(VII-148)	+	+	(VII-11)	++	++
(VII-154)	+	+++	(VII-12)	o	+
(VII-100)	+	+	(VII-13)	+	++
(VII-121)	+++	+++	(VII-14)	+	++
(VII-107)	+	+++	(VII-15)	+++	+++
(X-8)	+	+++	(VII-16)	++	+++
(VII-096)	+	++	(VII-17)	+++	+++
(VII-099)	++	+++	(VII-18)	+	++
(VII-106)	+	+++	(VII-19)	+++	++
(VII-108)	+	+++	(VII-20)		++
(VII-110)	+++	+++	(VII-21)	o	++
(VII-114)	+++	+++	(VII-22)	+	++
(VII-151)	++	+++	(VII-23)	++	++++
(X-7)	+++	+++	(VII-24)	+++	+++
(VII-123)	+	+++	(VII-25)		+++
(VII-147)	+	+++	(VII-26)	+	+
(VIII-051)	++	+++	(VII-27)	+	+
(VIII-043)	+	+++	(VII-28)	+++	+++
(VII-112)	+++	+++	(VII-29)	+	+++
(VII-120)	+	+++	(VII-30)	++	o
(VII-118)	+	+	(VII-31)	+	o
(VII-146)	+++	+++	(VII-32)	+	+

(VIII-050)	+++	+++	(VII-33)	o	o
(VII-145)	++	++	(VII-34)	+	++
(VIII-045)	+++	+++	(VII-35)	+	+
(VIII-048)	+++	+++	(VII-36)	o	o
(VII-116)	+	++	(VII-37)	o	+++
(VII-092)	+++	+++	(VII-38)	+	++
(VII-098)	++	+++	(VII-39)	+	+++
(VII-141)	++	+++	(VII-40)	+++	+++
(VII-153)	+++	+++	(VII-41)	o	+
(VII-152)	+	++	(VII-42)	o	+
(VII-143)	++	++	(VII-43)	o	+
(VII-103)	+	+	(VII-44)	+	+++
(VII-113)	+++	+++	(VII-45)		+++
(VII-111)	+++	++	(VII-46)		+++
(X-9)	+++	+++	(VII-51)	o	++
(VII-109)	+++	+++	(VII-52)	+	+
(VII-149)	+++	+++	(VII-53)	+++	+
(VII-122)	++	+++	(VII-54)	+++	+
(VII-105)		+++	(VII-55)	+++	+++
(XII-07)	+++	+++	(VII-56)	++	+
(VIII-053)	+++	+++	(VII-57)	+++	+++
(VIII-049)	+++	+++	(VII-58)	o	+++
(VII-117)	+++	+++	(VII-59)	+++	+++
(VII-142)	+++	+++	(VII-60)	+++	+++
(VII-097)	+++	+++	(VII-61)	++	+
(VIII-039)	+++	+++	(VII-62)	+++	+++

(VIII-052)	+++	+++	(VII-63)	+++	+++
(XII-06)	++	+++	(VII-64)	+++	+
(VIII-054)	+++	+++	(VII-65)	+	+++
(VIII-046)	+++	+++	(VII-66)	+++	+++
(VII-095)	+++	+++	(VII-67)	+++	+++
(XII-8)	+++	+++	(VII-68)	+	+
(VII-119)	++	+++	(VII-69)	+++	+++
(VIII-044)	+++	+++	(VII-70)	+++	+++
(XXX-4)	+++	+++	(VII-71)	+	+
(VIII-055)	+++	+++	(VII-72)	+	+
(VIII-040)	+++	+++	(VII-73)	++	+++
(XXX-3)	+++	+++	(VII-74)	+	+++
(XII-10)	+++	+++	(VII-75)	+++	+++
(XXX-9)	+++	+++	(VII-76)	+++	+
(VIII-047)	+++	+++	(VIII-01)	+	+++
(VII-124)	+++	+++	(VIII-02)	+++	+++
(VII-093)	+++	+++	(VIII-03)	+++	+++
(XXX-6)	+++	+++	(VIII-04)	+++	+++
(XII-9)	+++	+++	(VIII-05)	+++	+++
(XXX-5)	+++	+++	(VIII-06)	+++	+++
(XXX-4)	+++	+++	(VIII-07)	+++	+++
(XXX-2)	+++	+++	(VIII-08)	+++	+++
(XXX-7)	+++	+++	(VIII-09)	+++	+++
(XXX-8)	+++	+++	(VIII-10)	+++	+++
(VII-115)	+++	+++	(VIII-11)	++	+++
(VII-058)	+++	+++	(VIII-12)	+++	+++

(VIII-041)	+++	+++	(VIII-13)	+++	+++
(VII-01)	+	+++	(VIII-14)	+++	+++
(VII-02)	o	++	(VIII-15)	+++	+++
(VII-03)	o	+	(VIII-16)	+++	+++
(VII-05)	+++	+++	(VIII-17)	++	+++
(VII-06)	+++	+	(VIII-18)	+++	+++
(VII-07)	++	+	(VIII-19)	+++	+++
(VII-08)	++	++	(VIII-20)	+++	+++
(VII-09)	+++	+++	(VIII-21)	++	+++
(X-3)	++	+++	(VIII-22)	+++	+++
(X-4)	+	++	(VIII-23)	++	++
(X-5)	++	+++	(VIII-24)	+	++
(XII-1)	+++	+++	(VIII-25)	+	++
(XII-2)	+++	+++	(VIII-26)	+++	+++
(XII-3)	+++	+++	(VIII-27)	+++	+++
(XII-4)	+++	+++	(VIII-28)	+++	+++
(XII-5)	+++	+++	(VIII-31)	+++	+++
(VIII-36)	+++	++	(VIII-32)	++	+++
(VIII-37)	+++	+++	(VIII-33)	o	++
(VIII-38)	+++	+++	(VIII-34)	+++	+++
(X-1)	+	++	(VIII-35)	+++	+++
(X-2)	+	+			


Comp.: Compound

CDK2: Selectivity of CDK7 inhibition over CDK2 inhibition [fold]

5 CDK9: Selectivity of CDK7 inhibition over CDK9 inhibition [fold]

Comparative Examples:

- 5 In order to show the surprising effects of the compounds of the present invention the Comparative Examples C-I and C-II, wherein according to the compounds of the general formula (I) $R^3 = H$, have been tested in the enzymatic activity assays for CDK2, CDK7 and CDK9 as described above.
- 10 C-I and C-II have the following structural formulae:



- 15 The selectivity results of Comparable Examples C-I and C-II are directly comparable to the compounds of the present invention as summarized in Table 5. While all compounds show potency against CDK-7, only the compounds of the present invention do not significantly inhibit also CDK-2 and CDK-9. Therefore, the compounds of the present invention can selectively inhibit CDK-7. The degree of selectivity is demonstrated in Table 6 by the multiplicity of the CDK2 and CDK9 activity in terms of the CDK7 activity. For example, while C-I only shows a 9-fold CDK7 activity for CDK2 and a 14-fold CDK7 activity for CDK9 indicating that C-I rather inhibits all three CDK inhibitors, the compounds of the present invention selectively inhibit only CDK7 while the activities for CDK2 and CDK 9 are tremendously higher (up to over the 9000-fold activity of the CDK7 activity).
- 20
- 25

- Also, members of the CDK family have been validated as targets in cancer and inflammatory disease as well as in HIV-1 treatment. However, first generation CDK-inhibitors (Flavopiridol, Roscovitine, SNS-032) do typically inhibit more than one member of the CDK family. Such non specific-CDK inhibitors are meanwhile known for their toxicities and small therapeutic windows in clinical trials. Indeed, knockdown of multiple CDKs is lethal in a variety of model organisms, whereas knockdown of single CDKs is frequently tolerated; indicating that inhibition of single CDKs is less toxic.
- 30

Therefore, the main goal in the field of CDK-inhibition is the optimization for selective small-molecule based CDK-inhibitors.

As becomes apparent from Table 7 below first generation CDK-inhibitors generally do not show satisfactory CDK7 inhibition in comparison to the compounds of the present invention, nor do they show any significant effect that CDK 2 or CDK 9 are not inhibited simultaneously. This could at best be addressed for BS-181, however the comparative CDK 7 inhibition is poor and the CDK 2 and CDK 9 inhibition is far below a hundred-fold activity of the CDK 7 activity. In case of SNS-032 and Flavopiridol the CDK 2 and CDK 9 activities are even lower than the CDK 7 activity.

Table 6: Comparison of activity and selectivity to Comparative Examples **C-I** and **C-II**:


Compound	Selectivity CDK7 over CDK2 [fold]	IC50 [nM] CDK7	Selectivity CDK7 over CDK9 [fold]
C-I	9	+++	14
(VII-70)	183	+++	992
(VII-57)	270	+++	909
(VII-59)	3926	+++	9140
C-II	14	+++	18
(VII-29)	394	+++	3255

Table 7: Comparison of activity and selectivity to **state of the art** CDK-inhibitors:


Compound	IC50 [nM] CDK2	IC50 [nM] CDK7	IC50 [nM] CDK9
SNS-032	o	o	o
Flavopiridol	+	o	o
BS-181	+++	o	+++
(VII-38)	+	+++	++
(VII-51)	o	+++	++

	Selectivity CDK7 over CDK2 [fold]	IC50 [nM] CDK7	Selectivity CDK7 over CDK9 [fold]
SNS-032	0.1125	o	0.089
Flavopiridol	0.212	o	0.064
BS-181	56	o	33
(VII-38)	342	+++	2733
(VII-51)	54	+++	2277

The herein tested state of the art compounds have the following structural formulae:




BS-181



SNS-032


and



Flavopiridol

Claims

1. Compound of the general formula (I)



wherein

R^1 represents $-H$ or $-CH_3$;

R^2 represents $-R^8$, $-Q-R^8$, $-R^9$, $-Q-(CH_2)_n-R^9$, $-(CH_2)_n-R^9$, $-(CH_2)_n-NH-R^8$, $-(CH_2)_m-NH-(CH_2)_n-R^9$, $-CO-NH-(CH_2)_n-NH_2$, $-CO-NH-(CH_2)_n-R^9$, $-CO-R^9$, $-SO-R^9$, $-(CH_2)_n-NR^{10}-R^8$, $-(CH_2)_m-NR^{10}-(CH_2)_n-R^9$, $-CO-NR^{10}-(CH_2)_n-R^9$, $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-(CH_2)_g-R^8$, $-(Q)_b-(CH_2)_m-(G^1)_d-(CH_2)_e-R^8$, $-(Q)_b-(CH_2)_m-(G^1)_d-(CH_2)_n-R^9$, $-(CH_2)_a-(Q)_b-(CH_2)_c-(G^1)_d-(CH_2)_e-(G^2)_f-CH_2-R^9$, $-Q-R^{10}$, $-Q-CH(COOR^{10})-R^8$, $-Q-CH(R^{10})-R^8$, $-(CH_2)_n-OH$, $-CHO$, or $-OH$;

R^3 represents

- i) $-OH$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-I$, $-CN$, $-OR^{11}$, $-CO-O-R^{11}$, $-NR^{11}-CO-OR^{12}$, $-NHR^{11}$, $-NR^{11}R^{12}$, $-CONR^{11}R^{12}$, $-O-CO-NR^{11}R^{12}$, $-O-CO-OR^{11}$, $-CH_3$, $-NR^{11}-CO-NR^{12}R^{13}$, $-SO_2NR^{11}R^{12}$, $-C(=NR^{11})-NR^{12}R^{13}$, $-C(R^{12})=NR^{11}$, $-N=CR^{11}R^{12}$, $-N=S(=O)R^{11}R^{12}$, $-CR^{11}R^{12}R^{13}$, $-CR^{11}=CR^{12}R^{13}$, $-C\equiv CR^{11}$, $-NR^{11}-C(=NR^{12})-NR^{13}R^{14}$, $-SR^{11}$, $-S(=O)R^{11}$, $-NR^{11}-S(=O)R^{12}$, $-O-S(=O)R^{11}$, $-SO_2-R^{11}$, $-NR^{11}-SO_2-R^{12}$, $-O-SO_2-R^{11}$, $-SO(=NR^{11})-R^{12}$, $-CO-R^{11}$, $-O-CO-R^{11}$, $-NR^{11}-CO-R^{12}$, $-CH_2F$, $-CHF_2$, or $-CF_3$,

- ii) linear or branched C₁–C₈–alkyl, C₃–C₈–cycloalkyl, C₁–C₉–heterocyclyl, linear or branched C₂–C₈–alkenyl, linear or branched C₂–C₈–alkynyl, C₆–C₁₄–aryl, or C₁–C₁₀–heteroaryl, wherein the afore-mentioned residues can be substituted with 1 to 5 substituents selected from Z⁸, Z⁹, Z¹⁰, Z¹¹ or Z¹²,
- iii) 3-membered heterocyclyl, 4-membered heterocyclyl, 5-membered heterocyclyl, 6-membered heterocyclyl, monounsaturated 4-membered heterocyclyl, monounsaturated 5-membered heterocyclyl, monounsaturated 6-membered heterocyclyl, 3-membered carbocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, 6-membered carbocyclyl, 6-membered aryl, 5-membered heteroaryl, or 6-membered heteroaryl,

wherein all afore-mentioned ring systems can be substituted with 1 to 4 substituents selected from Z¹, Z², Z³ and Z⁴;

Z¹ and Z² if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z¹ and Z² are attached;

R³ together with **R⁴** can form a carbocyclic or heterocyclic 4-, 5-, 6- or 7-membered ring with the two carbon atoms of the benzo ring to which **R³** and **R⁴** are attached and that 4-, 5-, 6- or 7-membered ring can be partly saturated or unsaturated and can be substituted with 1 to 4 substituents selected from Z¹, Z², Z³ and Z⁴;

Z¹ and Z² if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z¹ and Z² are attached;

R⁴ – R⁷ represent independently of each other –H, –F, –Cl, or –CH₃;

R⁸ represents –(CH₂)_p–NH₂, –(CH₂)_p–N(R¹⁶R¹⁷), carbocyclyl, heterocyclyl, spirocarbocyclyl, or spiroheterocyclyl, wherein the afore-mentioned carbocyclyl, heterocyclyl, spirocarbocyclyl and spiroheterocyclyl residues are linked through a ring carbon atom and can be substituted with 1 to 3 substituents selected from Z⁵, Z⁶ and Z⁷;

Z⁵ and Z⁶ if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z⁵ and Z⁶ are attached;

R⁹ represents –R⁸, nitrogenheterocyclyl, or spironitrogencyclyl, wherein the afore-mentioned nitrogenheterocyclyl and spironitrogencyclyl residues are linked through a ring nitrogen atom and can be substituted with 1 to 3 substituents selected from Z⁵, Z⁶ and Z⁷;


Z^5 and Z^6 if attached to the same carbon atom can together represent =O to form a carbonyl group with the carbon atom to which Z^5 and Z^6 are attached;

R^{11} , R^{12} , R^{13} , R^{14} and R^{15} represent independently of each other
 5 $-H$, linear or branched C_1-C_8 -alkyl, C_3-C_8 -cycloalkyl, C_1-C_9 -heterocyclyl,
 linear or branched C_2-C_8 -alkenyl, linear or branched C_2-C_8 -alkynyl, C_6-C_{14} -
 aryl, or C_1-C_{10} -heteroaryl,
 wherein the afore-mentioned residues can be substituted with 1 to 5 substituents
 selected from Z^8 , Z^9 , Z^{10} , Z^{11} and Z^{12} ;

10 R^{11} together with R^{12} can form a carbocyclic or heterocyclic 4-, 5- or 6-membered
 ring and that 4-, 5- or 6-membered ring can be saturated or unsaturated and can be
 substituted with 1 to 8 substituents selected from Z^8 , Z^9 , Z^{10} , Z^{11} , Z^{12} , Z^{13} , Z^{14} and
 Z^{15} ;

15 Z^8 and Z^9 if attached to the same carbon atom can together represent =O to form a
 carbonyl group with the carbon atom to which Z^8 and Z^9 are attached;


R^{10} , R^{16} and R^{17} represent independently of each other
 $-H$, $-CH_3$, $-C_2H_5$, $-C_3H_7$, $-CH(CH_3)_2$, $-CH_2F$, $-CHF_2$, $-CF_3$,



20 , cyclo- C_3H_5 , cyclo- C_4H_7 , cyclo- C_5H_9 , cyclo- C_6H_{11} , cyclo- C_7H_{13} ,
 $-C_4H_9$, $-CH_2-CH(CH_3)_2$, $-CH(CH_3)-C_2H_5$, $-C(CH_3)_3$, $-C_5H_{11}$, $-CH(CH_3)-C_3H_7$,
 $-CH_2-CH(CH_3)-C_2H_5$, $-CH(CH_3)-CH(CH_3)_2$, $-C(CH_3)_2-C_2H_5$, $-CH_2-C(CH_3)_3$,
 $-CH(C_2H_5)_2$, $-C_2H_4-CH(CH_3)_2$, $-C_6H_{13}$, $-C_7H_{15}$, $-C_8H_{17}$, $-Ph$, $-CH_2-Ph$,
 $-CH_2-CH_2-Ph$, $-CH_2-CH=CH_2$, $-C(CH_3)=CH_2$, $-C_2H_4-CH=CH_2$,
 $-CH_2-CH=CH-CH_3$, $-CH_2-C(CH_3)=CH_2$, $-CH(CH_3)-CH=CH_2$,
 25 $-C(CH_3)=CH-CH_3$, $-CH_2-C\equiv CH$, $-C_2H_4-C\equiv CH$, $-CH_2-C\equiv C-CH_3$,
 $-C_2H_4-OCF_3$, $-C_3H_6-OCF_3$, $-C_2H_4-OCH_3$, $-C_3H_6-OCH_3$, $-C_2H_4-OC_2H_5$, or
 $-C_3H_6-OC_2H_5$;


30 Q , G^1 , and G^2 represent independently of each other $-O-$, $-S-$, $-NR^{15}-$, $-$
 $SO-$, $-NR^{15}-SO-$, $-SO-NR^{15}-$, $-SO_2-$, $-O-SO_2-$, $-SO_2-O-$, $-SO_2-$
 $NR^{15}-$, $-NR^{15}-SO_2-$, $-O-CO-$, $-O-CO-O-$, $-CO-$, $-CO-NR^{15}-$, $-NR^{15}-$
 $CO-$, $-NR^{15}-CO-NR^{15}-$, $-NR^{15}-CO-O-$, $-O-CO-NR^{15}-$, $-CO-O-$,
 $-(CH_2)_m-NR^{15}-$, bridging carbocyclyl, bridging heterocyclyl, bridging
 35 spirocarbocyclyl, or bridging spiroheterocyclyl;


$Z^1 - Z^{15}$ represent independently of each other



cyclo-C₃H₅, cyclo-C₄H₇, cyclo-C₅H₉, cyclo-C₆H₁₁, cyclo-C₇H₁₃,

-H, -OH, -OCH₃, -OC₂H₅, -OC₃H₇, -O-cyclo-C₃H₅, -OCH(CH₃)₂,
 -OC(CH₃)₃, -OC₄H₉, -OPh, -OCH₂-Ph, -OCPh₃, -CH₂-OCH₃, -C₂H₄-
 OCH₃, -C₃H₆-OCH₃, -CH₂-OC₂H₅, -C₂H₄-OC₂H₅, -C₃H₆-OC₂H₅, -CH₂-
 5 OC₃H₇, -C₂H₄-OC₃H₇, -C₃H₆-OC₃H₇, -CH₂-O-cyclo-C₃H₅, -C₂H₄-O-cyclo-
 C₃H₅, -C₃H₆-O-cyclo-C₃H₅, -CH₂-OCH(CH₃)₂, -C₂H₄-OCH(CH₃)₂, -C₃H₆-
 OCH(CH₃)₂, -CH₂-OC(CH₃)₃, -C₂H₄-OC(CH₃)₃, -C₃H₆-OC(CH₃)₃, -CH₂-
 OC₄H₉, -C₂H₄-OC₄H₉, -C₃H₆-OC₄H₉, -CH₂-OPh, -C₂H₄-OPh, -C₃H₆-OPh,
 -CH₂-OCH₂-Ph, -C₂H₄-OCH₂-Ph, -C₃H₆-OCH₂-Ph, -SH, -SCH₃, -SC₂H₅,
 10 -SC₃H₇, -S-cyclo-C₃H₅, -SCH(CH₃)₂, -SC(CH₃)₃, -F, -Cl, -Br, -I, -CN,
 -COCH₃, -COC₂H₅, -COC₃H₇, -CO-cyclo-C₃H₅, -COCH(CH₃)₂,
 -COC(CH₃)₃, -COOH, -COOCH₃, -COOC₂H₅, -COOC₃H₇, -COO-cyclo-
 C₃H₅, -COOCH(CH₃)₂, -COOC(CH₃)₃, -OOC-CH₃, -OOC-C₂H₅, -OOC-
 C₃H₇, -OOC-cyclo-C₃H₅, -OOC-CH(CH₃)₂, -OOC-C(CH₃)₃, -CONH₂,
 15 -CONHCH₃, -CONHC₂H₅, -CONHC₃H₇, -CONH-cyclo-C₃H₅,
 -CONH[CH(CH₃)₂], -CONH[C(CH₃)₃], -CON(CH₃)₂, -CON(C₂H₅)₂,
 -CON(C₃H₇)₂, -CON(cyclo-C₃H₅)₂, -CON[CH(CH₃)₂]₂, -CON[C(CH₃)₃]₂,
 -NHCOCH₃, -NHCOC₂H₅, -NHCOC₃H₇, -NHCO-cyclo-C₃H₅, -NHCO-
 CH(CH₃)₂, -NHCO-C(CH₃)₃, -NHCO-OCH₃, -NHCO-OC₂H₅, -NHCO-
 20 OC₃H₇, -NHCO-O-cyclo-C₃H₅, -NHCO-OCH(CH₃)₂, -NHCO-OC(CH₃)₃,
 -NH₂, -NHCH₃, -NHC₂H₅, -NHC₃H₇, -NH-cyclo-C₃H₅, -NHCH(CH₃)₂,
 -NHC(CH₃)₃, -N(CH₃)₂, -N(C₂H₅)₂, -N(C₃H₇)₂, -N(cyclo-C₃H₅)₂,
 -N[CH(CH₃)₂]₂, -N[C(CH₃)₃]₂, -SOCH₃, -SOC₂H₅, -SOC₃H₇, -SO-cyclo-
 C₃H₅, -SOCH(CH₃)₂, -SOC(CH₃)₃, -SO₂CH₃, -SO₂C₂H₅, -SO₂C₃H₇,
 25 -SO₂-cyclo-C₃H₅, -SO₂CH(CH₃)₂, -SO₂C(CH₃)₃, -SO₃H, -SO₃CH₃,
 -SO₃C₂H₅, -SO₃C₃H₇, -SO₃-cyclo-C₃H₅, -SO₃CH(CH₃)₂, -SO₃C(CH₃)₃,
 -SO₂NH₂, -SO₂NHCH₃, -SO₂NHC₂H₅, -SO₂NHC₃H₇, -SO₂NH-cyclo-C₃H₅,
 -SO₂NHCH(CH₃)₂, -SO₂NHC(CH₃)₃, -SO₂N(CH₃)₂, -SO₂N(C₂H₅)₂,
 -SO₂N(C₃H₇)₂, -SO₂N(cyclo-C₃H₅)₂, -SO₂N[CH(CH₃)₂]₂, -SO₂N[C(CH₃)₃]₂,
 30 -O-S(=O)CH₃, -O-S(=O)C₂H₅, -O-S(=O)C₃H₇, -O-S(=O)-cyclo-C₃H₅,
 -O-S(=O)CH(CH₃)₂, -O-S(=O)C(CH₃)₃, -S(=O)(=NH)CH₃, -S(=O)(=NH)C₂H₅,
 -S(=O)(=NH)C₃H₇, -S(=O)(=NH)-cyclo-C₃H₅, -S(=O)(=NH)CH(CH₃)₂,
 -S(=O)(=NH)C(CH₃)₃, -NH-SO₂-CH₃, -NH-SO₂-C₂H₅, -NH-SO₂-C₃H₇,
 -NH-SO₂-cyclo-C₃H₅, -NH-SO₂-CH(CH₃)₂, -NH-SO₂-C(CH₃)₃, -O-SO₂-
 35 CH₃, -O-SO₂-C₂H₅, -O-SO₂-C₃H₇, -O-SO₂-cyclo-C₃H₅, -O-SO₂-





a, c, e, and g are independently of each other selected from 0, 1, 2, 3,

b, d, and f are independently of each other 0 or 1,

n is an integer selected from 1, 2, 3, 4, 5, 6, 7 or 8,

m is an integer selected from 0, 1, 2, 3, 4, 5 or 6, and

p is an integer selected from 1, 2, 3, 4, 5, 6, 7 or 8,

or enantiomers, stereoisomeric forms, mixtures of enantiomers, diastereomers, mixtures of diastereomers, hydrates, solvates, acid salt forms, tautomers, or racemates of the above mentioned compounds, or pharmaceutically acceptable salts thereof.

2. The compound according to claim 1, wherein

R³ represents -OH, -NH₂, -F, -Cl, -Br, -I, -CN, -OR¹¹, -CO-O-R¹¹, -NR¹¹-CO-OR¹², -NHR¹¹, -NR¹¹R¹², -CONR¹¹R¹², -O-CO-NR¹¹R¹², -O-CO-OR¹¹, -CH₃, -NR¹¹-CO-NR¹²R¹³, -SO₂NR¹¹R¹², -C(=NR¹¹)-NR¹²R¹³, -C(R¹²)=NR¹¹, -N=CR¹¹R¹², -N=S(=O)R¹¹R¹², -CR¹¹R¹²R¹³, -CR¹¹=CR¹²R¹³, -C≡CR¹¹, -NR¹¹-C(=NR¹²)-NR¹³R¹⁴, -SR¹¹, -S(=O)R¹¹, -NR¹¹-S(=O)R¹², -O-S(=O)R¹¹, -SO₂-R¹¹, -NR¹¹-SO₂-R¹², -O-SO₂-R¹¹, -SO(=NR¹¹)-R¹², -CO-R¹¹, -O-CO-R¹¹, -NR¹¹-CO-R¹², -CH₂F, -CHF₂, -CF₃, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, imidazolyl, furyl, dihydrofuryl, tetrahydrofuryl, thienyl, dihydrothienyl, tetrahydrothienyl, 1,3-oxazolyl, dihydro-1,3-oxazolyl, 1,3-oxazolidinyl, isoxazolyl, dihydro-isoxazolyl, isoxazolidinyl, pyrrolyl, dihydropyrrolyl, pyrrolidinyl, imidazolyl, dihydroimidazolyl, imidazolidinyl, triazolyl, dihydrotriazolyl, triazolidinyl, pyrazolyl, dihydropyrazolyl, pyrazolidinyl, oxadiazolyl, dihydrooxadiazolyl, oxadiazolidinyl, thiadiazolyl, dihydrothiadiazolyl, thiadiazolidinyl, 1,3-thiazolyl, dihydro-1,3-thiazolyl, 1,3-thiazolidinyl, isothiazolyl, dihydroisothiazolyl, isothiazolidinyl, tetrazolyl, dihydrotetrazolyl, tetrazolidinyl, aziridinyl, azirenyl, oxiranyl, thiranyl, azetidiny, oxetanyl, thietanyl, cyclopentanonyl, cyclohexanonyl, pyrrolidinonyl, pyrrolidindionyl, piperidinonyl, piperidindionyl, 1-oxid-thiopyranyl, 1,1-dioxid-thiopyranyl, dihydro-1-oxid-thiopyranyl, dihydro-1,1-dioxid-thiopyranyl, tetrahydro-1-oxid-thiopyranyl, tetrahydro-1,1-dioxid-thiopyranyl, morpholinyl, thiomorpholinyl, 1,2-dioxanyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,2-dioxolanyl, 1,3-dioxolanyl, 1,4-dioxolanyl, piperazinyl, 2-oxo-azetidiny, 2-oxo-pyrrolidinyl, 2-oxo-piperidinyl, 2-oxo-oxazolidinyl, 2-oxo-imidazolidinyl, 2-oxo-1,3-oxazinanyl, or 2-oxo-tetrahydropyrimidinyl, wherein the afore-mentioned ring systems can be substituted with one to four substituents selected from Z¹, Z², Z³ and Z⁴;

R⁸ represents 4-membered heterocyclyl, 5-membered heterocyclyl, 6-membered heterocyclyl, 4-membered carbocyclyl, 5-membered carbocyclyl, 6-membered carbocyclyl, azaspiro[3,3]heptyl, azaspiro[3,4]octyl, azaspiro[3,5]nonyl, azaspiro[3,6]decyl, azaspiro[4,4]nonyl, azaspiro[4,5]decyl, azaspiro[4,6]undecyl, azaspiro[5,5]undecyl, azaspiro[5,6]dodecyl, azaspiro[6,6]tridecyl, diazaspiro[3,3]heptyl, diazaspiro[3,4]octyl,

- diazaspiro[3,5]nonyl, diazaspiro[3,6]decyl, diazaspiro[4,4]nonyl,
 diazaspiro[4,5]decyl, diazaspiro[4,6]undecyl, diazaspiro[5,5]undecyl,
 diazaspiro[5,6]dodecyl, diazaspiro[6,6]tridecyl, triazaspiro[3,5]nonyl,
 triazaspiro[3,6]decyl, triazaspiro[4,5]decyl, triazaspiro[4,6]undecyl,
 triazaspiro[5,5]undecyl, triazaspiro[5,6]dodecyl, triazaspiro[6,6]tridecyl,
 oxazaspiro[3,3]heptyl, oxazaspiro[3,4]octyl, oxazaspiro[3,5]nonyl,
 oxazaspiro[3,6]decyl, oxazaspiro[4,4]nonyl, oxazaspiro[4,5]decyl,
 oxazaspiro[4,6]undecyl, oxazaspiro[5,5]undecyl, oxazaspiro[5,6]dodecyl,
 oxazaspiro[6,6]tridecyl, oxadiazaspiro[3,5]nonyl, oxadiazaspiro[3,6]decyl,
 oxadiazaspiro[4,5]decyl, oxadiazaspiro[4,6]undecyl, oxadiazaspiro[5,5]undecyl,
 oxadiazaspiro[5,6]dodecyl, or oxadiazaspiro[6,6]tridecyl, wherein the afore-
 mentioned carbocyclyl, heterocyclyl, azaspiro, diazaspiro, triazaspiro, oxazaspiro,
 and oxadiazaspiro residues are linked through a ring carbon atom and wherein
 the afore-mentioned carbocyclyl, heterocyclyl, azaspiro, diazaspiro, triazaspiro,
 oxazaspiro, and oxadiazaspiro residues are substituted with one to three
 substituents selected from Z^5 , Z^6 and Z^7 ;
 Z^5 and Z^6 if attached to the same carbon atom can together represent =O to form a
 carbonyl group with the carbon atom to which Z^5 and Z^6 are attached; and
- R⁹** represents 4-membered nitrogenheterocyclyl, 5-membered
 nitrogenheterocyclyl, 6-membered nitrogenheterocyclyl, 5-membered
 dinitrogenheterocyclyl, 6-membered dinitrogenheterocyclyl,
 spiro[2,3]heterohexyl, spiro[2,4]heteroheptyl, spiro[2,5]heterooctyl,
 spiro[2,7]heterononyl, spiro[3,3]heteroheptyl, spiro[3,4]heterooctyl,
 spiro[3,5]heterononyl, spiro[3,6]heterodecyl, spiro[4,4]heterononyl,
 spiro[4,5]heterodecyl, spiro[4,6]heteroundecyl, spiro[5,5]heteroundecyl,
 spiro[5,6]heterododecyl, or spiro[6,6]heterotridecyl, wherein the afore-mentioned
 nitrogenheterocyclyl, dinitrogenheterocyclyl and spiro residues are linked through
 the or a ring nitrogen atom and wherein the afore-mentioned nitrogenheterocyclyl,
 dinitrogenheterocyclyl and spiro residues are substituted with one to three
 substituents selected from Z^5 , Z^6 and Z^7 ;
 Z^5 and Z^6 if attached to the same carbon atom can together represent =O to form a
 carbonyl group with the carbon atom to which Z^5 and Z^6 are attached;
- the residues R^1 , R^2 , $R^4 - R^7$, $R^{10} - R^{17}$, **a**, **b**, **c**, **d**, **e**, **f**, **g**, **m**, **n**, **p**, **Q**, G^1 , G^2 and
 $Z^1 - Z^{15}$ have the meanings as defined in claim 1.

3. The compound according to claim 1 or 2, wherein

R^2 represents $-R^8$, $-Q-R^8$, $-R^9$, $-Q-(CH_2)_n-R^8$, $-Q-(CH_2)_n-R^9$, $-(CH_2)_n-R^9$,
 $-(CH_2)_n-NH-R^8$, $-(CH_2)_m-NH-(CH_2)_n-R^9$, $-CO-NH-(CH_2)_n-NH_2$,
 $-CO-NH-(CH_2)_n-R^9$, $-CO-NR^{10}-(CH_2)_n-R^9$, $-CO-R^9$, $-SO-R^9$, $-Q-R^{10}$,
 $-(CH_2)_n-NR^{10}-R^8$, $-(CH_2)_m-NR^{10}-(CH_2)_n-R^9$, $-(Q)_b-(CH_2)_m-(G^1)_d-(CH_2)_e-R^8$,
 $-(Q)_b-(CH_2)_m-(G^1)_d-(CH_2)_n-R^9$, $-Q-CH(COOR^{10})-R^8$, or $-Q-CH(R^{10})-R^8$,

Q represents $-O-$, $-S-$, $-NR^{15}-$, $-SO-$, $-SO_2-$, $-(CH_2)_m-NR^{15}-$, bridging carbocyclyl, bridging heterocyclyl, bridging spirocarbocyclyl, or bridging spiroheterocyclyl;

$R^4 - R^7$ represent independently of each other $-H$ or $-F$; and

the residues R^1 , R^3 , $R^8 - R^{17}$, a , b , c , d , e , f , g , m , n , p , G^1 , G^2 and $Z^1 - Z^{15}$ have the meanings as defined in claim 1 or 2.

4. The compound according to any one of claims 1 to 3, wherein the compound is:

N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-2-(2-azaspiro[3.3]heptan-6-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,
2-(1-oxa-8-azaspiro[4.5]decan-3-yloxy)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(1-(2-(1H-pyrazol-1-yl)phenyl)ethyl)-8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-N-((S)-1-(2-methoxyphenyl)ethyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-N-((S)-1-(2-methoxyphenyl)ethyl)-2-((R)-pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-2-(pyrrolidin-3-yloxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-2-(piperidin-4-yloxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,

(S)-8-isopropyl-N-(1-(2-methoxyphenyl)ethyl)-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2-isopropoxybenzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-isopropoxybenzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2-isopropoxybenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(piperidin-4-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-(pyrrolidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-((S)-1-(2-chlorophenyl)ethyl)-8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-N-(2-(1-methyl-1H-tetrazol-5-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-5-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)quinoline 1-oxide,
(R)-8-isopropyl-N-(isoquinolin-8-ylmethyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)isoquinoline 2-oxide,
(R)-8-isopropyl-N-((1-methyl-1H-indazol-4-yl)methyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyridin-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(quinolin-8-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-((1H-indazol-4-yl)methyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-N-(2-(2-methyl-2H-tetrazol-5-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)-N,N-dimethylbenzenesulfonamide,
(R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)pyrrolidin-2-one,
(R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)azetidin-2-one,

(R)-N-(5-fluoro-2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(3-fluoro-2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(4-fluoro-2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2-fluoro-6-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-(pyridin-3-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyridin-3-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-phenoxybenzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-N-(2-phenoxybenzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-N-(2-(oxazol-2-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2-(furan-2-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)acetamide,
(R)-N-(2-(4-chloro-1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-N-(2-methylbenzyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(dimethylamino)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
2-(((8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzonitrile,
N-(2-fluorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-(trifluoromethyl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-imidazol-1-yl)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-morpholinobenzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(naphthalen-1-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-chloro-6-methylbenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2,6-dichlorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2,6-difluorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-isopropoxybenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,

(S)-8-isopropyl-N-(1-(2-methoxyphenyl)ethyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-chlorobenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(S)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)-N-(1-(naphthalen-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-ethoxybenzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-N-(2-methoxybenzyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(difluoromethoxy)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(difluoromethoxy)benzyl)-8-isopropyl-2-((1-methylpiperidin-4-yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
methyl 2-(((2-(2-(dimethylamino)ethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzoate,
2-(((6-aminospiro[3.3]heptan-2-yl)oxy)-8-isopropyl-N-(quinolin-5-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-2-(2-(piperidin-4-yl)ethoxy)-N-(quinolin-5-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-aminobenzyl)-2-(azetidin-3-ylmethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,
tert-butyl 2-(((8-isopropyl-2-(2-(piperidin-1-yl)ethoxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)carbamate,
N-(2-(((2-(2-(2-(dimethylamino)ethoxy)ethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methanesulfonamide,
N-(2-(((2-(2-((2-(dimethylamino)ethyl)(methyl)amino)ethoxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methanesulfonamide,
N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.4]octan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[4.4]nonan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,6-diazaspiro[3.5]nonan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.5]nonan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[4.5]decan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.4]octan-6-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,6-diazaspiro[3.3]heptan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,

N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,6-diazaspiro[3.3]heptan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[3.5]nonan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[4.4]nonan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,8-diazaspiro[5.5]undecan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,8-diazaspiro[5.5]undecan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[3.5]nonan-7-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[4.4]nonan-7-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-N-(2-(1-methyl-1H-tetrazol-5-yl)benzyl)-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-N-(2-(2-methyl-2H-tetrazol-5-yl)benzyl)-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[3.5]nonan-7-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,9-diazaspiro[5.5]undecan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,8-diazaspiro[4.5]decan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,9-diazaspiro[5.5]undecan-9-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-2-(4-(dimethylamino)piperidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(4-(methylamino)piperidin-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(3,9-diazaspiro[5.5]undecan-3-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,7-diazaspiro[4.5]decan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,6-diazaspiro[3.4]octan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
8-isopropyl-N4-((S)-1-(2-methoxyphenyl)ethyl)-N2-((R)-piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine,
(R)-N4-(2-isopropoxybenzyl)-8-isopropyl-N2-(piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine,
(R)-N4-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-N2-(piperidin-3-yl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(1,7-diazaspiro[3.5]nonan-1-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
2-(((8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)-N,N-dimethylbenzenesulfonamide,
N-(benzo[c][1,2,5]oxadiazol-4-ylmethyl)-8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2,8-diazaspiro[4.5]decan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,

- 1-(2-(((8-isopropyl-2-(1,8-diazaspiro[4.5]decan-8-yl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)pyrrolidin-2-one,
- N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- 8-isopropyl-2-(piperidin-4-ylsulfinyl)-N-(2-(thiophen-2-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- N-([1,1'-biphenyl]-2-ylmethyl)-8-isopropyl-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- N-(2-(1H-1,2,4-triazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- 8-isopropyl-N-(2-(2-methyl-1H-imidazol-1-yl)benzyl)-2-(piperidin-4-ylsulfinyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-(piperidin-4-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide,
- 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-N-(azetidin-3-ylmethyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxamide,
- 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-(pyrrolidin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide,
- 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-(piperidin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide,
- 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-N-(4-aminobutyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxamide,
- (R)-N-(4-chloro-2-methylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- (R)-N-(2-bromobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- 5 (R)-8-isopropyl-N-(2-(morpholinosulfonyl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- (R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyridin-2-yloxy)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- (R)-N-(2-cyclobutoxybenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- 10 (R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzamide,
- (R)-N-(2-(cyclopentyloxy)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- 15 (R)-N-(2,4-dichlorobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- 8-isopropyl-N-(4-methyl-2-((tetrahydrofuran-3-yl)oxy)benzyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
- (R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzyl)pyrrolidin-2-one,
- 20

N-(2-(((8-isopropyl-2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)methanesulfonamide,
 4-(benzyloxy)-8-isopropyl-2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazine
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(2-(piperazin-1-yl)ethoxy)pyrazolo[1,5-
 5 a][1,3,5]triazin-4-amine,
 N-(2-(1H-pyrazol-1-yl)benzyl)-2-((1R,5S)-3-azabicyclo[3.2.0]heptan-6-yloxy)-8-
 isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,
 2-((1,4-oxazepan-6-yl)oxy)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 10 2-(1-oxa-8-azaspiro[4.5]decan-3-yloxy)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-
 isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((1,2,3,6-tetrahydropyridin-3-
 yl)oxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
 (R)-N-(2-(cyclopentylthio)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-
 15 a][1,3,5]triazin-4-amine,
 (R)-8-isopropyl-N-(2-(methylthio)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-
 4-amine,
 (R)-8-isopropyl-2-(piperidin-3-yloxy)-N-((2',3',4',5'-tetrahydro-[1,1'-biphenyl]-2-
 yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
 20 (R)-N-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-6-yl)methyl)-8-isopropyl-2-(piperidin-3-
 yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
 (R)-N-(2-isobutoxy-4-methylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 (R)-1-ethyl-3-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 25 yl)amino)methyl)phenyl)urea,
 (R)-1-benzyl-3-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)phenyl)urea,
 (R)-1-cyclohexyl-3-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)phenyl)urea,
 30 (R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)phenyl)-3-phenylurea,
 (R)-1-(2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)phenyl)-3-propylurea,
 N-(but-3-yn-2-yl)-2-(((8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 35 yl)amino)methyl)benzamide,
 (R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)-
 N-methylbenzamide,

(R)-8-isopropyl-N-(2-((4-methylpiperazin-1-yl)sulfonyl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyrrolidin-1-ylsulfonyl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
5 (R)-N-isopropyl-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)benzenesulfonamide,
(R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)-N-methylbenzenesulfonamide,
(R)-N-(2,3-dichlorobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
10 (R)-N-(4-chloro-2-(trifluoromethyl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(1H-pyrazol-1-yl)benzyl)-2-(2-azabicyclo[2.2.1]heptan-5-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,
15 N-(2-iodobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
N-(2-(((8-isopropyl-2-(R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)-2-methylpropane-2-sulfonamide,
(R)-isobutyl (2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-yl)amino)methyl)phenyl)carbamate,
20 (R)-N-(2-((1H-pyrazol-1-yl)methyl)benzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-N-(2,5-dichlorobenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
(R)-8-isopropyl-2-(piperidin-3-yloxy)-N-(2-(pyrrolidin-1-yl)benzyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
25 (R)-8-isopropyl-N-(2-(piperidin-1-yl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
azetidin-3-yl (2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl)(methyl)carbamate,
30 N-(2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl)-3-(dimethylamino)-N-methylpropane-1-sulfonamide,
N-(2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl)-N-methylpiperidine-4-sulfonamide,
2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)ethyl azetidin-3-ylcarbamate,
35 2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)oxy)-N-(pyrrolidin-3-yl)ethanesulfonamide,

N-(2-(1H-pyrazol-1-yl)benzyl)-2-(8-azabicyclo[3.2.1]octan-3-yloxy)-8-
 isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,
 N-(2-(1H-pyrazol-1-yl)benzyl)-2-(2-azaspiro[3.3]heptan-5-yloxy)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 5 N-(2-(1H-pyrazol-1-yl)benzyl)-2-((4-aminocyclohexyl)oxy)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 (R)-N-(2-cyclobutylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 amine,
 (R)-N-(2-cyclopentylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-
 10 4-amine,
 N-(2-cyclopropylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 amine,
 (R)-N-(2-cyclohexylbenzyl)-8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-
 4-amine,
 15 (R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)phenyl acetate,
 (R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)phenyl ethylcarbamate,
 (R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 20 yl)amino)methyl)phenyl methanesulfonate,
 2-(((8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)phenyl 2-methylpropane-2-sulfinate,
 (R)-isobutyl (2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)phenyl) carbonate,
 25 (R)-2-(((8-isopropyl-2-(piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-
 yl)amino)methyl)phenol,
 (R)-8-isopropyl-N-(2-(methylsulfonyl)benzyl)-2-(piperidin-3-yloxy)pyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 8-isopropyl-N-(2-(methylsulfinyl)benzyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-
 30 a][1,3,5]triazin-4-amine,
 N-(2-(cyclopentylsulfinyl)benzyl)-8-isopropyl-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(3-aminopropyl)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazine-2,4-diamine,
 35 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(2-(pyrrolidin-1-yl)ethyl)pyrazolo[1,5-
 a][1,3,5]triazine-2,4-diamine,

N-(2-(1H-pyrazol-1-yl)benzyl)-2-(3-(3,3-difluoropyrrolidin-1-yl)azetidin-1-yl)-8-
 isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,
 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(2-
 morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine,
 5 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(pyrrolidin-3-yl)pyrazolo[1,5-
 a][1,3,5]triazine-2,4-diamine,
 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(3-morpholinopropyl)pyrazolo[1,5-
 a][1,3,5]triazine-2,4-diamine,
 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(2-(pyrrolidin-1-
 10 yl)ethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine,
 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(2-morpholinoethyl)pyrazolo[1,5-
 a][1,3,5]triazine-2,4-diamine,
 1-(1-(4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-
 yl)azetidin-3-yl)pyrrolidin-2-one,
 15 N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(2-(2-aminoethoxy)ethyl)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazine-2,4-diamine,
 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(3-(piperidin-1-
 yl)propyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine,
 N-(2-(1H-pyrazol-1-yl)benzyl)-2-(hexahydropyrrolo[3,4-b]pyrrol-5(1H)-yl)-8-
 20 isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,
 N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(2-aminoethyl)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazine-2,4-diamine,
 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(pyrrolidin-3-ylmethyl)pyrazolo[1,5-
 a][1,3,5]triazine-2,4-diamine,
 25 N-(2-(1H-pyrazol-1-yl)benzyl)-2-(3-aminopiperidin-1-yl)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 N-(2-(1H-pyrazol-1-yl)benzyl)-2-(3-aminopyrrolidin-1-yl)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 methyl 2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-
 30 yl)amino)-3-aminopropanoate,
 N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(2-amino-1-phenylethyl)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazine-2,4-diamine,
 N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(azetidin-3-ylmethyl)-8-isopropyl-N2-
 methylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine,
 35 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(2-
 morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine,

N-(2-(1H-pyrazol-1-yl)benzyl)-2-(4-aminopiperidin-1-yl)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(4-aminocyclohexyl)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazine-2,4-diamine,
 5 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((R)-((R)-piperidin-3-yl)sulfinyl)pyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylsulfonyl)pyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 (R)-N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-ylthio)pyrazolo[1,5-
 10 a][1,3,5]triazin-4-amine,
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-4-ylthio)pyrazolo[1,5-
 a][1,3,5]triazin-4-amine,
 (4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)(2,6-
 diazaspiro[3.3]heptan-2-yl)methanone,
 15 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-methyl-N-(2-
 morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide,
 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropyl-N-methyl-N-(2-(pyrrolidin-1-
 yl)ethyl)pyrazolo[1,5-a][1,3,5]triazine-2-carboxamide,
 (4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-
 20 yl)(piperazin-1-yl)methanone,
 4-((2-(1H-pyrazol-1-yl)benzyl)amino)-N-(3-aminopropyl)-8-isopropylpyrazolo[1,5-
 a][1,3,5]triazine-2-carboxamide,
 (4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)(4-
 aminopiperidin-1-yl)methanone,
 25 N1-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-
 yl)methyl)ethane-1,2-diamine,
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(((3-
 morpholinopropyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((methyl(2-(pyrrolidin-1-
 30 yl)ethyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(((2-(pyrrolidin-1-
 yl)ethyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(((2-
 morpholinoethyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,
 35 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((methyl(3-(piperidin-1-
 yl)propyl)amino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,

N-(2-(1H-pyrazol-1-yl)benzyl)-2-((3-(3,3-difluoropyrrolidin-1-yl)azetidin-1-yl)methyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,

1-(1-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)methyl)azetidin-3-yl)pyrrolidin-2-one,

5 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((4-(2-methoxyethyl)piperazin-1-yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,

N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-((pyrrolidin-3-ylamino)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,

10 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperazin-1-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,

N-(2-(1H-pyrazol-1-yl)benzyl)-2-(((azetidin-3-ylmethyl)(methyl)amino)methyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,

N-(2-(2-(((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)methyl)amino)ethoxy)ethyl)-2-(pyrrolidin-1-yl)acetamide,

15 N-(2-(1H-pyrazol-1-yl)benzyl)-2-((4-aminopiperidin-1-yl)methyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,

1-methylpyrrolidin-3-yl 4-((2-(1H-pyrazol-1-yl)benzyl) amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2-carboxylate,

8-isopropyl-N-(2-(S-methylsulfonimidoyl)benzyl)-2-((R)-piperidin-3-yloxy)pyrazolo[1,5-a][1,3,5]triazin-4-amine,

4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo [1,5-a][1,3,5]triazin-2-ol,

N-(2-(1H-pyrazol-1-yl)benzyl)-2-bromo-8-isopropylpyrazolo [1,5-a][1,3,5]triazin-4-amine, tert-butyl 2-(1H-pyrazol-1-yl)benzyl(2-bromo-8-isopropyl pyrazolo[1,5-a][1,3,5]triazin-4-yl)carbamate,

25 N-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-2-(piperidin-3-ylmethyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine,

N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-methyl-N2-(2-morpholinoethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine,

30 N-(2-(1H-pyrazol-1-yl)benzyl)-2-(4-aminopiperidin-1-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine,

N4-(2-(1H-pyrazol-1-yl)benzyl)-N2-(4-aminocyclohexyl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine,

N-(2-(2-((4-((2-(1H-pyrazol-1-yl)benzyl)amino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)ethoxy)ethyl)-2-(pyrrolidin-1-yl)acetamide,

35 N4-(2-(1H-pyrazol-1-yl)benzyl)-8-isopropyl-N2-(2-(piperazin-1-yl)ethyl)pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine, or

N-(2-(1H-pyrazol-1-yl)benzyl)-2-(azetidin-3-yloxy)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-amine.

5. Use of at least one compound according to any one of claims 1 to 4 for the preparation of a pharmaceutical composition for the prophylaxis and / or treatment of infectious diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction, diseases caused by abnormal stem cell survival, differentiation of proliferation, and stroke.

6. Use according to claim 5, wherein the infective disease is selected from the group comprising or consisting of AIDS, Adenovirus Infection, Alveolar Hydatid Disease (AHD, Echinococcosis), Amebiasis (Entamoeba histolytica Infection), Angiostrongylus Infection, Anisakiasis, Anthrax, Babesiosis (Babesia Infection), Balantidium Infection (Balantidiasis), Baylisascaris Infection (Raccoon Roundworm), Bilharzia (Schistosomiasis), Blastocystis hominis Infection (Blastomycosis), Boreliosis, Botulism, Brainerd Diarrhea, Brucellosis, BSE (Bovine Spongiform Encephalopathy), Candidiasis, Capillariasis (Capillaria Infection), CFS (Chronic Fatigue Syndrome), Chagas Disease (American Trypanosomiasis), Chickenpox (Varicella-Zoster virus), Chlamydia pneumoniae Infection, Cholera, Chronic Fatigue Syndrome, CJD (Creutzfeldt-Jakob Disease), Clonorchiasis (Clonorchis Infection), CLM (Cutaneous Larva Migrans, Hookworm Infection), Coccidioidomycosis, Conjunctivitis, Coxsackievirus A16 (Hand, Foot and Mouth Disease), Cryptococcosis, Cryptosporidium Infection (Cryptosporidiosis), Culex mosquito (Vector of West Nile Virus), Cutaneous Larva Migrans (CLM), Cyclosporiasis (Cyclospora Infection), Cysticercosis (Neurocysticercosis), Cytomegalovirus Infection, Dengue / Dengue Fever, Dipylidium Infection (Dog and Cat Flea Tapeworm), Ebola Virus Hemorrhagic Fever, Echinococcosis (Alveolar Hydatid Disease), Encephalitis, Entamoeba coli Infection, Entamoeba dispar Infection, Entamoeba hartmanni Infection, Entamoeba histolytica Infection (Amebiasis), Entamoeba polecki Infection, Enterobiasis (Pinworm Infection), Enterovirus Infection (Non-Polio), Epstein-Barr Virus Infection, Escherichia coli Infection, Foodborne Infection, Foot and mouth Disease, Fungal Dermatitis, Fungal Infections, Gastroenteritis, Group A streptococcal Disease, Group B streptococcal Disease, Hansen's Disease (Leprosy), Hantavirus Pulmonary Syndrome, Head Lice Infestation (Pediculosis), Helicobacter pylori Infection, Hematologic Disease, Hendra Virus Infection, Hepatitis (HCV, HBV), Herpes Zoster (Shingles), HIV Infection,

Human Ehrlichiosis, Human Parainfluenza Virus Infection, Influenza, Isosporiasis (Isospora Infection), Lassa Fever, Leishmaniasis, Kala-azar (Kala-azar, Leishmania Infection), Leprosy, Lice (Body lice, Head lice, Pubic lice), Lyme Disease, Malaria, Marburg Hemorrhagic Fever, Measles, Meningitis, mycobacteria-induced meningitis, Mosquito-borne Diseases, Mycobacterium avium Complex (MAC) Infection, Naegleria Infection, Nosocomial Infections, Nonpathogenic Intestinal Amebae Infection, Onchocerciasis (River Blindness), Opisthorciasis (Opisthorcis Infection), Papilloma virus Infection, Parvovirus Infection, Plague, PCP (Pneumocystis carinii Pneumonia), Polio, Polyomavirus Infection, Q Fever, Rabies, Respiratory Syncytial Virus (RSV) Infection, Rheumatic Fever, Rift Valley Fever, River Blindness (Onchocerciasis), Rotavirus Infection, Roundworms Infection, Salmonellosis, Salmonella Enteritidis, Scabies, Shigellosis, Shingles, Sleeping Sickness, Smallpox, Streptococcal Infection, Tapeworm Infection (Taenia Infection), Tetanus, Toxic Shock Syndrome, Tuberculosis, Ulcers (Peptic Ulcer Disease), Valley Fever, Vibrio parahaemolyticus Infection, Vibrio vulnificus Infection, Viral Hemorrhagic Fever, Warts, Waterborne infectious Diseases, West Nile Virus Infection (West Nile Encephalitis), Varicella-Zoster Virus infection, Whooping Cough, and Yellow Fever.

7. Use according to claim 5, wherein the immunological disease and/or autoimmune disease is selected from the group comprising or consisting of:
 asthma, diabetes, rheumatic diseases, AIDS, rejection of transplanted organs and tissues, rhinitis, chronic obstructive pulmonary diseases, osteoporosis, ulcerative colitis, sinusitis, lupus erythematosus, recurrent infections, atopic dermatitis / eczema and occupational allergies, food allergies, drug allergies, severe anaphylactic reactions, anaphylaxis, manifestations of allergic diseases, primary immunodeficiencies, antibody deficiency states, cell mediated immunodeficiencies, severe combined immunodeficiency, DiGeorge syndrome, Hyper-IgE syndrome, Wiskott-Aldrich syndrome, ataxia-telangiectasia, immune mediated cancers, white cell defects, autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis (RA), multiple sclerosis (MS), immune-mediated or Type 1 Diabetes Mellitus, immune mediated glomerulonephritis, scleroderma, pernicious anemia, alopecia, pemphigus, pemphigus vulgaris, myasthenia gravis, inflammatory bowel diseases, Crohn's disease, psoriasis, autoimmune thyroid diseases, Hashimoto's disease, dermatomyositis, goodpasture syndrome, myasthenia gravis pseudoparalytica, ophtalmia

sympatica, phakogene uveitis, chronic aggressive hepatitis, primary biliary cirrhosis, autoimmune hemolytic anemia, and Werlhofer disease.

8. Use according to claim 5, wherein the cardiovascular diseases are selected from the group comprising or consisting of:

cardiac hypertrophy, adult congenital heart disease, aneurysm, stable angina, unstable angina, angina pectoris, angioneurotic edema, aortic valve stenosis, aortic aneurysm, arrhythmia, arrhythmogenic right ventricular dysplasia, arteriosclerosis, arteriovenous malformations, atrial fibrillation, Behcet syndrome, bradycardia, cardiac tamponade, cardiomegaly, congestive cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, cardiovascular disease prevention, carotid stenosis, cerebral hemorrhage, Churg-Strauss syndrome, diabetes, Ebstein's Anomaly, Eisenmenger complex, cholesterol embolism, bacterial endocarditis, fibromuscular dysplasia, congenital heart defects, heart diseases, congestive heart failure, heart valve diseases, heart attack, epidural hematoma, hematoma, subdural, Hippel-Lindau disease, hyperemia, hypertension, pulmonary hypertension, hypertrophic growth, left ventricular hypertrophy, right ventricular hypertrophy, hypoplastic left heart syndrome, hypotension, intermittent claudication, ischemic heart disease, Klippel-Trenaunay-Weber syndrome, lateral medullary syndrome, long QT syndrome mitral valve prolapse, moyamoya disease, mucocutaneous lymph node syndrome, myocardial infarction, myocardial ischemia, myocarditis, pericarditis, peripheral vascular diseases, phlebitis, polyarteritis nodosa, pulmonary atresia, Raynaud disease, restenosis, Sneddon syndrome, stenosis, superior vena cava syndrome, syndrome X, tachycardia, Takayasu's arteritis, hereditary hemorrhagic telangiectasia, telangiectasis, temporal arteritis, tetralogy of fallot, thromboangiitis obliterans, thrombosis, thromboembolism, tricuspid atresia, varicose veins, vascular diseases, vasculitis, vasospasm, ventricular fibrillation, Williams syndrome, peripheral vascular disease, varicose veins and leg ulcers, deep vein thrombosis, and Wolff-Parkinson-White syndrome.

9. Use according to claim 5, wherein the proliferative disease is selected from the group comprising or consisting of:

adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neuroma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, desmoid tumor, bladder cancer, bronchial carcinoma, estrogen dependent and independent breast cancer, Burkitt's lymphoma, corpus cancer, CUP-syndrome (carcinoma of unknown primary), colorectal cancer, small

intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma,
 ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors,
 gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer,
 cervical cancer, glioblastomas, gynecologic tumors, ear, nose and throat tumors,
 5 hematologic neoplasias, hairy cell leukemia, urethral cancer, skin cancer, skin
 testis cancer, brain tumors (gliomas), brain metastases, testicle cancer,
 hypophysis tumor, carcinoids, Kaposi's sarcoma, laryngeal cancer, germ cell
 tumor, bone cancer, colorectal carcinoma, head and neck tumors (tumors of the
 ear, nose and throat area), colon carcinoma, craniopharyngiomas, oral cancer
 10 (cancer in the mouth area and on lips), cancer of the central nervous system, liver
 cancer, liver metastases, leukemia, eyelid tumor, lung cancer, lymph node cancer
 (Hodgkin's/Non-Hodgkin's lymphomas), lymphomas, stomach cancer, malignant
 melanoma, malignant neoplasia, malignant tumors gastrointestinal tract, breast
 carcinoma, rectal cancer, medulloblastomas, melanoma, meningiomas, Hodgkin's
 15 disease, mycosis fungoides, nasal cancer, neurinoma, neuroblastoma, kidney
 cancer, renal cell carcinomas, non-Hodgkin's lymphomas, oligodendroglioma,
 esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas,
 osteosarcomas, ovarian carcinoma, pancreatic carcinoma, penile cancer,
 plasmocytoma, prostate cancer, pharyngeal cancer, rectal carcinoma,
 20 retinoblastoma, vaginal cancer, thyroid carcinoma, Schneeberger disease,
 esophageal cancer, spinaliomas, T-cell lymphoma (mycosis fungoides), thymoma,
 tube carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial
 carcinoma, vulva cancer, wart appearance, soft tissue tumors, soft tissue
 sarcoma, Wilm's tumor, cervical carcinoma, tongue cancer, invasive ductal
 25 carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, lobular
 carcinoma in situ, small-cell lung carcinoma, non-small-cell lung carcinoma,
 bronchial adenoma, pleuropulmonary blastoma, mesothelioma, brain stem
 glioma, hypophtalmic glioma, cerebellar astrocytoma, cerebral astrocytoma,
 neuroectodermal tumours, pineal tumors, sarcoma of the uterus, salivary gland
 30 cancers, anal gland adenocarcinomas, mast cell tumors, pelvis tumours, ureter
 tumours, hereditary papillary renal cancers, sporadic papillary renal cancers,
 intraocular melanoma, hepatocellular carcinoma (liver cell carcinomas with or
 without fibrolamellar variant), cholangiocarcinoma (intrahepatic bile duct
 carcinoma), mixed hepatocellular cholangiocarcinoma, squamous cell carcinoma,
 35 malignant melanoma, Merkel cell skin cancer, non-melanoma skin cancer,
 hypopharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer, oral
 cavity cancer, squamous cell cancer, oral melanoma, AIDS-related lymphoma,
 cutaneous T-cell lymphoma, lymphoma of the central nervous system, malignant


fibrous histiocytoma, lymphosarcoma, rhabdomyosarcoma, malignant histiocytosis, fibrosarcoma, hemangiosarcoma, hemangiopericytoma, leiomyosarcoma, canine mammary carcinoma, and feline mammary carcinoma.

- 5 10. Use according to claim 5, wherein said inflammation is mediated by the cytokines TNF- α , IL-1 β , GM-CSF, IL-6 and/or IL-8.
11. Use according to claim 5 or 10 wherein the inflammatory disease is caused, induced, initiated and/or enhanced by bacteria, viruses, prions, parasites, fungi, and/or caused by irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic reasons.
- 10 12. Use according to claim 5, 10 or 11, wherein the inflammatory disease is selected from the group comprising or consisting of inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, and inflammatory diseases of the larynx.
- 15 13. Use according to claim 5 or 12 wherein the inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, inflammatory diseases of the larynx are selected from the group comprising or consisting of:
 - 20 abscessation, acanthameba, acanthamebiasis, acne vulgaris, actinomycosis, acute inflammatory dermatoses, acute laryngeal infections of adults, acute multifocal placoid pigmentary epitheliopathy, acute (thermal) injury, acute retinal necrosis, acute suppurative otitis media, algal disorders, allergic contact dermatitis, amyloidosis angioedema, ankylosing spondylitis, aspergillosis,
 - 25 atopic dermatitis, Aujeszky's disease, autoantibodies in vasculitis, babesiosis, bacterial disorders, bacterial laryngitis, bacterial meningitis, Behcet's disease, birdshot choroidopathy, blastomycosis, borna disease, brucellosis, bullous myringitis, bursitis, candidiasis, canine distemper encephalomyelitis, canine distemper encephalomyelitis in immature animals, canine ehrlichiosis, canine herpes virus encephalomyelitis, cholesteatoma, chronic (granulomatous) diseases,
 - 30 chronic inflammatory dermatoses, chronic relapsing encephalomyelitis, chronic suppurative otitis media, cicatricial pemphigoid,
 - 35

coccidiomycosis, coccidioidomycosis, common upper respiratory infection,
 contact ulcer and granuloma, Crohn's disease, cryptococcosis, cysticercosis,
 dermatomyositis, diphtheria, discoid lupus erythematosus, drug-induced
 vasculitis, drug or hypersensitivity reaction, encephalitozoonosis, eosinophilic
 5 meningoencephalitis, erythema multiforme (EM minor), feline leukemia virus,
 feline immunodeficiency virus, feline infectious peritonitis, feline
 polioencephalomyelitis, feline spongiform encephalopathy, fibromyositis, Fuch's
 heterochromic cyclitis, gastroesophageal (laryngopharyngeal) reflux disease,
 giant cell arteritis, glanders, glaucomatocyclitic crisis, gonorrhea granular
 10 myringitis, granulomatous meningoencephalomyelitis, herpes simplex,
 histoplasmosis, idiopathic diseases, idiopathic inflammatory disorders, immune
 and idiopathic disorders, infections of the immunocompromised host, infectious
 canine hepatitis, inhalation laryngitis, interstitial nephritis, irritant contact
 dermatitis, juvenile rheumatoid arthritis, Kawasaki's disease, La Crosse virus
 15 encephalitis, laryngeal abscess, laryngotracheitis (croup), leishmaniasis, lens-
 induced uveitis, leprosy, leptospirosis, leukemia, lichen planus, lupus, Lyme
 disease, lymphoma, meningitis, meningoencephalitis in greyhounds,
 miscellaneous meningitis / meningoencephalitis, microscopic polyangiitis,
 multifocal choroiditis, multifocal distemper encephalomyelitis in mature animals,
 20 multiple sclerosis, muscle tension dysphonias, mycotic (fungal) diseases,
 mycotic diseases of the CNS, necrotizing encephalitis, neosporosis, old dog
 encephalitis, onchocerciasis, parasitic encephalomyelitis, parasitic infections,
 pars planitis, parvovirus encephalitis, pediatric laryngitis, pollution and inhalant
 allergy, polymyositis, post-vaccinal canine distemper encephalitis, post-vaccinal
 25 rabies, prion protein induced diseases, protothecosis, protozoal encephalitis-
 encephalomyelitis, psoriasis, psoriatic arthritis, pug dog encephalitis,
 pyogranulomatous meningoencephalomyelitis, rabies, radiation injury, radiation
 laryngitis, radionecrosis, relapsing polychondritis, Reiter's syndrome, retinitis
 pigmentosa, retinoblastoma, rheumatoid arthritis, rickettsial disorders, rocky
 30 mountain spotted fever, salmon poisoning, sarcocystosis, sarcoidosis,
 schistosomiasis, scleroderma, scleroma, serpiginous choroiditis, shaker dog
 disease, Sjogren's syndrome, spasmodic croup, spirochetal (syphilis) diseases,
 spongiotic dermatitis, sporotrichosis, steroid responsive meningitis-arteritis,
 Stevens-Johnson syndrome (SJS, EM major), supraglottitis (epiglottitis),
 35 sympathetic ophthalmia, syngamus laryngeus, syphilis, systemic lupus
 erythematosus, systemic vasculitis in sarcoidosis, Takayasu's arteritis, tendinitis
 (tendonitis), thromboangiitis obliterans (Buerger's Disease), tick-borne
 encephalitis in dogs, toxic epidermal necrolysis (TEN), toxocariasis,

toxoplasmosis, trauma, traumatic laryngitis, trichinosis, trypanosomiasis, tuberculosis, tularemia, ulcerative colitis, urticaria (hives), vasculitis, vasculitis and malignancy, vasculitis and rheumatoid arthritis, vasculitis in systemic lupus erythematosus, vasculitis in the idiopathic inflammatory myopathies, vasculitis of the central nervous system, vasculitis secondary to bacterial, fungal, and parasitic infection, viral disorders, viral laryngitis, vitiligo, vocal abuse, vocal-cord hemorrhage, Vogt Koyanagi Harada syndrome, Wegener's granulomatosis, and Whipple's disease.

- 10 14. Pharmaceutical composition comprising at least one compound according to any one of claims 1 to 4 as active ingredient, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.



(I)